

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**



(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

**EP 1 054 064 A1**

(12)

**EUROPEAN PATENT APPLICATION**

(43) Date of publication:  
22.11.2000 Bulletin 2000/47

(51) Int. Cl.<sup>7</sup>: **C12N 15/86**, C12N 15/34,  
C12N 5/10, A61K 48/00

(21) Application number: 00201738.2

(22) Date of filing: 16.05.2000

(84) Designated Contracting States:  
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE  
Designated Extension States:  
AL LT LV MK RO SI

(30) Priority: 17.05.1999 EP 99201545

(71) Applicant: **Introgene B.V.**  
2333 AL Leiden (NL)

(72) Inventors:  
• **Bout, Abraham**  
2751 AR Moerkapelle (NL)  
• **Vogels, Ronald**  
3461 HW Linschoten (NL)

• **Havenga, Menzo Jans Emco**  
2401 BV Alphen aan den Rijn (NL)

(74) Representative:  
**Prins, Adrianus Willem et al**  
**Vereenigde,**  
**Nieuwe Parklaan 97**  
**2587 BN Den Haag (NL)**

Remarks:

The sequence listing, which is published as annex to the application documents, was filed after the date of filing. The applicant has declared that it does not include matter which goes beyond the content of the application as filed.

(54) **Adenovirus derived gene delivery vehicles comprising at least one element of adenovirus type 35**

(57) The serotypes differ in their natural tropism. The adenovirus serotypes 2, 4, 5 and 7 all have a natural affiliation towards lung epithelia and other respiratory tissues. In contrast, serotypes 40 and 41 have a natural affiliation towards the gastrointestinal tract. The serotypes described above, differ in at least capsid proteins (penton-base, hexon), proteins responsible for cell binding (fiber protein), and proteins involved in adenovirus replication. This difference in tropism and capsid protein among serotypes has led to the many research efforts aimed at redirecting the adenovirus tropism by modification of the capsid proteins

**EP 1 054 064 A1**

## Description

[0001] The present invention relates to the field of gene therapy, in particular gene therapy involving elements derived from viruses, more in particular elements of adenoviruses. Adenoviruses have been proposed as suitable vehicles to deliver genes to the host.

[0002] There are a number of features of adenoviruses that make them particularly useful for the development of gene-transfer vectors for human gene therapy:

The adenovirus genome is well characterized. It consists of a linear double-stranded DNA molecule of approximately 36000 base pairs. The adenovirus DNA contains identical Inverted Terminal Repeats (ITR) of approximately 90-140 base pairs with the exact length depending on the serotype. The viral origins of replication are within the ITRs exactly at the genome ends;

The biology of the adenoviruses is characterized in detail; the adenovirus is not associated with severe human pathology in immuno-competent individuals

The virus is extremely efficient in introducing its DNA into the host cell; the virus can infect a wide variety of cells and has a broad host-range;

The virus can be produced at high virus titers in large quantities;

The virus can be rendered replication defective by deletion of the early-region 1 (E1) of the viral genome (Brody et al, 1994). Most adenoviral vectors currently used in gene therapy have a deletion in the E1 region, where desired genetic information can be introduced.

[0003] Based on these features, preferred methods for *in vivo* gene transfer into human target cells, make use of adenoviral vectors as gene delivery vehicles.

[0004] However, there are still drawbacks associated with the therapeutic use of adenoviral vectors in humans. A major drawback is the existence of widespread pre-existing immunity among the population against adenoviruses. Exposure to wild-type adenoviruses is very common in humans, as has been documented extensively [reviewed in Wadell, 1984]. This exposure has resulted in immune responses against most types of adenoviruses, not alone against adenoviruses to which individuals have actually been exposed, but also against adenoviruses which have similar (neutralizing) epitopes.

[0005] This phenomenon of pre-existing antibodies in humans, in combination with a strong secondary humoral and cellular immune response against the virus, can seriously affect gene transfer using recombinant adenoviral vectors.

[0006] To date, six different subgroups of human adenoviruses have been proposed which in total encompasses 51 distinct adenovirus serotypes (see table 1). A serotype is defined on the basis of its immunological distinctiveness as determined by quantitative neutralization with animal antisera (horse, rabbit). If neutralization shows a certain degree of cross-reaction between two viruses, distinctiveness of serotype is assumed if A) the hemagglutinins are unrelated, as shown by lack of cross-reaction on hemagglutination-inhibition, or B) substantial biophysical/ biochemical differences in DNA exist (Francki et al, 1991). The nine serotypes identified last (42-51) were isolated for the first time from HIV-infected patients (Hierholzer et al 1988; Schnurr et al 1993;). For reasons not well understood, most of such immune-compromised patients shed adenoviruses that were rarely or never isolated from immune-competent individuals (Hierholzer et al 1988, 1992; Khoo et al, 1995, De Jong et al, 1998).

[0007] The vast majority of individuals have had previous exposure to adenoviruses, especially the well investigated adenovirus serotypes 5 and type 2 (Ad5 and Ad2) or immunologically related serotypes. Importantly, these two serotypes are also the most extensively studied for use in human gene therapy. from other (adeno) viruses, as long as one replaces an element which could lead to immunity against such a gene delivery vehicle by an element of adenovirus 35 or a functional homologue thereof, which has less of such a drawback and which preferably avoids such a drawback. In the present invention a gene delivery vehicle is any vehicle that is capable of delivering a nucleic acid of interest to a host cell. It must, according to the invention comprise an element of adenovirus 35 or a functional equivalent of such an element, which must have a beneficial effect regarding the immune response against such a vehicle. Basically all other elements making up the vehicle can be any elements known in the art or developed in the art, as long as together they are capable of delivering said nucleic acid of interest. In principle the person skilled in the art can use and/or produce any adenoviral products or production systems that can or have been applied in the adenoviral field.

[0008] Typically the products of the invention can be made in the packaging cells useable for e.g. adenovirus 5, typically the vectors based on adenovirus 35 can be produced and/or used in the same manner as those of other adenoviruses e.g. adenovirus 2 and/or 5. A good overview of the possibilities of minimal vectors, packaging systems, intracellular amplification, vector and plasmid based systems can be found in applicant's copending applications (PCT/NL99/00235 and PCT/NL96/00244) incorporated herein by reference. Non-viral delivery systems can also be provided with elements according to the invention as can viral delivery systems.

[0009] Both kinds of systems are well known in the art in many different set-ups and do therefor not need any further elaboration here. A review on the many different systems and their properties can be found in Robbins and Ghivizani (1998) and in Prince (1998) incorporated herein by reference.

[0010] Gene delivery vehicles typically contain a nucleic acid of interest. A nucleic acid of interest can be a gene or a functional part of a gene (wherein a gene is any nucleic acid which can be expressed) or a precursor of a gene or a transcribed gene on any nucleic acid level (DNA and/or RNA: double or single stranded). Genes of interest are well known in the art and typically include those encoding therapeutic proteins such as TPA, EPO, cytokines, antibodies or derivatives thereof, etc. An overview of therapeutic proteins to be applied in gene therapy are listed below.

Immune-stimulatory factors like tumor-specific antigens, cytokines, etc.;

Anti-angiogenic factors non-limiting examples endostatin, angiostatin, ATF-BPTI CDT-6, dominant negative VEGF-mutants, etc.;

Angiogenic factors non-limiting example VEGF, Fibroblast growth factors, Nitric oxide synthases, C-type natriuretic peptide, etc.;

Inflammation inhibiting proteins like soluble CD40, FasL, IL-12, IL-10, IL-4, IL-13 and excreted single chain antibodies to CD4, CD5, CD7, CD52, IL-2, IL-1, IL-6, TNF, etc. or excreted single chain antibodies to the T-cell receptor on the auto-reactive T-cells. Also, dominant negative mutants of PML may be used to inhibit the immune response.

[0011] Furthermore, antagonists of inflammation promoting cytokines may be used, for example IL-1RA (receptor antagonist) and soluble receptors like sIL-1RI, sIL-1RII, sTNFRI and sTNFRII. Growth and/or immune response inhibiting genes such as cNOS, Bcl3, cactus and I $\kappa$ B $\alpha$ ,  $\beta$  or  $\gamma$  and apoptosis inducing proteins like the VP3 protein of chicken anemia virus may also be used. Furthermore, suicide genes like HSV-TK, cytosine deaminase, nitroreductase and linamerase may be used.

[0012] A nucleic acid of interest may also be a nucleic acid which can hybridise with a nucleic acid sequence present in the host cell thereby inhibiting expression or transcription or translation of said nucleic acid. It may also block through cosuppression. In short a nucleic acid of interest is any nucleic acid that one may wish to provide a cell with in order to induce a response by that cell, which response may be production of a protein, inhibition of such production, apoptosis, necrosis, proliferation, differentiation etc.

[0013] The present invention is the first to disclose adenovirus 35 or a functional homologue thereof for therapeutic use, therefor the invention also provides an adenovirus serotype 35 or a functional homologue thereof or a chimaeric virus derived therefrom, or a gene delivery vehicle based on said virus its homologue or its chimaera for use as a pharmaceutical. The serotype of the present invention, adenovirus type 35, is in itself known in the art. It is an uncommon group B adenovirus that was isolated from patients with acquired immunodeficiency syndrome and other immunodeficiency disorders (Flomenberg *et al.*, 1987; De Jong *et al.*, 1983). Ad 35 has been shown to differ from the more fully characterized subgroup C (including Ad2 and Ad5) with respect to pathogenic properties (Basler *et al.*, 1996). It has been suggested that this difference may be correlated with differences in the E3 region of the Ad35 genome (Basler *et al.*, 1996). The DNA of Ad35 has been partially cloned and mapped (Kang *et al.*, 1989a and b; Valderrama-Leon *et al.*, 1985).

[0014] B type adenovirus serotypes such as 34 and 35 have a different E3 region than other serotypes. Typically this region is involved in suppressing immune response to adenoviral products. Thus the invention provides a gene delivery vehicle according to the invention whereby said elements involved in avoiding or diminishing immune response comprise adenovirus 35 E3 expression products or the genes encoding them or functional equivalents of either or both.

[0015] Another part of adenoviruses involved in immune responses is the capsid, in particular the penton and/or the hexon proteins. Thus the invention also provides a gene delivery vehicle according to the invention whereby the elements comprise at least one adenovirus 35 capsid protein or functional part thereof, such as fiber, penton and/or hexon proteins or a gene encoding at least one of them. It is not necessary that a whole protein relevant for immune response is of adenovirus 35 (or a functional homologue thereof) origin. It is very well possible to insert a part of an adenovirus fiber, penton or hexon protein into another fiber, penton or hexon. Thus chimaeric proteins are obtained.

[0016] It is also possible to have a penton of a certain adenovirus, a hexon from another and a fiber or an E3 region from yet another adenovirus. According to the invention at least one of the proteins or genes encoding them should comprise an element from adenovirus 35 or a functional homologue thereof, whereby said element has an effect on the immune response of the host. Thus the invention provides a gene delivery according to the invention, which is a chimaera of adenovirus 35 with at least one other adenovirus. In this way one can also modify the resulting virus in other aspects than the immune response alone. One can enhance its efficiency of infection with elements responsible therefor; one can enhance its replication on a packaging cell, or one can change its tropism.

[0017] Thus the invention e.g. provides a gene delivery vehicle according to the invention which has a different tropism than adenovirus 35. Of course the tropism should be altered preferably such that the gene delivery vehicle is delivered preferentially to a subset of the host's cells, i.e. the target cells. Changes in tropism and other changes which can

also be applied in the present invention of adenoviral or other gene delivery vehicles are disclosed in applicant's copending applications (nos. 98204482.8, 99200624.7 and 98202297.2) incorporated herein by reference. Of course the present application also provides any and all building blocks necessary and/or useful to get to the gene delivery vehicles and/or the chimaeras, etc. of the present invention. This includes packaging cells such as PER.C6 (ECACC deposit number 96022940) or cells based thereon, but adapted for Ad35 or a functional homologue thereof; it also includes any nucleic acids encoding functional parts of adenovirus 35 or a functional homologue thereof, such as helper constructs and packaging constructs, as well as vectors comprising genes of interest and e.g. an ITR, etc.

[0018] Typically applicant's application (PCT/NL96/00244) incorporated herein by reference, discloses elements necessary and useful for arriving at the invented gene delivery vehicles. Thus the invention also provides a nucleic acid encoding at least a functional part of a gene delivery vehicle according to the invention, or a virus, homologue or chimaera thereof according to the invention.

[0019] According to the invention, such elements, which encode functions that will end up in the resulting gene delivery vehicle must comprise or be encoded by a nucleic acid encoding at least one of the adenovirus serotype 35 elements or a functional equivalent thereof, responsible for avoiding or diminishing neutralising activity against adenoviral elements by the host to which the gene is to be delivered.

[0020] Typically the gene of interest would be present on the same nucleic acid which means that such a nucleic acid has such a gene or that it has a site for introducing a gene of interest therein.

[0021] Typically such a nucleic acid also comprises at least one ITR and if it is a nucleic acid to be packaged also a packaging signal. However, as mentioned before all necessary and useful elements and/or building blocks for the present invention can be found in applicant's application (PCT/NL96/00244). A set of further improvements in the field of producing adenoviral gene delivery vehicles is applicant's plasmid system disclosed in PCT/NL99/00235 mentioned herein before. This system works in one embodiment as a homologous recombination of an adapter plasmid and a longer plasmid, together comprising all elements of the nucleic acid to be incorporated in the gene delivery vehicle. These methods can also be applied to the presently invented gene delivery vehicles and their building elements.

[0022] Thus the invention also provides a nucleic acid according to the invention further comprising a region of nucleotides designed or useable for homologous recombination, preferably as part of at least one set of two nucleic acids comprising a nucleic acid according to the invention, whereby said set of nucleic acids is capable of a single homologous recombination event with each other, which leads to a nucleic acid encoding a functional gene delivery vehicle.

[0023] Both empty packaging cells (in which the vector to be packaged to make a gene delivery vehicle according to the invention still has to be introduced or produced) as well as cells comprising a vector according to the invention to be packaged are provided. Thus the invention also encompasses a cell comprising a nucleic acid according to the invention or a set of nucleic acids according to the invention, preferably a cell which complements the necessary elements for adenoviral replication which are absent from the nucleic acid according to be packaged, or from a set of nucleic acids according to the invention. In the present invention it has been found that E1-deleted adenovirus 35 vectors, are not capable of replication on cells that provide adenovirus 5 proteins *in trans*. The invention therefore further provides a cell capable of providing adenovirus 35 E1 proteins in trans. Such a cell is typically a human cell derived from the retina or the kidney. Embryonal cells such as amniocytes, have been shown to be particularly suited for the generation of an E1 complementing cell line. Such cells are therefor preferred in the present invention. Serotype specific complementation by E1 proteins can be due to one or more protein(s) encoded by the E1 region. It is therefor essential that at least the serotype specific protein is provided in trans in the complementing cell line. The non-serotype specific E1 proteins essential for effective complementation of an E1-deleted adenovirus can be derived from other adenovirus serotypes. Preferably, at least an E1 protein from the E1B region of adenovirus 35 is provided in trans to complement E1-deleted adenovirus 35 based vectors.

[0024] In one embodiment nucleic acid encoding the one or more serotype specific E1-proteins is introduced into the PER.C6 cell or a cell originating from a PER.C6 cell (ECACC deposit number 96022940), or a similar packaging cell complementing with elements from Ad 35 or a functional homologue thereof.

[0025] As already alluded to the invention also encompasses a method for producing a gene delivery vehicle according to the invention, comprising expressing a nucleic acid according to the invention in a cell according to the invention and harvesting the resulting gene delivery vehicle. The above refers to the filling of the empty packaging cell with the relevant nucleic acids. The format of the filled cell is of course also part of the present invention, which provides a method for producing a gene delivery vehicle according to the invention, comprising culturing a filled packaging cell (producer cell) according to the invention in a suitable culture medium and harvesting the resulting gene delivery vehicle.

[0026] The resulting gene delivery vehicles obtainable by any method according to the invention are of course also part of the present invention, particularly also a gene delivery vehicle according to the invention, which is derived from a chimaera of an adenovirus and an integrating virus.

[0027] It is well known that adenoviral gene delivery vehicles do not integrate into the host genome normally. For

long term expression of genes in a host cell it is therefor preferred to prepare chimaeras which do have that capability. Such chimaeras have been disclosed in our copending application PCT/NL98/00731 incorporated herein by reference. A very good example of such a chimaera of an adenovirus and an integrating virus wherein said integrating virus is an adeno associated virus. As discussed hereinbefore other useful chimaeras, which can also be combined with the above are chimaeras (be it in swapping whole proteins or parts thereof or both) which have altered tropism. A very good example thereof is a chimaera of Ad 35 and Ad 16, possibly with elements from for instance Ad 2 or Ad 5, wherein the tropism determining part of Ad 16 or a functional equivalent thereof is used to direct the gene delivery vehicle to synoviocytes and/or smooth muscle cells (see our copending applications nos. 98204482.8 and 99200624.7) incorporated herein by reference). Dendritic cells (DC) and hemopoietic stem cells (HSC) are not easily transduced with Ad2 or Ad5 derived gene delivery vehicles. The present invention provides gene delivery vehicles that posses increased transduction capacity of DC and HSC cells. Such gene delivery vehicles at least comprises the tissue tropism determining part of an Ad35 adenovirus. The invention therefore further provides the use of a tissue tropism determining part of an adenovirus 35 capsid for transducing dendritic cells and/or hemopoietic stem cells. Other B-type adenoviruses are also suited. A tissue tropism determining part comprises at least the knob and/or the shaft of a fiber protein. Of course it is very well possible for a person skilled in the art to determine the amino acid sequences responsible for the tissue tropism in the fiber protein. Such knowledge can be used to devise chimeric proteins comprising such amino acid sequences. Such chimaeric proteins are therefor also part of the invention. DC cells are very efficient antigen presenting cells. By introducing the gene delivery vehicle into such cells the immune system of the host can be triggered to toward specific antigens. Such antigens can be encoded by nucleic acid delivered to the DC or by the proteins of the gene delivery vehicle it self. The present invention therefor also provides a gene delivery vehicle with the capacity to evade to host immune system as a vaccine. The vector being capable to evade the immune system long enough to efficiently find it target cells and at the same time capable of delivering specific antigens to antigen presenting cells thereby allowing the induction and/or stimulation of an efficient immune responses toward the specific antigen(s). To further modulate the immune response, the gene delivery vehicle may comprise proteins and/or nucleic encoding such proteins capable of modulating an immune response. Non-limiting examples of such proteins are found among the interleukins, the adhesion molecules, the co-stimulatory proteins, the interferons etc. The invention therefore further provides a vaccine comprising a gene delivery vehicle of the invention. The invention further provides an adenovirus vector with the capacity to efficiently transduce DC and/or HSC, the vehicle comprising at least a tissue tropism determining part of serotype 35 adenovirus. The invention further provides the use of such delivery vehicles for the transduction of HSC and/or DC cells. Similar tissue tropisms are found among other adenoviruses of serotype B, particularly in serotype 11 and are also part of the invention. Of course it is also possible to provide other gene delivery vehicles with the tissue tropism determining part thereby providing such delivery vehicles with an enhanced DC and/or HSC transduction capacity. Such gene delivery vehicles are therefor also part of the invention.

**[0028]** The gene delivery vehicles according to the invention can be used to deliver genes or nucleic acids of interest to host cells. This will typically be a pharmaceutical use. Such a use is included in the present invention. Compositions suitable for such a use are also part of the present invention. The amount of gene delivery vehicle that needs to be present per dose or per infection (m.o.i) will depend on the condition to be treated, the route of administration (typically parenteral) the subject and the efficiency of infection, etc. Dose finding studies are well known in the art and those already performed with other (adenoviral) gene delivery vehicles can typically be used as guides to find suitable doses of the gene delivery vehicles according to the invention. Typically this is also where one can find suitable excipients, suitable means of administration, suitable means of preventing infection with the vehicle where it is not desired, etc. Thus the invention also provides a pharmaceutical formulation comprising a gene delivery vehicle according to the invention and a suitable excipient, as well as a pharmaceutical formulation comprising an adenovirus, a chimaera thereof, or a functional homologue thereof according to the invention and a suitable excipient.

#### Detailed description

**[0029]** As described above, the most extensively studied serotypes of adenovirus are not ideally suitable for delivering additional genetic material to host cells. This is partly due to the pre-existing immunity among the population against these serotypes. This presence of pre-existing antibodies in humans, in combination with a strong secondary humoral and cellular immune response against the virus will affect adenoviral gene therapy.

**[0030]** The present invention provides the use of at least elements of a serotype and functional homologues thereof of adenovirus which are very suitable as gene therapy vectors.

**[0031]** The present invention also discloses an automated high-throughput screening of all known adenovirus serotypes against sera from many individuals. Surprisingly, no neutralizing ability was found in any of the sera that were evaluated against one particular serotype, adenovirus 35 (Ad35). This makes the serotype of the present invention extremely useful as a vector system for gene therapy in man.

**[0032]** Such vector system is capable of efficiently transferring genetic material to a human cell without the inherent

problem of pre-existing immunity.

[0033] Typically, a virus is produced using an adenoviral vector (typically a plasmid, a cosmid or baculovirus vector). Such vectors are of course also part of the present invention. The invention also provides adenovirus derived vectors that have been rendered replication defective by deletion or inactivation of the E1 region. Of course, also a gene of interest can be inserted at for instance the site of E1 of the original adenovirus from which the vector is derived.

[0034] In all aspects of the invention the adenoviruses may contain deletions in the E1 region and insertions of heterologous genes linked either or not to a promoter. Furthermore, the adenoviruses may contain deletions in the E2, E3 or E4 regions and insertions of heterologous genes linked to a promoter. In these cases, E2 and/or E4 complementing cell lines are required to generate recombinant adenoviruses.

[0035] One may choose to use the Ad35 serotype itself for the preparation of recombinant adenoviruses to be used in gene therapy. Alternatively, one may choose to use elements derived from the serotype of the present invention in such recombinant adenoviruses. One may for instance develop a chimaeric adenovirus that combines desirable properties from different serotypes. Some serotypes have a somewhat limited host range, but have the benefit of being less immunogenic, some are the other way round. Some have a problem of being of a limited virulence, but have a broad host range and/or a reduced immunogenicity. Such chimaeric adenoviruses are known in the art, and they are intended to be within the scope of the present invention. Thus in one embodiment the invention provides a chimaeric adenovirus comprising at least a part of the adenovirus genome of the present serotype, providing it with absence of pre-existing immunity, and at least a part of the adenovirus genome from another adenovirus serotype resulting in a chimaeric adenovirus. In this manner the chimaeric adenovirus produced is such that it combines the absence of pre-existing immunity of the serotype of the present invention, to other characteristics of another serotype. Such characteristics may be temperature stability, assembly, anchoring, redirected infection, production yield, redirected or improved infection, stability of the DNA in the target cell, etc.

[0036] A packaging cell will generally be needed in order to produce sufficient amount of adenoviruses. For the production of recombinant adenoviruses for gene therapy purposes, several cell lines are available. These include but are not limited to the known cell lines PER.C6 (ECACC deposit number 96022940), 911, 293, and E1 A549.

[0037] An important feature of the present invention is the means to produce the adenovirus. Typically, one does not want an adenovirus batch for clinical applications to contain replication competent adenovirus. In general therefore, it is desired to omit a number of genes (but at least one) from the adenoviral genome on the adenoviral vector and to supply these genes in the genome of the cell in which the vector is brought to produce chimaeric adenovirus. Such a cell is usually called a packaging cell. The invention thus also provides a packaging cell for producing an adenovirus (a gene delivery vehicle) according to the invention, comprising in trans all elements necessary for adenovirus production not present on the adenoviral vector according to the invention. Typically vector and packaging cell have to be adapted to one another in that they have all the necessary elements, but that they do not have overlapping elements which lead to replication competent virus by recombination.

[0038] Thus the invention also provides a kit of parts comprising a packaging cell according to the invention and a recombinant vector according the invention whereby there is essentially no sequence overlap leading to recombination resulting in the production of replication competent adenovirus between said cell and said vector.

[0039] Thus the invention provides methods for producing adenovirus, which upon application will escape pre-existing humoral immunity, comprising providing a vector with elements derived from an adenovirus serotype against which virtually no natural immunity exists and transfecting said vector in a packaging cell according to the invention and allowing for production of viral particles.

[0040] In one aspect this invention describes the use of the adenovirus serotype of the present invention to overcome natural existing or induced, neutralising host activity towards adenoviruses administered in vivo for therapeutic applications. The need for a new serotype is stressed by observations that 1) repeated systemic delivery of recombinant adenovirus serotype 5 is unsuccessful due to formation of high titers of neutralising antibodies against the recombinant adenovirus serotype 5 (Schulick et al, 1997), and 2) pre-existing or humoral immunity is widespread in the population.

[0041] In another aspect this invention provides the use of gene delivery vehicles of the invention or the use of adenovirus serotype 35 for vaccination purposes. Such use prevents at least in part undesired immune responses of the host. Non-limiting examples of undesired immune responses are evoking an immune response against the gene delivery vehicle or adenovirus serotype 35 and/or boosting of an immune response against the gene delivery vehicle or adenovirus serotype 35.

[0042] In another aspect of the invention, alternating use is made of Ad vectors belonging to different subgroups. This aspect of the invention therefore circumvents the inability to repeat the administration of an adenovirus for gene therapy purposes.



## Example 1

A high throughput assay for the detection of neutralising activity in human serum

- 5 [0043] To enable screening of a large amount of human sera for the presence of neutralising antibodies against all adenovirus serotypes, an automated 96-wells assay was developed.

*Human sera*

- 10 [0044] A panel of 100 individuals was selected. Volunteers (50% male, 50% female) were healthy individuals between 20 and 60 years old with no restriction for race. All volunteers signed an informed consent form. People professionally involved in adenovirus research were excluded.

- [0045] Approximately 60 ml blood was drawn in dry tubes. Within two hours after sampling, the blood was centrifuged at 2500 rpm for 10 minutes. Approximately 30 ml serum was transferred to polypropylene tubes and stored frozen  
15 at -20°C until further use.

- [0046] Serum was thawed and heat-inactivated at 56°C for 10 minutes and then aliquotted to prevent repeated cycles of freeze/thawing. Part was used to make five steps of twofold dilutions in medium (DMEM, Gibco BRL) in a quantity enough to fill out approximately 70 96-well plates. Aliquots of undiluted and diluted sera were pipetted in deep well plates (96-well format) and using a programmed platemate dispensed in 100 µl aliquots into 96-well plates. This  
20 way the plates were loaded with eight different sera in duplo (100 µl/well) according to the scheme below:

25	S1/ 2	S1/ 4	S1/ 8	S1/ 16	S1/ 32	S5/ 2	S5/ 4	S5/ 8	S5/ 16	S5/ 32	-	-
	S1/ 2	S1/ 4	S1/ 8	S1/ 16	S1/ 32	S5/ 2	S5/ 4	S5/ 8	S5/ 16	S5/ 32	-	-
	S2/ 2	S2/ 4	S2/ 8	S2/ 16	S2/ 32	S6/ 2	S6/ 4	S6/ 8	S6/ 16	S6/ 32	-	-
	S2/ 2	S2/ 4	S2/ 8	S2/ 16	S2/ 32	S6/ 2	S6/ 4	S6/ 8	S6/ 16	S6/ 32	-	-
30	S3/ 2	S3/ 4	S3/ 8	S3/ 16	S3/ 32	S7/ 2	S7/ 4	S7/ 8	S7/ 16	S7/ 32	-	-
	S3/ 2	S3/ 4	S3/ 8	S3/ 16	S3/ 32	S7/ 2	S7/ 4	S7/ 8	S7/ 16	S7/ 32	-	-
	S4/ 2	S4/ 4	S3/ 8	S3/ 16	S3/ 32	S8/ 2	S8/ 4	S8/ 8	S8/ 16	S8/ 32	-	-
35	S4/ 2	S4/ 4	S3/ 8	S3/ 16	S3/ 32	S8/ 2	S8/ 4	S8/ 8	S8/ 16	S8/ 32	-	-

- [0047] Where S1/2 to S8/2 in columns 1 and 6 represent 1x diluted sera and Sx/4, Sx/8, Sx/16 and Sx/32 the two-fold serial dilutions. The last plates also contained four wells filled with 100µl foetal calf serum as a negative control. Plates were kept at -20°C until further use.

40

*Preparation of human adenovirus stocks*

- [0048] Prototypes of all known human adenoviruses were inoculated on T25 flasks seeded with PER.C6 cells (ECACC deposit number 96022940) (Fallaux *et al.*, 1998) and harvested upon full CPE. After freeze/thawing 1-2 ml of  
45 the crude lysates was used to inoculate a T80 flask with PER.C6 cells (ECACC deposit number 96022940) and virus was harvested at full CPE. The timeframe between inoculation and occurrence of CPE as well as the amount of virus needed to re-infect a new culture, differed between serotypes. Adenovirus stocks were prepared by freeze/thawing and used to inoculate 3-4 T175 cm<sup>2</sup> three-layer flasks with PER.C6 cells (ECACC deposit number 96022940). Upon occurrence of CPE, cells were harvested by tapping the flask, pelleted and virus was isolated and purified by a two step CsCl  
50 gradient as follows. Cell pellets were dissolved in 50 ml 10 mM NaPO<sub>4</sub> buffer (pH 7.2) and frozen at -20°C. After thawing at 37°C, 5.6 ml sodium deoxycholate (5% w/v) was added. The solution was mixed gently and incubated for 5-15 minutes at 37°C to completely lyse the cells. After homogenizing the solution, 1875 µl 1M MgCl<sub>2</sub> was added. After the addition of 375 µl DNase (10 mg/ml) the solution was incubated for 30 minutes at 37°C. Cell debris was removed by centrifugation at 1880xg for 30 minutes at PT without brake. The supernatant was subsequently purified from proteins  
55 by extraction with freon (3x). The cleared supernatant was loaded on a 1M Tris/HCl buffered cesiumchloride blockgradient (range: 1.2/1.4 gr/ml) and centrifugated at 21000 rpm for 2.5 hours at 10°C. The virus band is isolated after which a second purification using a 1M Tris/HCl buffered continuous gradient of 1.33 gr/ml of cesiumchloride was performed. The virus was then centrifuged for 17 hours at 55000 rpm at 10°C. The virus band is isolated and sucrose (50 % w/v)

is added to a final concentration of 1%. Excess cesiumchloride is removed by dialysis (three times 1 hr at RT) in dialysis slides (Slide-a-lizer, cut off 10000 kDa, Pierce, USA) against 1.5 ltr PBS supplemented with  $\text{CaCl}_2$  (0.9 mM),  $\text{MgCl}_2$  (0.5mM) and an increasing concentration of sucrose (1, 2, 5%). After dialysis, the virus is removed from the slide-a-lizer after which it is aliquoted in portions of 25 and 100  $\mu\text{l}$  upon which the virus is stored at  $-85^\circ\text{C}$ .

5 [0049] To determine the number of virus particles per milliliter, 50  $\mu\text{l}$  of the virus batch is run on a high-pressure liquid chromatograph (HPLC) as described by Shabram et al (1997).

[0050] Viruses were eluted using an NaCl gradient ranging from 0 to 600 mM. As depicted in table I, the NaCl concentration by which the viruses were eluted differed significantly among serotypes.

10 [0051] Most human adenoviruses replicated well on PER.C6 cells ((ECACC deposit number 96022940) with a few exceptions. Adenovirus type 8 and 40 were grown on 911-E4 cells (He *et al.*, 1998). Purified stocks contained between  $5 \times 10^{10}$  and  $5 \times 10^{12}$  virus particles/ml (VP/ml; see table I).

#### *Titration of purified human adenovirus stocks*

15 [0052] Adenoviruses were titrated on PER.C6 cells (ECACC deposit number 96022940) to determine the amount of virus necessary to obtain full CPE in five days, the length of the neutralisation assay. Hereto, 100  $\mu\text{l}$  medium was dispensed into each well of 96-well plates. 25  $\mu\text{l}$  of adenovirus stocks prediluted  $10^4$ ,  $10^5$ ,  $10^6$  or  $10^7$  times were added to column 2 of a 96-well plate and mixed by pipetting up and down 10 times. Then 25  $\mu\text{l}$  was brought from column 2 to column 3 and again mixed. This was repeated until column 11 after which 25  $\mu\text{l}$  from column 11 was discarded. This way serial dilutions in steps of 5 were obtained starting off from a prediluted stock. Then  $3 \times 10^4$  PER.C6 cells (ECACC deposit number 96022940) were added in a 100  $\mu\text{l}$  volume and the plates were incubated at  $37^\circ\text{C}$ , 5%  $\text{CO}_2$  for five or six days. CPE was monitored microscopically. The method of Reed and Muensch was used to calculate the cell culture inhibiting dose 50% (CCID50).

20 [0053] In parallel identical plates were set up that were analysed using the MTT assay (Promega). In this assay living cells are quantified by colorimetric staining. Hereto, 20  $\mu\text{l}$  MTT (7.5 mgr/ml in PBS) was added to the wells and incubated at  $37^\circ\text{C}$ , 5%  $\text{CO}_2$  for two hours. The supernatant was removed and 100  $\mu\text{l}$  of a 20:1 isopropanol/triton-X100 solution was added to the wells. The plates were put on a 96-wells shaker for 3-5 minutes to solubilise precipitated staining.

30 [0054] Absorbance was measured at 540 nm and at 690 nm (background). By this assay wells with proceeding CPE or full CPE can be distinguished.

#### *Neutralisation assay*

35 [0055] 96-well plates with diluted human serum samples were thawed at  $37^\circ\text{C}$ , 5%  $\text{CO}_2$ . Adenovirus stocks diluted to 200 CCID50 per 50  $\mu\text{l}$  were prepared and 50  $\mu\text{l}$  aliquots were added to columns 1-11 of the plates with serum. Plates were incubated for 1 hour at  $37^\circ\text{C}$ , 5%  $\text{CO}_2$ . Then 50  $\mu\text{l}$  PER.C6 cells (ECACC deposit number 96022940) at  $6 \times 10^5/\text{ml}$  were dispensed in all wells and incubated for 1 day at  $37^\circ\text{C}$ , 5%  $\text{CO}_2$ . Supernatant was removed using fresh pipet tips for each row and 200  $\mu\text{l}$  fresh medium was added to all wells to avoid toxic effects of the serum. Plates were incubated for another 4 days at  $37^\circ\text{C}$ , 5%  $\text{CO}_2$ . In addition, parallel control plates were set up in duplo with diluted positive control sera generated in rabbits and specific for each serotype to be tested in rows A and B and with negative control serum (FCS) in rows C and D. Also, in each of the rows E-H a titration was performed as described above with steps of five times dilutions starting with 200 CCID50 of each virus to be tested. On day 5 one of the control plates was analysed microscopically and with the MTT assay. The experimental titer was calculated from the control titration plate observed microscopically.

45 [0056] If CPE was found to be complete, i.e. the first dilution in the control titration experiment analysed by MTT shows clear cell death, all assay plates were processed. If not, the assay was allowed to proceed for one or more days until full CPE was apparent after which all plates were processed. In most cases the assay was terminated at day 5. For Ad1, 5, 33, 39, 42 and 43 the assay was left for six days and for Ad2 for eight days.

50 [0057] A serum sample is regarded to be non-neutralising when at the highest serum concentration a maximum protection is seen of 40% compared to the controls without serum.

[0058] The results of the analysis of 44 prototype adenoviruses against serum from 100 healthy volunteers is shown in figure 1. As expected the percentage of serum samples that contained neutralising antibodies to Ad2 and Ad5 was very high. This was also true for most of the lower numbered adenoviruses. Surprisingly, none of the serum samples contained neutralising antibodies to adenovirus serotype 35.

55 [0059] Also, the number of individuals with neutralising antibody titers to the serotypes 26, 34 and 48 was very low.

[0060] Therefore, recombinant E1-deleted adenoviruses based on Ad35 or one of the other above mentioned serotypes have an important advantage compared to recombinant vectors based on Ad5 with respect to clearance of the viruses by neutralising antibodies.

[0061] Also, Ad5-based vectors that have (parts of) the capsid proteins involved in immunogenic response of the host replaced by the corresponding (parts of) the capsid proteins of Ad35 or one of the other serotypes will be less, or even not, neutralised by the vast majority of human sera.

[0062] As can be seen in table I the VP/CCID50 ratio calculated from the virus particles per ml and the CCID50 obtained for each virus in the experiments was highly variable and ranged from 0.4 to 5 log. This is probably caused by different infection efficiencies of PER.C6 cells (ECACC deposit number 96022940) and by differences in replication efficiency of the viruses. Furthermore, differences in batch qualities may play a role. A high VP/CCID50 ratio means that more virus was put in the wells to obtain CPE in 5 days. As a consequence the outcome of the neutralisation study might be biased since more (inactive) virus particles could shield the antibodies. To check whether this phenomenon had taken place, the VP/CCID50 ratio was plotted against the percentage of serum samples found positive in the assay (Figure 2). The graph clearly shows that there is no negative correlation between the amount of viruses in the assay and neutralisation in serum.

## Example 2

### Generation of Ad5 plasmid vectors for the production of recombinant viruses and easy manipulation of adenoviral genes

#### *pBr/Ad.Bam-rITR (ECACC deposit P97082122)*

[0063] In order to facilitate blunt end cloning of the ITR sequences, wild-type human adenovirus type 5 (Ad5) DNA was treated with Klenow enzyme in the presence of excess dNTPs. After inactivation of the Klenow enzyme and purification by phenol/chloroform extraction followed by ethanol precipitation, the DNA was digested with BamHI. This DNA preparation was used without further purification in a ligation reaction with pBr322 derived vector DNA prepared as follows: pBr322 DNA was digested with EcoRV and BamHI, dephosphorylated by treatment with TSAP enzyme (Life Technologies) and purified on LMP agarose gel (SeaPlaque GTG). After transformation into competent *E.coli* DH5 $\alpha$  (Life Techn.) and analysis of ampicillin resistant colonies, one clone was selected that showed a digestion pattern as expected for an insert extending from the BamHI site in Ad5 to the right ITR.

[0064] Sequence analysis of the cloning border at the right ITR revealed that the most 3' G residue of the ITR was missing, the remainder of the ITR was found to be correct. Said missing G residue is complemented by the other ITR during replication.

#### *pBr/Ad.Sal-rITR (ECACC deposit P97082119)*

[0065] pBr/Ad.Bam-rITR was digested with BamHI and Sall. The vector fragment including the adenovirus insert was isolated in LMP agarose (SeaPlaque GTG) and ligated to a 4.8 kb Sall-BamHI fragment obtained from wt Ad5 DNA and purified with the GeneClean II kit (Bio 101, Inc.). One clone was chosen and the integrity of the Ad5 sequences was determined by restriction enzyme analysis. Clone pBr/Ad.Sal-rITR contains adeno type 5 sequences from the Sall site at bp 16746 up to and including the rITR (missing the most 3' G residue).

#### *pBr/Ad.Cla-Bam (ECACC deposit P97082117)*

[0066] wt Adeno type 5 DNA was digested with ClaI and BamHI, and the 20.6 kb fragment was isolated from gel by electro-elution. pBr322 was digested with the same enzymes and purified from agarose gel by GeneClean. Both fragments were ligated and transformed into competent DH5 $\alpha$ . The resulting clone pBr/Ad.Cla-Bam was analysed by restriction enzyme digestion and shown to contain an insert with adenovirus sequences from bp 919 to 21566.

#### *pBr/Ad.AflII-Bam (ECACC deposit P97082114)*

[0067] Clone pBr/Ad.Cla-Bam was linearized with EcoRI (in pBr322) and partially digested with AflII. After heat inactivation of AflII for 20' at 65°C the fragment ends were filled in with Klenow enzyme. The DNA was then ligated to a blunt double stranded oligo linker containing a PacI site (5'-AATTGTCCTTAATTAAACCGCTTAA-3'). This linker was made by annealing the following two oligonucleotides: 5'-AATTGTCCTTAATTAAACCGC-3' and 5'-AATTGCGGTTAATTAGAC-3', followed by blunting with Klenow enzyme. After precipitation of the ligated DNA to change buffer, the ligations were digested with an excess PacI enzyme to remove concatameres of the oligo. The 22016 bp partial fragment containing Ad5 sequences from bp 3534 up to 21566 and the vector sequences, was isolated in LMP agarose (SeaPlaque GTG), religated and transformed into competent DH5 $\alpha$ . One clone that was found to contain the PacI site and that had retained the large adeno fragment was selected and sequenced at the 5' end to verify correct insertion of the PacI linker

in the (lost) AflII site.

*pBr/Ad.Bam-r.ITRpac#2 (ECACC deposit P97082120) and pBr/Ad.Bam-r.ITRpac#8 (ECACC deposit P97082121)*

[0068] To allow insertion of a PacI site near the ITR of Ad5 in clone pBr/Ad.Bam-r.ITR about 190 nucleotides were removed between the ClaI site in the pBr322 backbone and the start of the ITR sequences. This was done as follows: pBr/Ad.Bam-r.ITR was digested with ClaI and treated with nuclease Bal31 for varying lengths of time (2', 5', 10' and 15'). The extent of nucleotide removal was followed by separate reactions on pBr322 DNA (also digested at the ClaI site), using identical buffers and conditions. Bal31 enzyme was inactivated by incubation at 75 °C for 10', the DNA was precipitated and resuspended in a smaller volume TE buffer.

[0069] To ensure blunt ends, DNAs were further treated with T4 DNA polymerase in the presence of excess dNTPs. After digestion of the (control) pBr322 DNA with Sall, satisfactory degradation (~150 bp) was observed in the samples created for 10' or 15'. The 10' or 15' treated pBr/Ad.Bam-r.ITR samples were then ligated to the above described blunted PacI linkers (See pBr/Ad.AflII-Bam). Ligations were purified by precipitation, digested with excess PacI and separated from the linkers on an LMP agarose gel. After religation, DNAs were transformed into competent DH5α and colonies analyzed. Ten clones were selected that showed a deletion of approximately the desired length and these were further analyzed by T-track sequencing (T7 sequencing kit, Pharmacia Biotech). Two clones were found with the PacI linker inserted just downstream of the r.ITR. After digestion with PacI, clone #2 has 28 bp and clone #8 has 27 bp attached to the ITR.

*pWE/Ad.AflII-r.ITR (ECACC deposit P97082116)*

[0070] Cosmid vector pWE15 (Clontech) was used to clone larger Ad5 inserts. First, a linker containing a unique PacI site was inserted in the EcoRI sites of pWE15 creating pWE.pac. To this end, the double stranded PacI oligo as described for pBr/Ad.AflII-BamHI was used but now with its EcoRI protruding ends. The following fragments were then isolated by electro-elution from agarose gel: pWE.pac digested with PacI, pBr/AflII-Bam digested with PacI and BamHI and pBr/Ad.Bam-r.ITR#2 digested with BamHI and PacI. These fragments were ligated together and packaged using λ phage packaging extracts (Stratagene) according to the manufacturer's protocol. After infection into host bacteria, colonies were grown on plates and analyzed for presence of the complete insert. pWE/Ad.AflII-r.ITR contains all adenovirus type 5 sequences from bp 3534 (AflII site) up to and including the right ITR (missing the most 3' G residue).

*pBr/Ad.IITR-Sal(9.4) (ECACC deposit P97082115)*

[0071] Adeno 5 wt DNA was treated with Klenow enzyme in the presence of excess dNTPs and subsequently digested with Sall. Two of the resulting fragments, designated left ITR-Sal(9.4) and Sal(16.7)-right ITR, respectively, were isolated in LMP agarose (Seaplaque GTG). pBr322 DNA was digested with EcoRV and Sall and treated with phosphatase (Life Technologies). The vector fragment was isolated using the GeneClean method (BIO 101, Inc.) and ligated to the Ad5 Sall fragments. Only the ligation with the 9.4 kb fragment gave colonies with an insert. After analysis and sequencing of the cloning border a clone was chosen that contained the full ITR sequence and extended to the Sall site at bp 9462.

*pBr/Ad.IITR-Sal(16.7) (ECACC deposit P97082118)* pBr/Ad.IITR-Sal(9.4) is digested with Sall and dephosphorylated (TSAP, Life Technologies). To extend this clone upto the third Sall site in Ad5, pBr/Ad.Cla-Bam was linearized with BamHI and partially digested with Sall. A 7.3 kb Sall fragment containing adenovirus sequences from 9462-16746 was isolated in LMP agarose gel and ligated to the Sall-digested pBr/Ad.IITR-Sal(9.4) vector fragment.

*pWE/Ad.AflII-EcoRI*

[0072] pWE.pac was digested with ClaI and 5' protruding ends were filled using Klenow enzyme. The DNA was then digested with PacI and isolated from agarose gel. pWE/AflII-r.ITR was digested with EcoRI and after treatment with Klenow enzyme digested with PacI. The large 24 kb fragment containing the adenoviral sequences was isolated from agarose gel and ligated to the ClaI-digested and blunted pWE.pac vector using the Ligation Express™ kit from Clontech. After transformation of Ultracompetent XL10-Gold cells from Stratagene, clones were identified that contained the expected insert. pWE/AflII-EcoRI contains Ad5 sequences from bp 3534-27336.

*Generation of pWE/Ad.AflII-r.ITRsp*

[0073] The 3' ITR in the vector pWE/Ad.AflII-r.ITR does not include the terminal G-nucleotide. Furthermore, the

PacI site is located almost 30 bp from the right ITR. Both these characteristics may decrease the efficiency of virus generation due to inefficient initiation of replication at the 3' ITR. Note that during virus generation the left ITR in the adapter plasmid is intact and enables replication of the virus DNA after homologous recombination.

- [0074] To improve the efficiency of initiation of replication at the 3' ITR, the pWE/Ad.AfIII-rITR was modified as follows: construct pBr/Ad.Bam-rITRpac#2 was first digested with PacI and then partially digested with AvrII and the 17.8 kb vector containing fragment was isolated and dephosphorylated using SAP enzyme (Boehringer Mannheim). This fragment lacks the adenosequences from nucleotide 35464 to the 3'ITR. Using DNA from pWE/Ad.AfIII-rITR as template and the primers ITR-EPH:

10 5'-CGG AAT TCT TAA TTA AGT TAA CAT CAT CAA TAA TAT ACC-3'  
and  
Ad101: 5'-TGA TTC ACA TCG GTC AGT GC-3'

- a 630 bp PCR fragment was generated corresponding to the 3' Ad5 sequences. This PCR fragment was subsequently cloned in the vector pCR2.1 (Invitrogen) and clones containing the PCR fragment were isolated and sequenced to check correct amplification of the DNA. The PCR clone was then digested with PacI and AvrII and the 0.5 kb adeno insert was ligated to the PacI/ partial AvrII digested pBr/Ad.Bam-rITRpac#2 fragment generating pBr/Ad.Bam-rITRsp. Next this construct was used to generate a cosmid clone (as described above) that has an insert corresponding to the adenosequences 3534 to 35938. This clone was named pWE/AfIII-rITRsp.

20 Generation of pWE/Ad.AfIII-rITRΔE2A:

- [0075] Deletion of the E2A coding sequences from pWE/Ad.AfIII-rITR (ECACC deposit P97082116) has been accomplished as follows.

- 25 [0076] The adenoviral sequences flanking the E2A coding region at the left and the right site were amplified from the plasmid pBr/Ad.Sal.rITR (ECACC deposit P97082119) in a PCR reaction with the Expand PCR system (Boehringer) according to the manufacturers protocol. The following primers were used: Right flanking sequences (corresponding Ad5 nucleotides 24033 to 25180):

30 ΔE2A.SnaBI: 5'-GGC GTA CGT AGC CCT GTC GAA AG-3'  
ΔE2A.DBP-start: 5'-CCA ATG CAT TCG AAG TAC TTC CTT CTC CTA TAG GC-3'

- [0077] The amplified DNA fragment was digested with SnaBI and NsiI (NsiI site is generated in the primer ΔE2A.DBP-start, underlined).

- 35 [0078] Left flanking sequences (corresponding Ad5 nucleotides 21557 to 22442):

ΔE2A.DBP-stop: 5'-CCA ATG CAT ACG GCG CAG ACG G-3'  
ΔE2A.BamHI: 5'-GAG GTG GAT CCC ATG GAC GAG-3'

- 40 [0079] The amplified DNA was digested with BamHI and NsiI (NsiI site is generated in the primer ΔE2A.DBP-stop, underlined).

- [0080] Subsequently, the digested DNA fragments were ligated into SnaBI/BamHI digested pBr/Ad.Sal.rITR. Sequencing confirmed the exact replacement of the DBP coding region with a unique NsiI site in plasmid pBr/Ad.Sal.rITRΔE2A. The unique NsiI site can be used to introduce an expression cassette for a gene to be transduced by the recombinant vector.

- 45 [0081] The deletion of the E2A coding sequences was performed such that the splice acceptor sites of the 100K encoding L4-gene at position 24048 in the top strand was left intact. In addition, the poly adenylation signals of the original E2A-RNA and L3-RNAs at the left hand site of the E2A coding sequences were left intact. This ensures proper expression of the L3-genes and the gene encoding the 100K L4-protein during the adenovirus life cycle.

- 50 [0082] Next, the plasmid pWE/Ad.AfIII-rITRΔE2A was generated. The plasmid pBr/Ad.Sal.rITRΔE2A was digested with BamHI and SpeI. The 3.9-Kb fragment in which the E2A coding region was replaced by the unique NsiI site was isolated. The pWE/Ad.AfIII-rITR was digested with BamHI and SpeI. The 35 Kb DNA fragment, from which the BamHI/SpeI fragment containing the E2A coding sequence was removed, was isolated. The fragments were ligated and packaged using λ phage-packaging extracts according to the manufacturer protocol (Stratagene), yielding the plasmid pWE/Ad.AfIII-rITRΔE2A.

- 55 [0083] This cosmid clone can be used to generate adenoviral vectors that are deleted for E2A by cotransfection of PacI digested DNA together with digested adapter plasmids onto packaging cells that express functional E2A gene product.

*Construction of adapter plasmids*

**[0084]** The absence of sequence overlap between the recombinant adenovirus and E1 sequences in the packaging cell line is essential for safe, RCA-free generation and propagation of new recombinant viruses. The adapter plasmid pMLPi.TK (described in PCT/NL96/00244) is an example of an adapter plasmid designed for use according to the invention in combination with the improved packaging cell lines of the invention. This plasmid was used as the starting material to make a new vector in which nucleic acid molecules comprising specific promoter and gene sequences can be easily exchanged.

**[0085]** First, a PCR fragment was generated from pZipΔMo+PyF101(N<sup>-</sup>) template DNA (described in PCT/NL96/00195) with the following primers: LTR-1: 5'-CTG TAC GTA CCA GTG CAC TGG CCT AGG CAT GGA AAA ATA CAT AAC TG-3' and LTR-2: 5'-GCG GAT CCT TCG AAC CAT GGT AAG CTT GGT ACC GCT AGC GTT AAC CGG GCG ACT CAG TCA ATC G-3'. Pwo DNA polymerase (Boehringer Mannheim) was used according to manufacturers protocol with the following temperature cycles: once 5' at 95°C; 3' at 55°C; and 1' at 72°C, and 30 cycles of 1' at 95°C, 1' at 60°C, 1' at 72°C, followed by once 10' at 72°C. The PCR product was then digested with BamHI and ligated into pMLP10 (Levero *et al.*, 1991) vector digested with PvuII and BamHI, thereby generating vector pLTR10. This vector contains adenoviral sequences from bp 1 up to bp 454 followed by a promoter consisting of a part of the Mo-MuLV LTR having its wild-type enhancer sequences replaced by the enhancer from a mutant polyoma virus (PyF101). The promoter fragment was designated L420. Next, the coding region of the murine HSA gene was inserted. pLTR10 was digested with BstBI followed by Klenow treatment and digestion with NcoI. The HSA gene was obtained by PCR amplification on pUC18-HSA (Kay *et al.*, 1990) using the following primers: HSA1, 5'-GCG CCA CCA TGG GCA GAG CGA TGG TGG C-3' and HSA2, 5'-GTT AGA TCT AAG CTT GTC GAC ATC GAT CTA CTA ACA GTA GAG ATG TAG AA-3'. The 269 bp amplified fragment was subcloned in a shuttle vector using the NcoI and BglII sites. Sequencing confirmed incorporation of the correct coding sequence of the HSA gene, but with an extra TAG insertion directly following the TAG stop codon. The coding region of the HSA gene, including the TAG duplication was then excised as a NcoI(sticky)-SalI(blunt) fragment and cloned into the 3.5 kb NcoI(sticky)/BstBI(blunt) fragment from pLTR10, resulting in pLTR-HSA10.

**[0086]** Finally, pLTR-HSA10 was digested with EcoRI and BamHI after which the fragment containing the left ITR, packaging signal, L420 promoter and HSA gene was inserted into vector pMLPi.TK digested with the same enzymes and thereby replacing the promoter and gene sequences. This resulted in the new adapter plasmid pAd/L420-HSA that contains convenient recognition sites for various restriction enzymes around the promoter and gene sequences. SnaBI and AvrII can be combined with HpaI, NheI, KpnI, HindIII to exchange promoter sequences, while the latter sites can be combined with the ClaI or BamHI sites 3' from HSA coding region to replace genes in this construct.

**[0087]** Another adapter plasmid that was designed to allow easy exchange of nucleic acid molecules was made by replacing the promoter, gene and poly A sequences in pAd/L420-HSA with the CMV promoter, a multiple cloning site, an intron and a poly-A signal. For this purpose, pAd/L420-HSA was digested with AvrII and BglII followed by treatment with Klenow to obtain blunt ends. The 5.1 kb fragment with pBR322 vector and adenoviral sequences was isolated and ligated to a blunt 1570 bp fragment from pcDNA1/amp (Invitrogen) obtained by digestion with HhaI and AvrII followed by treatment with T4 DNA polymerase. This adapter plasmid was named pAd5/CLIP. To enable removal of vector sequences from the left ITR in pAd5/Clip, this plasmid was partially digested with EcoRI and the linear fragment was isolated. An oligo of the sequence 5' TTAAGTCGAC-3' was annealed to itself resulting in a linker with a SalI site and EcoRI overhang. The linker was ligated to the partially digested pAd5/Clip vector and clones were selected that had the linker inserted in the EcoRI site 23 bp upstream of the left adenovirus ITR in pAd5/Clip resulting in pAd5/Clipsal. Likewise, the EcoRI site in pAd5/Clip has been changed to a PacI site by insertion of a linker of the sequence 5'-AATTGTCTTAATTAACCGCAATT-3'. The pAd5/Clip vector was partially digested with EcoRI, dephosphorylated and ligated to the PacI linker with EcoRI overhang. The ligation mixture was digested with PacI to remove concatamers, isolated from agarose gel and religated. The resulting vector was named pAd5/Clippac. These changes enable more flexibility to liberate the left ITR from the plasmid vector sequences.

**[0088]** The vector pAd5/L420-HSA was also modified to create a SalI or PacI site upstream of the left ITR. Hereto pAd5/L420-HSA was digested with EcoRI and ligated to the above described PacI linker. The ligation mixture was digested with PacI and religated after isolation of the linear DNA from agarose gel to remove concatamerised linkers. This resulted in adapter plasmid pAd5/L420-HSApac. This construct was used to generate pAd5/L420-HSAsal as follows: pAd5/L420-HSApac was digested with Scal and BsrGI and the vector fragment was ligated to the 0.3 kb fragment isolated after digestion of pAd5/Clipsal with the same enzymes.

#### *Generation of adapter plasmids pAdMire and pAdApt*

**[0089]** To create an adapter plasmid that only contains a polylinker sequence and no promoter or polyA sequences, pAd5/L420-HSApac was digested with AvrII and BglII. The vector fragment was ligated to a linker oligonucleotide

digested with the same restriction enzymes. The linker was made by annealing oligos of the following sequence:

PLL-1: 5'- GCC ATC CCT AGG AAG CTT GGT ACC GGT GAA TTC GCT AGC GTT AAC GGA TCC TCT AGA  
CGA GAT CTG G-3' and

PLL-2: 5'- CCA GAT CTC GTC TAG AGG ATC CGT TAA CGC TAG CGA ATT CAC CGG TAC CAA GCT TCC TAG  
GGA TGG C-3'.

[0090] The annealed linkers were digested with *AvrII* and *BglII* and separated from small ends by column purification (Qiaquick nucleotide removal kit) according to manufacturers recommendations. The linker was then ligated to the *AvrII/BglII* digested pAd5/L420-HSAPac fragment. A clone, named AdMire, was selected that had the linker incorporated and was sequenced to check the integrity of the insert.

[0091] Adapter plasmid AdMire enables easy insertion of complete expression cassettes.

[0092] An adapter plasmid containing the human CMV promoter that mediates high expression levels in human cells was constructed as follows: pAd5/L420-HSAPac was digested with *AvrII* and 5' protruding ends were filled in using Klenow enzyme. A second digestion with *HindIII* resulted in removal of the L420 promoter sequences. The vector fragment was isolated and ligated to a PCR fragment containing the CMV promoter sequence. This PCR fragment was obtained after amplification of CMV sequences from pCMVLacI (Stratagene) with the following primers:

CMVplus: 5'-GATCGGTACCACTGCACTGGTCAATATTGGCCATTAGCC-3' and

CMVminA: 5'-GATCAAGCTTCCAATGCACCGTTCCCGGC-3'.

[0093] The PCR fragment was first digested with *PstI* (underlined in CMVplus) after which the 3'-protruding ends were removed by treatment with T4 DNA polymerase. Then the DNA was digested with *HindIII* (underlined in CMVminA) and ligated into the above described pAd5/L420-HSAPac vector fragment digested with *AvrII* and *HindIII*. The resulting plasmid was named pAd5/CMV-HSAPac. This plasmid was then digested with *HindIII* and *BamHI* and the vector fragment was isolated and ligated to the polylinker sequence obtained after digestion of AdMire with *HindIII* and *BglII*. The resulting plasmid was named pAdApt. Adapter plasmid pAdApt contains nucleotides - 735 to +95 of the human CMV promoter (Boshart et al., 1985). A second version of this adapter plasmid containing a *Sall* site in place of the *PacI* site upstream of the left ITR was made by inserting the 0.7 kb *Scal-BsrGI* fragment from pAd5/Clipsal into pAdApt digested with *Scal* and partially digested with *BsrGI*. This clone was named pAdApt.sal.

#### *Generation of recombinant adenoviruses based on Ad5*

[0094] RCA free recombinant adenoviruses can be generated very efficiently using the above described adapter plasmids and the pWE/Ad.AfIII-rITR or pWE/Ad.AfIII-rITRsp constructs.

[0095] Generally, the adapter plasmid containing the desired transgene in the desired expression cassette is digested with suitable enzymes to liberate the insert from vector sequences at the 3' and/or at the 5' end. The adenoviral complementation plasmids pWE/Ad.AfIII-rITR or pWE/Ad.AfIII-rITRsp are digested with *PacI* to liberate the adeno sequences from the vector plasmids. As a non-limiting example the generation of AdApt-LacZ is described. Adapter plasmid pAdApt-LacZ was generated as follows. The *E.coli* LacZ gene was amplified from the plasmid pMLP.nlsLacZ (EP 95-202 213) by PCR with the primers 5'-GGGGTGGCCAGGGTACCTCTAGGCTTTTGCAA-3' and 5'-GGGGGGATCCATAACAAGTTCAGATCC-3'. The PCR reaction was performed with Ex Tag (Takara) according to the suppliers protocol at the following amplification program: 5 minutes 94°C, 1 cycle; 45 seconds 94°C and 30 seconds 60°C and 2 minutes 72°C, 5 cycles; 45 seconds 94°C and 30 seconds 65°C and 2 minutes 72°C, 25 cycles; 10 minutes 72°C and 30 seconds 60°C and 2 minutes 72°C, 5 cycles, 1 cycle. The PCR product was subsequently digested with *KpnI* and *BamHI* and the digested DNA fragment was ligated into *KpnI/BamHI* digested pcDNA3 (Invitrogen), giving rise to pcDNA3.nlsLacZ. Construct pcDNA3.nlsLacZ was then digested with *KpnI* and *BamHI* and the 3 kb LacZ fragment was isolated from gel using the gene clean spin kit (Bio 101, Inc.).

[0096] pAdApt was also digested with *KpnI* and *BamHI* and the linear vector fragment was isolated from gel as above. Both isolated fragments were ligated and one clone containing the LacZ insert was selected. Construct pAdApt-LacZ was digested with *Sall*, purified by the gene clean spin kit and subsequently digested with *PacI*. pWE/Ad.AfIII-rITRsp was digested with *PacI*. Both digestion mixtures were treated for 30' by 65 °C to inactivate the enzymes. Samples were put on gel to estimate the concentration. 2.5x10<sup>6</sup> PER.C6 cells (ECACC deposit number 96022940) were seeded in T25 flasks in DMEM with 10% FCS and 10mM MgCl. The next day four microgram of each plasmid was transfected into PER.C6 cells (ECACC deposit number 96022940) using lipofectamine transfection reagent (Life Technologies Inc.) according to instructions of the manufacturer. The next day the medium was replaced by fresh culture medium and cells were further cultured at 37° C, 10% CO<sub>2</sub>. Again 24 hrs. later cells were trypsinised, seeded into T80 flasks and cultured at 37°C, 10% CO<sub>2</sub>. Full CPE was obtained 6 days after seeding in the T80 flask. Cells were har-

vested in the medium and subjected to one freeze/thaw cycle. The crude lysate obtained this way was used to plaque purify the mixture of viruses. Ten plaques were picked, expanded in a 24 well plate and tested for LacZ expression following infection of A549 cells. Viruses from all ten plaques expressed LacZ.

### 5 Example 3

#### Generation of chimeric recombinant adenoviruses

##### *Generation of hexon chimeric Ad5-based adenoviruses*

10

[0097] Neutralising antibodies in human serum are mainly directed to the hexon protein and to a lesser extent to the penton protein. Hexon proteins from different serotypes show highly variable regions present in loops that are predicted to be exposed at the outside of the virus (Athappilly et al., 1994; J. Mol. Biol. 242, 430-455). Most type specific epitopes have been mapped to these highly variable regions (Toogood et al., 1989; J. Gen Virol. 70, 3203-3214). Thus replacement of (part of) the hexon sequences with corresponding sequences from a different serotype is an effective strategy to circumvent (pre-existing) neutralising antibodies to Ad5. Hexon coding sequences of adenovirus serotype 5 are located between nucleotides 18841 and 21697.

15

[0098] To facilitate easy exchange of hexon coding sequences from alternative adenovirus serotypes into the adenovirus serotype 5 backbone, first a shuttle vector was generated.

20

[0099] This subclone, coded pBr/Ad.Eco-PmeI, was generated by first digesting plasmid pBr322 with EcoRI and EcoRV and inserting the 14 kb PmeI-EcoRI fragment from pWE/Ad.AfIII-Eco. In this shuttle vector a deletion was made of a 1430 bp SanDI fragment by digestion with SanDI and religation to give pBr/Ad.Eco-PmeI ΔSanDI. The removed fragment contains unique SpeI and MnlI sites. From pBr/Ad.Eco-PmeIΔSanDI the adenovirus serotype 5 DNA encoding hexon was deleted.

25

[0100] Hereto, the hexon flanking sequences were PCR amplified and linked together thereby generating unique restriction sites replacing the hexon coding region. For these PCR reactions four different oligonucleotides were required: Δhex1-Δhex4.

Δhex1: 5'- CCT GGT GCT CCC AAC AGC-3'

30

Δhex2: 5'- CCG GAT CCA CTA GTG GAA AGC GGG CGC GCG-3'

Δhex3: 5'- CCG GAT CCA ATT GAG NAG CAA GCA ACA TCA ACA AC-3'

Δhex4: 5'- GAG AAG GGC ATG GAG GCT G-3'

35

[0101] The amplified DNA product of ± 1100 bp obtained with oligonucleotides Δhex1 and Δhex2 was digested with BamHI and FseI. The amplified DNA product of ± 1600 bp obtained with oligonucleotides Δhex3 and Δhex4 was digested with BamHI and SbfI. These digested PCR fragments were subsequently purified from agarose gel and in a tri-part ligation reaction using T4 ligase enzyme linked to pBr/Ad.Eco-PmeI Δ SanDI digested with FseI and SbfI. The resulting construct was coded pBr/Ad.Eco-PmeIΔHexon. This construct was sequenced in part to confirm the correct nucleotide sequence and the presence of unique restriction sites MnlI and SpeI.

40

[0102] pBr/Ad.Eco-PmeIΔHexon serves as a shuttle vector to introduce heterologous hexon sequences amplified from virus DNA from different serotypes using primers that introduce the unique restriction sites MnlI and SpeI at the 5' and 3' ends of the hexon sequences respectively. To generate Ad5-based vectors that contain hexon sequences from the serotypes to which healthy individuals have no, or very low, titers of NAB the hexon sequences of Ad35, Ad34, Ad26 and Ad48 were amplified using the following primers:

45

Hex-up2: 5'-GACTAGTCAAGATGGCYACCCCHTCGATGATG-3' and

Hex-do2: 5'-GCTGGCCAATTGTTATGKGTGCGTTRCCGGC-3'.

50

[0103] These primers were designed using the sequences of published hexon coding regions (for example hexon sequences of Ad2, Ad3, Ad4, Ad5, Ad7, Ad16, Ad40 and Ad41 can be obtained at Genbank). Degenerated nucleotides were incorporated at positions that show variation between serotypes.

[0104] PCR products were digested with SpeI and MnlI and cloned into the pBr/Ad.Eco-PmeIΔHexon construct digested with the same enzymes.

55

[0105] The hexon modified sequences were subsequently introduced in the construct pWE/Ad.AfIII-rITR by exchange of the AscI fragment generating pWE/Ad.AfIII-rITRHexXX where XX stands for the serotype used to amplify hexon sequences.

[0106] The pWE/Ad.AfIII-rITRHexXX constructs are then used to make viruses in the same manner as described above for Ad5 recombinant viruses.



*Generation of penton chimeric Ad5-based recombinant viruses*

[0107] The adenovirus type 5 penton gene is located between sequences 14156 and 15869. Penton base is the adenovirus capsid protein that mediates internalisation of the virus into the target cell. At least some serotypes (type C and B) have been shown to achieve this by interaction of an RGD sequence in penton with integrins on the cell surface.

[0108] However, type F adenoviruses do not have an RGD sequence and for most viruses of the A and D group the penton sequence is not known. Therefore, penton may be involved in target cell specificity. Furthermore, as a capsid protein, the penton protein is involved in the immunogenicity of the adenovirus (Gahery-Segard *et al.*, 1998). Therefore, replacement of Ad5 penton sequences with penton sequences from serotypes to which no or low titers of NAB exist in addition to replacement of the hexon sequences will prevent clearance of the adenoviral vector more efficiently than replacement of hexon alone. Replacement of penton sequences may also affect infection specificity.

[0109] To be able to introduce heterologous penton sequences in Ad5 we made use of the plasmid-based system described above.

[0110] First a shuttle vector for penton sequences was made by insertion of the 7.2 kb *NheI*-*EcoRV* fragment from construct pWE/Ad.AfIII-*EcoRI* into pBr322 digested with the same enzymes. The resulting vector was named pBr/XN. From this plasmid Ad5 penton sequences were deleted and replaced by unique restriction sites that are then used to introduce new penton sequences from other serotypes. Here to, the left flanking sequences of penton in pBr/XN were PCR amplified using the following primers:

DP5-F: 5'- CTG TTG CTG CTG CTA ATA GC-3' and  
DP5-R: 5'- CGC GGA TCC TGT ACA ACT AAG GGG AAT ACA AG-3'

[0111] DP5-R has an *Bam*HI site (underlined) for ligation to the right flanking sequence and also introduces a unique *Bsr*GI site (bold face) at the 5'-end of the former Ad5 penton region.

[0112] The right flanking sequence was amplified using:

DP3-F: 5'-CGC GGA TCC CTT AAG GCA AGC ATG TCC ATC CTT-3' and  
DP3-3R: 5'- AAA ACA CGT TTT ACG CGT CGA CCT TTC-3'

[0113] DP3-F has an *Bam*HI site (underlined) for ligation to the left flanking sequence and also introduces a unique *Afl*III site (bold face) at the 3'-end of the former Ad5 penton region.

[0114] The two resulting PCR fragments were digested with *Bam*HI and ligated together. Then this ligation mixture was digested with *Avr*II and *Bgl*II. pBr/XN was also digested with *Avr*II and *Bgl*II and the vector fragment was ligated to the digested ligated PCR fragments. The resulting clone was named pBr/Ad.Δpenton. Penton coding sequences from Ad35, Ad34, Ad26 and Ad48 were PCR amplified such that the 5' and 3' ends contained the *Bsr*GI and *Afl*III sites respectively. Here to, the following primers were used:

For Ad34 and Ad35:

P3-for: 5'-GCT CGA TGT ACA ATG AGG AGA CGA GCC GTG CTA-3'  
P3-rev: 5'-GCT CGA CTT AAG TTA GAA AGT GCG GCT TGA AAG-3'

For Ad26 and Ad48:

P17F: 5'-GCT CGA TGT ACA ATG AGG CGT GCG GTG GTG TCT TC-3'  
P17R: 5'-GCT CGA CTT AAG TTA GAA GGT GCG ACT GGA AAG C-3'

[0115] Amplified PCR products were digested with *Bfr*I and *Bsr*GI and cloned into pBr/Ad.Δpenton digested with the same enzymes.

[0116] Introduction of these heterologous penton sequences in pBr/Ad.Δpenton generated constructs named pBr/Ad.pentonXX where XX represents the number of the serotype corresponding to the serotype used to amplify the inserted penton sequences. Subsequently the new penton sequences were introduced in the pWE/Ad.AfIII-rITR vector having a modified hexon. For example penton sequences from Ad35 were introduced in the construct pWE/Ad.AfIII-rITRHex35 by exchange of the common *Fse*I fragment. Other combinations of penton and hexon sequences were also made. Viruses with modified hexon and penton sequences were made as described above using cotransfection with an adapter plasmid on PER.C6 cells (ECACC deposit number 96022940). In addition, penton sequences were introduced in the pWE/Ad.AfIII-rITR construct. The latter constructs contain only a modified penton and viruses generated from these constructs will be used to study the contribution of penton sequences to the neutralisation of adenoviruses and

also for analysis of possible changes in infection efficiency and specificity.

#### Generation of fiber chimeric Ad5-based viruses

[0117] Adenovirus infection is mediated by two capsid proteins fiber and penton. Binding of the virus to the cells is achieved by interaction of the protruding fiber protein with a receptor on the cell surface. Internalisation then takes place after interaction of the penton protein with integrins on the cell surface. At least some adenovirus from subgroup C and B have been shown to use a different receptor for cell binding and therefore have different infection efficiencies on different cell types. Thus it is possible to change the infection spectrum of adenoviruses by changing the fiber in the capsid. The fiber coding sequence of adenovirus serotype 5 is located between nucleotides 31042 and 32787. To remove the adenovirus serotype 5 DNA encoding fiber we started with construct pBr/Ad.Bam-rITR. First a NdeI site was removed from this construct. For this purpose, pBr322 plasmid DNA was digested with NdeI after which protruding ends were filled using Klenow enzym. This pBr322 plasmid was then religated, digested with NdeI and transformed into *E.coli* DH5 $\alpha$ . The obtained pBr/ $\Delta$ NdeI plasmid was digested with Scal and Sall and the resulting 3198 bp vector fragment was ligated to the 15349 bp Scal-Sall fragment derived from pBr/Ad.BamrITR, resulting in plasmid pBr/Ad.Bam-rITR $\Delta$ NdeI which hence contained a unique NdeI site. Next a PCR was performed with oligonucleotides

NY-up:

5'-CGA CAT ATG TAG ATG CAT TAG TTT GTG TTA TGT TTC AAC GTG-3'

and

NY-down:

5'-GGA GAC CAC TGC CAT GTT-3'

[0118] During amplification, both a NdeI (bold face) and a NsiI restriction site (underlined) were introduced to facilitate cloning of the amplified fiber DNAs. Amplification consisted of 25 cycles of each 45 sec. at 94°C, 1 min. at 60°C, and 45 sec. at 72°C. The PCR reaction contained 25 pmol of oligonucleotides NY-up or NY-down, 2mM dNTP, PCR buffer with 1.5 mM MgCl<sub>2</sub>, and 1 unit of Elongase heat stable polymerase (Gibco, The Netherlands). One-tenth of the PCR product was run on an agarose gel which demonstrated that the expected DNA fragment of  $\pm$  2200 bp was amplified. This PCR fragment was subsequently purified using GeneClean kit system (Bio101 Inc.). Then, both the construct pBr/Ad.Bam-rITR $\Delta$ NdeI as well as the PCR product were digested with restriction enzymes NdeI and SbfI. The PCR fragment was subsequently cloned using T4 ligase enzyme into the NdeI and SbfI digested pBr/Ad.Bam-rITR $\Delta$ NdeI, generating pBr/Ad.BamR $\Delta$ Fib.

[0119] This plasmid allows insertion of any PCR amplified fiber sequence through the unique NdeI and NsiI sites that are inserted in place of the removed fiber sequence. Viruses can be generated by a double homologous recombination in packaging cells described in patent No. PCT/NL96/00244 using an adapter plasmid, construct pBr/Ad.AfIII-EcoRI digested with PacI and EcoRI and a pBr/Ad.BamR $\Delta$ Fib construct in which heterologous fiber sequences have been inserted. To increase the efficiency of virus generation, the construct pBr/Ad.BamR $\Delta$ Fib was modified to generate a PacI site flanking the right ITR. Hereto, pBr/Ad.BamR $\Delta$ Fib was digested with AvrII and the 5 kb adenofragment was isolated and introduced into the vector pBr/Ad.Bam-rITR.pac#8 described above replacing the corresponding AvrII fragment. The resulting construct was named pBr/Ad.BamR $\Delta$ Fib.pac.

[0120] Once a heterologous fiber sequence is introduced in pBr/Ad.BamR $\Delta$ Fib.pac, the fiber modified right hand adenovirus clone is introduced into a large cosmid clone as described above for pWE/Ad.AfIII-rITR. Such a large cosmid clone allows generation of adenovirus by only one homologous recombination. Ad5-based viruses with modified fibers have been made and described (nos. 98204482.8 and 99200624.7). In addition, hexon and penton sequences from serotypes from

[0121] this invention are combined with the desired fiber sequences to generate viruses which infect the target cell of choice very efficiently. For example smooth muscle cells, endothelial cells or synoviocytes all from human origin are very well infected with Ad5 based viruses with a fiber from subgroup B viruses especially adenovirus type 16.

[0122] The above described examples in which specific sequences can be deleted from the Ad5 backbone in the plasmids and replaced by corresponding sequences from other serotypes clearly show the flexibility of the system. It is evident that by the methods described above any combination of capsid gene from different serotypes can be made. Thus, chimeric recombinant Ad5-based adenoviruses are designed with desired hexon and penton sequences making the virus less sensitive for neutralisation and with desired fiber sequences allowing efficient infection in specific target tissues.

## Example 4

Construction of a plasmid-based system to generate Ad35 recombinant viruses

5 **[0123]** Partial restriction maps of Ad35 have been published previously (Valderrama-Leon *et al.*, 1985; Kang *et al.*, 1989; Li *et al.* 1991). An example of a functional plasmid-based system to generate recombinant adenoviruses based on Ad35 consists of the following elements:

- 10 1. An adapter plasmid comprising a left ITR and packaging sequences derived from Ad35 and at least one restriction site for insertion of an heterologous expression cassette and lacking E1 sequences. Furthermore, the adapter plasmid contains Ad35 sequences 3' from the E1B coding region including the pIX promoter and coding sequences sufficient to mediate homologous recombination of the adapter plasmid with a second nucleotide.
2. A second nucleotide comprising sequences homologous to the adapter plasmid and Ad35 sequences necessary for the replication and packaging of the recombinant virus, that is early, intermediate and late genes that are not present in the packaging cell.
- 15 3. A packaging cell providing at least functional E1 proteins capable of complementing the E1 function of Ad35.

**[0124]** Ad35 DNA was isolated from a purified virus batch as follows. To 100  $\mu$ l of virus stock (Ad35:  $3.26 \times 10^{12}$  VP/ml) 10  $\mu$ l 10x DNase buffer (130 mM Tris-HCl pH7.5; 1,2 M  $\text{CaCl}_2$ ; 50mM  $\text{MgCl}_2$ ) was added. After addition of 10  $\mu$ l 10mgr/ml DNase I (Roche Diagnostics) the mixture was incubated for 1 hr. at 37°C. Following addition of 2.5  $\mu$ l 0.5M EDTA, 3.2  $\mu$ l 20% SDS and 1.5  $\mu$ l ProteinaseK (Roche Diagnostics; 20mgr/ml) samples were incubated at 50°C for 1 hr. Next, the viral DNA was isolated using the GeneClean spin kit (Bio101 Inc.) according to the manufacturers instructions. DNA was eluted from the spin column with 25  $\mu$ l sterile MilliQ water.

**[0125]** In the following sizes of DNA fragments and fragment numbering will be used according to Kang *et al.* (1989). Ad35 DNA was digested with EcoRI and the three fragments (approximately 22.3 (A), 7.3 (B) and 6 kb (C)) were isolated from gel using the GeneClean kit (Bio101, Inc.). pBr322 was digested with EcoRI or with EcoRI and EcoRV and digested fragments were isolated from gel and dephosphorylated with Tsap enzyme (Gibco BRL). Next, the 6 kb Ad35 C fragment was ligated to the pBr322xEcoRI fragment and the ITR-containing Ad35 fragment (EcoRI-B) was ligated to the pBr322xEcoRI/EcoRV fragment. Ligations were incubated at 16°C overnight and transformed into DH5 $\alpha$  competent bacteria (Life Techn.). Minipreps of obtained colonies were analysed for correct insertion of the Ad35 fragments by restriction analysis. Both the 6 kb and the 7.3 kb Ad35 fragment were found to be correctly inserted in pBr322. The 6kb fragment was isolated in both orientations pBr/Ad35-Eco6.0<sup>+</sup> and pBr/Ad35-Eco6.0<sup>-</sup> whereby the + stands for 5' to 3' orientation relative to pBr322. The clone with the 7.3 kb Ad35 B insert, named pBr/Ad35-Eco7.3 was partially sequenced to check correct ligation of the 3' ITR. It was found that the ITR had the sequence 5'- CATCATCAAT...-3' in the lower strand. Then pBr/Ad35-Eco7.3 was extended to the 5' end by insertion of the 6kb Ad35 fragment. Hereto, pBr/Ad35-Eco7.3 was digested with EcoRI and dephosphorylated. The fragment was isolated from gel and ligated to the 6kb Ad35 EcoRI fragment. After transformation clones were tested for correct orientation of the insert and one clone was selected, named pBr/Ad35-Eco13.3.

**[0126]** This clone is then extended with the ~5.4 kb Sall D fragment obtained after digestion of wt Ad35 with Sall. Hereto, the Sall site in the pBr322 backbone is removed by partial digestion of pBr/Ad35-Eco13.3 with Sall, filling in of the sticky ends by Klenow treatment and religation. One clone is selected that contains a single Sall site in the adenoviral insert. This clone, named pBr $\Delta$ sall/Ad35-Eco13.3 is then linearised with AatII which is present in the pBr322 backbone and ligated to a Sall linker with AatII complementary ends. The DNA is then digested with excess Sall and the linear fragment is isolated and ligated to the 5.4 kb Sall-D fragment from Ad35. One clone is selected that contains the Sall fragment inserted in the correct orientation in pBr/Ad35-Eco13.3. The resulting clone, pBr/Ad35.Sall2-rITR contains the 3' ~17 kb of Ad35 including the right ITR. To enable liberation of the right ITR from the vector sequences at the time of virus generation, a NotI site flanking the right ITR is introduced by PCR.

**[0127]** The Ad35 EcoRI-A fragment of 22.3 kb was also cloned in pBr322xEcoRI/EcoRV. One clone, named pBr/Ad35-EcoA3', was selected that apparently had a deletion of approximately 7kb of the 5' end. It did contain the Sall site at 9.4 kb in Ad35 wt DNA and approximately 1.5 kb of sequences upstream. Using this Sall site and the unique NdeI site in the pBr322 backbone this clone is extended to the 5' end by insertion of an approximately 5 kb Ad35 fragment 5' from the first Sall in Ad35 in such a way that a NotI restriction site is created at the 5' end of the Ad35 by insertion of a linker.

**[0128]** This clone, named pBr/Ad35.pIX-EcoA does not contain the left end sequences (ITR, packaging sequences and E1) and at the 3' end it has approximately 3.5 kb overlap with clone pBr/Ad35.Sall2-rITR.

**[0129]** To create an adapter plasmid, Ad35 was digested with Sall and the left end B fragment of ~9.4 kb was isolated. pBr322 was digested with EcoRV and Sall, isolated from gel and dephosphorylated with Tsap enzyme. Both fragments are ligated and clones with correct insertion and correct sequence of the left ITR are selected. To enable

liberation of the left ITR from the vector sequences at the time of virus generation, a NotI site flanking the left ITR is introduced by PCR. From this clone the E1 sequences are deleted and replaced by a polylinker sequence using PCR. The polylinker sequence is used to introduce an expression cassette for a gene of choice.

[0130] Recombinant Ad35 clones are generated by transfection of PER.C6 cells with the adapter plasmid, pBr/Ad35.pIX-EcoA and pBr/Ad35.Sal2-rITR as shown in figure 3. Homologous recombination gives rise to recombinant viruses.

#### Example 5

*The prevalence of neutralizing activity (NA) to Ad35 is low in human sera from different geographic locations*

[0131] In example 1 we have described the analysis of neutralizing activity (NA) in human sera from one location in Belgium. Strikingly, of a panel of 44 adenovirus serotypes tested, one serotype, Ad35, was not neutralized in any of the 100 sera assayed. In addition, a few serotypes, Ad26, Ad34 and Ad48 were found to be neutralized in 8%, or less, of the sera tested. This analysis was further extended to other serotypes of adenovirus not previously tested and, using a selection of serotypes from the first screen, was also extended to sera from different geographic locations.

[0132] Hereto, adenoviruses were propagated, purified and tested for neutralization in the CPE-inhibition assay as described in example 1. Using the sera from the same batch as in example 1, adenovirus serotypes 7B, 11, 14, 18 and 44/1876 were tested for neutralization. These viruses were found to be neutralized in respectively 59, 13, 30, 98 and 54 % of the sera. Thus, of this series Ad11 is neutralized with a relatively low frequency.

[0133] Since it is known that the frequency of isolation of adenovirus serotypes from human tissue as well as the prevalence of NA to adenovirus serotypes may differ on different geographic locations, we further tested a selection of the adenovirus serotypes against sera from different places. Human sera were obtained from two additional places in Europe (Bristol, UK and Leiden, The Netherlands) and from two places in the United States (Stanford, CA and Great Neck, NY). Adenoviruses that were found to be neutralized in 20% or less of the sera in the first screen, as well as Ad2, Ad5, Ad27, Ad30, Ad38, Ad43, were tested for neutralization in sera from the UK. The results of these experiments are presented in Figure 4.

[0134] Adenovirus serotypes 2 and 5 were again neutralized in a high percentage of human sera. Furthermore, some of the serotypes that were neutralized in a low percentage of sera in the first screen are neutralized in a higher percentage of sera from the UK, e.g. Ad26 (7% vs. 30%), Ad28 (13% vs. 50%), Ad34 (5% vs. 27%) and Ad48 (8% vs. 32%). Neutralizing activity against Ad11 and Ad49 that were found in a relatively low percentage of sera in the first screen, are found in an even lower percentage of sera in this second screen (13% vs. 5% and 20% vs. 11% respectively). Serotype Ad35 that was not neutralized in any of the sera in the first screen, was now found to be neutralized in a low percentage (8%) of sera from the UK. The prevalence of NA in human sera from the UK is the lowest to serotypes Ad11 and Ad35.

[0135] For further analysis, sera were obtained from two locations in the US (Stanford, CA and Great Neck, NY) and from the Netherlands (Leiden). Figure 5 presents an overview of data obtained with these sera and the previous data. Not all viruses were tested in all sera, except for Ad5, Ad11 and Ad35. The overall conclusion from this comprehensive screen of human sera is that the prevalence of neutralizing activity to Ad35 is the lowest of all serotypes throughout the western countries: on average 7% of the human sera contain neutralizing activity (5 different locations).

[0136] Another B-group adenovirus, Ad11 is also neutralized in a low percentage of human sera (average 11% in sera from 5 different locations). Adenovirus type 5 is neutralized in 56% of the human sera obtained from 5 different locations.

[0137] Although not tested in all sera, D-group serotype 49 is also neutralized with relatively low frequency in samples from Europe and from one location of the US (average 14%).

[0138] In the above described neutralization experiments a serum is judged non-neutralizing when in the well with the highest serum concentration the maximum protection of CPE is 40% compared to the controls without serum. The protection is calculated as follows:

$$\% \text{ protection} = \frac{\text{OD corresponding well} - \text{OD virus control}}{\text{OD non-infected control} - \text{OD virus control}} \times 100\%$$

[0139] As described in example 1, the serum is plated in five different dilutions ranging from 4x to 64x diluted.

[0140] Therefore, it is possible to distinguish between low titers (i.e. neutralization only in the highest serum concentrations) and high titers of NA (i.e. also neutralization in wells with the lowest serum concentration). Of the human sera used in our screen that were found to contain neutralizing activity to Ad5, 70% turned out to have high titers whereas of the sera that contained NA to Ad35, only 15% had high titers. Of the sera that were positive for NA to Ad11 only 8% had high titers.

[0141] For Ad49 this was 5%. Therefore, not only is the frequency of NA to Ad35, Ad11 and Ad49 much lower as

compared to Ad5, but of the sera that do contain NA to these viruses, the vast majority has low titers. Adenoviral vectors based on Ad11, Ad35 or Ad49 have therefore a clear advantage over Ad5 based vectors when used as gene therapy vehicles or vaccination vectors *in vivo* or in any application where infection efficiency is hampered by neutralizing activity.

- 5 [0142] In the following examples the construction of a vector system for the generation of safe, RCA-free Ad35-based vectors is described.

#### Example 6

##### 10 Sequence of the human adenovirus type 35

[0143] Ad35 viruses were propagated on PER.C6 cells and DNA was isolated as described in example 4. The total sequence was generated by Qiagen Sequence Services (Qiagen GmbH, Germany). Total viral DNA was sheared by sonification and the ends of the DNA were made blunt by T4 DNA polymerase.

- 15 [0144] Sheared blunt fragments were size fractionated on agarose gels and gel slices corresponding to DNA fragments of 1.8 to 2.2 kb were obtained. DNA was purified from the gel slices by the QIAquick gel extraction protocol and subcloned into a shotgun library of pUC19 plasmid cloning vectors. An array of clones in 96-wells plates covering the target DNA 8 (+/-2) times was used to generate the total sequence. Sequencing was performed on Perkin-Elmer 9700 thermo cyclers using BigDyeTerminator chemistry and AmpliTaq FS DNA polymerase followed by purification of sequencing reactions using QIAGEN DyeEx 96 technology. Sequencing reaction products were then subjected to automated separation and detection of fragments on ABI 377 XL 96 lane sequencers. Initial sequence contig sequence and gaps were filled in by primer walking reads on the target DNA or by direct sequencing of PCR products. The ends of the virus turned out to be absent in the shotgun library, most probably due to cloning difficulties resulting from the amino acids of pTP that remain bound to the ITR sequences after proteinase K digestion of the viral DNA.

- 25 [0145] Additional sequence runs on viral DNA solved most of the sequence in those regions, however it was difficult to obtain a clear sequence of the most terminal nucleotides. At the 5' end the sequence obtained was 5'-CCAATAATATACCT...-3' while at the 3' end the obtained sequence was 5'-...AGGTATATTATTGATGATGGG-3'. Most human adenoviruses have a terminal sequence 5'-CATCATCAATAATATACC-3'. In addition, a clone representing the 3' end of the Ad35 DNA obtained after cloning the terminal 7 kb Ad35 EcoRI fragment into pBr322 (see example 4) also turned out to have the typical CATCATCAATAAT... sequence. Therefore, Ad35 may have the typical end sequence and the differences obtained in sequencing directly on the viral DNA are due to artefacts correlated with run-off sequence runs and the presence of residual amino acids of pTP.

- 30 [0146] The total sequence of Ad35 with corrected terminal sequences is given in Figure 6. Based sequence homology with Ad5 (genbank # M72360) and Ad7 (partial sequence Genbank # X03000) and on the location of open reading frames, the organization of the virus is identical to the general organization of most human adenoviruses, especially the subgroup B viruses. The total length of the genome is 34794 basepairs.

#### Example 7

##### 40 Construction of a plasmid-based vector system to generate recombinant Ad35-based viruses.

[0147] A functional plasmid-based vector system to generate recombinant adenoviral vectors comprises the following components:

- 45 1. An adapter plasmid comprising a left ITR and packaging sequences derived from Ad35 and at least one restriction site for insertion of an heterologous expression cassette and lacking E1 sequences. Furthermore, the adapter plasmid contains Ad35 sequences 3' from the E1B coding region including the pIX promoter and coding sequences enough to mediate homologous recombination of the adapter plasmid with a second nucleic acid molecule.
- 50 2. A second nucleic acid molecule, comprising sequences homologous to the adapter plasmid, and Ad35 sequences necessary for the replication and packaging of the recombinant virus, that is early, intermediate and late genes that are not present in the packaging cell.
3. A packaging cell providing at least functional E1 proteins capable of complementing the E1 function of Ad35.

- 55 [0148] Other methods for the generation of recombinant adenoviruses on complementing packaging cells are known in the art and may be applied to Ad35 viruses without departing from the invention. As an example, the construction of a plasmid based system, as outlined above, is described in detail below.

# 1) Construction of Ad35 adapter plasmids.

[0149] Hereto, the adapter plasmid pAdApt (Figure 7; described in example 2) was first modified to obtain adapter plasmids that contain extended polylinkers and that have convenient unique restriction sites flanking the left ITR and the adenovirus sequence at the 3' end to enable liberation of the adenovirus insert from plasmid vector sequences. Construction of these plasmids is described below in detail: Adapter plasmid pAdApt (Example 2) was digested with Sall and treated with Shrimp Alkaline Phosphatase to reduce religation. A linker, composed of the following two phosphorylated and annealed oligo's: ExSalPacF 5' - TCG ATG GCA AAC AGC TAT TAT GGG TAT TAT GGG TTC GAA TTA ATT AA- 3'; and ExSalPacR 5' - TCG ATT AAT TAA TTC GAA CCC ATA ATA CCC ATA ATA GCT GTT TGC CA- 3'; was directly ligated into the digested construct, thereby replacing the Sall restriction site by Pi-Pspl, Sma and PacI. This construct was named pADAPT+ExSalPac linker. Furthermore, part of the left ITR of pAdApt was amplified by PCR using the following primers: PCLIPMSF: 5'- CCC CAA TTG GTC GAC CAT CAT CAA TAA TAT ACC TTA TTT TGG -3' and pCLIPBSRG1: 5'- GCG AAA ATT GTC ACT TCC TGT G -3'. The amplified fragment was digested with MunI and BsrGI and cloned into pAd5/Clip (see Example 2), which was partially digested with EcoRI and after purification digested with BsrGI, thereby re-inserting the left ITR and packaging signal. After restriction enzyme analysis, the construct was digested with Sma and SgrAI and an 800 bp fragment was isolated from gel and ligated into Sma/SgrAI digested pADAPT+ExSalPac linker. The resulting construct, named pIPspSalAdapt, was digested with Sall, dephosphorylated, and ligated to the phosphorylated ExSalPacF/ExSalPacR doublestranded linker mentioned above. A clone in which the PacI site was closest to the ITR was identified by restriction analysis and sequences were confirmed by sequence analysis. This novel pAdApt construct, termed pIPspAdapt (Figure 8) thus harbors two ExSalPac linkers containing recognition sequences for PacI, Pi-Pspl and BstBI, which surround the adenoviral part of the adenoviral adapter construct, and which can be used to linearize the plasmid DNA prior to cotransfection with adenoviral helper fragments.

[0150] In order to further increase transgene cloning permutations a number of polylinker variants were constructed based on pIPspAdapt. For this purpose pIPspAdapt was first digested with EcoRI and dephosphorylated. A linker composed of the following two phosphorylated and annealed oligo's:

Ecolinker+: 5' -AAT TCG GCG CGC CGT CGA CGA TAT CGA TAG CCG

CCG C -3' and Ecolinker-: 5' -AAT TGC GGC CGC TAT CGA TAT CGT CGA CGG CGC GCC G -3' was ligated into this construct, thereby creating restriction sites for Ascl, Sall, EcoRV, ClaI and NotI. Both orientations of this linker were obtained and sequences were confirmed by restriction analysis and sequence analysis. The plasmid containing the polylinker in the order 5' HindIII, KpnI, AgeI, EcoRI, Ascl, Sall, EcoRV, ClaI, NotI, NheI, HpaI, BamHI and XbaI was termed pIPspAdapt1 (Figure 9) while the plasmid containing the polylinker in the order HindIII, KpnI, AgeI, NotI, ClaI, EcoRV, Sall, Ascl, EcoRI, NheI, HpaI, BamHI and XbaI was termed pIPspAdapt2.

[0151] To facilitate the cloning of other sense or antisense constructs, a linker composed of the following two oligonucleotides was designed, to reverse the polylinker of pIPspAdapt: HindXba+: 5'-AGC TCT AGA GGA TCC GTT AAC GCT AGC GAA TTC ACC GGT ACC AAG CTT A-3'; HindXba-: 5'-CTA GTA AGC TTG GTA CCG GTG AAT TCG CTA GCG TTA ACG GAT CCT CTA G-3'.

[0152] This linker was ligated into HindIII/XbaI digested pIPspAdapt and the correct construct was isolated.

[0153] Confirmation was done by restriction enzyme analysis and sequencing. This new construct, pIPspAdaptA, was digested with EcoRI and the above mentioned Ecolinker was ligated into this construct. Both orientations of this linker were obtained, resulting in pIPspAdapt3 (Figure 10), which contains the polylinker in the order XbaI, BamHI, HpaI, NheI, EcoRI, Ascl, Sall, EcoRV, ClaI, NotI, AgeI, KpnI and HindIII. All sequences were confirmed by restriction enzyme analysis and sequencing.

[0154] Adapter plasmids based on Ad35 were then constructed as follows:

[0155] The left ITR and packaging sequence corresponding to Ad35 wt sequences nucleotides 1 to 464 (Figure 6) were amplified by PCR on wtAd35 DNA using the following primers:

Primer 35F1:

5'-CGG AAT TCT TAA TTA ATC GAC ATC ATC AAT AAT ATA CCT TAT AG-3'

Primer 35R2:

5'-GGT GGT CCT AGG CTG ACA CCT ACG TAA AAA CAG-3'

[0156] Amplification introduces a PacI site at the 5' end and an AvrII site at the 3' end of the sequence.

[0157] For the amplification Platinum Pfx DNA polymerase enzyme (LTI) was used according to manufacturers instructions but with primers at 0.6  $\mu$ M and with DMSO added to a final concentration of 3%. Amplification program was as follows: 2 min. at 94°C, (30 sec. 94°C, 30 sec. at 56°C, 1 min. at 68°C) for 30 cycles, followed by 10 min. at 68°C.

[0158] The PCR product was purified using a pcr purification kit (LTI) according to the manufacturers instructions and digested with PacI and AvrII. The digested fragment was then purified from gel using the geneclon kit (Bio 101, Inc.).

5 [0159] The Ad5-based adapter plasmid pIPspAdApt-3 (Figure 10) was digested with AvrII and then partially with PacI and the 5762 bp fragment was isolated in an LMP agarose gel slice and ligated with the abovementioned PCR fragment digested with the same enzymes and transformed into electrocompetent DH10B cells (LTI). The resulting clone is named pIPspAdApt3-Ad35IIIR.

[0160] In parallel, a second piece of Ad35 DNA was amplified using the following primers:

10 35F3: 5'- TGG TGG AGA TCT GGT GAG TAT TGG GAA AAC-3'  
35R4: 5'- CGG AAT TCT TAA TTA AGG GAA ATG CAA ATC TGT GAG G-3'

[0161] The sequence of this fragment corresponds to nucl. 3401 to 4669 of wtAd35 (Figure 6) and contains 1.3 kb of sequences starting directly 3' from the E1B 55k coding sequence.

15 [0162] Amplification and purification was done as described above for the fragment containing the left ITR and packaging sequence. The PCR fragment was then digested with PacI and subcloned into pNEB193 vector (New England Biolabs) digested with SmaI and PacI. The integrity of the sequence of the resulting clone was checked by sequence analysis.

20 [0163] pNEB/Ad35pF3R4 was then digested with BglII and PacI and the Ad35 insert was isolated from gel using the QIAExII kit (Qiagen). pIPspAdApt3-Ad35IIIR was digested with BglII and then partially with PacI. The 3624 bp fragment (containing vector sequences, the Ad35 ITR and packaging sequences as well as the CMV promoter, multiple cloning region and polyA signal), was also isolated using the QIAExII kit (Qiagen).

25 [0164] Both fragments were ligated and transformed into competent DH10B cells (LTI). The resulting clone, pAdApt35IP3 (Figure 11), has the expression cassette from pIPspAdApt3 but contains the Ad35 left ITR and packaging sequences and a second fragment corresponding to nucl. 3401 to 4669 from Ad35. A second version of the Ad35 adapter plasmid having the multiple cloning site in the opposite orientation was made as follows:

30 pIPspAdapt1 (Figure 9) was digested with NdeI and BglII and the 0.7 kbp band containing part of the CMV promoter, the MCS and SV40 polyA was isolated and inserted in the corresponding sites of pAdApt35IP3 generating pAdApt35IP1 (Figure 12).

pAdApt35.LacZ and pAdApt35.Luc adapter plasmids were then generated by inserting the transgenes from pcDNA.LacZ (digested with KpnI and BamHI) and pAdApt.Luc (digested with HindIII and BamHI) into the corresponding sites in pAdApt35IP1. The generation of pcDNA.LacZ and pAdApt.Luc is described in WO99/55132.

## 35 2) Construction of cosmid pWE.Ad35.pXI-rITR

[0165] Figure 13 presents the various steps undertaken to construct the cosmid clone containing Ad35 sequences from bp 3401 to 34794 (end of the right ITR) that are described in detail below.

[0166] A first PCR fragment (pIX-NdeI) was generated using the following primer set:

40 35F5: 5'-CGG AAT TCG CGG CCG CGG TGA GTA TTG GGA AAA C -3'  
35R6: 5'-CGC CAG ATC GTC TAC AGA ACA G-3'

45 [0167] DNA polymerase Pwo (Roche) was used according to manufacturers instructions, however, with an endconcentration of 0.6  $\mu$ M of both primers and using 50 ngr wt Ad35 DNA as template.

[0168] Amplification was done as follows: 2 min. at 94 °C, 30 cycles of 30 sec. at 94 °C, 30 sec. at 65 °C and 1 min. 45 sec. at 72 °C, followed by 8 min. at 68 °C. To enable cloning in the TA cloning vector PCR2.1, a last incubation with 1 unit superTaq polymerase (HT Biotechnology LTD) for 10 min. at 72 °C was performed.

50 [0169] The 3370 bp amplified fragment contains Ad35 sequences from bp 3401 to 6772 with a NotI site added to the 5' end.

[0170] Fragments were purified using the PCR purification kit (LTI).

[0171] A second PCR fragment (NdeI-rITR) was generated using the following primers:

55 35F7: 5'-GAA TGC TGG CTT CAG TTG TAA TC -3'  
35R8: 5'- CGG AAT TCG CGG CCG CAT TTA AAT CAT CAT CAA TAA TAT ACC-3'

[0172] Amplification was done with pfx DNA polymerase (LTI) according to manufacturer's instructions but with 0.6  $\mu$ M of both primers and 3% DMSO using 10 ngr. of wtAd35 DNA as template. The program was as follows:

3 min. at 94 °C and 5 cycles of 30 sec. at 94 °C, 45 sec. at 40 °C, 2 min.45 sec. at 68 °C followed by 25 cycles of 30 sec. at 94 °C, 30 sec. at 60 °C, 2 min.45 sec. at 68 °C. To enable cloning in the TA-cloning vector PCR2.1, a last incubation with 1 unit superTag polymerase for 10 min. at 72 °C was performed. The 1.6 kb amplified fragment ranging from nucl. 33178 to the end of the right ITR of Ad35, was purified using the PCR purification kit ( LTI).

[0173] Both purified PCR fragments were ligated into the PCR2.1 vector of the TA-cloning kit (Invitrogen) and transformed into STBL-2 competent cells (LTI). Clones containing the expected insert were sequenced to confirm correct amplification. Next, both fragments were excised from the vector by digestion with NotI and NdeI and purified from gel using the geneClean kit (BIO 101, Inc.). Cosmid vector pWE15 (Clontech) was digested with NotI, dephosphorylated and also purified from gel. These three fragments were ligated and transformed into STBL2 competent cells (LTI). One of the correct clones that contained both PCR fragments was then digested with NdeI and the linear fragment was purified from gel using the geneClean kit. Ad35 wtDNA was digested with NdeI and the 26.6 kb fragment was purified from LMP gel using agarase enzyme (Roche) according to the manufacturers instructions. These fragments were ligated together and packaged using  $\lambda$  phage packaging extracts (Stratagene) according to the manufacturer's protocol. After infection into STBL-2 cells, colonies were grown on plates and analyzed for presence of the complete insert. One clone with the large fragment inserted in the correct orientation and having the correct restriction patterns after independent digestions with three enzymes (NcoI, PvuII and ScaI) was selected. This clone is named pWE.Ad35.pIX-rITR. It contains the Ad35 sequences from bp 3401 to the end and is flanked by NotI sites (Figure 14).

### 3) Generation of Ad35 based recombinant viruses on PER.C6.

[0174] Wild type Ad35 virus can be grown on PER.C6 packaging cells to very high titers. However, whether the Ad5-E1 region that is present in PER.C6 is able to complement E1-deleted Ad35 recombinant viruses is unknown. To test this, PER.C6 cells were cotransfected with the above described adapter plasmid pAdApt35.LacZ and the large backbone fragment pWE.Ad35.pIX-rITR. First, pAdApt35.LacZ was digested with PacI and pWE.Ad35.pIX-rITR was digested with NotI. Without further purification 4  $\mu$ g of each construct was mixed with DMEM (LTI) and transfected into PER.C6 cells, seeded at a density of  $5 \times 10^6$  cells in a T25 flask the day before, using Lipofectamin (LTI) according to the manufacturers instructions. As a positive control, 6  $\mu$ g of PacI digested pWE.Ad35.pIX-rITR DNA was cotransfected with a 6.7 kb NheI fragment isolated from Ad35 wt DNA containing the left end of the viral genome including the E1 region.

[0175] The next day medium (DMEM with 10% FBS and 10mM  $MgCl_2$ ) was refreshed and cells were further incubated. At day 2 following the transfection, cells were trypsinized and transferred to T80 flasks. The positive control flask showed CPE at five days following the transfection, showing that the pWE.Ad35.pIX-rITR construct is functional at least in the presence of Ad35-E1 proteins. The transfection with the Ad35 LacZ adapter plasmid and pWE.Ad35.pIX-rITR did not give rise to CPE. These cells were harvested in the medium at day 10 and freeze/thawed once to release virus from the cells. 4 ml of the harvested material was added to a T80 flask with PER.C6 cells (at 80% confluency) and incubated for another five days. This harvest/re-infection was repeated for two times but there was no evidence for virus associated CPE.

[0176] From this experiment it seems that the Ad5-E1 proteins are not, or not well enough, capable of complementing Ad35 recombinant viruses, however, it may be that the sequence overlap of the adapter plasmid and the pWE.Ad35.pIX-rITR backbone plasmid is not large enough to efficiently recombine and give rise to a recombinant virus genome. The positive control transfection was done with a 6.7 kb left end fragment and therefore the sequence overlap was about 3.5 kb. The adapter plasmid and the pWE.Ad35.pIX-rITR fragment have a sequence overlap of 1.3 kb. To check whether the sequence overlap of 1.3 kb is too small for efficient homologous recombination, a cotransfection was done with PacI digested pWE.Ad35.pIX-rITR and a PCR fragment of Ad35 wtDNA generated with the above mentioned 35F1 and 35R4 using the same procedures as described before. The PCR fragment thus contains left end sequences up to bp 4669 and therefore has the same overlap sequences with pWE.Ad35.pIX-rITR as the adapter plasmid pAdApt35.LacZ but has Ad35 E1 sequences.

[0177] Following PCR column purification, the DNA was digested with Sall to remove possible intact template sequences. A transfection with the digested PCR product alone served as a negative control. Four days after the transfection, CPE occurred in the cells transfected with the PCR product and the Ad35 pIX-rITR fragment, and not in the negative control.

[0178] This shows that 1.3 kb overlapping sequences is sufficient to generate viruses in the presence of Ad35 E1 proteins.

[0179] From these experiments we conclude that the presence of at least one of the Ad35.E1 proteins is necessary to generate recombinant Ad35 based vectors from plasmid DNA on Ad5 complementing cell lines.



**Example 8****1) Construction of Ad35.E1 expression plasmids**

5 [0180] Since Ad5-E1 proteins in PER.C6 are not capable of complementing Ad35 recombinant viruses efficiently, Ad35 E1 proteins have to be expressed in Ad5 complementing cells (e.g. PER.C6) or a new packaging cell line expressing Ad35 E1 proteins has to be made, starting from either diploid primary human cells or established cell lines not expressing adenovirus E1 proteins. To address the first possibility, the Ad35 E1 region was cloned in expression plasmids as described below.

10 [0181] First, the Ad35 E1 region from bp 468 to bp 3400 was amplified from wtAd35 DNA using the following primer set:

35F11: 5'-GGG GTA CCG AAT TCT CGC TAG GGT ATT TAT ACC-3'

35F10: 5'-GCT CTA GAC CTG CAG GTT AGT CAG TTT CTT CTC CAC TG-3'

15 [0182] This PCR introduces a KpnI and EcoRI site at the 5' end and a SbfI and XbaI site at the 3' end.

[0183] Amplification on 5 ngr. template DNA was done with Pwo DNA polymerase (Roche) using manufacturers instructions, however, with both primers at a final concentration of 0.6  $\mu$ M. The program was as follows: 2 min. at 94 °C, 5 cycles of 30 sec. at 94 °C, 30 sec. at 56 °C and 2 min. at 72 °C, followed by 25 cycles of 30 sec. at 94 °C, 30 sec. at 20 60 °C and 2 min. at 72 °C, followed by 10 min. at 72 °C. PCR product was purified by a PCR purification kit (LTI) and digested with KpnI and XbaI. The digested PCR fragment was then ligated to the expression vector pRSVhsvNeo (see below), also digested with KpnI and XbaI. Ligations were transformed into competent STBL-2 cells (LTI) according to manufacturers instructions and colonies were analysed for the correct insertion of Ad35E1 sequences into the polylinker in between the RSV promoter and HBV polyA.

25 [0184] The resulting clone was named pRSV.Ad35-E1 (Figure 15). The Ad35 sequences in pRSV.Ad35-E1 were checked by sequence analysis.

[0185] pRSVhsvNeo was generated as follows: pRc-RSV (Invitrogen) was digested with PvuII, dephosphorylated with TSAP enzyme (LTI) and the 3 kb vector fragment was isolated in low melting point agarose (LMP). Plasma pPG-KneopA (Figure 16; described in WO96/35798, was digested with SspI completely to linearise the plasmid and facilitate 30 partial digestion with PvuII. Following the partial digestion with PvuII, the resulting fragments were separated on a LMP agarose gel and the 2245 bp PvuII fragment, containing the PGK promoter, neomycine resistance gene and HBVpolyA, was isolated. Both isolated fragments were ligated to give the expression vector pRSV-pNeo that now has the original SV40prom-neo-SV40polyA expression cassette replaced by a PGKprom-neo-HBVpolyA cassette (Figure 17). This plasmid was further modified to replace the BGHpA with the HBVpA as follows: pRSVpNeo was linearised with Scal and further digested with XbaI. The 1145 bp fragment, containing part of the Amp gene and the RSV promoter 35 sequences and polylinker sequence, was isolated from gel using the GeneClean kit (Bio Inc. 101).

[0186] Next pRSVpNeo was linearised with Scal and further digested with EcoRI partially and the 3704 bp fragment containing the PGKneo cassette and the vector sequences were isolated from gel as above. A third fragment, containing the HBV polyA sequence flanked by XbaI and EcoRI at the 5' and 3' end respectively, was then generated 40 by PCR amplification on pRSVpNeo using the following primer set:

HBV-F: 5'- GGC TCT AGA GAT CCT TCG CGG GAC GTC -3' and

HBV-R: 5'- GGC GAA TTC ACT GCC TTC CAC CAA GC -3'.

45 [0187] Amplification was done with Elongase enzyme (LTI) according to the manufacturers instructions with the following conditions: 30 seconds at 94°C, then 5 cycles of 45 seconds at 94 °C, 1 minute at 42 °C and 1 minute 68 °C, followed by 30 cycles of 45 seconds at 94 °C, 1 minute at 65 °C and 1 minute at 68 °C, followed by 10 minutes at 68 °C. The 625 bp PCR fragment was then purified using the Qiaquick PCR purification kit, digested with EcoRI and XbaI and purified from gel using the GeneClean kit. The three isolated fragments were ligated and transformed into DH5 $\alpha$  competent cells (LTI) to give the construct pRSVhsvNeo (Figure 18). In this construct the transcription regulatory regions of 50 the RSV expression cassette and the neomycine selection marker are modified to reduce overlap with adenoviral vectors that often contain CMV and SV40 transcription regulatory sequences.

**2) Generation of Ad35 recombinant viruses on PER.C6 cells cotransfected with an Ad35-E1 expression construct.**

55 [0188] PER.C6 cells were seeded at a density of  $5 \times 10^6$  cells in a T25 flask and the next day transfected with a DNA mixture containing:

- 1 µg pAdApt35.LacZ digested with PacI
- 5 µg pRSV.Ad35E1 undigested
- 2 µg pWE.Ad35.pIX-riTR digested with NotI

[0189] Transfection was done using Lipofectamine according to the manufacturers instructions. Five hours after addition of the transfection mixture to the cells, medium was removed and replaced by fresh medium. After two days cells were transferred to T80 flasks and further cultured. One week post-transfection 1 ml of the medium was added to A549 cells and the following day cells were stained for LacZ expression. Blue cells were clearly visible after two hours of staining indicating that recombinant LacZ expressing viruses were produced. The cells were further cultured but no clear appearance of CPE was noted. However, after 12 days clumps of cells appeared in the monolayer and 18 days following transfection cells were detached. Cells and medium were then harvested, freeze-thawed once and 1 ml of the crude lysate was used to infect PER.C6 cells in a 6-well plate. Two days after infection cells were stained for LacZ activity. After two hours 15% of the cells were stained blue. To test for the presence of wt and / or replicating competent viruses, A549 cells were infected with these viruses and further cultured. No signs of CPE were found indicating the absence of replication competent viruses.

[0190] These experiments show that recombinant AdApt35.LacZ viruses were made on PER.C6 cells cotransfected with an Ad35-E1 expression construct.

### 3) Ad35 recombinant viruses escape neutralization in human serum containing neutralizing activity to Ad5 viruses.

[0191] The AdApt35.LacZ viruses were then used to investigate infection in the presence of serum that contains neutralizing activity to Ad5 viruses. Purified Ad5-based LacZ virus served as a positive control for NA. Hereto, PER.C6 cells were seeded in a 24-wells plate at a density of  $2 \times 10^5$  cells/well. The next day a human serum sample with high neutralizing activity to Ad5 was diluted in culture medium in five steps of five times dilutions. 0.5 ml of diluted serum was then mixed with  $4 \times 10^6$  virus particles AdApt5.LacZ virus in 0.5 ml medium and after 30 minutes of incubation at 37 °C, 0.5 ml of the mixture was added to PER.C6 cells in duplicate. For the AdApt35.LacZ viruses, 0.5 ml of the diluted serum samples were mixed with 0.5 ml crude lysate containing AdApt35.LacZ virus and after incubation 0.5 ml of this mixture was added to PER.C6 cells in duplo.

[0192] Virus samples incubated in medium without serum was used as a positive control for infection. After two hours of infection at 37 °C, medium was added to reach a final volume of 1 ml and cells were further incubated. Two days after infection cells were stained for LacZ activity. The results are shown in Table II. From these results it is clear that whereas AdApt5.LacZ viruses are efficiently neutralized, AdApt35.LacZ viruses remain infectious irrespective of the presence of human serum. This proves that recombinant Ad35-based viruses escape neutralization in human sera that contain NA to Ad5-based viruses.

### Example 9:

#### *An Ad5/fiber35 chimeric vector with cell type specificity for hemopoietic CD34 Lin stem cells*

[0193] In example 3 we have described the generation of a library of Ad5 based adenoviruses harboring fiber proteins of other serotypes. As a non-limiting example for the use of this library we here describe the identification of fiber-modified adenoviruses that show improved infection of hemopoietic stem cells.

[0194] Cells isolated from human bone marrow, umbilical cord blood, or mobilized peripheral blood carrying the flow cytometric phenotype of being positive for the CD34 antigen and negative for the early differentiation markers CD33, CD38, and CD71 (lin) are commonly referred to as hemopoietic stem cells (HSC). Genetic modification of these cells is of major interest since all hemopoietic lineages are derived from these cells and therefore the HSC is a target cell for the treatment of many acquired or congenital human hemopoietic disorders. Examples of diseases that are amendable for genetic modification of HSC, but not limited to, include Hurlers disease, Hunters disease, Sanfilippus disease, Morquios disease, Gaucher disease, Farbers disease, Niemann-Pick disease, Krabbe disease, Metachromatic Leucodystrophy, I-cell disease, severe immunodeficiency syndrome, Jak-3 deficiency, Fucosidose deficiency, thalassemia, and erythropoietic porphyria. Besides these hemopoietic disorders also strategies to prevent or treat acquired immunodeficiency syndrome (AIDS) and hemopoietic cancers are based on the genetic modification of HSCs or cells derived from the HSCs such as CD4 positive T lymphocytes in case of AIDS. The examples listed above thus aim at introducing DNA into the HSC in order to complement on a genetic level for a gene and protein deficiency. In case of strategies for AIDS or cancer, the DNA to be introduced into the HSC can be anti-viral genes or suicide genes.

[0195] Besides the examples listed above, there are several other areas in which efficient transduction of HSCs using adenoviral vectors plays an important role. For instance in the field of tissue engineering. In this area it is important to drive differentiation of HSCs to specific lineages. Some, non-limiting, examples are *ex vivo* bone formation, car-

tilage formation, skin formation, as well as the generation of T-cell precursors or endothelial cell precursors. The generation of bone, cartilage or skin in bioreactors can be used for transplantation after bone fractures or spinal cord lesions or severe burn injuries.

[0196] Naturally, transduced cells can also directly be re-infused into a patient. The formation of large numbers of endothelial cell precursor from HSCs is of interest since these endothelial precursor cells can home, after re-infusion, to sites of cardiovascular injury such as ischemia. Likewise, the formation of large numbers of T-cells from HSCs is of interest since these T-cell precursors can be primed, *ex vivo*, to eradicate certain targets in the human body after reinfusion of the primed T-cells. Preferred targets in the human body can be tumours or virus infected cells.

[0197] From the examples described above, it can be concluded that efficient gene delivery to HSCs is a major interest for the field of gene therapy. Therefore, alteration of the adenovirus serotype 5 host cell range to be able to target HSCs *in vitro* as well as *in vivo* is a major interest of the invention. To identify a chimeric adenovirus with preferred infection characteristics for human HSCs, we generated a library of Ad5 based viruses carrying the fiber molecule from alternative serotypes (serotypes 8, 9, 13, 16, 17, 32, 35, 45, 40-L, 51). The generation of this fiber modified library is described in example 3. Ad5 was taken along as a reference. A small panel of this library was tested on human TF-1 (erythroidleukemia, ATCC CRL-2003) whereas all chimaeric viruses generated were tested on human primary stroma cells and human HSCs. Human TF-1 cell were routinely maintained in DMEM supplemented with 10% FCS and 50 ng/ml IL-3 (Sandoz, Basel, Switzerland). Human primary fibroblast-like stroma, isolated from a bone marrow aspirate, is routinely maintained in DMEM/ 10% FCS. Stroma was seeded at a concentration of  $1 \times 10^5$  cells per well of 24-well plates. 24 hours after seeding cells were exposed for 2 hours to 1000 virus particles per cell of Ad5, Ad5.Fib16, Ad5.Fib17, Ad5.Fib35, Ad5.Fib40-L, or Ad5.Fib51 all carrying the green fluorescent protein (GFP) as a marker. After 2 hours cells were washed with PBS and reseeded in medium without addition of virus. TF-1 cells were seeded at a concentration of  $2 \times 10^5$  cells per well of 24-well plates and were also exposed for 2 hours to 1000 virus particles of the different chimeric adenoviruses. Virus was removed by washing the cells after the 2 hours exposure. Both cell types were harvested 48 hours after virus exposure and analysed for GFP expression using a flow cytometer. The results on TF-1 cells, shown in figure 19, demonstrates that chimeric adenoviruses carrying a fiber from serotypes 16, 35, or 51 (all derived from adenovirus subgroup B) have preferred infection characteristics as compared to Ad5 (subgroup C), Ad5.Fib17 (subgroup D), or Ad5.Fib40-L (subgroup F). Primary human stroma was tested since these cells are commonly used as a "feeder" cell to allow proliferation and maintenance of HSCs under *ex vivo* culture conditions. In contrast to the transduction of TF-1 cells, none of the fiber chimeric adenoviruses were able to efficiently transduce human primary stroma (Figure 20). Reasonable infection of human fibroblast-like primary stroma was observed only with Ad5 despite the observation that none of the known receptor molecules are expressed on these cells (see table III). The absence of infection of human stroma using the chimeric viruses is advantageous since in a co-culture setting, the chimeric adenovirus will not be absorbed primarily by the stroma "feeder" cells.

[0198] To test the transduction capacity of the fiber chimaeric viruses, a pool of umbilical cord blood (3 individuals) was used for the isolation of stem cells. CD34<sup>+</sup> cells were isolated from mononuclear cell preparation using a MACS laboratory separation system (Miltenyi Biotec) using the protocol supplied by the manufacturer. Of the CD34<sup>+</sup> cells,  $2 \times 10^5$  were seeded in a volume of 150  $\mu$ l DMEM (no serum; Gibco, Gaithersburg, MD) and 10  $\mu$ l of chimeric adenovirus (to give a final virus particles/cell ratio of 1000) was added. The chimeric adenoviruses tested were Ad5, Ad5.Fib16, Ad5.Fib35, Ad5.Fib17, Ad5.Fib51 all containing Green fluorescent protein (GFP) as a marker. Cells were incubated for 2 hours in a humidified atmosphere of 10% CO<sub>2</sub> at 37°C.

[0199] Thereafter, cells were washed once with 500  $\mu$ l DMEM and resuspended in 500  $\mu$ l of StemPro-34 SF medium (Life Technologies, Grand Island, NY).

[0200] Cells were then cultured for 5 days in 24-well plates (Greiner, Frickenhausen, Germany) on irradiated (20 Gy) pre-established human bone marrow stroma (ref 1), in a humidified atmosphere of 10% CO<sub>2</sub> at 37°C. After 5 days, the entire cell population was collected by trypsinization with 100  $\mu$ l 0.25% Trypsin-EDTA (Gibco). The number of cells before and after 5 days of culture was determined using a hemacytometer. The number of CD34<sup>+</sup> and CD34<sup>+</sup>CD33,38,71 cells in each sample was calculated from the total number of cells recovered and the frequency of the CD34<sup>+</sup>CD33,38,71<sup>+</sup> cells in the whole population as determined by FACS analysis. The transduction efficiency was determined by FACS analysis while monitoring in distinct sub populations the frequency of GFP expressing cells as well as the intensity of GFP per individual cell. The results of this experiment, shown in figure 21, demonstrates that adenovirus serotype 5 or the chimeric adenovirus Ad5.Fib17 does not infect CD34<sup>+</sup>Lin<sup>-</sup> cells as witnessed by the absence of GFP expression. In contrast, with the chimeric viruses carrying the fiber molecule of serotypes 16, 51, or 35 high percentages of GFP positive cells are scored in this cell population. Specificity for CD34<sup>+</sup>Lin<sup>-</sup> is demonstrated since little GFP expression is observed in CD34<sup>+</sup> cells that are also expressing CD33, CD38, and CD71. Subfractionation of the CD34<sup>+</sup>Lin<sup>-</sup> cells (Figure 22) showed that the percentage of cells positive for GFP declines using Ad5.Fib16, Ad5.Fib35, or Ad5.Fib51 when the cells become more and more positive for the early differentiation markers CD33 (myeloid), CD71 (erythroid), and CD38 (common early differentiation marker).

[0201] These results thus demonstrate the specificity of the chimeric adenoviruses Ad5.Fib16, Ad5.Fib35, and

Ad5.Fib51 for HSCs. Figure 23 shows an alignment of the Ad5 fiber with the chimeric B-group fiber proteins derived from Ad16, 35 and 51. By determining the number of cells recovered after the transduction procedure the toxicity of adenovirus can be determined. The recovery of the amount of CD34<sup>+</sup> cells as well as the amount of CD34<sup>+</sup>Lin<sup>-</sup> (Figure 24) demonstrates that a 2 hour exposure to 1000 adenovirus particles did not have an effect on the number of cells recovered.

#### Example 10

##### *An Ad5/fiber35 chimeric vector with cell type specificity for Dendritic cells*

[0202] Dendritic cells are antigen presenting cells (APC), specialized to initiate a primary immune response and able to boost a memory type of immune response. Dependent on their stage of development, DC display different functions: immature DC are very efficient in the uptake and processing of antigens for presentation by Major Histocompatibility Complex (MHC) class I and class II molecules, whereas mature DC, being less effective in antigen capture and processing, perform much better at stimulating naive and memory CD4<sup>+</sup> and CD8<sup>+</sup> T cells, due to the high expression of MHC molecules and co-stimulatory molecules at their cell surface. The immature DCs mature *in vivo* after uptake of antigen, travel to the T-cell areas in the lymphoid organs, and prime T-cell activation.

[0203] Since DCs are the cells responsible for triggering an immune response there has been a long standing interest in loading DCs with immunostimulatory proteins, peptides or the genes encoding these proteins to trigger the immune system. The applications for this strategy are in the field of cancer treatment as well as in the field of vaccination. So far, anti-cancer strategies have focussed primarily on *ex vivo* loading of DCs with antigen (protein or peptide). These studies have revealed that this procedure resulted in induction of cytotoxic T cell activity. The antigens used to load the cells are generally identified as being tumor specific. Some, non-limiting, examples of such antigens are GP100, mage, or Mart-1 for melanoma.

[0204] Besides treatment of cancer many other potential human diseases are currently being prevented through vaccination. In the vaccination strategy, a "crippled" pathogen is presented to the immune system via the action of the antigen presenting cells, i.e. the immature DCs. Well-known examples of disease prevention via vaccination strategies include Hepatitis A, B, and C, influenza, rabies, yellow fever, measles. Besides these well-known vaccination programs, research programs for treatment of malaria, ebola, river blindness, HIV and many other diseases are being developed.

[0205] Many of the above mentioned pathogens are considered to dangerous for the generation of a "crippled" pathogen vaccine. This latter thus calls for the isolation and characterization of proteins of each pathogen which is able to mount a "full blown" immune response thus resulting in complete protection upon challenge with wild type pathogen.

[0206] For this strategy of loading DCs with immunostimulatory proteins or peptides to become therapeutically feasible

[0207] At least two distinct criteria have to be met 1) the isolation of large numbers of DCs which can be isolated, manipulated, and reinfused into a patient, making the procedure autologous. To date, it is possible to obtain such large quantities of immature DCs from cultured peripheral blood monocytes from any given donor. 2) a vector which can transduce DCs efficiently such that the DNA encoding for an immunostimulatory protein can be delivered. The latter is extremely important since it has become clear that the time required for DCs to travel to the lymphoid organs is such that most proteins or peptides are already released from the DCs resulting in incomplete immune priming. Because DCs are terminally differentiated and thus non-dividing cells, recombinant adenoviral vectors are being considered for delivering the DNA encoding for antigens to DCs. Ideally this adenovirus should have a high affinity for dendritic cells but also should not be recognized by neutralizing antibodies of the host such that *in vivo* transduction of DCs can be accomplished. This latter would omit the need for *ex vivo* manipulations of DCs but would result in a medical procedure identical to the vaccination programs which are currently in place, i.e. intramuscular or subcutaneous injection predominantly. Thus, DC transduced by adenoviral vectors encoding an immunogenic protein may be ideally suited to serve as natural adjuvants for immunotherapy and vaccination

[0208] From the above described examples, it can be concluded that efficient gene delivery to DCs is a major interest for the field of gene therapy. Therefore, alteration of the adenovirus serotype 5 host cell range to be able to target DCs *in vitro* as well as *in vivo* is a major interest of the invention. To identify a chimeric adenovirus with preferred infection characteristics for human DCs, we generated a library of Ad5 based viruses carrying the fiber molecule from alternative serotypes (serotypes 8, 9, 13, 16, 17, 32, 35, 45, 40-L, 51). Ad5 was taken along as a reference.

[0209] We evaluated the susceptibility of human monocyte derived immature and mature DC to recombinant chimeric adenoviruses expressing different fibers.

[0210] Human PBMC from healthy donors were isolated through Ficoll-Hypaque density centrifugation. Monocytes were isolated from PBMC by enrichment for CD14<sup>+</sup> cells using staining with FITC labeled anti-human CD 14 monoclonal antibody (Becton Dickinson), anti FITC microbeads and MACS separation columns (Miltenyi Biotec).

[0211] This procedure usually results in a population of cells that are < 90 % CD14<sup>+</sup> as analysed by FACS. Cells

were placed in culture using RPMI-1640 medium (Gibco) containing 10% Foetal Bovine Serum (Gibco), 200 ng/ml rhu GM-CSF (R&D/ITK diagnostics, 100 ng/ml rhu IL-4 (R&D/ITK diagnostics) and cultured for 7 days with feeding of the cultures with fresh medium containing cytokines on alternate days. The immature DC resulting from this procedure after 7 days express a phenotype CD83<sup>+</sup>, CD14<sup>low</sup> or CD14<sup>+</sup>, HLA-DR<sup>+</sup>, as was demonstrated by FACS analysis. Immature DC are matured by culturing the cells in medium containing 100 ng/ml TNF- $\alpha$  for 3 days, where after they expressed CD83 on their cell surface.

[0212] In a pilot experiment  $5 \cdot 10^5$  immature DCs were seeded in wells of 24-well plates and exposed for 24 hours to 100 and 1000 virus particles per cell of each fiber recombinant virus. Virus tested was adenovirus serotype 5 (Ad5), and the fiber chimeric viruses based on Ad5: Ad5.Fib12, Ad5.Fib16, Ad5.Fib28, Ad5.Fib32, Ad5.Fib40-L (long fiber of serotype 40), Ad5.Fib49, and Ad5.Fib51 (where Fibxx stands for the serotype of which the fiber molecule is derived). these viruses are derived from subgroup C, A, B, D, D, F, D, and B respectively. After 24-hours cells were lysed (1% Triton X-100/ PBS) and luciferase activity was determined using a protocol supplied by the manufacturer (Promega, Madison, WI, USA). The results of this experiment, shown in figure 25, demonstrates that Ad5 poorly infects immature DCs as witnessed by one low level of transgene expression. In contrast, Ad5.Fib16 and Ad5.Fib51 (both a B-group fiber chimeric virus) and also Ad5.Fib40-L (Subgroup F) show efficient infection of immature DCs based on luciferase transgene expression.

[0213] In a second experiment,  $5 \cdot 10^5$  immature and mature DC were infected with 10000 virus particles per cell of Ad5, Ad5.Fib16, Ad5.Fib40-L, and Ad5.Fib51 all carrying the LacZ gene as a marker. LacZ expression was monitored by flow cytometric analysis using a CM-FDG kit system and the instructions supplied by the manufacturer (Molecular probes, Leiden, The Netherlands). The results of this experiment, shown in figure 26, correlates with the previous experiment in that Ad5.Fib16 and Ad5.Fib51 are superior to Ad5 in transducing mature and immature human DCs. Also, this experiment shows that Ad5.Fib40-L is not as good as Ad5.Fib16 and Ad5.Fib51 but better than Ad5.

[0214] Based on these results we tested other chimeric adenoviruses containing fibers of B group viruses e.g. Ad5.Fib11 and Ad5.Fib35 for their capacity to infect DCs. We focussed on immature DCs since these are the cells that process an expressed transgene product into MHC class I and II presentable peptides. Immature DC's were seeded at a cell density of  $5 \cdot 10^5$  cells/well in 24 well plates (Costar) and infected with 1000 and 5000 virus particles per cell after which the cells were cultured for 48 hours under conditions for immature DCs prior to cell lysis and Luciferase activity measurements. The result of this experiment, shown in figure 27, demonstrate that Ad5 based chimeric adenoviruses containing fibers of group-B viruses efficiently infect immature DCs. In a fourth experiment we again infected immature DCs identically as described in the former experiments but this time Ad5, Ad5.Fib16, and Ad5.Fib35 were used carrying green fluorescent protein (GFP) as a marker gene. The results on GFP expression measured with a flow cytometer 48 hours after virus exposure is shown in figure 28 and correlates with the data obtained so far.

[0215] Thus, the results so far are consistent in that Ad5 based vectors carrying a fiber from an alternative adenovirus derived from subgroup B predominantly fiber of 35, 51, 16, and 11 are superior to Ad5 for transducing human DCs.

[0216] The adenoviruses disclosed herein are also very suitable in vaccination of animals. To illustrate this, we tested DCs derived from mouse and chimpanzee to identify whether these viruses can be used in these animal models. This latter in particular since the receptor for human adenovirus derived from subgroup B is unknown to date and therefore it is unknown whether this protein is conserved among species. For both species immature DCs were seeded at a density of  $10^5$  cells per well of 24-well plates. Cells were subsequently exposed for 48 hours to 1000 virus particles per cell of Ad5, Ad5.Fib16, and Ad5.Fib51 in case of mouse DC and Ad5, and Ad.Fib35 in case of chimpanzee DCs (see figure 29). The mouse experiment was performed with viruses carrying luciferase as a marker and demonstrated approximately 10-50 fold increased luciferase activity as compared to Ad5. The chimpanzee DCs were infected with the GFP viruses and were analysed using a flow cytometer. These results, also shown in figure 29, demonstrate that Ad5 (3%) transduces chimpanzee DCs very poorly as compared to Ad5.Fib35 (66.5%).

## Example 11

### *Construction of a plasmid-based vector system to generate Ad11-based recombinant viruses*

[0217] The results of the neutralization experiments described in Example 5 show that Ad11, like Ad35, was also not neutralized in the vast majority of human serum samples.

[0218] Therefore, recombinant adenoviruses based on Ad11 are preferred above the commonly used Ad2 and Ad5-based vectors as vectors for gene therapy treatment and vaccination. Both Ad35 and Ad11 are B-group viruses and are classified as viruses belonging to DNA homology cluster 2 (Wadell, 1984).

[0219] Therefore, the genomes of Ad35 and Ad11 are very similar. To generate a plasmid based system for the production of Ad11-based recombinant viruses the adapter plasmid pAdApt35IP1 generated in Example 7 is modified as follows. Construct pAdApt35IP1 is digested with AvrII and then partially with PacI. The digestion mixture is separated on gel and the 4.4 kb fragment containing the expression cassette and the vector backbone is isolated using the gene-

clean kit (BIO 101, Inc.). Then a PCR amplification is performed on wtAd11 DNA using the primers 35F1 and 35R2 (see Example 7) using Pwo DNA polymerase according to the manufacturers instructions. The obtained PCR fragment of 0.5 kb is purified using the PCR purification kit (LTI) and ligated to the above prepared fragment of pAdApt35IP1. This gives construct pAdApt11-35IP1 in which the 5' adenovirus fragment is exchanged for the corresponding sequence of Ad11. Next, pAdApt11-35IP1 is digested with BglII and partially with PacI. The obtained fragments are separated on gel and the 3.6 kb fragment containing the vector sequences, the 5' adenovirus fragment and the expression cassette is purified from gel as above. Next, a PCR fragment is generated using primers 35F3 and 35R4 (see Example 7) on wtAd11 DNA.

[0220] Amplification is done as above and the obtained 1.3 kb fragment is purified and digested with BglII and PacI.

The isolated fragments are then ligated to give construct pAdApt11IP1. This adapter plasmid now contains Ad11 sequences in stead of Ad35 sequences. Correct amplification of PCR amplified Ad11 sequences, is verified by comparison of the sequence in this clone with the corresponding sequence of Ad11 DNA. The latter is obtained by direct sequencing on Ad11 DNA using the indicated PCR primers. The large cosmid clone containing the Ad11 backbone is generated as follows. First, a PCR fragment is amplified on Ad11 DNA using the primers 35F5 and 35R6 with Pwo DNA polymerase as described in Example 7 for Ad35 DNA. The PCR fragment is then purified using the PCR purification kit (LTI) and digested with NotI and NdeI. The resulting 3.1 kb fragment is isolated from gel using the gene clean kit (Bio 101, Inc.). A second PCR fragment is then generated on Ad11 DNA using the primers 35F7 and 35R8 (see Example 7) with Pwo DNA polymerase according to the manufacturers instructions and purified using the PCR purification kit (LTI). This amplified fragment is also digested with NdeI and NotI and the resulting 1.6 kb fragment is purified from gel as above.

[0221] The two digested PCR fragments are then ligated together with cosmid vector pWE15, previously digested with NotI and dephosphorylated using Tsap enzyme (LTI) according to manufacturers instructions. One clone is selected that has one copy of both fragments inserted. Correct clones are selected by analytical NotI digestion that gives a fragment of 4.7 kb. Confirmation is obtained by a PCR reaction using primers 35F5 and 35R8 that gives a fragment of the same size. The correct clone is then linearized with NdeI and isolated from gel. Next, wtAd11 DNA is digested with NdeI and the large 27 kb fragment is isolated from Low melting point agarose gel using agarase enzyme (Roche) according to the manufacturers instructions. Both fragments are then ligated and packaged using  $\lambda$  phage packaging extracts (Stratagene) according to the manufacturers protocol. After infection into STBL-2 cells (LTI) colonies are grown on plates and analysed for the presence of the complete insert.

[0222] The functionality of selected clones is then tested by cotransfection on PER.C6. Hereto, the DNA is digested with NotI and 6  $\mu$ gr is cotransfected with 2  $\mu$ gr of a PCR fragment generated on Ad11 DNA with primers 35F1 and 35R4 (see example 7). Correct clones give CPE within one week following transfection. The correct clone is named pWE.Ad11.pIX-rITR.

[0223] Using the above described procedure, a plasmid-based system consisting of an adapter plasmid suitable for insertion of foreign genes and a large helper fragment containing the viral backbone is generated. Recombinant Ad11-based viruses are made using the methods described inhere for Ad35-based recombinant viruses.

## Example 12

### Neutralization of adenoviruses in samples derived from patients

[0224] In the neutralization experiments described in Examples 1 and 5, all samples were derived from healthy volunteers.

[0225] Since one of the applications of non-neutralized vectors is in the field of gene therapy, it is interesting to investigate whether Ad35 is also neutralized with a low frequency and with low titers in groups of patients that are candidates for treatment with gene therapy.

#### - Cardio-vascular disease patients

[0226] 26 paired serum and pericardial fluid (PF) samples were obtained from patients with heart failure. These were tested against Ad5 and Ad35 using the neutralization assay described in Example 1. The results confirmed the previous data with samples from healthy volunteers. 70% of the serum samples contained NA to Ad5 and 4% to Ad35. In the pericardial fluid samples the titers were lower resulting in a total of 40% with NA to Ad5 and none to Ad35. There was a good correlation between NA in PF and serum i.e. there were no positive PF samples without NA in the paired serum sample. These results show that non-neutralized vectors based on Ad35 are preferred over Ad5 vectors for treatment of cardio-vascular diseases. As is true for all forms of non-neutralized vectors in this application, the vector may be based on the genome of the non-neutralized serotype or may be based on Ad5 (or another serotype) though displaying at least the major capsid proteins (hexon, penton and optionally fiber) of the non-neutralized serotype.

- Rheumatoid Arthritis patients

[0227] The molecular determinant underlying arthritis is not yet known but both T-cell dysfunction and imbalanced growth factor production in joints is known to cause inflammation and hyperplasia of synovial tissue. The synoviocytes start to proliferate and invade the cartilage and bone which leads to destruction of these tissues. Current treatment starts (when in an early stage) with administration of anti-inflammatory drugs (anti-TNF, IL1-RA, IL-10) and/or conventional drugs (e.g. MTX, sulfasalazine). In late stage RA synovectomy is performed which is based on surgery, radiation, or chemical intervention. An alternative or additional option is treatment via gene therapy where an adenoviral vector is delivered directly into the joints of patients and expresses an anti-inflammatory drug or a suicide gene. Previous studies performed in rhesus monkeys suffering from collagen-induced arthritis have shown that Ad5-based vectors carrying a marker gene can transduce synoviocytes. Whether in the human situation adenoviral delivery is hampered by the presence of NA is not known. To investigate the presence of NA in synovial fluid (SF) of RA patients, SF samples were obtained from a panel of 53 random selected patients suffering from rheumatoid arthritis (RA).

[0228] These were tested against several wt adenoviruses using the neutralization assay as described in Example 1. Results of this screen are presented in Table III. Adenovirus type 5 was found to be neutralized in 72% of the SF samples. Most of these samples contain high titers of NA as also the highest dilution of the SF sample that was tested (64x) neutralized Ad5 viruses. This means that adenoviral vector delivery to the synoviocytes in the joints of RA patients will be very inefficient. Moreover, since the titers in the SF are so high it is doubtful whether lavage of the joints prior to vector injection will remove enough of the NA. Of the other serotypes that were tested Ad35 was shown to be neutralized in only 4% of the samples. Therefore, these data confirm the results obtained in serum samples from healthy patients and show that for treatment of rheumatoid arthritis Ad35-based vectors or chimeric vectors displaying at least some of the capsid proteins from Ad35 are preferred vectors.

#### Example 13

##### *Modifications in the backbone of Ad35-based viruses*

##### 1) Generation of pBr/Ad35.Pac-rITR and pBr/Ad35.PRN

[0229] Example 4 describes the generation of the Ad35 subclone pBr/Ad35.Eco13.3. This clone contains Ad35 sequences from bp 21943 to the end of the right ITR cloned into the EcoRI and EcoRV sites of pBr322. To extend these sequences to the PacI site located at bp 18137 in Ad35, pBr/Ad35.Eco13.3 (see Example 4) was digested with AatII and SnaBI and the large vector -containing fragment was isolated from gel using the QIAEX II gel extraction kit (Qiagen). Ad35 wt DNA was digested with PacI and SnaBI and the 4.6 kb fragment was isolated as above. This fragment was then ligated to a double-stranded (ds) linker containing a PacI and an AatII overhang. This linker was obtained after annealing the following oligonucleotides:

A-P1: 5'-CTG GTG GTT AAT-3'

A-P2: 5'-TAA CCA CCA GAC GT-3'

[0230] The ligation mix containing the ds linker and the PacI-SnaBI Ad35 fragment was separated from unligated linker on a LMP gel. The 4.6 kb band was cut out the gel, molten at 65 °C, and then ligated to the purified pBr/Ad35.Eco13.3 vector fragment digested with AatII and SnaBI. Ligations were transformed into electrocompetent DH10B cells (Life Technologies Inc.). The resulting clone, pBr/Ad35.Pac-rITR, contained Ad35 sequences from the PacI site at bp 18137 upto the right ITR.

[0231] Next, a unique restriction site was introduced at the 3' end of the right ITR to be able to free the ITR from vector sequences. Hereto, a PCR fragment was used that covers Ad35 sequences from the NdeI site at bp 33165 to the right ITR having the restriction sites Swal, NotI and EcoRI attached to the rITR. The PCR fragment was generated using primers 35F7 and 35R8 (described in example 7). After purification, the PCR fragment was cloned into the AT cloning vector (Invitrogen) and sequenced to verify correct amplification.

[0232] The correct amplified clone was then digested with EcoRI, blunted with Klenow enzyme and subsequently digested with NdeI and the PCR fragment was isolated. In parallel, the NdeI in the pBr vector in pBr/Ad35.Pac-rITR was removed as follows: A pBr322 vector from which the NdeI site was removed by digestion with NdeI, Klenow treatment and religation, was digested with AatII and NheI. The vector fragment was isolated in LMP gel and ligated to the 16.7 kb Ad35 AatII-NheI fragment from pBr/Ad35.Pac-rITR that was also isolated in an LMP gel. This generated pBr/Ad35.Pac-rITR.ΔNdeI. Next pBr/Ad35.Pac-rITR.ΔNdeI was digested with NheI, the ends were filled in using Klenow enzyme and the DNA was then digested with NdeI. The large fragment containing the vector and Ad35 sequences was isolated. Ligation of this vector fragment and the PCR fragment resulted in pBr/Ad35.PRN. In this clone specific

sequences coding for fiber, E2A, E3, E4 or hexon can be manipulated. In addition, promoter sequences that drive for instance the E4 proteins or the E2 can be mutated or deleted and exchanged for heterologous promoters.

## 2) Generation of Ad35-based viruses with fiber proteins from different serotypes.

[0233] Adenoviruses infect human cells with different efficiencies. Infection is accomplished by a two step process involving: 1. the fiber proteins that mediate binding of the virus to specific receptors on the cells, and 2. the penton proteins that mediate internalization by interaction of for example the RGD sequence to integrins present on the cell surface. For subgroup B viruses of which Ad35 is a member, the cellular receptor for the fiber protein is not known. There are striking differences in infection efficiency of human cells of subgroup B viruses compared to subgroup C viruses like Ad5 (see WO 00/03029 and EP 99200624.7). Even within one subgroup infection efficiencies of certain human cells may differ between various serotypes. For example, the fiber of Ad16, when present on an Ad5-based recombinant virus infects primary endothelial cells, smooth muscle cells and synoviocytes of human and rhesus monkey origin better than Ad5 chimeric viruses carrying the fiber of Ad35 or Ad51. Thus, to obtain high infection efficiencies of Ad35-based viruses, it may be necessary to change the fiber protein for a fiber protein of a different serotype. The technology for such fiber chimeras is described for Ad5-based viruses in Example 3, and is below exemplified for Ad35 viruses.

[0234] First, most fiber sequences are deleted from the Ad35 backbone in construct pBr/Ad35.PRN as follows: The left flanking sequences and part of the fiber protein in Ad35 ranging from bp 30225 upstream of a unique MluI site up to bp 30872 (numbers according to wt Ad35 sequence as disclosed in Figure 6) in the tail of fiber are amplified using primers

DF35-1 : 5'-CAC TCA CCA CCT CCA ATT CC-3'

and

DF35-2: 5'-CGG GAT CCC GTA CGG GTA GAC AGG GTT GAA GG-3'

[0235] This PCR amplification introduces an unique BsiWI site in the tail of the fiber gene.

[0236] The right flanking sequences ranging from the end of the fiber protein at bp 31798 to bp 33199 (numbering according to wtAd35 sequence, Figure 6) , 3' from the unique NdeI site is amplified using primers

DF35-3: 5'-CGG GAT CCG CTA GCT GAA ATA AAG TTT AAG TGT TTT TAT TTA AAA TCA C-3'

and

DF35-4: 5'-CCA GTT GCA TTG CTT GGT TGG-3'.

[0237] This PCR introduces a unique NheI site in the place of the fiber sequences. PCR amplification is done with Pwo DNA polymerase (Roche) according to the manufacturers instructions. After amplification the PCR products are purified using a PCR purification kit and the fragments are digested with BamHI and ligated together. The 2 kb ligated fragments are purified from gel and cloned in the PCR Script Amp vector (Stratagene). Correct amplification is checked by sequencing. The PCR fragment is then excised as a MluI/NdeI fragment and cloned in pBr/Ad35.PRN digested with the same enzymes. This generates pBr/Ad35.PRΔfib, a shuttle vector suitable to introduce fiber sequences of alternative serotypes. This strategy is analogous to the fiber modification strategy for Ad5-based viruses as disclosed in WO00/03029. Primers that are listed in Table I of that application were used to amplify fiber sequences of various subgroups of adenovirus. For amplification of fibers that are cloned in the pBr/Ad35.PRΔfib the same (degenerate) primer sequences can be used, however, the NdeI site in the forward primers (tail oligonucleotides A to E) should be changed to a BsiWI site and the NsiI site in the reverse oligo (knob oligonucleotide 1 to 8) should be changed in a NheI site. Thus fiber 16 sequences are amplified using the following degenerate primers:

5'- CCK GTS TAC CCG TAC GAA GAT GAA AGC-3' and 5'-CCG GCT AGC TCA GTC ATC TTC TCT GAT ATA-3'. Amplified sequences are then digested with BsiWI and NheI and cloned into pBr/Ad35.PRΔfib digested with the same enzymes to generate pBr/Ad35.PRfib16. The latter construct is then digested with PacI and SmaI and the insert is isolated from gel. The PacI/SmaI Ad35 fragment with modified fiber is then cloned into the corresponding sites of pWE/Ad35.pIX-rITR to give pWE/Ad35.pIX-rITR.fib16. This cosmid backbone can then be used with an Ad35-based adapter plasmid to generate Ad35 recombinant viruses that display the fiber of Ad16. Other fiber sequences can be amplified with (degenerate) primers as mentioned above. If one of the fibers sequences turns out to have an internal BsiWI or NheI site, the PCR fragment has to be digested partially with that enzyme.

## 3) Generation of Ad35-based viruses with inducible, E1 independent, E4 expression.

[0238] The adenovirus E4 promoter is activated by expression of E1 proteins. It is not known whether the Ad5 E1 proteins are capable of mediating activation of the Ad35 E4 promoter.



[0239] Therefore, to enable production of Ad35 recombinant viruses on PER.C6 cells, it may be advantageous to make E4 expression independent of E1. This can be achieved by replacing the Ad35-E4 promoter by heterologous promoter sequences like, but not limited to, the 7xTetO promoter.

[0240] Recombinant E1-deleted Ad5-based vectors are shown to have residual expression of viral genes from the vector backbone in target cells, despite the absence of E1 expression. Viral gene expression increases the toxicity and may trigger a host immune response to the infected cell. For most applications of adenoviral vectors in the field of gene therapy and vaccination it is desired to reduce or diminish the expression of viral genes from the backbone. One way to achieve this is to delete all, or as much as possible, sequences from the viral backbone. By deleting E2A, E2B or E4 genes and/or the late gene functions, one has to complement for these functions during production. This complementation can either be by means of a helper virus or through stable addition of these functions, with or without inducible transcription regulation, to the producer cell.

[0241] Methods to achieve this have been described for Ad5 and are known in the art. One specific method is replacement of the E4 promoter by promoter sequences that are not active in the target cells. E4 proteins play a role in for example replication of adenoviruses through activation of the E2 promoter and in late gene expression through regulation of splicing and nuclear export of late gene transcripts. In addition, at least some of the E4 proteins are toxic to cells. Therefore, reduction or elimination of E4 expression in target cells will further improve Ad35-based vectors. One way to achieve this is to replace the E4 promoter by a heterologous promoter that is inactive in the target cells.

[0242] An example of a heterologous promoter/activator system that is inactive in target cells is the tetracyclin inducible TetO system (Gossen and Bujard, 1992). Other prokaryotic or synthetic promoter/activator systems may be used. In this example, the E4 promoter in the backbone of the viral vector is replaced by a DNA fragment containing 7 repeats of the tetracyclin responsive element from the tet operon (7xTetO).

[0243] A strong transactivator for this promoter is a fusion protein containing the DNA binding domain of the tet repressor and the activation domain of VP16 (Tet transactivator protein, Tta). Strong E4 expression, independent of E1 expression, can be accomplished in PER.C6 cells expressing Tta. Tta expressing PER.C6 cells have been generated and described (see Example 15). Ad5 derived E1-deleted viruses with E4 under control of 7xTetO can be generated and propagated on these cells. Following infection in cells of human or animal origin (that do not express the Tta transactivator), E4 expression was found to be greatly diminished compared to E1 deleted viruses with the normal E4 promoter.

[0244] Below the construction of pWE/Ad35.pIX-riTR.TetO-E4, a cosmid helper vector to produce viruses with the E4 promoter replacement, is described.

[0245] First, a fragment was generated by PCR amplification on pBr/Ad35.PRn DNA using the following primers:

355ITR: 5'- GAT CCC GAG CTC ACA ACG TCA TTT TCC CAC G-3'

and

353ITR: 5'-CGG AAT TCG CGG CCG CAT TTA AAT C-3'

[0246] This fragment contains sequences between bp 34656 (numbering according to wtAd35) and the NotI site 3' or the right ITR in pBr/Ad35.PRn and introduces an SstI site 5' of the right ITR sequence.

[0247] A second PCR fragment was generated on pBr/Ad35.PRn DNA using primers:

35DE4: 5'-CCC AAG CTT GCT TGT GTA TAT ATA TTG TGG-3' and

35F7: See example 7.

[0248] This PCR amplifies Ad35 sequences between bp 33098 and 34500 (numbering according to wtAd35) and introduces a HindIII site upstream of the E4 Tata-box. With these two PCR reactions the right- and left -flanking sequences of the E4 promoter are amplified. For amplification, Pwo DNA polymerase was used according to manufacturers instructions. A third fragment containing the 7xTetO promoter was isolated from construct pAAO-E-TATA-7xTetO by digestion with SstI and HindIII. The generation of pAAO-E-TATA-7xTetO is described below. The first PCR fragment (355/353) was then digested with SstI and NotI and ligated to the 7xTetO fragment. The ligation mixture was then digested with HindIII and NotI and the 0.5 kb fragment is isolated from gel. The second PCR fragment (35DE4/35F7) was digested with NdeI and HindIII and gel purified. These two fragments are then ligated into pBr/Ad35.PRn digested with NdeI and NotI to give pBr/Ad35.PR.TetOE4. The modification of the E4 promoter is then transferred to the Ad35 helper cosmid clone by exchanging the PacI/SwaI fragment of the latter with the one from pBr/Ad35.PR.TetOE4 to give pWE/Ad35.pIX-riTR.TetOE4. pAAO-E-TATA.7xTetO was generated as follows. Two oligonucleotides were synthesized:

TATApus: 5'-AGC TTT CTT ATA AAT TTT CAG TGT TAG ACT AGT AAA TTG CTT AAG-3' and

TATAmin: 5'-AGC TCT TAA GCA ATT TAC TAG TCT AAC ACT GAA AAT TTA TAA GAA-3'

(The underlined sequences form a modified TATA box).

[0249] The oligonucleotides were annealed to yield a double stranded DNA fragment with 5' overhangs that are compatible with HindIII digested DNA. The product of the annealing reaction was ligated into HindIII digested pGL3-Enhancer Vector (Promega) to yield pAAO-E-TATA. The clone that had the HindIII site at the 5' end of the insert restored was selected for further cloning.

5 [0250] Next, the heptamerized tet-operator sequence was amplified from the plasmid pUHC-13-3 (Gossen and Bujard, 1992) in a PCR reaction using the Expand PCR system (Roche) according to the manufacturers protocol. The following primers were used:

tet3: 5'- CCG GAG CTC CAT GGC CTA ACT CGA GTT TAC CAC TCC C-3'

10 tet5: 5'-CCC AAG CTT AGC TCG ACT TTC ACT TTT CTC-3'

[0251] The amplified fragment was digested with SstI and HindIII (these sites are present in tet3 and tet5 respectively) and cloned into SstI/HindIII digested pAAO-E-TATA giving rise to pAAO-E-TATA-7xtetO

[0252] To test the functionality of the generated pWE/Ad35.pIX-rITR.TetOE4 cosmid clone, the DNA was digested with NotI. The left end of wtAd35 DNA was then amplified using primers 35F1 and 35R4 (see example 7). Following amplification, the PCR mixture was purified and digested with SalI to remove intact viral DNA. Then 4µg of both the digested pWE/Ad35.pIX-rITR.TetOE4 and the PCR fragment was cotransfected into PER.C6-tTA cells that were seeded in T25 flasks the day before. Transfected cells were transferred to T80 flasks after two days and another two days later CPE was obtained, showing that the cosmid backbone is functional.

#### 20 Example 14

Generation of cell lines capable of complementing E1-deleted Ad35 viruses

#### 25 Generation of pIG135 and pIG270

[0253] Construct pIG.E1A.E1B contains E1 region sequences of Ad5 corresponding to nucleotides 459 to 3510 of the wt Ad5 sequence (Genbank accession number M72360) operatively linked to the human phosphoglycerate kinase promoter (PGK) and the Hepatitis B Virus polyA sequences. The generation of this construct is described in WO97/00326. The E1 sequences of Ad5 were replaced by corresponding sequences of Ad35 as follows. pRSV.Ad35-E1 (described in example 8) was digested with EcoRI and Sse8387I and the 3 kb fragment corresponding to the Ad35 E1 sequences was isolated from gel. Construct pIG.E1A.E1B was digested with Sse8387I completely and partially with EcoRI. The 4.2 kb fragment corresponding to vector sequences without the Ad5 E1 region but retaining the PGK promoter were separated from other fragments on LMP agarose gel and the correct band was excised from gel. Both obtained fragments were ligated resulting in pIG.Ad35-E1.

[0254] This vector was further modified to remove the LacZ sequences present in the pUC119 vector backbone. Hereto, the vector was digested with BsaAI and BstXI and the large fragment was isolated from gel. A double stranded oligo was prepared by annealing the following two oligos:

40 BB1: 5'-GTG CCT AGG CCA CGG GG-3' and

BB2: 5'-GTG GCC TAG GCA C-3'

[0255] Ligation of the oligo and the vector fragment resulted in construct pIG135. Correct insertion of the oligo restores the BsaAI and BstXI sites and introduces a unique AvrII site. Next, we introduced a unique site at the 3' end of the Ad35-E1 expression cassette in pIG135. Hereto, the construct was digested with SapI and the 3' protruding ends were made blunt by treatment with T4 DNA polymerase. The thus treated linear plasmid was further digested with BsrGI and the large vector containing fragment was isolated from gel. To restore the 3' end of the HBVpolyA sequence and to introduce a unique site, a PCR fragment was generated using the following primers:

50 270F: 5'- CAC CTC TGC CTA ATC ATC TC -3' and

270R: 5'- GCT CTA GAA ATT CCA CTG CCT TCC ACC -3'

[0256] The PCR was performed on pIG.Ad35.E1 DNA using Pwo polymerase (Roche) according to the manufacturers instructions. The obtained PCR product was digested with BsrGI and dephosphorylated using Tsap enzym (LTI), the latter to prevent insert dimerization on the BsrGI site. The PCR fragment and the vector fragment were ligated to yield construct pIG270.

*Ad35 E1 sequences are capable of transforming rat primary cells*

[0257] New born WAG/RIJ rats were sacrificed at 1 week of gestation and kidneys were isolated. After careful removal of the capsule, kidneys were disintegrated into a single cell suspension by multiple rounds of incubation in trypsin/EDTA (LTI) at 37 °C and collection of floating cells in cold PBS containing 1% FBS. When most of the kidney was trypsinized all cells were resuspended in DMEM supplemented with 10% FBS and filtered through a sterile cheese cloth. Baby Rat Kidney (BRK) cells obtained from one kidney were plated in 5 dishes (Greiner, 6 cm). When a confluency of 70-80% was reached, the cells were transfected with 1 or 5 µgr DNA/dish using the CaPO<sub>4</sub> precipitation kit (LTI) according to the manufacturers instructions. The following constructs were used in separate transfections: pIG.E1A.E1B (expressing the Ad5-E1 region), pRSV.Ad35-E1, pIG.Ad35-E1 and pIG270 (the latter expressing the Ad35-E1). Cells were incubated at 37 °C, 5% CO<sub>2</sub> until foci of transformed cells appeared. Table IV shows the number of foci that resulted from several transfection experiments using circular or linear DNA. As expected, the Ad5-E1 region efficiently transformed BRK cells. Foci also appeared in the Ad35-E1 transfected cell layer although with lower efficiency. The Ad35 transformed foci appeared at a later time point: ~2 weeks post transfection compared with 7-10 days for Ad5-E1. These experiments clearly show that the E1 genes of the B group virus Ad35 are capable of transforming primary rodent cells.

[0258] This proves the functionality of the Ad35-E1 expression constructs and confirms earlier findings of the transforming capacity of the B-group viruses Ad3 and Ad7 (Dijkema, 1979).

[0259] To test whether the cells in the foci were really transformed a few foci were picked and expanded. From the 7 picked foci at least 5 turned out to grow as established cell lines.

*Generation of new packaging cells derived from primary human amniocytes*

[0260] Amniotic fluid obtained after amnioscentesis was centrifugated and cells were resuspended in AmnioMax medium (LTI) and cultured in tissue culture flasks at 37 °C and 10 % CO<sub>2</sub>. When cells were growing nicely (approximately one cell division/24 hrs.), the medium was replaced with a 1:1 mixture of AmnioMax complete medium and DMEM low glucose medium (LTI) supplemented with Glutamax I (end concentration 4mM, LTI) and glucose (end concentration 4.5 gr/L, LTI) and 10% FBS (LTI). For transfection ~ 5x10<sup>5</sup> cells were plated in 10 cm tissue culture dishes. The day after, cells were transfected with 20 µgr of circular pIG270/dish using the CaPO<sub>4</sub> transfection kit (LTI) according to manufacturers instructions and cells were incubated overnight with the DNA precipitate. The following day, cells were washed 4 times with PBS to remove the precipitate and further incubated for over three weeks until foci of transformed cells appeared.

[0261] Once a week the medium was replaced by fresh medium. Other transfection agents like, but not limited to, LipofectAmine (LTI) or PEI (Polyethylenimine, high molecular weight, water-free, Aldrich) were used. Of these three agents PEI reached the best transfection efficiency on primary human amniocytes: ~1% blue cells 48 hrs. following transfection of pAdApt35.LacZ.

[0262] Foci are isolated as follows. The medium is removed and replaced by PBS after which foci are isolated by gently scraping the cells using a 50-200 µl Gilson pipette with a disposable filter tip. Cells contained in 10 µl PBS were brought in a 96 well plate containing 15 µl trypsin/EDTA (LTI) and a single cell suspension was obtained by pipetting up and down and a short incubation at room temperature.

[0263] After addition of 200 µl of the above described 1:1 mixture of AmnioMax complete medium and DMEM with supplements and 10% FBS, cells were further incubated. Clones that continued to grow were expanded and analysed their ability to complement growth of E1-deleted adenoviral vectors of different sub-groups, specifically ones derived from B-group viruses specifically from Ad35 or Ad11.

*Generation of new packaging cell lines from human embryonic retinoblasts*

[0264] Human retina cells are isolated from the eyes of aborted fetuses and cultured in DMEM medium (LTI) supplemented with 10% FES (LTI). The day before transfection, ~5x10<sup>5</sup> cells are plated in 6 cm dishes and cultured overnight at 37 °C and 10% CO<sub>2</sub>. Transfection is done using the CaPO<sub>4</sub> precipitation kit (LTI) according to the manufacturers instructions. Each dish is transfected with 8-10 µgr pIG270 DNA, either as a circular plasmid or as a purified fragment. To obtain the purified fragment, pIG270 was digested with AvrII and XbaI and the 4 kb fragment corresponding to the Ad35 E1 expression cassette was isolated from gel by agarase treatment (Roche). The following day, the precipitate is washed away carefully by four washes with sterile PBS. Then fresh medium is added and transfected cells are further cultured until foci of transformed cells appear. When large enough (>100 cells) foci are picked and brought into 96-wells as described above. Clones of transformed human embryonic retinoblasts that continue to grow, are expanded and tested for their ability to complement growth of E1-deleted adenoviral vectors of different sub-groups specifically ones derived from B-group viruses specifically from Ad35 or Ad11.

*New packaging cell lines derived from PER.C6*

[0265] As described in example 8, it is possible to generate and grow Ad35 E1-deleted viruses on PER.C6 cells with cotransfection of an Ad35-E1 expression construct, e.g. pRSV.Ad35.E1. However, large scale production of recombinant adenoviruses using this method is cumbersome because for each amplification step a transfection of the Ad35-E1 construct is needed. In addition, this method increases the risk of non-homologous recombination between the plasmid and the virus genome with high chances of generation of recombinant viruses that incorporate E1 sequences resulting in replication competent viruses. To avoid this, the expression of Ad35-E1 proteins in PER.C6 has to be mediated by integrated copies of the expression plasmid in the genome. Since PER.C6 cells are already transformed and express Ad5-E1 proteins, addition of extra Ad35-E1 expression may be toxic for the cells, however, it is not impossible to stably transfect transformed cells with E1 proteins since Ad5-E1 expressing A549 cells have been generated..

[0266] In an attempt to generate recombinant adenoviruses derived from subgroup B virus Ad7, Abrahamsen *et al.* (1997) were not able to generate E1-deleted viruses on 293 cells without contamination of wt Ad7. Viruses that were picked after plaque purification on 293-ORF6 cells (Brough *et al.*, 1996) were shown to have incorporated Ad7 E1B sequences by non-homologous recombination. Thus, efficient propagation of Ad7 recombinant viruses proved possible only in the presence of Ad7-E1B expression and Ad5-E4-ORF6 expression. The E1B proteins are known to interact with cellular as well as viral proteins (Bridge *et al.*, 1993; White, 1995). Possibly, the complex formed between the E1B 55K protein and E4-ORF6 which is necessary to increase mRNA export of viral proteins and to inhibit export of most cellular mRNAs, is critical and in some way serotype specific. The above experiments suggest that the E1A proteins of Ad5 are capable of complementing an Ad7-E1A deletion and that Ad7-E1B expression in adenovirus packaging cells on itself is not enough to generate a stable complementing cell line. To test whether one or both of the Ad35-E1B proteins is/are the limiting factor in efficient Ad35 vector propagation on PER.C6 cells, we have generated an Ad35 adapter plasmid that does contain the E1B promoter and E1B sequences but lacks the promoter and the coding region for E1A. Hereto, the left end of wtAd35 DNA was amplified using the primers 35F1 and 35R4 (both described in Example 7) with Pwo DNA polymerase (Roche) according to the manufacturers instructions. The 4.6 kb PCR product was purified using the PCR purification kit (LTI) and digested with SnaBI and Apal enzymes. The resulting 4.2 kb fragment was then purified from gel using the QIAEXII kit (Qiagen).

[0267] Next, pAdApt35IP1 (Example 7) was digested with SnaBI and Apal and the 2.6 kb vector containing fragment was isolated from gel using the GeneClean kit (BIO 101, Inc). Both isolated fragments were ligated to give pBr/Ad35.leftITR-pIX. Correct amplification during PCR was verified by a functionality test as follows: The DNA was digested with BstBI to liberate the Ad35 insert from vector sequences and 4 µgr of this DNA was cotransfected with 4 µgr of NotI digested pWE/Ad35.pIX-rITR (Example 7) into PER.C6 cells.

[0268] The transfected cells were passaged to T80 flasks at day 2 and again two days later CPE had formed showing that the new pBr/Ad35.leftITR-pIX construct contains functional E1 sequences. The pBr/Ad35.leftITR-pIX construct was then further modified as follows. The DNA was digested with SnaBI and HindIII and the 5' HindIII overhang was filled in using Klenow enzyme. Religation of the digested DNA and transformation into competent cells (LTI) gave construct pBr/Ad35.leftITR-pIXΔE1A. This latter construct contains the left end 4.6 kb of Ad35 except for E1A sequences between bp 450 and 1341 (numbering according to wtAd35, Figure 6) and thus lacks the E1A promoter and most of the E1A coding sequences. pBr/Ad35.leftITR-pIXΔE1A was then digested with BstBI and 2 µgr of this construct was cotransfected with 6 µgr of NotI digested pWE/Ad35.pIX-rITR (Example 7) into PER.C6 cells. One week following transfection full CPE had formed in the transfected flasks.

[0269] This experiment shows that the Ad35-E1A proteins are functionally complemented by Ad5-e1A expression in PER.C6 cells and that at least one of the Ad35-E1B proteins cannot be complemented by Ad5-E1 expression in PER.C6. It further shows that it is possible to make a complementing cell line for Ad35 E1-deleted viruses by expressing Ad35-E1B proteins in PER.C6. Stable expression of Ad35-E1B sequences from integrated copies in the genome of PER.C6 cells may be driven by the E1B promoter and terminated by a heterologous poly-adenylation signal like, but not limited to, the HBVpA.

[0270] The heterologous pA signal is necessary to avoid overlap between the E1B insert and the recombinant vector, since the natural E1B termination is located in the pIX transcription unit which has to be present on the adenoviral vector.

[0271] Alternatively, the E1B sequences may be driven by a heterologous promoter like, but not limited to the human PGK promoter or by an inducible promoter like, but not limited to the 7xtetO promoter (Gossen and Bujard, 1992). Also in these cases the transcription termination is mediated by a heterologous pA sequence, e.g. the HBV pA. The Ad35-E1B sequences at least comprise one of the coding regions of the E1B 21K and the E1B 55K proteins located between nucleotides 1611 and 3400 of the wt Ad35 sequence. The insert may also include (part of the) Ad35-E1B sequences between nucleotides 1550 and 1611 of the wt Ad35 sequence.

## Example 15

Generation of producer cell lines for the production of recombinant adenoviral vectors deleted in early region 1 and early region 2A

Generation of PER.C6-tTA cells

[0272] Here is described the generation of cell lines for the production of recombinant adenoviral vectors that are deleted in early region 1 (E1) and early region 2A (E2A).

[0273] The producer cell lines complement for the E1 and E2A deletion from recombinant adenoviral vectors *in trans* by constitutive expression of both E1 and E2A genes. The pre-established Ad5-E1 transformed human embryo retinoblast cell line PER.C6 (WO 97/00326) was further equipped with E2A expression cassettes.

[0274] The adenoviral E2A gene encodes a 72 kDa DNA Binding Protein with has a high affinity for single stranded DNA.

[0275] Because of its function, constitutive expression of DBP is toxic for cells. The ts125E2A mutant encodes a DBP which has a Pro→Ser substitution of amino acid 413. Due to this mutation, the ts125E2A encoded DBP is fully active at the permissive temperature of 32°C, but does not bind to ssDNA at the non-permissive temperature of 39°C. This allows the generation of cell lines that constitutively express E2A, which is not functional and is not toxic at the non-permissive temperature of 39°C. Temperature sensitive E2A gradually becomes functional upon temperature decrease and becomes fully functional at a temperature of 32°C, the permissive temperature.

A. Generation of plasmids expressing the wild type E2A- or temperature sensitive ts125E2A gene.

[0276]

pcDNA3wtE2A: The complete wild-type early region 2A (E2A) coding region was amplified from the plasmid pBR/Ad.Bam-riTR (ECACC deposit P97082122) with the primers DBPpcr1 and DBPpcr2 using the Expand™ Long Template PCR system according to the standard protocol of the supplier (Boehringer Mannheim). The PCR was performed on a Biometra Trio Thermoblock, using the following amplification program: 94°C for 2 minutes, 1 cycle; 94°C for 10 seconds + 51°C for 30 seconds + 68°C for 2 minutes, 1 cycle; 94°C for 10 seconds + 58°C for 30 seconds + 68°C for 2 minutes, 10 cycles; 94°C for 10 seconds + 58°C for 30 seconds + 68°C for 2 minutes with 10 seconds extension per cycle, 20 cycles; 68°C for 5 minutes, 1 cycle. The primer DBPpcr1: CGG GAT CCG CCA CCA TGG CCA GTC GGG AAG AGG AG (5' to 3') contains a unique *Bam*HI restriction site (underlined) 5' of the Kozak sequence (italic) and start codon of the E2A coding sequence. The primer DBPpcr2: CGG AAT TCT TAA AAA TCA AAG GGG TTC TGC CGC (5' to 3') contains a unique *Eco*RI restriction site (underlined) 3' of the stop codon of the E2A coding sequence. The bold characters refer to sequences derived from the E2A coding region. The PCR fragment was digested with *Bam*HI/*Eco*RI and cloned into *Bam*HI/*Eco*RI digested pcDNA3 (Invitrogen), giving rise to pcDNA3wtE2A.

pcDNA3tsE2A: The complete ts125E2A-coding region was amplified from DNA isolated from the temperature sensitive adenovirus mutant H5ts125. The PCR amplification procedure was identical to that for the amplification of wtE2A. The PCR fragment was digested with *Bam*HI/*Eco*RI and cloned into *Bam*HI/*Eco*RI digested pcDNA3 (Invitrogen), giving rise to pcDNA3tsE2A. The integrity of the coding sequence of wtE2A and tsE2A was confirmed by sequencing.

B. Growth characteristics of producer cells for the production of recombinant adenoviral vectors cultured at 32-, 37- and 39°C.

[0277] PER.C6 cells were cultured in Dulbecco's Modified Eagle Medium (DMEM, Gibco BRL) supplemented with 10% Fetal Bovine Serum (FBS, Gibco BRL) and 10mM MgCl<sub>2</sub> in a 10% CO<sub>2</sub> atmosphere at either 32°C, 37°C or 39°C. At day 0, a total of 1 x 10<sup>6</sup> PER.C6 cells were seeded per 25cm<sup>2</sup> tissue culture flask (Nunc) and the cells were cultured at either 32°C, 37°C or 39°C. At day 1-8, cells were counted. Figure 30 shows that the growth rate and the final cell density of the PER.C6 culture at 39°C are comparable to that at 37°C. The growth rate and final density of the PER.C6 culture at 32°C were slightly reduced as compared to that at 37°C or 39°C. No significant cell death was observed at any of the incubation temperatures. Thus PER.C6 performs very well both at 32°C and 39°C, the permissive and non-permissive temperature for ts125E2A, respectively.

## C. Transfection of PER.C6 with E2A expression vectors; colony formation and generation of cell lines

[0278] One day prior to transfection,  $2 \times 10^6$  PER.C6 cells were seeded per 6 cm tissue culture dish (Greiner) in DMEM, supplemented with 10% FBS and 10mM  $MgCl_2$  and incubated at 37°C in a 10%  $CO_2$  atmosphere. The next day, the cells were transfected with 3, 5 or 8µg of either pcDNA3, pcDNA3wtE2A or pcDNA3tsE2A plasmid DNA per dish, using the LipofectAMINE PLUS™ Reagent Kit according to the standard protocol of the supplier (Gibco BRL), except that the cells were transfected at 39°C in a 10%  $CO_2$  atmosphere. After the transfection, the cells were constantly kept at 39°C, the non-permissive temperature for ts125E2A. Three days later, the cells were put in DMEM supplemented with 10% FBS, 10mM  $MgCl_2$  and 0.25mg/ml G418 (Gibco BRL), and the first G418 resistant colonies appeared at 10 days post transfection. As shown in table 1, there was a dramatic difference between the total number of colonies obtained after transfection of pcDNA3 (~200 colonies) or pcDNA3tsE2A (~100 colonies) and pcDNA3wtE2A (only 4 colonies). These results indicate that the toxicity of constitutively expressed E2A can be overcome by using a temperature sensitive mutant of E2A (ts125E2A) and culturing of the cells at the non-permissive temperature of 39°C.

[0279] From each transfection, a number of colonies was picked by scraping the cells from the dish with a pipette. The detached cells were subsequently put into 24 wells tissue culture dishes (Greiner) and cultured further at 39°C in a 10%  $CO_2$  atmosphere in DMEM, supplemented with 10% FBS, 10mM  $MgCl_2$  and 0.25mg/ml G418. As shown in table 1, 100% of the pcDNA3 transfected colonies (4/4) and 82% of the pcDNA3tsE2A transfected colonies (37/45) were established to stable cell lines (the remaining 8 pcDNA3tsE2A transfected colonies grew slowly and were discarded). In contrast, only 1 pcDNA3wtE2A-transfected colony could be established. The other 3 died directly after picking.

[0280] Next, the E2A expression levels in the different cell lines were determined by Western blotting. The cell lines were seeded on 6 well tissue culture dishes and sub-confluent cultures were washed twice with PBS (NPBI) and lysed and scraped in RIPA (1% NP-40, 0.5% sodium deoxycholate and 0.1% SDS in PBS, supplemented with 1mM phenylmethylsulfonylfluoride and 0.1 mg/ml trypsin inhibitor). After 15 minutes incubation on ice, the lysates were cleared by centrifugation. Protein concentrations were determined by the Bio-Rad protein assay, according to standard procedures of the supplier (BioRad). Equal amounts of whole-cell extract were fractionated by SDS-PAGE on 10% gels. Proteins were transferred onto Immobilon-P membranes (Millipore) and incubated with the αDBP monoclonal antibody B6. The secondary antibody was a horseradish-peroxidase-conjugated goat anti mouse antibody (BioRad). The Western blotting procedure and incubations were performed according to the protocol provided by Millipore. The complexes were visualized with the ECL detection system according to the manufacturer's protocol (Amersham). Figure 31 shows that all of the cell lines derived from the pcDNA3tsE2A transfection expressed the 72-kDa E2A protein (left panel, lanes 4-14; middle panel, lanes 1-13; right panel, lanes 1-12). In contrast, the only cell line derived from the pcDNAwtE2A transfection did not express the E2A protein (left panel, lane 2). No E2A protein was detected in extract from a cell line derived from the pcDNA3 transfection (left panel, lane 1), which served as a negative control. Extract from PER.C6 cells transiently transfected with pcDNA3ts125 (left panel, lane 3) served as a positive control for the Western blot procedure. These data confirmed that constitutive expression of wtE2A is toxic for cells and that using the ts125 mutant of E2A could circumvent this toxicity.

## D. Complementation of E2A deletion in adenoviral vectors on PER.C6 cells constitutively expressing full-length ts125E2A.

[0281] The adenovirus Ad5.dl802 is an Ad 5 derived vector deleted for the major part of the E2A coding region and does not produce functional DBP. Ad5.dl802 was used to test the E2A trans-complementing activity of PER.C6 cells constitutively expressing ts125E2A. Parental PER.C6 cells or PER.C6tsE2A clone 3-9 were cultured in DMEM, supplemented with 10% FBS and 10mM  $MgCl_2$  at 39°C and 10%  $CO_2$  in 25 cm<sup>2</sup> flasks and either mock infected or infected with Ad5.dl802 at an m.o.i. of 5. Subsequently the infected cells were cultured at 32°C and cells were screened for the appearance of a cytopathic effect (CPE) as determined by changes in cell morphology and detachment of the cells from the flask. Full CPE appeared in the Ad5.dl802 infected PER.C6tsE2A clone 3-9 within 2 days.

[0282] No CPE appeared in the Ad5.dl802 infected PER.C6 cells or the mock infected cells. These data showed that PER.C6 cells constitutively expressing ts125E2A complemented in trans for the E2A deletion in the Ad5.dl802 vector at the permissive temperature of 32°C.

## E. Serum-free suspension culture of PER.C6tsE2A cell lines.

[0283] Large-scale production of recombinant adenoviral vectors for human gene therapy requires an easy and scalable culturing method for the producer cell line, preferably a suspension culture in medium devoid of any human or animal constituents. To that end, the cell line PER.C6tsE2A c5-9 (designated c5-9) was cultured at 39°C and 10%  $CO_2$  in a 175 cm<sup>2</sup> tissue culture flask (Nunc) in DMEM, supplemented with 10% FBS and 10mM  $MgCl_2$ . At sub-confluency (70-80% confluent), the cells were washed with PBS (NPBI) and the medium was replaced by 25 ml serum free

suspension medium Ex-cell™ 525 (JRH) supplemented with 1 x L-Glutamine (Gibco BRL), hereafter designated SFM. Two days later, cells were detached from the flask by flicking and the cells were centrifuged at 1,000 rpm for 5 minutes. The cell pellet was resuspended in 5 ml SFM and 0.5 ml cell suspension was transferred to a 80 cm<sup>2</sup> tissue culture flask (Nunc), together with 12 ml fresh SFM. After 2 days, cells were harvested (all cells are in suspension) and counted in a  
 5 Burkner cell counter. Next, cells were seeded in a 125 ml tissue culture erlenmeyer (Corning) at a seeding density of  $3 \times 10^5$  cells per ml in a total volume of 20 ml SFM. Cells were further cultured at 125 RPM on an orbital shaker (GFL) at 39°C in a 10% CO<sub>2</sub> atmosphere. Cells were counted at day 1-6 in a Burkner cell counter. In Figure 4, the mean growth curve from 8 cultures is shown. PER.C6tsE2A c5-9 performed well in serum free suspension culture. The maximum cell density of approximately  $2 \times 10^6$  cells per ml is reached within 5 days of culture.

10 F. Growth characteristics of PER.C6 and PER.C6/E2A at 37°C and 39°C.

[0284] PER.C6 cells or PER.C6ts125E2A (c8-4) cells were cultured in Dulbecco's Modified Eagle Medium (DMEM, Gibco BRL) supplemented with 10% Fetal Bovine Serum (FBS, Gibco BRL) and 10mM MgCl<sub>2</sub> in a 10% CO<sub>2</sub> atmosphere at either 37°C (PER.C6) or 39°C (PER.C6ts125E2A c8-4). At day 0, a total of  $1 \times 10^6$  cells were seeded per  
 15 25cm<sup>2</sup> tissue culture flask (Nunc) and the cells were cultured at the respective temperatures. At the indicated time points, cells were counted. The growth of PER.C6 cells at 37°C was comparable to the growth of PER.C6ts125E2A c8-4 at 39°C (Figure 33).

[0285] This shows that constitutive expression of ts125E2A encoded DBP had no adverse effect on the growth of  
 20 cells at the non-permissive temperature of 39°C.

G. Stability of PER.C6ts125E2A

[0286] For several passages, the PER.C6ts125E2A cell line clone 8-4 was cultured at 39°C and 10% CO<sub>2</sub> in a 25  
 25 cm<sup>2</sup> tissue culture flask (Nunc) in DMEM, supplemented with 10% FBS and 10 mM MgCl<sub>2</sub> in the absence of selection pressure (G418). At sub-confluency (70-80% confluent), the cells were washed with PBS (NPBI) and lysed and scraped in RIPA (1% NP-40, 0.5% sodium deoxycholate and 0.1% SDS in PBS, supplemented with 1mM phenylmethylsulfonylfluoride and 0.1 mg/ml trypsin inhibitor). After 15 minutes incubation on ice, the lysates were cleared by centrifuga-  
 30 tion. Protein concentrations were determined by the BioRad protein assay, according to standard procedures of the supplier (BioRad). Equal amounts of whole-cell extract were fractionated by SDS-PAGE in 10% gels. Proteins were transferred onto Immobilon-P membranes (Millipore) and incubated with the αDBP monoclonal antibody B6. The secondary antibody was a horseradish-peroxidase-conjugated goat anti mouse antibody (BioRad). The Western blotting procedure and incubations were performed according to the protocol provided by Millipore. The complexes were visu-  
 35 alized with the ECL detection system according to the manufacturer's protocol (Amersham). The expression of ts125E2A encoded DBP was stable for at least 16 passages, which is equivalent to approximately 40 cell doublings (Figure 34). No decrease in DBP levels was observed during this culture period, indicating that the expression of ts125E2A was stable, even in the absence of G418 selection pressure.

Example 16

#### 40 Generation of tTA expressing packaging cell lines

A. Generation of a plasmid from which the tTA gene is expressed.

45 [0287]

pcDNA3.1-tTA: The tTA gene, a fusion of the tetR and VP16 genes, was removed from the plasmid pUHD 15-1 (Gossen and Bujard, 1992) by digestion using the restriction enzymes *Bam*HI and *Eco*RI. First, pUHD15-1 was digested with *Eco*RI.

50 The linearized plasmid was treated with Klenow enzyme in the presence of dNTPs to fill in the *Eco*RI sticky ends. Then, the plasmid was digested with *Bam*HI. The resulting fragment, 1025 bp in length, was purified from agarose. Subsequently, the fragment was used in a ligation reaction with *Bam*HI/*Eco*RV digested pcDNA 3.1 HYGRO (-) (Invitrogen) giving rise to pcDNA3.1-tTA. After transformation into competent *E. Coli* DH5α (Life Techn.) and analysis of ampicillin resistant colonies, one clone was selected that showed a digestion pattern as expected for  
 55 pcDNA3.1-tTA.

*B. Transfection of PER.C6 and PER.C6/E2A with the tTA expression vector; colony formation and generation of cell lines*

[0288] One day prior to transfection,  $2 \times 10^6$  PER.C6 or PER.C6/E2A cells were seeded per 60 mm tissue culture dish (Greiner) in Dulbecco's modified essential medium (DMEM, Gibco BRL) supplemented with 10% FBS (JRH) and 10 mM  $MgCl_2$  and incubated at 37°C in a 10%  $CO_2$  atmosphere. The next day, cells were transfected with 4-8  $\mu g$  of pcDNA3.1-tTA plasmid DNA using the LipofectAMINE PLUS™ Reagent Kit according to the standard protocol of the supplier (Gibco BRL). The cells were incubated with the LipofectAMINE PLUS™-DNA mixture for four hours at 37°C and 10%  $CO_2$ . Then, 2 ml of DMEM supplemented with 20% FBS and 10 mM  $MgCl_2$  was added and cells were further incubated at 37°C and 10%  $CO_2$ . The next day, cells were washed with PBS and incubated in fresh DMEM supplemented with 10% FBS, 10 mM  $MgCl_2$  at either 37°C (PER.C6) or 39°C (Per.C6/E2A) in a 10%  $CO_2$  atmosphere for three days. Then, the media were exchanged for selection media; PER.C6 cells were incubated with DMEM supplemented with 10% PBS, 10 mM  $MgCl_2$  and 50  $\mu g/ml$  hygromycin B (GIBCO) while PER.C6/E2A cells were maintained in DMEM supplemented with 10% PBS, 10 mM  $MgCl_2$  and 100  $\mu g/ml$  hygromycin B.

[0289] Colonies of cells that resisted the selection appeared within three weeks while nonresistant cells died during this period.

[0290] From each transfection, a number of independent, hygromycin resistant cell colonies were picked by scraping the cells from the dish with a pipette and put into 2.5  $cm^2$  dishes (Greiner) for further growth in DMEM containing 10% FBS, 10 mM  $MgCl_2$  and supplemented with 50  $\mu g/ml$  (PER.C6 cells) or 100  $\mu g/ml$  (PER.C6/E2A cells) hygromycin in a 10%  $CO_2$  atmosphere and at 37°C or 39°C, respectively.

[0291] Next, it was determined whether these hygromycin-resistant cell colonies expressed functional tTA protein.

[0292] Therefore, cultures of PER.C6/tTA or PER/E2A/tTA cells were transfected with the plasmid pUHC 13-3 that contains the reporter gene luciferase under the control of the 7xtetO promoter (Gossens and Bujard, 1992). To demonstrate that the expression of luciferase was mediated by tTA, one half of the cultures was maintained in medium without doxycycline.

[0293] The other half was maintained in medium with 8  $\mu g/ml$  doxycycline (Sigma). The latter drug is an analogue of tetracycline and binds to tTA and inhibits its activity. All PER.C6/tTA and PER/E2A/tTA cell lines yielded high levels of luciferase, indicating that all cell lines expressed the tTA protein (Figure 35). In addition, the expression of luciferase was greatly suppressed when the cells were treated with doxycycline. Collectively, the data showed that the isolated and established hygromycin-resistant PER.C6 and PER/E2A cell clones all expressed functional tTA.

Legend to the figures:

[0294]

Figure 1:

Bar graph showing the percentage of serum samples positive for neutralisation for each human wt adenovirus tested (see example 1 for description of the neutralisation assay).

Figure 2:

Graph showing absence of correlation between the VP/CCID50 ratio and the percentage of neutralisation.

Figure 3:

Schematic representation of a partial restriction map of Ad35 (taken from Kang *et al.*, 1989) and the clones generated to make recombinant Ad35-based viruses.

Figure 4: Bar graph presenting the percentage sera samples that show neutralizing activity to a selection of adenovirus serotypes. Sera were derived from healthy volunteers from Belgium and the UK.

Figure 5: Bar graph presenting the percentage sera samples that show neutralizing activity to adenovirus serotypes 5, 11, 26, 34, 35, 48 and 49. Sera were derived from five different locations in Europe and the United States.

Figure 6: Sequence of human adenovirus type 35. As explained in the text the nucleotide sequence of the terminal ends of the virus are not definite resolved.

Figure 7: Map of pAdApt

Figure 8: Map of pIPspAdapt



Figure 9: Map of pIPspAdapt1

Figure 10: Map of pIPspAdapt3

5 Figure 11: Map of pAdApt35IP3

Figure 12: Map of pAdApt35IP1

10 Figure 13: Schematic representation of the steps undertaken to construct pWE.Ad35.pIX-rITR

Figure 14: Map of pWE.Ad35.pIX-rITR

Figure 15: Map of pRSV.Ad35-E1

15 Figure 16: Map of PGKneopA

Figure 17: Map of pRSVpNeo Figure 18: Map of pRSVhvbvNeo

20

Figure 19: Flow cytometric analyses on Green fluorescent protein (GFP) expression in human TF-1 cells. Non-transduced TF-1 cells were used to set a background level of 1%. GFP expression in cells transduced with Ad5, Ad5.Fib16, Ad5.Fib17, Ad5.Fib40-L, Ad5.Fib35, and Ad5.Fib51 is shown.

25 Figure 20: Transduction of primary human fibroblast-like stroma. Cells were analysed 48 hours after a two hour exposure to the different chimaeric fiber viruses. Shown is percentage of cells found positive for the transgene: green fluorescent protein (GFP) using a flow cytometer. Non-transduced stroma cells were used to set a background at 1%. Results of different experiments (n=3) are shown  $\pm$  standard deviation.

30 Figure 21: Transduction of primary human fibroblast-like stroma, CD34<sup>+</sup> cells and CD34<sup>+</sup>Lin<sup>-</sup> cells. Cells were analyzed 5 days after a two hour exposure to the different chimaeric fiber viruses. Shown is percentage of cells found positive for the transgene: green fluorescent protein (GFP) using a flow cytometer. Non-transduced cells were used to set a background at 1%. Also shown is the number of GFP positive events divided by the total number of events analysed (between brackets).

35

Figure 22 A) Flow cytometric analysis of GFP positive cells after transduction of CD34<sup>+</sup> cells with Ad5.Fib51. All cells gated in R2-R7 are positive for CD34 but differ in their expression of early differentiation markers CD33, CD38, and CD71 (Lin). Cells in R2 are negative for CD33, CD38, CD71 whereas cells in R7 are positive for these markers. To demonstrate specificity of Ad5.Fib51 the percentage of GFP positive cells was determined in R2-R7 which proved to decline from 91% (R2) to 15% (R7). B) Identical experiment as shown under A (X-axis is R2-R7) but for the other Ad fiber chimaeric viruses showing that Ad5.Fib35, and Ad5.Fib16 behave similar as Ad5.Fib51.

40

Figure 23: Alignment of the chimeric fiber proteins of Ad5fib16, Ad5fib35 and Ad5fib51 with the Ad5 fiber sequence.

45 Figure 24: Toxicity of Adenovirus exposure to primitive human Bone marrow cells and Stem cells. Cell cultures were counted just before and 5 days after adenovirus transduction. Shown is the percentage of primitive human bone marrow cells (CD34<sup>+</sup>) and HSCs (CD34<sup>+</sup>Lin<sup>-</sup>) recovered as compared to day 0.

50 Figure 25: Transduction of immature DCs at a virus dose of 100 or 1000 virus particles per cell. Virus tested is Ad5 and Ad5 based vectors carrying the fiber of serotype 12 (Ad5.Fib12), 16 (Ad5.Fib16), 28 (Ad5.Fib28), 32 (Ad5.Fib32), the long fiber of 40 (Ad5.Fib40-L, 49 (Ad5.Fib49), 51 (Ad5.Fib51). Luciferase transgene expression is expressed as relative light units per microgram of protein.

55 Figure 26: Flow cytometric analyses of LacZ expression on immature and mature DCs transduced with 10000 virus particles per cell of Ad5 or the fiber chimaeric vectors Ad5.Fib16, Ad5.Fib40-L, or Ad5.Fib51. Percentages of cells scored positive are shown in upper left corner of each histogram.

Figure 27: Luciferase transgene expression in human immature DCs measured 48 hours after transduction with

1000 or 5000 virus particles per cell. Virus tested were fiber chimaeric viruses carrying the fiber of subgroup B members (serotypes 11, 16, 35, and 51).

Figure 28: Green fluorescent protein (GFP) expression in immature human DCs 48 hours after transduction with 1000 virus particles per cell of Ad5, Ad5.Fib16, and Ad5.Fib35.

Non-transduced cells were used to set a background level of approximately 1% (-).

Figure 29: Transduction of mouse and chimpanzee DCs.

Luciferase transgene expression measured in mouse DCs 48 hours after transduction is expressed as relative light units per microgram of protein. Chimpanzee DCs were measured 48 hours after transduction using a flow cytometer. GFP expression demonstrates the poor transduction of Ad (35) in contrast to Ad5.Fib35 (66%).

Figure 30: Temperature dependent growth of PER.C6.

PER.C6 cells were cultured in Dulbecco's Modified Eagle Medium supplemented with 10% Fetal Bovine Serum (FBS, Gibco BRL) and 10mM MgCl<sub>2</sub> in a 10% CO<sub>2</sub> atmosphere at either 32°C, 37°C or 39°C. At day 0, a total of 1 x 10<sup>6</sup> PER.C6 cells were seeded per 25cm<sup>2</sup> tissue culture flask (Nunc) and the cells were cultured at either 32°C, 37°C or 39°C. At day 1-8, cells were counted. The growth rate and the final cell density of the PER.C6 culture at 39°C are comparable to that at 37°C.

The growth rate and final density of the PER.C6 culture at 32°C were slightly reduced as compared to that at 37°C or 39°C.

PER.C6 cells were seeded at a density of 1 x 10<sup>6</sup> cells per 25 cm<sup>2</sup> tissue culture flask and cultured at either 32-, 37- or 39°C. At the indicated time points, cells were counted in a Burkert cell counter. PER.C6 grows well at both 32-, 37- and 39°C.

Figure 31: DBP levels in PER.C6 cells transfected with pcDNA3, pcDNA3wtE2A or pcDNA3ts125E2A.

Equal amounts of whole-cell extract were fractionated by SDS-PAGE on 10% gels. Proteins were transferred onto Immobilon-P membranes and DBP protein was visualized using the αDBP monoclonal B6 in an ECL detection system. All of the cell lines derived from the pcDNA3ts125E2A transfection express the 72-kDa E2A-encoded DBP protein (left panel, lanes 4-14; middle panel, lanes 1-13; right panel, lanes 1-12). In contrast, the only cell line derived from the pcDNAwtE2A transfection did not express the DBP protein (left panel, lane 2). No DBP protein was detected in extract from a cell line derived from the pcDNA3 transfection (left panel, lane 1), which serves as a negative control. Extract from PER.C6 cells transiently transfected with pcDNA3ts125 (left panel, lane 3) served as a positive control for the Western blot procedure. These data confirm that constitutive expression of wtE2A is toxic for cells and that using the ts125 mutant of E2A can circumvent this toxicity.

Figure 32: Suspension growth of PER.C6ts125E2A C5-9.

The tsE2A expressing cell line PER.C6tsE2A.c5-9 was cultured in suspension in serum free Ex-cell™. At the indicated time points, cells were counted in a Burkert cell counter. The results of 8 independent cultures are indicated. PER.C6tsE2A grows well in suspension in serum free Ex-cell™ medium.

Figure 33: Growth curve PER.C6 and PER.C6tsE2A.

PER.C6 cells or PER.C6ts125E2A (c8-4) cells were cultured at 37°C or 39°C, respectively. At day 0, a total of 1 x 10<sup>6</sup> cells was seeded per 25cm<sup>2</sup> tissue culture flask. At the indicated time points, cells were counted. The growth of PER.C6 cells at 37°C is comparable to the growth of PER.C6ts125E2A c8-4 at 39°C. This shows that constitutive overexpression of ts125E2A has no adverse effect on the growth of cells at the non-permissive temperature of 39°C.

Figure 34: Stability of PER.C6ts125E2A.

For several passages, the PER.C6ts125E2A cell line clone 8-4 was cultured at 39°C in medium without G418. Equal amounts of whole-cell extract from different passage numbers were fractionated by SDS-PAGE on 10% gels. Proteins were transferred onto Immobilon-P membranes and DBP protein was visualized using the αDBP monoclonal B6 in an ECL detection system. The expression of ts125E2A encoded DBP is stable for at least 16 passages, which is equivalent to approximately 40 cell doublings. No decrease in DBP levels were observed during this culture period, indicating that the expression of ts125E2A is stable, even in the absence of G418 selection pressure.

Figure 35: tTA activity in hygromycin resistant PER.C6/tTA (A) and PER/E2A/tTA (B) cells.

Sixteen independent hygromycin resistant PER.C6/tTA cell colonies and 23 independent hygromycin resistant

PER/E2A/tTA cell colonies were grown in 10 cm<sup>2</sup> wells to sub-confluency and transfected with 2 µg of pUHC 13-3 (a plasmid that contains the reporter gene luciferase under the control of the 7xtetO promoter). One half of the cultures was maintained in medium containing doxycycline to inhibit the activity of tTA. Cells were harvested at 48 hours after transfection and luciferase activity was measured. The luciferase activity is indicated in relative light units (RLU) per µg protein.

Table I:

Serotype	Elution [NaCl] mM	VP/ml	CCID50	log <sub>10</sub> VP/CCID50 ratio
1	597	8.66x10 <sup>10</sup>	5.00x10 <sup>7</sup>	3.2
2	574	1.04x10 <sup>12</sup>	3.66x10 <sup>11</sup>	0.4
3	131	1.19x10 <sup>11</sup>	1.28x10 <sup>7</sup>	4.0
4	260	4.84x10 <sup>11</sup>	2.50x10 <sup>8</sup>	3.3
5	533	5.40x10 <sup>11</sup>	1.12x10 <sup>10</sup>	1.7
6	477	1.05x10 <sup>12</sup>	2.14x10 <sup>10</sup>	1.7
7	328	1.68x10 <sup>12</sup>	2.73x10 <sup>9</sup>	2.4
9	379	4.99x10 <sup>11</sup>	3.75x10 <sup>7</sup>	4.1
10	387	8.32x10 <sup>12</sup>	1.12x10 <sup>9</sup>	3.9
12	305	3.64x10 <sup>11</sup>	1.46x10 <sup>7</sup>	4.4
13	231	4.37x10 <sup>12</sup>	7.31x10 <sup>8</sup>	3.8
15	443	5.33x10 <sup>12</sup>	1.25x10 <sup>9</sup>	3.6
16	312	1.75x10 <sup>12</sup>	5.59x10 <sup>8</sup>	3.5
17	478	1.39x10 <sup>12</sup>	1.45x10 <sup>9</sup>	3.0
19	430	8.44x10 <sup>11</sup>	8.55x10 <sup>7</sup>	4.0
20	156	1.41x10 <sup>11</sup>	1.68x10 <sup>7</sup>	3.9
21	437	3.21x10 <sup>11</sup>	1.12x10 <sup>8</sup>	3.5
22	385	1.45x10 <sup>10</sup>	3.39x10 <sup>6</sup>	3.3
23	132	2.33x10 <sup>11</sup>	1.57x10 <sup>7</sup>	4.2
24	405	5.12x10 <sup>12</sup>	4.27x10 <sup>8</sup>	4.1
25	405	7.24x10 <sup>11</sup>	5.59x10 <sup>7</sup>	4.1
26	356	1.13x10 <sup>12</sup>	1.12x10 <sup>8</sup>	4.0
27	342	2.00x10 <sup>12</sup>	1.28x10 <sup>8</sup>	4.2
28	347	2.77x10 <sup>12</sup>	5.00x10 <sup>7</sup>	4.7
29	386	2.78x10 <sup>11</sup>	2.00x10 <sup>7</sup>	4.1
30	409	1.33x10 <sup>12</sup>	5.59x10 <sup>8</sup>	3.4
31	303	8.48x10 <sup>10</sup>	2.19x10 <sup>7</sup>	3.6
33	302	1.02x10 <sup>12</sup>	1.12x10 <sup>7</sup>	5.0
34	425	1.08x10 <sup>12</sup>	1.63x10 <sup>11</sup>	0.8
35	446	3.26x10 <sup>12</sup>	1.25x10 <sup>11</sup>	1.4
36	325	9.26x10 <sup>12</sup>	3.62x10 <sup>9</sup>	3.4
37	257	5.86x10 <sup>12</sup>	2.8x10 <sup>9</sup>	3.3
38	337	3.61x10 <sup>12</sup>	5.59x10 <sup>7</sup>	4.8
39	241	3.34x10 <sup>11</sup>	1.17x10 <sup>7</sup>	4.5
42	370	1.95x10 <sup>12</sup>	1.12x10 <sup>8</sup>	4.2

Continued on next page.

Serotype #	Elution [NaCl] mM	VP/ml	CCID50	log <sub>10</sub> VP/CCID50 ratio
43	284	2.42x10 <sup>12</sup>	1.81x10 <sup>8</sup>	4.1
44	295	8.45x10 <sup>11</sup>	2.00x10 <sup>7</sup>	4.6
45	283	5.20x10 <sup>11</sup>	2.99x10 <sup>7</sup>	4.2
46	282	9.73x10 <sup>12</sup>	2.50x10 <sup>8</sup>	4.6
47	271	5.69x10 <sup>11</sup>	3.42x10 <sup>7</sup>	4.2
48	264	1.68x10 <sup>12</sup>	9.56x10 <sup>8</sup>	3.3
49	332	2.20x10 <sup>12</sup>	8.55x10 <sup>7</sup>	4.4
50	459	7.38x10 <sup>12</sup>	2.80x10 <sup>9</sup>	3.4
51	450	8.41x10 <sup>11</sup>	1.88x10 <sup>8</sup>	3.7

Legend to table I:

[0295] All human adenoviruses used in the neutralisation experiments were produced on PER.C6 cells (ECACC deposit number 96022940) (Fallaux *et al.*, 1998) and purified on CsCl as described in example 1. The NaCl concentration at which the different serotypes eluted from the HPLC column is shown. Virus particles/ml (VP/ml) were calculated from an Ad5 standard. The titer in the experiment (CCID50) was determined on PER.C6 cells (ECACC deposit number 96022940) as described in example 1 by titrations performed in parallel with the neutralisation experiment. The CCID50 is shown for the 44 viruses used in this study and reflects the dilution of the virus needed to obtain CPE in 50% of the wells after 5 days. The ratio of VP/CCID50 is depicted in log<sub>10</sub> and is a measurement of the infectivity of the different batches on PER.C6 cells (ECACC deposit number 96022940).

Table II

AdApt35.LacZ viruses escape neutralization by human serum.						
Virus	Human serum dilution					
	no serum	10x	50x	250x	1250x	6250x
AdApt5.LacZ moi: 5 VP/cell	100 %	0 %	0 %	1 %	40 %	80 %
AdApt35.LacZ 250 µl crude lysate	100 %	100 %	100 %	100 %	100 %	100 %

Table III

Percentage of synovial fluid samples containing neutralizing activity (NA) to wt adenoviruses of different serotypes.		
	% of SF samples with NA (all positives)	% of SF samples with NA (positives at ≥64x dilution)
Ad5	72	59
Ad26	66	34
Ad34	45	19
Ad35	4	0
Ad48	42	4

Table IV

The numbers of foci obtained with the different E1 expression constructs in BRK transformation experiments.			
Average # of foci/dish:			
	Construct	1 µgr	5 µgr
Experiment 1	pIG.E1A.E1 B	nd	60
	pIG.E1A.E1 B	nd	35
	pRSVAd35E1	0	3
	pIG.Ad35.E 1	3	7
Experiment 2	pIG.E1A.E1 B	37	nd
	pIG.Ad35.E 1	nd	2
Experiment 3	pIG.E1A.E1 B	nd	140
	pIG.Ad35.E 1	nd	20
	pIG270	nd	30

## REFERENCES

30 [0296]

Abrahamsen, K., Kong, H-L., Mastrangeli, A., Brough, D., Lizonova, A., Crystal, R. and Falck-Pedersen, E. (1997) Construction of an adenovirus type 7a E1A vector. *J. Virol.* 71, no. 11, p8946-8951.

35 Athappilly, F.K., Murali, R., Rux, J.J., Cai, Z. and Burnett, R.M. (1994). The refined crystal structure of hexon, the major coat protein of adenovirus type 2, at 2.9 Å resolution. *J. Mol. Biol.* 242, 430-455.

Basler, C.F., Droguett, G., Horwitz, M.S. (1996). Sequence of the immunoregulatory early region 3 and flanking sequences of adenovirus type 35. *Gene* 170:249-54

40

Bridge, E., Medghalchi, S., Ubol, S., Leesong, M. and Ketner, G. (1993) Adenovirus early region 4 and viral DNA synthesis. *Virology* 193, 794-801.

Brody, S.L. and Crystal, R.G. (1994) Adenovirus mediated in vivo gene transfer. *Ann. N. Y. Acad. Sci.* 716:90-101.

45

Boshart, M., Weber, F., Jahn, G., Dorsch-Hasler, K., Fleckenstein B. and Schaffner W. (1985). A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus. *Cell* 41, 521-530,

Dijkema, R., Dekker, B.M.M., van der Feitz, M.J.M. and van der Eb, A.J. (1979). Transformation of primary rat kidney cells by DNA fragments of weakly oncogenic adenoviruses. *J. Virol.* 32, No 3, 943-950.

50

Fallaux, F.J., Bout, A., van der Velde, I., van den Wollenberg, D.J., Hehir, K.M., Keegan, J., Auger, C., Cramer, S.J., van Ormondt, H., van der Eb, A.J., Valerio, D. and Hoeben, R.C. (1998). New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication competent adenoviruses. *Hum. Gene Ther.* 9, 1909-1917.

55

Gossen, M., and H. Bujard (1992) Tight control of gene expression in mammalian cells by tetracyclin-responsive promoters. *Proc. Natl. Acad. Sci. USA* 89; 5547-5551.

Flomenberg, P.R., Chen, M., Munk, G., Horwitz, M.S. (1987). Molecular epidemiology of adenovirus type 35 infections in immunocompromised hosts. *J. Infect Dis.* 155(6): 1127-34.

5 Francki, R.I.B., Fauquet, C.M., Knudson, D.L. and Brown, F. (1991). Classification and nomenclature of viruses. Fifth report of the international Committee on taxonomy of viruses. *Arch. Virol. Suppl.* 2: 140-144.

Gahery-Segard, H., Farace, F., Godfrin, D., Gaston, J., Lengagne, R., Tursz, P., Boulanger, P. and Guillet, J.-G. (1998). Immune response to recombinant capsid proteins of adenovirus in humans: Antifiber and anti-penton base antibodies have a synergistic effect on neutralising activity. *J. Virol.* 72, 2388-2397.

10 He, T.-C., Zhou, S., Da Costa, L.T., Yu, J., Kinzler, K.W., Vogelstein, B. (1998). A simplified system for generating recombinant adenoviruses. *Proc. Natl. Acad. Sci. USA* 95, 2509-2514.

15 Hierholzer, J.C., Wigand, R., Anderson, L.J., Adrian, T., and Gold, J.W.M. (1988) Adenoviruses from patients with AIDS: a plethora of serotypes and a description of five new serotypes of subgenus D (types 43-47). *J. Infect. Dis.* 158, 804-813.

De Jong, P.J., Valderrama, G., Spigland, I. and Horwitz, M.S. (1983). Adenovirus isolates from urine of patients with acquired immunodeficiency syndrome. *Lancet* 1(8337): 1293-1296.

20 Kay, R., Takei, F., and Humphries, R.K. (1990). Expression cloning of a cDNA encoding M1/69. *J. Immunol.* 145, 1952-1959.

25 Kang, W.G., Berencsi, G., Takacs, M., Ascher, Z., Fejer, G., Nasz, I. (1989a). Molecular cloning and physical mapping of the DNA of human adenovirus type 35. *Acta Microbiol Hung* 36(1): 67-75.

Kang, W.G., Berencsi, G., Banrevi, A., Ascher, Z., Fejer, G., Takacs, M., Kiss, A., Nasz, I. (1989b). Relationship of E1 and E3 regions of human adenovirus 35 to those of human adenovirus subgroups A, C and D. *Acta Microbiol Hung* 36(4): 445-57.

30 Levrero, M., Barban, V., Manteca, S., Ballay, A., Balsamo, C., Avantaggiati, M.L., Natoli, G., Skellekens, H., Tiollais, P., and Perricaudet, M. (1991). Defective and nondefective adenovirus vectors for expressing foreign genes in vitro and in vivo. *Gene* 101, 195-202.

35 Li, Q.G., Hambraeus, J. and Wadell, G. (1991). Genetic relationship between thirteen genomes of types of adenovirus 11, 34, and 35 with different tropisms. *Intervirology* 32, 338-350.

Prince, H.M. (1998). Gene transfer: a review of methods and applications. *Pathology* 30(4), 335-347.

40 Robbins, P.D. and Ghivizzani, S.C. (1998). Viral vectors for gene therapy. *Pharmacol Ther.* 80, 35-47.

Schnurr, D and Dondero, M.E. (1993). Two new candidate adenovirus serotypes. *Intervirology* 36, 79-83.

45 Schulick, A.H., Vassalli, G., Dunn, P.F., Dong, G., Rade, J.J., Zamarron, C. and Dichek, D.A. (1997). Established immunity precludes adenovirus-mediated gene transfer in rat carotid arteries. Potential for immunosuppression and vector engineering to overcome barriers of immunity. *J. Clin. Invest.* 99(2), 209-19.

50 Shabram, P.W., Giroux, D.D., Goudreau, A.M., Gregory, R.J., Horn, M.T., Huyghe, B.G., Liu, X., Nunnally, M.H., Sugarman, B.J. and Sutjipto, S. (1997) Analytical anion-exchange HPLC of recombinant type-5 adenoviral particles. *Hum. Gene Ther.* 8(4): 453-465.

Toogood et al., 1989; *J. Gen Virol.* 70, 3203-3214

55 Toogood, C.I., Murali, R., Burnett, R.M., Hay, R.T.(1989). The adenovirus type 40 hexon: sequence, predicted structure and relationship to other adenovirus hexons. *J. Gen. Virol.* 70, 3203-14.

Valderrama-Leon, G., Flomenberg, P., Horwitz, M.S. (1985). Restriction endonuclease mapping of adenovirus 35, a type isolated from immunocompromised hosts. *J Virol.* 56(2):647-50.

## EP 1 054 064 A1

Wadell, G. (1984). Molecular epidemiology of adenoviruses. Curr. Top. Microbiol. Immunol. 110, 191-220.

White, E. (1995) Regulation of p53-dependent apoptosis by E1a and E1b. Curr. Top. Microbiol. Immunol. 199, 34-58.

### SEQUENCE LISTING

<110> Introgene B.V.

<120> Serotype of Adenovirus and uses Thereof

<130> P49636EP10

<140> 00201738.2

<141> 2000-05-16

<150> EP 99201545.3

<151> 1999-05-17

<160> 88

<170> PatentIn Ver. 2.1

<210> 1

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: linker  
containing a PacI site

<220>

<221> misc\_feature

<222> (1)..(23)

<400> 1

aattgtctta attaaccgct taa

23

<210> 2

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: oligonucleotide

<220>

<221> misc\_feature

<222> (1)..(19)

<400> 2

aattgtctta attaaccgc

19

<210> 3

5  
 <211> 19  
 <212> DNA  
 <213> Artificial Sequence

10  
 <220>  
 <223> Description of Artificial Sequence: oligonucleotide

15  
 <220>  
 <221> misc\_feature  
 <222> (1)..(19)

<400> 3  
 aattgcggtt aattaagac 19

20  
 <210> 4  
 <211> 39  
 <212> DNA  
 <213> Artificial Sequence

25  
 <220>  
 <223> Description of Artificial Sequence: primer ITR-EPH

30  
 <220>  
 <221> misc\_feature  
 <222> (1)..(39)

<400> 4  
 cggaattctt aattaagtta acatcatcaa taatatacc 39

35  
 <210> 5  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence

40  
 <220>  
 <223> Description of Artificial Sequence: primer Ad101

45  
 <220>  
 <221> misc\_feature  
 <222> (1)..(20)

<400> 5  
 tgattcacat cggtcagtc 20

50  
 <210> 6  
 <211> 23  
 <212> DNA  
 <213> Artificial Sequence

55



5 <220>  
 <223> Description of Artificial Sequence: primer delta E2A.SnaBI  
  
 <220>  
 <221> misc\_feature  
 <222> (1)..(23)  
  
 <400> 6  
 10 ggcgtacgta gcctgtcga aag 23  
  
 <210> 7  
 <211> 35  
 15 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence: primer delta E2A.DBP-start  
 20  
 <220>  
 <221> misc\_feature  
 <222> (1)..(35)  
  
 <400> 7  
 25 ccaatgcatt cgaagtactt ccttctecta taggc 35  
  
 <210> 8  
 <211> 22  
 30 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence: primer delta E2A.DBP-stop  
 35  
 <220>  
 <221> misc\_feature  
 <222> (1)..(22)  
  
 <400> 8  
 40 ccaatgcata cggcgcagac gg 22  
  
 <210> 9  
 <211> 21  
 45 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence: primer delta E2A.BamHI  
 50  
 <220>  
  
 55

<221> misc\_feature

<222> (1)..(21)

5

<400> 9

gaggtggatc ccatggacga g

21

10

<210> 10

<211> 47

<212> DNA

<213> Artificial Sequence

15

<220>

<223> Description of Artificial Sequence: primer LTR-1

<220>

<221> misc\_feature

<222> (1)..(47)

20

<400> 10

ctgtacgtac cagtgcactg gcctaggcat ggaaaaatac ataactg

47

25

<210> 11

<211> 64

<212> DNA

<213> Artificial Sequence

30

<220>

<223> Description of Artificial Sequence: primer LTR-2

<220>

<221> misc\_feature

<222> (1)..(64)

35

<400> 11

gcggatcctt cgaacatgg taagcttggt accgctagcg ttaaccgggc gactcagtca 60

atcg

64

40

<210> 12

<211> 28

<212> DNA

<213> Artificial Sequence

45

<220>

<223> Description of Artificial Sequence: primer HSA1

50

<220>

<221> misc\_feature

<222> (1)..(28)

55

5  
 10  
 15  
 20  
 25  
 30  
 35  
 40  
 45  
 50  
 55

<400> 12  
 gcgccaccat ggcagagcg atggtggc 28

<210> 13  
 <211> 50  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: primer HSA2

<220>  
 <221> misc\_feature  
 <222> (1)..(50)

<400> 13  
 gttagatcta agcttgcga catcgatcta ctaacagtag agatgtagaa 50

<210> 14  
 <211> 10  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: oligonucleotide

<220>  
 <221> misc\_feature  
 <222> (1)..(10)

<400> 14  
 ttaagtcgac 10

<210> 15  
 <211> 23  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: linker

<220>  
 <221> misc\_feature  
 <222> (1)..(23)

<400> 15  
 aattgtctta attaaccgca att 23

<210> 16  
 <211> 67  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: oligonucleotide PLL-1

<220>  
 <221> misc\_feature  
 <222> (1)..(67)

<400> 16  
 gccatcccta ggaagcttgg taccggtgaa ttcgctagcg ttaacggatc ctctagacga 60  
 gatctgg 67

<210> 17  
 <211> 67  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: oligonucleotide PLL-2

<220>  
 <221> misc\_feature  
 <222> (1)..(67)

<400> 17  
 ccagatctcg tctagaggat ccgttaacgc tagcgaattc accggtacca agcttcctag 60  
 ggatggc 67

<210> 18  
 <211> 39  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: primer CMVplus

<220>  
 <221> misc\_feature  
 <222> (1)..(39)

<400> 18  
 gatcgtacc actgcagtgg tcaatattgg ccattagcc 39

<210> 19  
 <211> 29

5  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <223> Description of Artificial Sequence: primer CMVminA  
 <220>  
 <221> misc\_feature  
 10 <222> (1)..(29)  
 <400> 19  
 gatcaagctt ccaatgcacc gttcccggc 29  
 15  
 <210> 20  
 <211> 32  
 <212> DNA  
 <213> Artificial Sequence  
 20  
 <220>  
 <223> Description of Artificial Sequence: primer  
 <220>  
 <221> misc\_feature  
 25 <222> (1)..(32)  
 <400> 20  
 ggggtggcca gggtagctct aggttttgc aa 32  
 30  
 <210> 21  
 <211> 29  
 <212> DNA  
 35 <213> Artificial Sequence  
 <220>  
 <223> Description of Artificial Sequence: primer  
 <220>  
 <221> misc\_feature  
 40 <222> (1)..(29)  
 <400> 21  
 45 ggggggatcc ataaacaagt tcagaatcc 29  
 <210> 22  
 <211> 18  
 <212> DNA  
 50 <213> Artificial Sequence  
 <220>  
 55

<223> Description of Artificial Sequence: primer delta hex1

<220>

<221> misc\_feature

<222> (1)..(18)

<400> 22

cctggtgctg ccaacagc

18

<210> 23

<211> 30

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer delta hex2

<220>

<221> misc\_feature

<222> (1)..(30)

<400> 23

ccggatccac tagtggaag cgggcgcgcg

30

<210> 24

<211> 35

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer delta hex3

<220>

<221> misc\_feature

<222> (1)..(35)

<400> 24

ccggatccaa ttgagaagca agcaacatca acaac

35

<210> 25

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer delta hex4

<220>

<221> misc\_feature

<222> (1)..(19)

<400> 25

gagaagggca tggaggctg

19

<210> 26

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer Hex-up2

<220>

<221> misc\_feature

<222> (1)..(32)

<400> 26

gactagtcaa gatggcyacc cchtgatga tg

32

<210> 27

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer Hex-do2

<220>

<221> misc\_feature

<222> (1)..(33)

<400> 27

gctggccaat tggtatgtkg tkgcgttrcc ggc

33

<210> 28

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer DP5-F

<220>

<221> misc\_feature

<222> (1)..(20)

<400> 28

ctgttgctgc tgctaatagc

20

5  
 <210> 29  
 <211> 32  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: primer DP5-R

10  
 <220>  
 <221> misc\_feature  
 <222> (1)..(32)

15  
 <400> 29  
 cgcggatcct gtacaactaa gggaataca ag 32

20  
 <210> 30  
 <211> 33  
 <212> DNA  
 <213> Artificial Sequence

25  
 <220>  
 <223> Description of Artificial Sequence: primer DP3-F

30  
 <220>  
 <221> misc\_feature  
 <222> (1)..(33)

35  
 <400> 30  
 cgcggatccc ttaaggcaag catgtccatc ctt 33

40  
 <210> 31  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence

45  
 <220>  
 <223> Description of Artificial Sequence: primer DP3-3R

50  
 <220>  
 <221> misc\_feature  
 <222> (1)..(27)

55  
 <400> 31  
 aaaacacgtt ttacgcgtcg acctttc 27



5  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <223> Description of Artificial Sequence: primer P3-for  
 <220>  
 <221> misc\_feature  
 10 <222> (1)..(33)  
 <400> 32  
 gctcgatgta caatgaggag acgagccgtg cta 33  
 15  
 <210> 33  
 <211> 33  
 <212> DNA  
 <213> Artificial Sequence  
 20  
 <220>  
 <223> Description of Artificial Sequence: primer P3-rev  
 <220>  
 <221> misc\_feature  
 25 <222> (1)..(33)  
 <400> 33  
 gctcgactta agttagaaag tgcggcttga aag 33  
 30  
 <210> 34  
 <211> 35  
 <212> DNA  
 35 <213> Artificial Sequence  
 <220>  
 <223> Description of Artificial Sequence: primer P17F  
 <220>  
 <221> misc\_feature  
 40 <222> (1)..(35)  
 <400> 34  
 45 gctcgatgta caatgaggcg tgcggtggtg tcttc 35  
 <210> 35  
 <211> 34  
 <212> DNA  
 50 <213> Artificial Sequence  
 <220>  
 55

<223> Description of Artificial Sequence: primer P17R

<220>

<221> misc\_feature

<222> (1)..(34)

<400> 35

gctcgactta agttagaagg tgcgactgga aagc

34

<210> 36

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer NY-up

<220>

<221> misc\_feature

<222> (1)..(42)

<400> 36

cgacatatgt agatgcatta gttgtgtta tgttcaacg tg

42

<210> 37

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer NY-down

<220>

<221> misc\_feature

<222> (1)..(18)

<400> 37

ggagaccact gccatggt

18

<210> 38

<211> 10

<212> DNA

<213> Adenoviridae

<220>

<221> misc\_feature

<222> (1)..(10)

<223> /note="Partial sequence of an adenovirus ITR"

5  
10  
15  
20  
25  
30  
35  
40  
45  
50  
55

<400> 38  
catcatcaat 10

<210> 39  
<211> 14  
<212> DNA  
<213> Adenoviridae

<220>  
<221> misc\_feature  
<222> (1)..(14)  
<223> /note="Partial sequence of an adenovirus ITR"

<400> 39  
ccaataatat acct 14

<210> 40  
<211> 21  
<212> DNA  
<213> Adenoviridae

<220>  
<221> misc\_feature  
<222> (1)..(21)  
<223> /note="Partial sequence of an adenovirus ITR"

<400> 40  
aggatatatta ttgatgatgg g 21

<210> 41  
<211> 18  
<212> DNA  
<213> Adenoviridae

<220>  
<221> misc\_feature  
<222> (1)..(18)  
<223> /note="Partial sequence of an adenovirus ITR"

<400> 41  
catcatcaat aatataacc 18

<210> 42  
<211> 13  
<212> DNA  
<213> Adenoviridae

<220>

5  
 <221> misc\_feature  
 <222> (1)..(13)  
 <223> /note="Partial sequence of an adenovirus ITR"  
 <400> 42  
 catcatcaat aat 13  
 10  
 <210> 43  
 <211> 47  
 <212> DNA  
 <213> Artificial Sequence  
 15  
 <220>  
 <223> Description of Artificial Sequence: oligo ExSalPacF  
 <220>  
 20  
 <221> misc\_feature  
 <222> (1)..(47)  
 <400> 43  
 tcgatggcaa acagctatta tgggtattat gggttcgaat taattaa 47  
 25  
 <210> 44  
 <211> 47  
 <212> DNA  
 <213> Artificial Sequence  
 30  
 <220>  
 <223> Description of Artificial Sequence: oligo ExSalPacR  
 <220>  
 35  
 <221> misc\_feature  
 <222> (1)..(47)  
 <400> 44  
 40  
 tcgattaatt aattcgaacc cataatacce ataatagctg ttgcca 47  
 <210> 45  
 <211> 42  
 <212> DNA  
 <213> Artificial Sequence  
 45  
 <220>  
 <223> Description of Artificial Sequence: primer PCLIPMSF  
 <220>  
 50  
 <221> misc\_feature  
 <222> (1)..(42)  
 55

5  
 10  
 15  
 20  
 25  
 30  
 35  
 40  
 45  
 50  
 55

<400> 45  
 ccccaattgg tcgaccatca tcaataatat accttatttt gg 42

<210> 46  
 <211> 22  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: primer pCLIPBSRGI

<220>  
 <221> misc\_feature  
 <222> (1)..(22)

<400> 46  
 gcgaaaattg tcacttcctg tg 22

<210> 47  
 <211> 37  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Ecolinker+

<220>  
 <221> misc\_feature  
 <222> (1)..(37)

<400> 47  
 aattcggcgc gccgtcgacg atatcgatag cggccgc 37

<210> 48  
 <211> 37  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: Ecolinker-

<220>  
 <221> misc\_feature  
 <222> (1)..(37)

<400> 48  
 aattcgggcc gctatcgata tcgtcgacgg cgccgcg 37

5  
 <210> 49  
 <211> 49  
 <212> DNA  
 <213> Artificial Sequence  
  
 <220>  
 <223> Description of Artificial Sequence: linker HindXba+  
  
 10  
 <220>  
 <221> misc\_feature  
 <222> (1)..(49)  
  
 15  
 <400> 49  
 agctctagag gatccgtaa cgctagcga ttcaccgga ccaagctta 49  
  
 20  
 <210> 50  
 <211> 49  
 <212> DNA  
 <213> Artificial Sequence  
  
 25  
 <220>  
 <223> Description of Artificial Sequence: linker HindXba-  
  
 30  
 <220>  
 <221> misc\_feature  
 <222> (1)..(49)  
  
 35  
 <400> 50  
 ctagtaagct tggtagcggg gaattcgcta gcgttaacgg atcctctag 49  
  
 40  
 <210> 51  
 <211> 44  
 <212> DNA  
 <213> Artificial Sequence  
  
 45  
 <220>  
 <223> Description of Artificial Sequence: primer 35F1  
  
 50  
 <220>  
 <221> misc\_feature  
 <222> (1)..(44)  
  
 55  
 <400> 51  
 cggaattctt aattaatcga catcatcaat aatatacctt atag 44  
  
 <210> 52  
 <211> 33  
 <212> DNA  
 <213> Artificial Sequence

5  
 <220>  
 <223> Description of Artificial Sequence: primer 35R2  
 <220>  
 <221> misc\_feature  
 <222> (1)..(33)  
 10  
 <400> 52  
 gggtggtccta ggctgacacc tacgtaaaaa cag 33  
 15  
 <210> 53  
 <211> 30  
 <212> DNA  
 <213> Artificial Sequence  
 20  
 <220>  
 <223> Description of Artificial Sequence: primer 35F3  
 <220>  
 <221> misc\_feature  
 <222> (1)..(30)  
 25  
 <400> 53  
 tgggtggagat ctggtgagta ttgggaaaac 30  
 30  
 <210> 54  
 <211> 37  
 <212> DNA  
 <213> Artificial Sequence  
 35  
 <220>  
 <223> Description of Artificial Sequence: primer 35R4  
 <220>  
 <221> misc\_feature  
 40  
 <222> (1)..(37)  
 <400> 54  
 cggaattctt aattaaggga aatgcaaatac tgtgagg 37  
 45  
 <210> 55  
 <211> 34  
 <212> DNA  
 <213> Artificial Sequence  
 50  
 <220>  
 <223> Description of Artificial Sequence: primer 35F5  
 55

5  
 <220>  
 <221> misc\_feature  
 <222> (1)..(34)  
 <400> 55  
 cggaattcgc ggccgcgggtg agtattggga aaac 34

10  
 <210> 56  
 <211> 22  
 <212> DNA  
 <213> Artificial Sequence

15  
 <220>  
 <223> Description of Artificial Sequence: primer 35R6

20  
 <220>  
 <221> misc\_feature  
 <222> (1)..(22)  
 <400> 56  
 cgccagatcg tctacagaac ag 22

25  
 <210> 57  
 <211> 23  
 <212> DNA  
 <213> Artificial Sequence

30  
 <220>  
 <223> Description of Artificial Sequence: primer 35F7

35  
 <220>  
 <221> misc\_feature  
 <222> (1)..(23)  
 <400> 57  
 gaatgctggc ttcagttgta atc 23

40  
 <210> 58  
 <211> 42  
 <212> DNA  
 <213> Artificial Sequence

45  
 <220>  
 <223> Description of Artificial Sequence: primer 35R8

50  
 <220>  
 <221> misc\_feature  
 <222> (1)..(42)

55



<400> 58

cggaattcgc ggccgcattt aaatcatcat caataatata cc

42

<210> 59

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer 35F11

<220>

<221> misc\_feature

<222> (1)..(33)

<400> 59

ggggtaccga attctcgcta ggggtatttat acc

33

<210> 60

<211> 38

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer 35F10

<220>

<221> misc\_feature

<222> (1)..(38)

<400> 60

gctctagacc tgcaggtag tcagtttctt ctccactg

38

<210> 61

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer HBV-F

<220>

<221> misc\_feature

<222> (1)..(27)

<400> 61

ggctctagag atccttcgcg ggacgtc

27

5  
 <210> 62  
 <211> 26  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <223> Description of Artificial Sequence: primer HBV-R  
 10  
 <220>  
 <221> misc\_feature  
 <222> (1)..(26)  
 <400> 62  
 15 ggcggaattca ctgccttcca ccaagc 26  
 <210> 63  
 <211> 12  
 20 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <223> Description of Artificial Sequence: oligonucleotide A-P1  
 25 <220>  
 <221> misc\_feature  
 <222> (1)..(12)  
 30 <400> 63  
 ctggtggta at 12  
 <210> 64  
 <211> 14  
 35 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <223> Description of Artificial Sequence:  
 40 oligonucleotide A-P2  
 <220>  
 <221> misc\_feature  
 <222> (1)..(14)  
 45 <400> 64  
 taaccaccag acgt 14  
 50 <210> 65  
 <211> 20  
 <212> DNA  
 55

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer DF35-1

<220>

<221> misc\_feature

<222> (1)..(20)

<400> 65

cactcaccac ctccaattcc

20

<210> 66

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer DF35-2

<220>

<221> misc\_feature

<222> (1)..(32)

<400> 66

cgggatcccg tacgggtaga cagggttgaa gg

32

<210> 67

<211> 49

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer DF35-3

<220>

<221> misc\_feature

<222> (1)..(49)

<400> 67

cgggatccgc tagctgaaat aaagttaaag tgtttttatt taaaatcac

49

<210> 68

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer DF35-4

5  
 <220>  
 <221> misc\_feature  
 <222> (1)..(21)  
 <400> 68  
 ccagttgcat tgcttggttg g 21

10  
 <210> 69  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence

15  
 <220>  
 <223> Description of Artificial Sequence: degenerated primer

20  
 <220>  
 <221> misc\_feature  
 <222> (1)..(27)  
 <400> 69  
 cckgtstacc cgtacgaaga tgaaagc 27

25  
 <210> 70  
 <211> 30  
 <212> DNA  
 <213> Artificial Sequence

30  
 <220>  
 <223> Description of Artificial Sequence: degenerated primer

35  
 <220>  
 <221> misc\_feature  
 <222> (1)..(30)  
 <400> 70  
 ccggctagct cagtcattt ctctgatata 30

40  
 <210> 71  
 <211> 31  
 <212> DNA  
 <213> Artificial Sequence

45  
 <220>  
 <223> Description of Artificial Sequence: primer 355ITR

50  
 <220>  
 <221> misc\_feature  
 <222> (1)..(31)

55

5  
 10  
 15  
 20  
 25  
 30  
 35  
 40  
 45  
 50  
 55

<400> 71  
 gatccggagc tcacaacgtc attttccac g 31

<210> 72  
 <211> 25  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: primer 353ITR

<220>  
 <221> misc\_feature  
 <222> (1)..(25)

<400> 72  
 cggaattgc ggccgcattt aaatc 25

<210> 73  
 <211> 30  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: primer 35DE4

<220>  
 <221> misc\_feature  
 <222> (1)..(30)

<400> 73  
 cccaagcttg cttgtgtata tatattgtgg 30

<210> 74  
 <211> 45  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <223> Description of Artificial Sequence: oligonucleotide TATA-plus

<220>  
 <221> misc\_feature  
 <222> (1)..(45)

<400> 74  
 agctttctta taaatttca gtgttagact agtaaattgc ttaag 45

5  
 <210> 75  
 <211> 45  
 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <223> Description of Artificial Sequence: oligonucleotide TATA-min  
 10  
 <220>  
 <221> misc\_feature  
 <222> (1)..(45)  
 <400> 75  
 15 agctcttaag caatttacta gtctaact gaaaatttat aagaa 45  
 <210> 76  
 <211> 37  
 20 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <223> Description of Artificial Sequence: primer tet3  
 25 <220>  
 <221> misc\_feature  
 <222> (1)..(37)  
 <400> 76  
 30 ccggagctcc atggcctaac tcgagtttac cactccc 37  
 <210> 77  
 <211> 30  
 35 <212> DNA  
 <213> Artificial Sequence  
 <220>  
 <223> Description of Artificial Sequence: primer tet5  
 40 <220>  
 <221> misc\_feature  
 <222> (1)..(30)  
 45 <400> 77  
 cccaagctta gctcgacttt cactttctc 30  
 <210> 78  
 <211> 17  
 <212> DNA  
 55

5  
 <213> Artificial Sequence  
 <220>  
 <223> Description of Artificial Sequence: oligo BB1  
 <220>  
 <221> misc\_feature  
 <222> (1)..(17)  
 <400> 78  
 gtgcctaggc cacgggg 17  
 15  
 <210> 79  
 <211> 13  
 <212> DNA  
 <213> Artificial Sequence  
 20  
 <220>  
 <223> Description of Artificial Sequence: oligo BB2  
 <220>  
 <221> misc\_feature  
 <222> (1)..(13)  
 <400> 79  
 gtggcctagg cac 13  
 25  
 30  
 <210> 80  
 <211> 20  
 <212> DNA  
 <213> Artificial Sequence  
 35  
 <220>  
 <223> Description of Artificial Sequence: primer 270F  
 <220>  
 <221> misc\_feature  
 <222> (1)..(20)  
 <400> 80  
 cacctctgcc taatcatctc 20  
 40  
 45  
 <210> 81  
 <211> 27  
 <212> DNA  
 <213> Artificial Sequence  
 50  
 <220>  
 <223> Description of Artificial Sequence: primer 270R  
 55

<220>

<221> misc\_feature

<222> (1)..(27)

<400> 81

gctctagaaa ttccactgcc ttccacc

27

<210> 82

<211> 35

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer DBPpcr1

<220>

<221> misc\_feature

<222> (1)..(35)

<400> 82

cgggatccgc caccatggcc agtcgggaag aggag

35

<210> 83

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer DBPpcr2

<220>

<221> misc\_feature

<222> (1)..(33)

<400> 83

cggaattctt aaaaatcaaa ggggttctgc cgc

33

<210> 84

<211> 34794

<212> DNA

<213> Adenoviridae

<220>

<221> misc\_feature

<222> (1)..(34794)

<223> /note="Nucleic acid sequence of Ad35"

<400> 84



catcatcaat aatatacctt atagatggaa tgggtccaat atgtaaatga ggtgatttta 60  
aaaagtgtgg gccgtgtggt gattggctgt ggggttaacg gttaaaagg ggcgcgcgcg 120  
cgtgggaaaa tgacgttita tgggggtgga gttttttgc aagtgtgcgc gggaaatgtt 180  
acgcataaaa aggctctttt tctcacggaa ctacttagtt tccacaggt atttaacagg 240  
aatgaggta gtttgaccg gatgcaagt aaaattgctg atttcgcgc gaaaactgaa 300  
tgaggaagt tttttctgaa taatgtgga tttatggcag ggtggagtat ttgttcagg 360  
ccaggtagac ttgacctat taccgtggagg ttctgattac cgtgttttt acctgaattt 420  
ccgcgtaccg tgtcaaagtc ttctgtttt acgtagggtg cagctgatcg ctagggtatt 480  
tatacctcag ggtttgtgtc aagaggccac tcttgagtgc cagcgagaag agttttctcc 540  
tctgcgcgcg cagtttaata ataaaaaaat gagagatttg cgatttctgc ctcaggaaat 600  
aatctctgct gagactggaa atgaaatatt ggagctgtg gtgcacgccc tgatgggaga 660  
cgatccggag ccacctgtgc agctttttga gctctctacg cttcaggaac tgtatgattt 720  
agaggtagag ggtacggagg attctaata ggaagctgtg aatggctttt ttaccgattc 780  
tatgctttta gctgtaaat aaggattaga attagatccg ctttggaca cttcaatac 840  
tcagggggtg atttgggaaa gcggtacagg tgaagaaaa ttacctgatt tgagtccgt 900  
ggactgtgat ttgactgct atgaagacgg gtttctccg agtgatgagg aggacctga 960  
aaaggagcag tccatgcaga ctgcagcggg tgaggagtg aaggctcca atgttggtt 1020  
tcagttggat tgcgggagc ttccggaca tggctgtaag tctgtgaat ttcacaggaa 1080  
aaatactgga gtaaggaaac tgttatgtc gctttgtat atgagacgc actgccactt 1140  
tatttacagt aagtgtgtt aagttaaat ttaaggaa atgctgtttt tcacatgtat 1200  
attgagtgtg agttttgtc ttctattat aggtctgtg tctgatgtg atgaatcac 1260  
atctctgat tctactact cactcctga tattcaagca cctgttctg tggacgtgcg 1320  
caagccatt cctgtgaagc ttaagcctg gaaacgtcca gcagtggaga aacttgagg 1380  
ctgttacag ggtgggagc gacctttga cttgagtaca cggaaacgc caagacaata 1440  
agtgttccat atccgtgtt acttaagggt acgtcaatat ttgtgtgaga gtgcaatga 1500  
ataaaaatat gttactgtt cactgtttt tattgtttt tggcgggga ctcaggata 1560  
taagtagaag cagacctgtg tggtagctc ataggagctg gcttcatcc atggaggtt 1620  
gggccatttt ggaagacct aggaagacta ggcaactgtt agagagcgtc tggacggag 1680  
tctccggtt ttggagattc tggctgcta gtgaattagc taggtagtt ttaggataa 1740  
aacaggacta taaacaagaa ttgaaaagt tegtgtaga ttgccagga cttttgaag 1800  
ctcttaattt ggccatcag gttcactta aagaaaaagt ttatcagtt ttagactttt 1860  
caacccagg tagaactgct gctgctgtg cttttctac tttatatta gataaatga 1920  
tccgcagac tcatttcagc aggggatac ttttgattt catagccaca gcattgtga 1980  
gaacatggaa ggttcgaag atgaggacaa tcttaggta ctggccagt cagccttg 2040  
gtgtagcggg aatcctgagg catccaccg tcatgccagc ggttctggag gaggaacagc 2100  
aagaggacaa cccgagagcc ggctggacc ctccagtga ggagcggag tagctgactt 2160  
gtctctgaa ctgcaacggg tgcctactg atctacgtc actggacggg atagggcgct 2220  
taagaggag agggcatcca gtggtactga tctagatct gatttgctt taagttaat 2280  
gagtcgcaga cgtctgaaa ccatttggtg gcattgaggt cagaaagagg gaaggatga 2340  
agtttctgta ttgcaggaga aatattcact ggaacagggt aaaaatggtt ggttgagcc 2400  
agaggatgat tggcggttg ccattaaaaa ttatgccaag atagctttga ggcctgata 2460  
acagtataag atcagtagac ggattaatat ccggaatgct tttacatat ctggaatgg 2520  
ggctgaggtg gtaatagata ctcaagacaa gacagttatt agatgtgca tgatggat 2580  
gtggcctgga gtatcggtg tgggaagcag cactttgtg aatgttaagt ttaggggaga 2640  
tggttataat ggaatagtgt ttatggcaa taccaaactt atattgcatg gtttagctt 2700  
ttttgtttc aacaatact gttagatgc ctgggacag gttagtgtac ggggtgtag 2760  
tttctatgcg tttggattg ccacagctg cagaaccaag agtcaattgt ctctgaagaa 2820  
atgcataatc caaagatgta acctgggcat tctgaatgaa ggcgaagcaa ggtccgtc 2880  
ctgccttct acagatactg gatgtttat ttaattaag ggaatgcca gcgtaagca 2940  
taacatgatt tttgtgtct ccgatgag gcttatcaa atgctcactt gtgctggtg 3000  
gcattgta atgtgtgta ctgtcatat tgttccat caacgcaaaa aatggcctgt 3060  
ttttgatcac aatgtgtga ccaagtgcac catgcatga ggtggcgta gaggaatgtt 3120

tatgccttac cagtgttaaca tgaatcatgt gaaagtgttg ttggaaccag atgccttttc 3180  
 cagaatgagc ctaacaggaa tctttgacat gaacacgcaa atctggaaga tctgaggtta 3240  
 tgatgatacg agatcgaggg tgcgcgcatg cgaatgcgga ggcaagcatg ccaggttcca 3300  
 gccggtgtgt gtagatgtga ccgaagatct cagaccggat catttggtta ttgccgcac 3360  
 tggagcagag ttccgatcca gtggagaaga aactgactaa ggtgagtatt gggaaaactt 3420  
 tggggtggga tttcagatg gacagattga gtaaaaattt gtttttctg tcttgcagct 3480  
 gacatgagtg gaaatgttc ttttaagggg ggagtttca gcccttatct gacagggcgt 3540  
 ctcccatctt gggcaggagt tcgtcagaat gttatggat ctactgtgga tggaaagacc 3600  
 gtccaacccg ccaattcttc aacgctgacc tatgctactt taagtcttc accttggac 3660  
 gcagctgcag ccgctgcgc gcctctgtc gccgtaaca ctgtcgttg aatgggttac 3720  
 tatggaagca tcgtggctaa ttccacttc tctaataacc ctctacact gactcaggac 3780  
 aagttacttg tcttttggc ccagctggag gcttgacc aacgtctgg tgaacttct 3840  
 cagcaggttg ccgagttgc agtacaaact gagtctgtc tcggcacggc aaagtctaa 3900  
 taaaaaaat tcagaaatca atgaataat aaacgagctt gttgtgatt taaaatcaag 3960  
 tgttttatt tcatttttc gcacgggtat gccctggacc accgatctg atcattgaga 4020  
 actcgttga tttttccag aatcctatag aggtgggatt gaatgtttag atacatgggc 4080  
 attagccgtt ctgtgggtg gagatagctc cattgaaggg attcatgctc cgggtagtg 4140  
 ttgtaaatca ccagtcata acaaggctgc agtgcattgt gttgcacat atcttttaga 4200  
 agtaggctga ttgccacaga taagcccttg gttaggtgt ttacaaaccg gttgagcttg 4260  
 gaggggtgca ttccaggtga aattatgtc attttggatt ggattttta gttggcaata 4320  
 ttgcccaa gatccgtct tgggttcag ttatgaagga ctaccaagac ggtgatccg 4380  
 gtacatttag gaaattatc gtgcagctt gatggaaaag cgtggaaaaa ttggagaca 4440  
 ccttctgtc ctccagatt ttccatgcac tcacatga taatagcaat gggccgttg 4500  
 gcacggcgc gggcaaacac gtccgtggg tctgacacat catagttag ttctgagtt 4560  
 aaatcatcat aagccattt aatgaattg ggcggagcg taccagattg gggatgaat 4620  
 gttcctcgg gccccggagc atagtcccc tcacagatt gcatttcca agctttagt 4680  
 tctgaggtg gaatcatgt cactggggg gctatgaaga acacgttcc gggggcggg 4740  
 gtgattagt gggatgatag caagtctg agcaattgag atttgcaca tccgtgggg 4800  
 ccataaataa ttccgattac aggttgcagg tggtagtta gggaacggca actgccgtct 4860  
 tctcgaagca agggggccc ctcgttcac atttccctta catgcattt ttccgcacc 4920  
 aaatccatta ggaggcgtc tctcctagt gatagaagt ctgtagtga ggaaaagtt 4980  
 ttccagcgtt ttgacgtc agcatgggc attttgaaa gatttctg caaaagttct 5040  
 agtctgttc acagttcagt gatgtgtct atggcatctc gatccagcag acctcctgt 5100  
 ttccgggtt tggacgctc ctggagtag gtatgagac atgggcgtcc agcgtgcca 5160  
 ggggtcggtc ttccaggtt ctcagtgtc gactcaggt tgttccgtc acagtgaag 5220  
 ggtgtgcgc tcttggggc cttgcaggg tgcgttcag actcattctg ctggtggaga 5280  
 acttctgtc cttgggcgc tgtatgtcg ccaagtagca gtttaccatg agttcgtagt 5340  
 tgagcgtc ggttcgttg ctttgggcg gagcttacc ttggaagtt ttctgcata 5400  
 ccgggcagta taggcattc agcgcatca gcttgggcg aaggaaaatg gatttgggg 5460  
 agtatgcac cgcgcgcag gagcgcaaa cagtttaca ttccaccagc caggttaaat 5520  
 ccggttcatt ggggtcaaaa acaagtttc cgcataatt ttgatgcgt ttcttacct 5580  
 tggctccat aagttcgtt cctcgttag tgacaaacag gctgtcgtt tctccgtaga 5640  
 ctgattttac aggccttct tccagtggag tgcctcgtc ttctcgtac aggaactctg 5700  
 accactctga tacaaggcg cgcgtccagg ccagcaca aaaggagctatg tgggaggggt 5760  
 agcgatcgtt gtcaacagg ggtccacct ttccaaagt atgcaaacac atgtcacct 5820  
 cttcaacac caggaatgtt attgcttgt aggtgtatt cagtgacct ggggtcccg 5880  
 ctgggggggt ataaaagggg gcgttctt gcttctctc actgtctcc ggtcgtgt 5940  
 ccaggaaagt cagctgttg gtaggtatt cctctcgaa gccgggcatg acctctgcac 6000  
 tcagttgtc agtttctaag aacgaggagg atttgatatt gacagtccg gttgagatgc 6060  
 ctttcatgag gtttctec atttggcag aaaacacaat tttttattg tcaagtttg 6120  
 tggcaaatga tccatacag gcgttgata aaagttggc aatggatcg atggttgg 6180  
 tcttttctt gtccgcgc tcttggcg cgatgttag ttggacatc tcggtgcca 6240

ggcaattcca ttgggggaag atagtgtta attcatctgg cagattctc acttgccacc 6300  
 ctgattatg caaggtaatt aaatccacac tggggccac ctgcctcga aggggttcat 6360  
 tggccaaca gagcctacct ctttcttag aacagaaagg gggagtggt tctagcataa 6420  
 5 gttcatcggg aggggtctga tccatggtaa agattcccgg aagtaaatcc ttatcaaaat 6480  
 agctgatggg agtggggta tetaaggcca ttgcccattc tggagctgcc agtgcgcgt 6540  
 catatgggtt aaggggactg cccaggggca tgggatgggt gagagcagag gcatacatgc 6600  
 cacagatgtc atagacgtag atgggatcct caaagatgcc tatgtagggt ggatagcatc 6660  
 gccccctct gatacttct cgcacatagt catatagttc atgtatggc gctagcagcc 6720  
 10 ccggacccaa gttggtcga ttgggtttt ctgtctgta gacgatctgg cgaaagatgg 6780  
 cgtgagaatt ggaagagatg gtgggtctt gaaaaatgtt gaaatgggca tgaggtagac 6840  
 ctacagagtc tctgacaaag tgggcataag attctgaag ctggttacc agttcggcg 6900  
 tgacaagtac gctagggcg cagtgtcaa gtgttcttg aatgatgtca taacctggtt 6960  
 ggttttctt tccacagt tgcgggtga gaaggatctc ttcgcatcc ttccagtact 7020  
 15 ctctagcgg aaacccgtct ttgtctgcac ggtaagatcc tagcatgtag aactgattaa 7080  
 ctgcttcta agggcagcag ccttctcta cggtagaga gtatgcttga gcagctttc 7140  
 gtgagcaagc gtgagtaagg gcaaagggtg ctctgacct gactttgaga aattgtatt 7200  
 tgaagtcac gtctcacag gctcctgtt cccagagtg gaagtctacc cgcttctgt 7260  
 aggcggggtt gggcaaaagc aaagtaacat cattgaagag aatcttacc gctctgggca 7320  
 20 taaaattgcg agtgatgcg aaaggctgtg gtacttcgc tggattgtg atcacctggg 7380  
 cagctaggac gatttcgtcg aaaccgttga tgtgtgtcc tacgatgtat aattctatga 7440  
 aacgcggcgt gctctgacg tgaggtagct tactgagctc atcaaagggt aggtctgtg 7500  
 ggtcagataa ggcgtagtgt tggagagccc attcgtcag gtgaggattt gcattagga 7560  
 atgatacca aagatctacc gccagtctg ttgtactg gtccgatac tgacgaaaat 7620  
 25 gcccgaatc tgcattttt tctgagtgta cacagtagaa gttctgggg tctgtgtcc 7680  
 atcgatcca cttgagtta atgctagat cgtgggcat gttgacgaga cgctctctc 7740  
 ctgagagttt catgaccagc atgaaaggaa ctagtgttt gccaaaggat cccatccagg 7800  
 tgtaagtct cacatctag gtcaggaaga gtcttctgt gcgaggatga gagccgatcg 7860  
 ggaagaactg gatttctgc caccagtgg aggattggt gtgatgtga tggaagtaga 7920  
 30 agtttctgc gcgcgcag cattcgtgt tctgttga cagacggcg cagtgtcgc 7980  
 agcgtgcac ggggtgtatc tctgaatga gctgtacct gcttccctg acgagaaatt 8040  
 tcagtggaa gccaggcct ggcgattgta tctgtctc tctatattc gctgtatcg 8100  
 ctgtctatc ttctgttcg atggtgtca tctgacgag ccccgcggg aggcaagtc 8160  
 agacctcgc gcggagggg cggagctga gacgagagc gcgaggctg gagctgtcca 8220  
 35 gactctgag acgctcggc ctgaggttag taggtaggga cagaagatta acttgcatga 8280  
 tctttccag ggcgtcggg aggttcagat ggtactgat ttccacaggt tctttgtag 8340  
 agacgtcaat gcttcagg gttcgtgtc cttggggc cactaccgta ctttgttt 8400  
 ttctttgat cgtgtgtgc tcttctgt cttgcatgt cagaagcgt gacggggacg 8460  
 cgcgcgggc ggcagcggtt gttccggacc cgggggcatg gctggtagt gcacgtcggc 8520  
 40 gccgcgacg ggcaggttct ggtattgcg tctgagaaga ctgcgtgc ccaccacgc 8580  
 tctgttgcg tctgtatct gacgtctcg ggtgaaagct accggccc tgagcttgaa 8640  
 cctgaaagag agttcaacag aatcaattc ggtatctga acggcagct gtctcagta 8700  
 ttctgtacg tcaccagagt tctctgta ggcgatctc gccatgaact gctgattc 8760  
 ttctctga agatctcgc gaccgtct ttcagcgtg gccgcaggt cattggagat 8820  
 45 accgcccag agtgggaga atgcattcat gccgcctc ttcagacgc gctgtaaac 8880  
 caccgcccc tggagctc ttgcgcgat caccacctga gcgaggttaa gctccacgtg 8940  
 tctgtgaag accgcatagt tgcattggc ctgaaaagg tagttgagt tggtgcaat 9000  
 gtgtcggcg acgaagaaat acatgatcca tctctcagc gccatttgc taacatgcc 9060  
 cagagcttc aagcgtcca tggctcgtg gaagtccac gcaaaattaa aaaactggga 9120  
 50 gtttcgcgc gacacgtca attctctc gagaagacg atgagttcg ctatggtgc 9180  
 ccgtactcg cgttgaagg ctccggat ctctctc tctctatct cttctccac 9240  
 taacatctt tctctgtt caggcgggg cggaggggc acgcggcgc gtcacggcg 9300  
 caccggcaaa cggctgatga atcgtcaat gacctctcg cggcgcggc gcattgttc 9360

55

agtgacggcg cgccgttct cgcgcggtcg cagagtaaaa acaccgccgc gcattctctt 9420  
 aaagtgggta ctgggaggtt ctccgttgg gagggagagg gcgctgatta tacattttat 9480  
 taattggccc gtagggactg cgcgcagaga tctgatcgtg tcaagatcca cgggatctga 9540  
 aaacctttcg acgaaagcgt ctaaccagtc acagtcacaa ggtaggctga gtacggcttc 9600  
 ttgtgggccc ggggtggtat gtgttcggtc tgggtcttct gtttcttctt catctcggga 9660  
 aggtgagacg atgctgctgg tgatgaaatt aaagtaggca gttctaagac ggcggatggt 9720  
 ggcgaggagc accaggtctt tgggtccgce ttgctggata cgcaggcgat tggccattcc 9780  
 ccaagcatta tcttgacatc tagcaagatc tttgtagtag tcttgcatga gccgttctac 9840  
 gggcacttct tcttcacccg ttctgccatg catacgtgtg agtccaaatc cgcgcattgg 9900  
 ttgtaccagt gccaaagtcag ctacgactct ttccgagagg atggcttgcgt gtacttgggt 9960  
 aagggtggtc tgaagtcac caaaatccac aaagcgggtg taagccccg tattaatggt 10020  
 gtaagcacag ttggccatga ctgaccagtt aactgtctgg tgaccagggc gcacgagctc 10080  
 ggtgtattta aggcgcgaat aggcgcgggt gtcaaagatg taatcgttgc aggtgcgcac 10140  
 cagatactgg taccctataa gaaaatgcgg cgggtggttg cggtagagag gccatcgttc 10200  
 ttagctgga cgcgcagggg cgaggtcttc caacataagg cggtagatgc cgtagatgta 10260  
 cctggacatc caggtgattc ctgcggcggt agtagaagcc cgaggaaact cgcgtacgcg 10320  
 gttccaaatg ttgcgtagcg gcataagta gttcattgta ggcacgggtt gaccagttag 10380  
 gcgcgcgcag tcattgatgc tctatagaca cggagaaaat gaaagcgttc agcactcga 10440  
 ctccgtagcc tggaggaaag tgaacgggtt gggtcgcggt gtaccccggt tcgagacttg 10500  
 tactcgagcc ggccggagcc gcggctaacc tggattggc actcccgctc cgaccagcc 10560  
 tacaanaatc caggatagcg aatcgagtcg ttttgcgtt ttccgaatgg cagggaagt 10620  
 agtctattt tttttttt tttccgctc agatgcatec cgtgctgca cagatgcgc 10680  
 cccaacaaca cccccctc cagcagcgc agcagcaacc acaaaaggct gtccctgcaa 10740  
 ctactgcaac tgcgcgctg agcgtgctg gacagccgc ctatgatctg gacttggaa 10800  
 agggcgaagg actggcacgt ctaggctgc ctccgccga gggcatccg cgagttaac 10860  
 tgaanaaaga tctcgcgag gcgtatgtgc ccaacagaa cctatttaga gacagaagcg 10920  
 gcgaggagcc ggaggagatg cgagcttccc gcttaacgc gggctgtgag ctgcgtcacg 10980  
 gtttgaccg aagacgagtg ttgcgagcg aggtattcga agttgatga gtgacaggga 11040  
 tcagctctgc cagggcacac gtgctgcag ccaacctgt atcggttac gagcagacag 11100  
 taaaggaaga gcgttaactc caaagtcct ttaataatca tgtgcgaacc ctgattgcc 11160  
 gcgaagaag tacccttgg ttgatgcatt tgtgggatt gatggaagct atcattcaga 11220  
 accctactag caaacctc accgccagc tgtttctgt ggtcaacac agcagagaca 11280  
 atgaggcttt cagagaggcg ctgctgaaca tcaccgaacc cgaggggaga tggttgatg 11340  
 atcttatcaa cattctacag agtatcatag tgcaggagcg gagcctggcg ctggccgaga 11400  
 aggtagctgc catcaattac tgggtttga gcttgggaaa atattacgt cgcaaatct 11460  
 acaagactcc atagttccc atagacaagg aggtgaagat agatgggttc tacatgcga 11520  
 tgacgtcaa ggtcttgacc ctgagcgatg atcttgggt gtatcgcaat gacagaatgc 11580  
 atcgcgcggt tagcgcagc agggagcgcg agttaagcga cagggaactg atgcacagt 11640  
 tgcaagagc tctgactgga gctggaacc aggtgagaa ttacttcgac atgggagctg 11700  
 acttgacgt gcagctagt cgcagggtc tgagcgccg gacggcagga tgtgagcttc 11760  
 cttacataga agaggcggt gaaggcgagg aggaagagg cgagtactg gaagactgat 11820  
 ggcacaacc gtgtttttg ctataggaag cagcaagcac cggatccgc aatcgggcg 11880  
 gcgctcaga gccagccgc cggcattaac tctcggagc attggacca ggccatgcaa 11940  
 cgtatcatgg cgttgacgac tcgcaacccc gaagccttta gacagcaacc ccaggccaac 12000  
 cgtctatcg ccatcatgga agctgtagt ccttcccgat ctaatccac tcatgagaa 12060  
 gtctggcca tctgaacgc gttggtggag aacaaagcta ttctccaga tgaggccgga 12120  
 ctggtataca acgtctctt agaacgcgt gctcgtaca acagtagcaa tgtcaaac 12180  
 aatttgacc gtatgataac agatgtacg gaagcgtgt ctacgcga aaggttcag 12240  
 cgtgatgcca acctgggtc gctggtggc ttaaatgct tcttgagtac tcagcctgt 12300  
 aatgtccgc gtggtcaaca ggattatac aacttttaa gtgcttgag actgatgta 12360  
 tcagaagtac ctacagcga agttatcag tccgtcctg attactctt tcagactagc 12420  
 agacagggt tgcagacgtt aaatctgagc caagcttta aanaacctaa aggtttgtg 12480

ggagtgcacg ccccggtagg agaagagca accgtgtcta gcttgtaac tccgaactcc 12540  
 cgctgttat tactgttgg agctccttc accgacagcg gtacatcga ccgtaattcc 12600  
 tatttgggtt acctactaaa cctgtatcgc gaagccatag ggcaaagtca ggtggacgag 12660  
 5 cagacctatc aagaattac ccaagtcagt cgcgtttgg gacaggaaga cactggcagt 12720  
 ttggaagcca ctctgaactt ctgtctacc aatcggctc aaaagatccc tctcaatat 12780  
 gctcttactg cggaggagga gaggatcctt agatatgtgc agcagagcgt gggattgtt 12840  
 ctgatgaag agggggcaac tccgactgca gcactggaca tgacagcgcg aaatatggag 12900  
 10 cccagcatgt atgccagtaa ccgaccttc attacaacac tctggacta ctgcacaga 12960  
 gctccgcta tgaactctga ttatttcacc aatgccatct taaaccgca ctggctgcc 13020  
 ccacctggtt tctacacggg cgaatatgac atgcccacc ctaatgacgg atttctgtg 13080  
 gacgacgtg acagcgatgt ttttcaact cttctgac atgcacgtg gaaaaaggaa 13140  
 ggcggtgata gaatgacac tctgcatcg ctgtccggg tcatgggtg taccggcgt 13200  
 gagccgagt ctgcaagtcc tttctagt ctaccttt ctctacacag tgtacgtac 13260  
 15 agcgaagtgg gtagaataag tgcgccagt ttaatggcg aagaggagta cctaaacgat 13320  
 tcttgcctca gaccggcaag agaaaaaat tcccaaaac atggaataga aagttgtg 13380  
 gataaaatga gtatgtgaa gacttatgt caggatcaca gagacgagcc tggatcatg 13440  
 gggactacaa gttagcggag ccgtagacgc cagcgccatg acagacagag ggtcttctg 13500  
 tgggacgatg aggattcggc cgtatgacgc agcgtgttg acttgggtg gagaggaa 13560  
 20 ggcaaccgtt ttgtcattt gcgcctcgc ttgggtgta tgtgtgaaa aaaaaataa 13620  
 aagaaaaact caccaaggcc atggcgacga gcgtacgttc gttctcttt attatctgt 13680  
 tctagtataa tgaggcgagt cgtgctagc ggagcggtg tlatccgga ggtcctct 13740  
 ccttctacg agagcgatg gcagcagcag cagcgacgg cggatgac atccccactg 13800  
 gaggctcct ttgtcctcc gcgatacctg gcactacgg agggcagaaa cagcattcgt 13860  
 25 tactcggaac tggcacctca gtacgatacc accaggtgt atctgttga caacaagtc 13920  
 cgggacattg cttctctgaa ctatcagaat gaccacgca actcttgac caggtgtg 13980  
 cagaacaatg actttaccc tacggaagcc agcaccaga ccattaact tgaagaacga 14040  
 tgcggtggg gcggtcagct aaagaccac atgcatac acatgcaaa cgtgaacgag 14100  
 tataatgta gtaacaagt caaagcgct gtatgtgtt ccagaaaacc tccgacggt 14160  
 30 gctgcagtg gggataccta gtacacaag caggatattt tgaatatga gtggttcgag 14220  
 ttactttgc cagaaggcaa ctttcagtt actatgacta ttgattgat gaacaatgcc 14280  
 atcatagata attacttgaa agtgggtaga cagaatggag tcttgaaa tgacattgt 14340  
 gttaaagtgc acaccaggaa ctcaagctg ggtgggac ccgaaaccaa gttgatcatg 14400  
 cctggagtgt atacgtatga agccttcac cctgacattg tcttactgc tggctgcga 14460  
 35 gtgatttta ccgagagtcg tttagcaac cttcttgta tcagaaaaaa acagccattt 14520  
 caagagggtt ttaagattt gtatgaagt ttagaagggt gtaatatcc ggccctctg 14580  
 gatgtatag cctatgaaa cagtaagaaa gaacaaaaag ccaaataga agctgctaca 14640  
 gctgctcag aagctaaggc aaacatagtt gccagcgact ctacaagggt tgcatacgt 14700  
 ggagaggta caggagacaa tttgcgca acactgttc cgaactgaga atcattattg 14760  
 40 gccgatgtg ctgaaggaa gcacgtgaaa ctactatc aacctgtag aanaatagt 14820  
 aagaataga gctataatgt gttggaagc aaatcaaca cagcctatc cagttggtat 14880  
 cttctgtaca attatggcga tccgaaaaa ggatgctgt cctggacatt gctaccacc 14940  
 tcagatgta cctgcggagc agagcaggtt tactggtgc ttccagacat gatgaaggat 15000  
 cctgtcactt tccgtccac tagacaagtc agtaactacc ctgtgtggg tgcagagct 15060  
 45 atgcccgtt tctcaagag cttctacaac gaacaagctg tgaactcca gcagctccg 15120  
 cagtcacct cgttacgca cgtctcaac cgttctctg agaaccagat ttaatccgt 15180  
 ccgcggcgc ccaccattac caccgtcagt gaaaacgttc ctgtctcac agatcacggg 15240  
 acctgccgt tgcgcagcag tatccggga gtccaacgtg tgaccgttac tgacgccaga 15300  
 cgcgcacct gtcctacgt gtacaaggca ctgggcatag tgcaccgcg cgtccttca 15360  
 50 agccgacatt tctaaaaaa aaaaatgtc attcttatct cgcacgtaa taacacgggt 15420  
 tgggtctgc gcgtccaag caagatgtac ggaggcgac gcaaacgttc taccacacat 15480  
 cccgtgctg ttcgggaca tttcgcgt ccatgggtg cctcaaggc ccgactcgc 15540  
 gttcgaacca ccgtcgatga tgaatcgat caggtgttg ccgacgccg taattatact 15600

cctactgcgc ctacatctac tgtggatgca gttattgaca gtgtagtggc tgacgtcgc 15660  
 aactatgctc gagtaagag ccggcgaagg cgcattgccca gacgccaccg agtaccact 15720  
 gccatgcgag ccgcaagagc tctgtacga agagctagac gcgtggggcg aagagccatg 15780  
 5 cttagggcgg ccagacgtgc agcttcgggc gccagcgccg gcaggtcccg caggcaagca 15840  
 gccgtgtcg cagcggcgac tattccgcac atggcccaat cgcgaagagg caatgtatac 15900  
 tgggtgcgtg acgtgccac cggtaacgt gtaccgtgc gcaccgtcc cctcgcact 15960  
 tagaagatac tgagcagctc ccatgttct gtcccagcgg caggaatgc caagcraaa 16020  
 tacaaggaag aaatgttga gttatcgca cctgaagtct acggccaacc gttgaaggat 16080  
 10 gaaaaaaac ccgcraaat caagcgggtt aaaaaggaca aaaaagaaga ggaagatggc 16140  
 gatgatgggc tggcggagtt tgtgcgcag tttgcccac ggcgacgct gcaatggcgt 16200  
 gggcgcaag ttcgacatgt gttgagacct ggaacttcgg tggctttac acccggcgag 16260  
 cgttaacgc ctactttta gcgttctat gatgaggtgt acggggatga tgatattctt 16320  
 gagcaggcgg ctgaccgatt aggcgagttt gttatggca agcgtagtag aataacttc 16380  
 15 aaggatgaga cagtgtcaat acccttgat catggaaac ccaccctag tctaaaccg 16440  
 gtcacttgc agcaagtgt acccgtaac ccgcgaacag gtgttaaac cgaaggtaga 16500  
 gatttgatc ccactatga actgatgta cccaaacgc agaagttaga ggacgtttg 16560  
 gagaaagtaa aagtggatcc agatattcaa cctgaggta aagttagacc cattaagcag 16620  
 gtacgcctg gtctgggggt acaactgtga gacattaaga tccactga aagtatgga 16680  
 20 gtcaaacg aaccgcraa gctactgcc acctccactg aagtcaaac ggaatccatg 16740  
 atgccatgc ctattacaac tgacgcgcg ggtccactc gaagatcccg acgaaagtac 16800  
 ggtccagcaa gtcgttgat gcccaattat gttgtacac catctattat tctactcct 16860  
 ggttaccgag gcactgcga ctatgcgac gaaacagta cctccgcg tcgcgcag 16920  
 acactgcaa atgcagtcg tcgcgtaga gcacaagca aaccgactcc cggcgccctg 16980  
 25 tgcgcgaag gtaccgcaa tggtagtgc gaaccttga cactccgcg tcgcggtac 17040  
 catccagta tcatcacta atcaatgtt ccgctgcct cttgcagata tggccctac 17100  
 ttgtgcctt cgcgttcca tctctgtta ccgaggaaga aactcgcgc gtagaagagg 17160  
 gatgttggga cgcggaatgc gacgtacag gcgacggcgt gctatccga agcaattgcg 17220  
 ggggtgttt ttaccagct taattccat tatcgtgtc gcaattggcg cgaatccag 17280  
 30 catagcttc gtggcgctt aggcctgcga acgacattga cattggaaa aaaacgtata 17340  
 aataaaaaa aatacaatgg actctgacac tctgttct gtgactatgt tttctagag 17400  
 atggaagaca tcaattttt atcttggct ccgcgacag gcacgaagcc gtacatggc 17460  
 aactggagcg acatcgccac gagccaactg aacggggcg cctcaattg gagcagtat 17520  
 tggagcggc ttaaaaattt tggctcaacc ataaaaacat acgggaacaa agcttgaac 17580  
 35 agcagtacag gacagcgct tagaataaa cttaaagacc agaactcca aaaaaagta 17640  
 gtcgatggga tagcttcgg catcaatgga gtgtagatt tggtaacca ggctgtgcag 17700  
 aaaaagataa acagtgttt ggaccgcg ccagcaacc caggtgaaat gcaagtggag 17760  
 gaagaaattc ctccgcaga aaaacgagc gacaagcgtc cgctcccga ttggaagag 17820  
 acgtgtgta cgcgctaga tgaaccgtt tttatgagg aagcaacga gcttgaatg 17880  
 40 ccaccacta gaccgatag ccaatggcc accgggtga tgaaccttc tcagttgat 17940  
 cgaccgtca ctttgattt gccctccc cctgtgcta ctgtgtacc cgcttctag 18000  
 cctgtcgtg cccgaaacc agtcgcgta gccaggtcac gtccggggg cgctcctgt 18060  
 ccaaatgcgc actggcaaaa tactctgaac agcatcgtg gtctaggcgt gcaagtgt 18120  
 aaacgcgtc gctgtttta attaatatg gtagtcgct taactgcct atctgttat 18180  
 45 atgtgtcatt acacgcgtc acagcagcag aggaaaaag gaagaggtcg tgcgtgcag 18240  
 ctgagttact tcaagatgg cccccatc gatgtgccc caatggcat acatgcacat 18300  
 cgccggacag gatgttcgg agtacctgag tccgggtct gtgcagttc cccgcgcac 18360  
 agacacctac tcaatctgg gaaataagtt tagaaatccc accgtagcgc cgaccacga 18420  
 tgtgaccacc gaccgtacc agcgcctcat gttgccttc gtcccggtt accgggagga 18480  
 caatacatac tcttcaaaag tgggtacac cctggcgtg ggcgacaaca gtagtctgga 18540  
 50 tatggccagc acgttcttt acattagggg cgtgttgac agaggtcca gttcaaac 18600  
 ctattctgt acggttaca actctctgc tctaaaggc gtcraaatg catctaatg 18660  
 gattgcaaaa ggcgtacca ctgcagcgc gcaggcaat ggtgaagaag aacatgaac 18720

agaggagaaa acigctactt acacttttgc caatgctcct gtaaaagccg aggcctcaaat 18780  
 taaaaaagag ggcttaccaa taggtttgga gatttcagct gaaaacgaat ctaaacccat 18840  
 ctatgcagat aaactttatc agccagaacc tcaagtggga gatgaaactt ggactgacct 18900  
 5 agacgggaaaa accgaagagt atggaggcag ggctctaaag cctactacta acatgaaacc 18960  
 ctgttacggg tctatgcga agcctactaa tttaaaaggt ggtcaggcaa aaccgaaaaa 19020  
 ctcggaaccg tggagtgaat aaattgaata tgatattgac atggaatfff ttgataactc 19080  
 atcgcaaaga acaaaactca gtctaaaaat tgcattgat gcagaaaatg taggtttgga 19140  
 aacgccagac actcatgtag tctacaaacc tggaaacagaa gacacaagtt ccgaagctaa 19200  
 10 tttgggacaa cagctatgc ccaacagacc caactacatt ggcttcagag ataactttat 19260  
 tggactcatg tactataaca gtactggtaa catgggggtg ctggctggtc aagcgtctca 19320  
 gttaaatgca gtggttgact tgcaggacag aaacacagaa cttcttacc aactcttgct 19380  
 tgactctctg ggcgacagaa ccagatactt tagcatgtgg aatcaggctg tggacagtta 19440  
 tgatcctgat gtactgttta ttgaaaatca tgggtggaa gatgaacttc ccaactattg 19500  
 15 tttccactg gacggcatag gtgtccaac aaccagttac aaatcaatag ttccaaatgg 19560  
 agaagataat aataattgga aagaacctga agtaaatgga acaagtga tggacaggg 19620  
 taattttgtt gccatgaaa ttaacctca agccaatcta tggcgaagtt tcttttattc 19680  
 caatgtggt ctgtatctcc cagactcgt aataacacc cgtccaatg tcaactttcc 19740  
 agaaaaacaaa aacacctacg actacatgaa cggcggggtg gtgcggccat ctctagtaga 19800  
 20 cacctatgtg aacattgggt ccagggtgct tctggatgcc atggacaatg tcaaccatt 19860  
 caaccaccac cgtaacgtg gcttgcgtta ccgatctatg ctctgggtta acggacgtta 19920  
 tgtgccttc cacatacaag tgcctcaaaa attctcgt gttaaaaacc tgetgcttct 19980  
 ccagggtccc tacacttatg agtggaaact taggaaggat gtgaacatgg ttctacagag 20040  
 ttccctcgtt aacgacctgc ggttagatgg gcggacatc agtttcacga gcatacaact 20100  
 25 ctatgtact ttttccca tggctcaca caccgttcc acccttgaag ccattgctgc 20160  
 gaatgacacc aatgatcagt cattcaacga ctacctatct gcagtaaca tgctctacc 20220  
 cattctgcc aatgcaacca atattccat ttcatctct tctgcaact gggcggttt 20280  
 cagaggctgg tcatctacca gactgaaaac caaagaact cctctttgg ggtctggatt 20340  
 tgacccctac ttgtctatt ctggtctat tccctactg gatggtacct tctactgaa 20400  
 30 ccacactttt aagaagggtt ccatcatgtt tgactctca gtgagctggc ctggaaatga 20460  
 caggttacta tctctaacy aatttgaaat aaagcgact gtggatggcg aaggctaca 20520  
 cgtagcccaa tgcaaatga ccaagactg gttcttgga cagatgctcg ccaactaca 20580  
 catcggtat cagggttct acattccaga aggatacaa gatcgcatgt attcatttt 20640  
 cagaacttc cagccatga gcaggcaggt ggtgatgag gtcaattaca aagacttca 20700  
 35 ggcgtgcgc atacctacc aacacaacaa ctctggctt gtgggttaca tggctccgac 20760  
 catcgcccaa ggtcaacct atccgctaa ctatccctat ccactcattg gaacaactgc 20820  
 cgtaaatagt gttacgcaga aaaagtctt gtgtgacaga accatgtggc gcataccgtt 20880  
 ctgagcaac ttcattgcta tgggggccc tacagacttg ggacagaata tgctctatgc 20940  
 caactcagct catgctctg acatgacctt tgaggtggat cccatggatg agccaccct 21000  
 40 gctttatct ctctcgaag ttttcagct ggtcagagt catcagccac accgcggcat 21060  
 catcgagga gtctactgc gtacacgtt ctggccggt aacgtacca cgtagaagc 21120  
 ttcttgctt ttgcaaatag cagctgcaac catggctgc ggtcccaaa acggctccag 21180  
 cgagcaagag ctgagagca ttgtccaaga cctgggttg gcacctatt ttttgggaac 21240  
 ctacgataag cgctcccg ggttcattgg cccgataag ctgcctgtg ccattgtaaa 21300  
 45 tacggccgga cgtgagacgg ggggagagca ctggttggt ttcggttga acccagttc 21360  
 taacacctgc taccttttg atcttttg attctcggat gatcgtctca aacagattta 21420  
 ccagtttga tatgagggtc tctgcgcg cagcgtctt gctaccaagg accgtgtat 21480  
 tacgttgaa aaatctacc agaccgtga gggcccccgt tctgcgcct gcggacttt 21540  
 ctgctgatg ttcttcacg ccttttgca ctggctgac cgtccatgg acggaaacc 21600  
 50 caccatgaaa ttgtaactg gattgcaaaa caacatgctt cattctcta aagtcagcc 21660  
 caccctgtgt gacaatcaa aagactcta ccttttctt aataccatt cgcttattt 21720  
 tgcctctat cgtacacaa tgaagggc cactgcgtt gaccgtatg atgttaata 21780  
 atgactcatg taaacaact gttcaataa catcactta ttttttaca tgtatcaag 21840

55

ctctggatta cttatttatt tacaagtca atgggttctg acgagaatca gaatgacctg 21900  
 caggcagtga tacgttgccg aactgatact tgggttgcca cttgaattcg ggaatcacca 21960  
 acttgggaac cggatatcg ggcaggatgt cactccacag cttctggtc agctgcaaag 22020  
 ctccaagcag gtcaggagcc gaaatcttga aatcacaatt aggaccagtg ctctgagcgc 22080  
 gagagttgcg gtacaccgga ttgcagcact gaaacacat cagcgacgga tgtctcacgc 22140  
 ttgccagcac ggtgggatct gcaatcatgc ccacatccag atcttcagca ttggcaatgc 22200  
 tgaacggggg catcttgca gctgctcat ccattggcgg cacccaatta ggcttgggt 22260  
 tgcaatcgca gtgcaggggg atcagtatca tcttgccctg atcctgtctg attcctggat 22320  
 acacggctct catgaaagca tcatattgct tgaagcctg ctgggcttta ctaccctcg 22380  
 tataaaacat cccgaggac ctgctcgaaa actggttagc tgcacagccg gcatcattca 22440  
 cacagcagcg ggcgtcattg ttggctattt gcaccacact tctgcccag cggttttggg 22500  
 tgattttgt tgcctcgga tctctctta agctcgttg tccgtctcg ctggccacat 22560  
 ccactcgtat aatctgctc tctgaaatca taatttgcc atgcaggcac ttcagcttgc 22620  
 cctcataatc attgcagcca tgaggccaca acgcacagcc tgtacattcc caattatggt 22680  
 ggcgagatcg agaaaaagaa tgtatcattc cctgcagaaa tcttccatc atcgtgtca 22740  
 gtgtcttggt actagtgaat gttactgga tgcctcggtg ctctcgttt acgtactggt 22800  
 gacagatgcg cttgtattgt tctgttctg caggcattag tttaaaacag gttctaagtt 22860  
 cgttatccag cctgtacttc tcatcagca gacacatcac ttcattgctt tctcccaag 22920  
 cagacacagc gggcaagcta atcggtattt taacagtga ggcagcagct ctttagcca 22980  
 gagggctcgc tttagcagc tctcaatgc tcttttgc atccttctca acgatgcga 23040  
 cggcggggta gctgaaaccc actgtacaa gtgcgcctc tctcttctt tctcgtgt 23100  
 ctgactgat gcttgcatg gggatattgt tggcttctt tggcttctt ttgggggta 23160  
 tccgaggagg aggactgtcg ctccgttccg gagacagga ggattgtgac gtttcgtca 23220  
 ccattaccaa ctgactgtcg gtagaagaac ctgacccac acggcgacag gtgttttct 23280  
 tccggggcag aggtggagcg gattgcgaag ggcgtcggtc cgaactggaa ggcggatgac 23340  
 tggcagaacc ccttcgcgt tccgggggtg gctccctg ggcgtcgtt aactgattc 23400  
 ctccgcgctt ggccattgtg tctcctagg cagagaaaca acagacatgg aaactcagcc 23460  
 attcgttca acatcgccac gattgcatc acatctctc ctacggcagc aggaaaagga 23520  
 gcagagctta agcattccac cgcacgtcc tgcaccacc tctacctag aagataagga 23580  
 ggtcgagcga tctcatgaca tgcagaataa aaaagcgaaa gattctgaga cagacatga 23640  
 gcaagaccgc ggtctgtga caccgttga acacgaggaa gattgaaac gctttctaga 23700  
 gagagaggat gaaaactgcc caaaacagcg agcagataac taccaccaag atgttgaaa 23760  
 tagggatcag aacaccgact acctcatagg gcttgacggg gaagacgcgc tcttaaaca 23820  
 tctagcaaga cagtgcctca tagtcaagga tgcattattg gacagaactg aagtgccat 23880  
 cagtgtgga gagctcagct gcgctacga gcttaacctt tttcacctc gtactcccc 23940  
 caaacgtcag ccaaacggca cctgcagacc aaatcctgc taaactttt atccagctt 24000  
 tctgtgccca gaagtactgg ctacctatca catcttttt aaaaatcaaa aaattccagt 24060  
 ctctgcccgc gctaalcga ccgcgcga tgcctactc aatctgggac ctggttcag 24120  
 cttacctgat atagcttct tggagaggt tccaaagatc ttcgagggtc tggcaataa 24180  
 tgagactcgg gccgcaaatg ctctgcaaaa gggagaaaat ggcattggatg agcatcacag 24240  
 cgttctgggtg gaattggaag gcgataatgc cagactcgca gtactcaagc gaagcgtcga 24300  
 ggtcacacac ttcgcatatc ccgtgtcaa cctgccccct aaagtcatga cggcggtcat 24360  
 ggaccagtta ctcatgaagc gcgcaagtcc ctttcagaa gacatgcatg accagatgc 24420  
 ctgtgatgag ggtaaacagg tggtcagtga tgagcagcta accgatggc tgggcaccga 24480  
 ctctccccgg gatttgaag agcgtcgca gcttatgat gcggtggtc tggttaccgt 24540  
 agaactagag tgtctccgac gtttctttac cgattcagaa accttgcga aactcgaaga 24600  
 gaactcgac tacacttita gacacggctt tgtcggcag gcatgcaaga tatctaact 24660  
 ggaactcacc aactgtttt cctacatggg tattctgcat gagaatgcc taggacaaag 24720  
 cgtgtgcac agcaccctta agggggaagc ccgcgtgat tacatccgc atttgtcta 24780  
 tctctacctg tgcacacgt ggcaaacgg catgggtga tggcagcaat gttagaaga 24840  
 acagaacttg aaagagctg acaagctct acagaaatct ctaaggttc tgtggacag 24900  
 gttcgacgag cgcaccgtc ctccgacct ggcagacctc atctccagc agcgtctcag 24960



ggttactttg cgaaacggat tgctgactt tatgagccag agcatgctta acaattttcg 25020  
 ctctttcacc ctggaacgct ccggtatcct gccgccacc tgetgpcac tgcctccga 25080  
 5 ctttgtgct ctcacctacc gcgagtccc cccgcccta tggagtcaat gctacctgtt 25140  
 ccgtctggcc aactatctct cctaccactt ggatgtgatc gaggatgtga gcggagacgg 25200  
 cttgtggag tgccactgcc gctgcaatct gtgcacgcc caccggccc tagcttgcaa 25260  
 cccccagtg atgagcgaac cccagataat aggcaccttt gaattgcaag gccccagcag 25320  
 ccaagggcat gggcttctc ctggcgaag tttaaaactg accccgggac tgtggacctc 25380  
 10 cgctacttg cgcaagttg ctccgaaga ttaccacccc tatgaaatca agttctatga 25440  
 ggaccaatca cagcctccaa aggcgaact ttcggcttg gtcacaccc agggggcaat 25500  
 tctggccaa ttgcaagcca tccaaaaatc ccgcaagaa tttctactga aaaagggtaa 25560  
 gggggtctac cttgacccc agaccggcga ggaactcaac acaaggttcc ctcaggatgt 25620  
 cccaacgacg agaaaacaag aagtgaagg tgcagccgc gccccagaa gatattggag 25680  
 aagattggga cagttaggca gaggaggcgg agggaggacg tctggaggac agtctggagg 25740  
 15 aagacagttt ggaggaggaa aacgaggagg cagaggagggt ggaagaagta accccgaca 25800  
 aacagttatc ctgggtgcg gagacaagca acagcgctac catctccgt ccgagtcgag 25860  
 gaacccggcg gctccaccg agtagatggg acgagaccgg acgttcccg aaccaacca 25920  
 gcgttccaa gaccgtaag aagatcggc agggatacaa gtctggcgg gggcataaga 25980  
 atgccatcat ctctgcttg catgagtgcg ggggcaacat atccttcacg cggcgctact 26040  
 20 tgetatcca ccatgggtg aactttccg gcaatgttt gcattactac cgtcacctcc 26100  
 acagcccta ctatagccag caaatccga cagtctgac agataaagac agcggcgcg 26160  
 acctcaaca gaaaaccagc agcggcagtt agaaaatata caacaagtgc agcaacagga 26220  
 ggattaaaga ttacagccaa cgagccagcg caaacccgag agttaagaaa tcggatcttt 26280  
 ccaacctgt atgcatctt ccagcagagt cgggtcaag agcaggaact gaaaataaaa 26340  
 25 aaccgatctc tgcgttccg caccagaagt tgtttgtatc acaagagcga agatcaactt 26400  
 cagcgactc tcgaggacgc caggctctc ttcaacaagt actgcgcgt gactcttaa 26460  
 gaggtagcag cgaccgctt tattcaaaaa aggcgggaat tacatcatcc tcgacatgag 26520  
 taagaaatt ccacgcctt acatgtggag ttatcaacc caaatggat tggcagcagg 26580  
 cgctccag gactactca ccccatgaa ttggctcagc gccgggctt ctatgattc 26640  
 30 tcgagttaat gatatacgc cctaccgaa caaatactt ttggaacagt cagctctac 26700  
 caccagccc cgcaacacc ttaatccag aaattggccc gccccctag tgtaccagga 26760  
 aagtcocgt ccaccactg tattactcc tcgagacgc caggccgaag tccaatgac 26820  
 taatgcaggt gcgcagtag ctggcggtc caccctatgt cgtcacaggc ctggcataa 26880  
 tataaacgc ctgatgatca gaggccagg tatccagtc aacgacaggt cgtgagtc 26940  
 35 tccgttgtt ctacgaccag acggaatct tcagattgcc ggctgcggga gatcttctt 27000  
 caccctcgt caggctgtc tgaatttga aagttctct tcgcaaccc gtcggggcg 27060  
 aatcgggacc gttaattt tagaggagt tactccctt gctacttca acccttctc 27120  
 cggatctct gggcactacc cggacaggt caccgcaac ttgcacgca ttacgagtc 27180  
 agtggacgc tacgattgat gtctgtgac gcgctgagc tatctcggt gcgacatca 27240  
 40 gaccactgcc gccgtttc ctgctttgcc cgggaactta ttgattcat ctactcgaa 27300  
 ctcccaagg atcacctca aggtccgcc caggagtgc ggattactat cgaaggcaaa 27360  
 atagactct gcctcaacg aattttctc cagcgcccg tctgatcga gcgagaccag 27420  
 ggaaacacca cggttccat ctactgcatt tgaatcacc ccgattgca tgaagcctt 27480  
 tctgtctta tgtgtactga gtttaataaa aactgaatta agactctct acggactgcc 27540  
 45 gcttctcaa cccgatttt acaaccagaa gaacaaaact tttctgtc tcaggactc 27600  
 ttttaacttc accttcta ctacaaact agaagctca cactacacc gttttccag 27660  
 aagcatttct cctactata ctacttcaa aaccggagg gagctccac gtctccctac 27720  
 agaaaacct tgggtggaag cgggcttgt agtactagga attcttgcg gtgggctgt 27780  
 gattattctt tgetacctat acacacctt cttacttct ctagtgtgt tgtgtattg 27840  
 50 gtttaaaaa tggggccat actagtctt ctgttttac tttcgtttt ggaaccgggt 27900  
 tctgccaatt acgatccatg tctagacttt gaccagaaa actgcacact tactttgca 27960  
 cccgacaaa gcccatctg tggagtctt attaatgag gatgggaatg caggtccgtt 28020  
 gaaattacac acaatacaa aacctggaac aatacttat ccaccacatg ggagccagga 28080

55

gtccccgagt ggtacactgt ctctgtccga ggctctgacg gttccatccg cattagtaac 28140  
 aacactttca tttttctga aatgtgcgat ctggccatgt tcatgagcaa acagtattct 28200  
 ctatggccct ctagcaagga caacatcgta acgtttccca ttgctattg ctgtgcgct 28260  
 5 tgccttcta ctgctttact gtgcgtatgc atacacctgc ttgtaaccac tgcctcaaa 28320  
 aacgccaata acaaaagaaa aatgccttaa cctctttctg tttacagaca tggcttctct 28380  
 tacatctctc atatttgtca gcattgtcac tgcgctcac ggacaaacag tegtctctat 28440  
 cccactagga cataattaca ctctcatagg accccaatc acttcagagg tcatctggac 28500  
 caaactggga agcgttgatt actttgatat aatctgtaac aaaacaaaac caataatagt 28560  
 10 aacttgcaac atacaaaatc ttacattgat taatgttagc aaagtttaca gcggttacta 28620  
 ttatggttat gacagatata gtagtcaata tagaaattac ttggttcgtg ttaccagtt 28680  
 gaaaaccacg aaaatgccaa atatggcaaa gattcgatcc gatgacaatt ctctagaanc 28740  
 ttttacatct cccaccacac ccgacgaaaa aaacatccca gattcaatga ttgcaattgt 28800  
 tgcagcggtg gcagtgtgga tggcactaat aataatatgc atgcttttat atgcttgcg 28860  
 15 ctacaaaaag ttctatccta aaaaacaaga tctctacta aggttaaca tttatttct 28920  
 tttatcacag ccattggttc cactaccaca ttcttatgc ttactagtct cgcaactctg 28980  
 actctgtctc gctcacacct cactgtaact ataggctcaa actgcacact aaaaggacct 29040  
 caagggtggtc atgtcttttg gtggagaata tatgacaatg gatggtttac aaaaccatgt 29100  
 gaccaacctg gtagattttt ctgcaacggc agagacctaa ccattatcaa cgtgacagca 29160  
 20 aatgacaaag gcttctatta tggaaaccgac tataaaagta gtttagatta taacattatt 29220  
 gtactgccat ctaccactcc agcaccocgc acaactactt tctctagcag cagtgtcgtc 29280  
 aacaatacaa ttccaatcc aactttgccc gcgttttaa aacgcactgt gaataattct 29340  
 acaactcac atacaacaat ttccactca acaatcagca tcatcgtgc agtgacaatt 29400  
 ggaatatcta ttctgtttt taccataacc tactacgctc gctgctatag aaaagacaaa 29460  
 25 cataaagggt atccattact tagatttgat atttaatttg ttctttttt ttatttacag 29520  
 tatggtgaac accaatcatg gtacctagaa atttctctt caccatactc atctgtgctt 29580  
 ttaatgtttg cgtactttc acagcagtag ccacagcaac cccagactgt ataggagcat 29640  
 ttgcttcta tgcactttt gcttttgta ctgtcatctg cgtatgtagc atagtctgc 29700  
 tggttattaa tttttccaa ctctagact ggatcctgt gcgaattgcc tacctgcgc 29760  
 30 accatccga ataccgcaac caaatatcg cggcacttct tagactatc taaaaccatg 29820  
 caggctatc taccatatt ttgcttcta ttgcttccct acgtgtctc aacccagct 29880  
 gcctatagta ctccaccaga acacttaga aatgcaaat tccaacaacc gtggtcattt 29940  
 ctgtctgtc atcgagaaaa atcagaaatc ccccaaat taataatgat tcttgaata 30000  
 attaatataa tctgtgcac cataattica ttttgatat acccctatt tgattttgc 30060  
 35 tggatgtct ccaatgcaca tcatcatcca caagaccag aggaacacat tccccacaa 30120  
 aacatgcaac atccaatagc gctaatagat tacgaaagt aaccacaacc cccactactc 30180  
 cctgttatta gttacttcaa cctaaccgc ggagatgact gaaacactca ccactccaa 30240  
 ttccgcgag gatctgtcg atatggacgg ccgctctca gaacaacgac ttgccaaact 30300  
 acgcatccg cagcagcagg aacgctggc caaagagctc agagatgtca tccaattca 30360  
 40 ccaatgcaaa aaaggcatat tctgttgggt aaaacaagcc aagatatcct acgagatcac 30420  
 cgtactgac catcgcctct cttaagaaat tggccoccaa cgacaaaaat ttactgcat 30480  
 ggtgggaatc aacccatag ttatcccca acaagtgga gatactaagg gttgcattca 30540  
 ctgctcctgc gattccatcg agtgaccta cccctgctg aagacctat gcggcctaag 30600  
 agacctgcta ccaatgaatt aaaaaaaat gattaataaa aaatcactta ctgaaatca 30660  
 45 gcaataaggt ctctgttgaa attttctcc agcagcact cactccctc ttccaaactc 30720  
 tggatttcta aacccgttc agcgcatac ttctccata cttaaaggg gatgtcaat 30780  
 tttagctct ctctgtacc cacaatctc atgtcttct tccagatga ccaagagagt 30840  
 ccggtcagt gactcctca accctgtcta cccctatga gatgaaagca cctcccaaca 30900  
 ccccttata aaccagggt ttatttccc aaatggctc acacaaagcc cagacggagt 30960  
 50 tcttacttta aaatgtttaa cccactaac aaccacagc ggatctctac agctaaaagt 31020  
 gggaggggga cttacagtgg atgacactga tggtaactta caagaaaca tacgtgctac 31080  
 agcaaccatt actaaaaata atcactctgt agaactatcc attggaaatg gattagaac 31140  
 tcaaaacaat aaactatgt ccaaatggg aaatgggtta aaatttaaca acgtgacat 31200

ttgtataaag gatagtatta acaccttatg gactggaata aacctccac ctaactgtca 31260  
 aattgtggaa aacactaata caaatgatgg caaacttact ttagtattag taaaaaatgg 31320  
 5 agggcttgtt aatggctacg tgtctctagt tgggtatca gacactgtga accaaatgtt 31380  
 cacacaaaag acagcaaaca tccaattaag attatattt gactcttctg gaaatctatt 31440  
 aactgaggaa tcagacttaa aaattccact taaaaataaa tctctacag cgaccagtga 31500  
 aactgtagcc agcagcaaag cctttatgcc aagtactaca gttatccct tcaacaccac 31560  
 tactagggat agtgaanaact acattcatgg aatatgttac tacatgacta gttatgatag 31620  
 10 aagtctattt ccttgaaca tttctataat gctaaacagc cgtatgattt cttccaatgt 31680  
 tgcctatgcc atacaatttg aatggaatct aaatgcaagt gaatctccag aaagcaacat 31740  
 agctacgctg accacatccc ccttttctt ttcttactt acagaagagc acaactaaaa 31800  
 taaagttaa gtgtttttat ttaaaatcac aaaattcgag tagttattt gctccacct 31860  
 tccatttga cagaatacac caatctctcc ccacgcacag ctttaaacat ttggatacca 31920  
 ttagagatag acattgtttt agattccaca ttccaaacag tticagagcg agccaatctg 31980  
 15 gggtcagtga tagataaaaa tccatcgca tagtcttta aagcgcttc acagtccaac 32040  
 tgcgtcgat ggcactccgg agtttgatc acggtcatct ggaagaagaa cgatgggaat 32100  
 cataatccga aaacggtatc ggacgattgt gtctcatcaa acccacaagc agccgctgtc 32160  
 tgcgtcgtc cgtgcgactg ctgtttatgg gatcagggtc cacagtctc tgaagcatga 32220  
 ttttaatagc ccttaacatc aactttctgg tgcgatcgc gcagcaacgc attctgattt 32280  
 20 cactcaaatc tttgcagtga gtacaacaca ttattacaat attgtttaat aaaccataat 32340  
 taaaagcgct ccagocaaaa ctcatatctg atataatgc cctgcatga ccatcatacc 32400  
 aaagttaat ataaattaaa tgacgttccc tcaaaaacac actaccaca tacatgatct 32460  
 cttttggcat gtgcatatta acaatctgtc tgiaccatgg acaacgttgg ttaatcatgc 32520  
 aaccaalat aacctccgg aaccacactg ccaacacgc tccccagcc atgcatgaa 32580  
 25 gtgaacctg ctgattacaa tgacaatgaa gaaccaat ctctcgaccg tgaatcactt 32640  
 gagaatgaaa aatatctata gtggcacaac atagacataa atgcatgcat ctctcataa 32700  
 ttttaactc ctgagattt agaaacatat ccagggaat aggaagctct tgcagaacag 32760  
 taaagctggc agaacaagga agaccacgaa cacaactac actatgcata gtcatagtat 32820  
 cacaatctg caacagcggg tggctctcag tcatagaagc tgggtttca tttctctac 32880  
 30 aacgtggtaa tgggctctg gtgtaagggt gatgtctggc gcatgatgtc gagcgtgcgc 32940  
 gcaacctgt cataatggag ttgctctctg acattctctg attttgata gcaaaacgcg 33000  
 gcoctggcag aacacactct tcttcgctt ctatctctcc gcttagcgtg ttccgtgtga 33060  
 tagtcaagt acagccacac tcttaagtg gtcaaaagaa tgcgtgctc agttgtaac 33120  
 aaaactccat cgcactaat tgtctgagg aaatcatcca cggtagcata tgcaaatccc 33180  
 35 aaccaagcaa tgcaactgga ttgcgtttca agcaggagag gagagggaag agacggaaga 33240  
 accatgttaa ttttatcc aaacgatctc gcagtactc aaattgtaga tgcgcagat 33300  
 ggcatctct gccccactg tgttgggtga aaagcacagc taaatcaaaa gaaatgcgat 33360  
 ttcaagggt ctcaacgggt gttccaaca aagcctccac gcgcacatcc aagaacaaaa 33420  
 gaataccaaa agaaggagca ttttctaact cctcaatcat catattacat tctgcacca 33480  
 40 tcccagata attttcagct tccagcctt gaattattc tgcagtctt tgttgtaaat 33540  
 ccaatccaca cattacaaac aggtcccggg gggcgccctc caccaccatt cttaaacaca 33600  
 cctcataat gacaaaatat ctgtctctg tgcacctgt agcgaattga gaatggcaac 33660  
 atcaattgac atgcccctgg ctctaagttc ttctttaagt tctagttgta aaaactctct 33720  
 catattatca ocaaactgct tagccagaag cccccggga acaagagcag gggacgctac 33780  
 45 agtcagtac aagcgcagac ctcccgaat ggctccagca aaaacaagat tggataaagc 33840  
 atattgggaa ccaccagtaa tatcatgaa gtgtctggaa atataatcag gcaggtttc 33900  
 ttgtagaat tgaataaaag aaaaatttgc caaaaaaaca ttcaaaacct ctgggatgca 33960  
 aatgcaatag gttaccgctg tgcgtccaa cattgttagt tttgaattag tctgcaaaaa 34020  
 taaaaaaaaa acaagcgtca tatcatagta gctgacgaa cagggtgata aatcagttt 34080  
 50 tccatcaca gacaagccac aggtctcca gctgacctt cgtaaaacct gtcactgtga 34140  
 ttaacaaca gcaccgaaag ttctcgcgg tgaccagcat gaataagtct tgatgaagca 34200  
 tacaatccag acatgttagc atcagtttag gagaanaaac agccaacata gcctttgggt 34260  
 ataattatgc ttaatcgtaa gtatagcaaa gccacccctc gcgatacaa agtaaaagc 34320

acaggagaat aaaaaatata attatttctc tgctgtgtt taggcaacgt cgcccccggt 34380  
 ccctctaat acacatacaa agcctcatca gccatggctt accagagaaa gtacagcggg 34440  
 cacacaaacc acaagctcta aagtcactct ccaacctctc cacaatatat atacacaagc 34500  
 cctaaactga cgtaatggga ctaaagtgt aaaaatcccg ccaaaccctaa cacacacccc 34560  
 gaaactgcgt caccagggaa aagtacagtt tcaattccgc aatcccaaca agcgtcactt 34620  
 cctctttctc acggtacgtc acatcccatt aacttacaac gtcattttcc cagggccgcg 34680  
 ccgccccctt taaccgttaa cccacagcc aatcaccaca cgcccacac tttttaaant 34740  
 cacctcattt acatattggc accattccat ctataaggt aattattgat gatg 34794

<210> 85

<211> 585

<212> PRT

<213> Adenoviridae

<220>

<221> CHAIN

<222> (1)..(585)

<223> /note="Fiber protein of Adenovirus serotype 5"

<400> 85

Met Leu Leu Gln Met Lys Arg Ala Arg Pro Ser Glu Asp Thr Phe Asn.

1 5 10 15

Pro Val Tyr Pro Tyr Asp Thr Glu Thr Gly Pro Pro Thr Val Pro Phe

20 25 30

Leu Thr Pro Pro Phe Val Ser Pro Asn Gly Phe Gln Glu Ser Pro Pro

35 40 45

Gly Val Leu Ser Leu Arg Leu Ser Glu Pro Leu Val Thr Ser Asn Gly

50 55 60

Met Leu Ala Leu Lys Met Gly Asn Gly Leu Ser Leu Asp Glu Ala Gly

65 70 75 80

Asn Leu Thr Ser Gln Asn Val Thr Thr Val Ser Pro Pro Leu Lys Lys

85 90 95

Thr Lys Ser Asn Ile Asn Leu Glu Ile Ser Ala Pro Leu Thr Val Thr

100 105 110

Ser Glu Ala Leu Thr Val Ala Ala Ala Pro Leu Met Val Ala Gly

115 120 125

Asn Thr Leu Thr Met Gln Ser Gln Ala Pro Leu Thr Val His Asp Ser

130 135 140

Lys Leu Ser Ile Ala Thr Gln Gly Pro Leu Thr Val Ser Glu Gly Lys

145 150 155 160

Leu Ala Leu Gln Thr Ser Gly Pro Leu Thr Thr Thr Asp Ser Ser Thr

	165	170	175
5	Leu Thr Ile Thr Ala Ser Pro Pro Leu Thr Thr Ala Thr Gly Ser Leu		
	180	185	190
	Gly Ile Asp Leu Lys Glu Pro Ile Tyr Thr Gln Asn Gly Lys Leu Gly		
	195	200	205
10	Leu Lys Tyr Gly Ala Pro Leu His Val Thr Asp Asp Leu Asn Thr Leu		
	210	215	220
	Thr Val Ala Thr Gly Pro Gly Val Thr Ile Asn Asn Thr Ser Leu Gln		
15	225	230	235 240
	Thr Lys Val Thr Gly Ala Leu Gly Phe Asp Ser Gln Gly Asn Met Gln		
	245	250	255
20	Leu Asn Val Ala Gly Gly Leu Arg Ile Asp Ser Gln Asn Arg Arg Leu		
	260	265	270
	Ile Leu Asp Val Ser Tyr Pro Phe Asp Ala Gln Asn Gln Leu Asn Leu		
	275	280	285
25	Arg Leu Gly Gln Gly Pro Leu Phe Ile Asn Ser Ala His Asn Leu Asp		
	290	295	300
	Ile Asn Tyr Asn Lys Gly Leu Tyr Leu Phe Thr Ala Ser Asn Asn Ser		
30	305	310	315 320
	Lys Lys Leu Glu Val Asn Leu Ser Thr Ala Lys Gly Leu Met Phe Asp		
	325	330	335
35	Ala Thr Ala Ile Ala Ile Asn Ala Gly Asp Gly Leu Glu Phe Gly Ser		
	340	345	350
	Pro Asn Ala Pro Asn Thr Asn Pro Leu Lys Thr Lys Ile Gly His Gly		
	355	360	365
40	Leu Glu Phe Asp Ser Asn Lys Ala Met Val Pro Lys Leu Gly Thr Gly		
	370	375	380
	Leu Ser Phe Asp Ser Thr Gly Ala Ile Thr Val Gly Asn Lys Asn Asn		
	385	390	395 400
45	Asp Lys Leu Thr Leu Trp Thr Thr Pro Ala Pro Ser Pro Asn Cys Arg		
	405	410	415
	Leu Asn Ala Glu Lys Asp Ala Lys Leu Thr Leu Val Leu Thr Lys Cys		
50	420	425	430
	Gly Ser Gln Ile Leu Ala Thr Val Ser Val Leu Ala Val Lys Gly Ser		
	435	440	445

55

Leu Ala Pro Ile Ser Gly Thr Val Gln Ser Ala His Leu Ile Ile Arg  
450 455 460

Phe Asp Glu Asn Gly Val Leu Leu Asn Asn Ser Phe Leu Asp Pro Glu  
465 470 475 480

Tyr Trp Asn Phe Arg Asn Gly Asp Leu Thr Glu Gly Thr Ala Tyr Thr  
485 490 495

Asn Ala Val Gly Phe Met Pro Asn Leu Ser Ala Tyr Pro Lys Ser His  
500 505 510

Gly Lys Thr Ala Lys Ser Asn Ile Val Ser Gln Val Tyr Leu Asn Gly  
515 520 525

Asp Lys Thr Lys Pro Val Thr Leu Thr Ile Thr Leu Asn Gly Thr Gln  
530 535 540

Glu Thr Gly Asp Thr Thr Pro Ser Ala Tyr Ser Met Ser Phe Ser Trp  
545 550 555 560

Asp Trp Ser Gly His Asn Tyr Ile Asn Glu Ile Phe Ala Thr Ser Ser  
565 570 575

Tyr Thr Phe Ser Tyr Ile Ala Gln Glu  
580 585

<210> 86  
<211> 356  
<212> PRT  
<213> Adenoviridae

<220>  
<221> CHAIN  
<222> (1)..(356)  
<223> /note="Fiber protein of Adenovirus serotype 16"

<400> 86  
Met Leu Leu Gln Met Lys Arg Ala Arg Pro Ser Glu Asp Thr Phe Asn  
1 5 10 15

Pro Val Tyr Pro Tyr Glu Asp Glu Ser Ser Ser Gln His Pro Phe Ile  
20 25 30

Asn Pro Gly Phe Ile Ser Ser Asn Gly Phe Ala Gln Ser Pro Asp Gly  
35 40 45

Val Leu Thr Leu Lys Cys Val Asn Pro Leu Thr Thr Ala Ser Gly Pro  
50 55 60

5 Leu Gln Leu Lys Val Gly Ser Ser Leu Thr Val Asp Thr Ile Asp Gly  
 65 70 75 80  
 Ser Leu Glu Glu Asn Ile Thr Ala Ala Ala Pro Leu Thr Lys Thr Asn  
 85 90 95  
 10 His Ser Ile Gly Leu Leu Ile Gly Ser Gly Leu Gln Thr Lys Asp Asp  
 100 105 110  
 Lys Leu Cys Leu Ser Leu Glu Asp Gly Leu Val Thr Lys Asp Asp Lys  
 115 120 125  
 15 Leu Cys Leu Ser Leu Gly Asp Gly Leu Ile Thr Lys Asn Asp Val Leu  
 130 135 140  
 Cys Ala Lys Leu Gly His Gly Leu Val Phe Asp Ser Ser Asn Xaa Ile  
 145 150 155 160  
 20 Thr Ile Glu Asn Asn Thr Leu Trp Thr Gly Ala Lys Pro Ser Ala Asn  
 165 170 175  
 Cys Val Ile Lys Glu Gly Glu Asp Ser Pro Asp Cys Lys Leu Thr Leu  
 25 180 185 190  
 Val Leu Val Lys Asn Gly Gly Leu Ile Asn Gly Tyr Ile Thr Leu Met  
 195 200 205  
 30 Gly Ala Ser Glu Tyr Thr Asn Thr Leu Phe Lys Asn Asn Gln Val Thr  
 210 215 220  
 Ile Asp Val Asn Leu Ala Phe Asp Asn Thr Gly Gln Ile Ile Thr Tyr  
 225 230 235 240  
 35 Leu Ser Ser Leu Lys Ser Asn Leu Asn Phe Lys Asp Asn Gln Asn Met  
 245 250 255  
 Ala Thr Gly Thr Ile Thr Ser Ala Lys Gly Phe Met Pro Ser Thr Thr  
 40 260 265 270  
 Ala Tyr Pro Phe Ile Thr Tyr Ala Thr Glu Thr Leu Asn Glu Asp Tyr  
 275 280 285  
 45 Ile Tyr Gly Glu Cys Tyr Tyr Lys Ser Thr Asn Gly Thr Leu Phe Pro  
 290 295 300  
 Leu Lys Val Thr Val Thr Leu Asn Arg Arg Met Leu Ala Ser Gly Met  
 50 305 310 315 320  
 Ala Tyr Ala Met Asn Phe Ser Trp Ser Leu Asn Ala Glu Glu Ala Pro  
 325 330 335  
 55

Glu Thr Thr Glu Val Thr Leu Ile Thr Ser Pro Phe Phe Phe Ser Tyr  
340 345 350

Ile Arg Glu Asp  
355

<210> 87  
<211> 325  
<212> PRT  
<213> Adenoviridae

<220>  
<221> CHAIN  
<222> (1)..(325)  
<223> /note="Fiber protein of Adenovirus serotype 35"

<400> 87  
Met Leu Leu Gln Met Lys Arg Ala Arg Pro Ser Glu Asp Thr Phe Asn  
1 5 10 15

Pro Val Tyr Pro Tyr Glu Asp Glu Ser Thr Ser Gln His Pro Phe Ile  
20 25 30

Asn Pro Gly Phe Ile Ser Pro Asn Gly Phe Thr Gln Ser Pro Asp Gly  
35 40 45

Val Leu Thr Leu Lys Cys Leu Thr Pro Leu Thr Thr Thr Gly Gly Ser  
50 55 60

Leu Gln Leu Lys Val Gly Gly Gly Leu Thr Val Asp Asp Thr Asp Gly  
65 70 75 80

Thr Leu Gln Glu Asn Ile Arg Ala Thr Ala Pro Ile Thr Lys Asn Asn  
85 90 95

His Ser Val Glu Leu Ser Ile Gly Asn Gly Leu Glu Thr Gln Asn Asn  
100 105 110

Lys Leu Cys Ala Lys Leu Gly Asn Gly Leu Lys Phe Asn Asn Gly Asp  
115 120 125

Ile Cys Ile Lys Asp Ser Ile Asn Thr Leu Trp Thr Gly Ile Asn Pro  
130 135 140

Pro Pro Asn Cys Gln Ile Val Glu Asn Thr Asn Thr Asn Asp Gly Lys  
145 150 155 160

Leu Thr Leu Val Leu Val Lys Asn Gly Gly Leu Val Asn Gly Tyr Val  
165 170 175



5 Ser Leu Val Gly Val Ser Asp Thr Val Asn Gln Met Phe Thr Gln Lys  
 180 185 190  
 Thr Ala Asn Ile Gln Leu Arg Leu Tyr Phe Asp Ser Ser Gly Asn Leu  
 195 200 205  
 10 Leu Thr Glu Glu Ser Asp Leu Lys Ile Pro Leu Lys Asn Lys Ser Ser  
 210 215 220  
 Thr Ala Thr Ser Glu Thr Val Ala Ser Ser Lys Ala Phe Met Pro Ser  
 225 230 235 240  
 15 Thr Thr Ala Tyr Pro Phe Asn Thr Thr Thr Arg Asp Ser Glu Asn Tyr  
 245 250 255  
 Ile His Gly Ile Cys Tyr Tyr Met Thr Ser Tyr Asp Arg Ser Leu Phe  
 260 265 270  
 20 Pro Leu Asn Ile Ser Ile Met Leu Asn Ser Arg Met Ile Ser Ser Asn  
 275 280 285  
 Val Ala Tyr Ala Ile Gln Phe Glu Trp Asn Leu Asn Ala Ser Glu Ser  
 290 295 300  
 25 Pro Glu Ser Asn Ile Met Thr Leu Thr Thr Ser Pro Phe Phe Phe Ser  
 305 310 315 320  
 30 Tyr Ile Thr Glu Asp  
 325  
 35 <210> 88  
 <211> 325  
 <212> PRT  
 <213> Adenoviridae  
 40 <220>  
 <221> CHAIN  
 <222> (1)..(325)  
 <223> /note="Fiber protein of Adenovirus serotype 51"  
 45 <400> 88  
 Met Leu Leu Gln Met Lys Arg Ala Arg Pro Ser Glu Asp Thr Phe Asn  
 1 5 10 15  
 Pro Val Tyr Pro Tyr Glu Asp Glu Ser Thr Ser Gln His Pro Phe Ile  
 20 25 30  
 50 Asn Pro Gly Phe Ile Ser Pro Asn Gly Phe Thr Gln Ser Pro Asp Gly  
 35 40 45  
 55

Val Leu Thr Leu Asn Cys Leu Thr Pro Leu Thr Thr Thr Gly Gly Pro  
 50 55 60  
 5  
 Leu Gln Leu Lys Val Gly Gly Gly Leu Ile Val Asp Asp Thr Asp Gly  
 65 70 75 80  
 Thr Leu Gln Glu Asn Ile Arg Val Thr Ala Pro Ile Thr Lys Asn Asn  
 85 90 95  
 10  
 His Ser Val Glu Leu Ser Ile Gly Asn Gly Leu Glu Thr Gln Asn Asn  
 100 105 110  
 Lys Leu Cys Ala Lys Leu Gly Asn Gly Leu Lys Phe Asn Asn Gly Asp  
 115 120 125  
 15  
 Ile Cys Ile Lys Asp Ser Ile Asn Thr Leu Trp Thr Gly Ile Lys Pro  
 130 135 140  
 20  
 Pro Pro Asn Cys Gln Ile Val Glu Asn Thr Asp Thr Asn Asp Gly Lys  
 145 150 155 160  
 Leu Thr Leu Val Leu Val Lys Asn Gly Gly Leu Val Asn Gly Tyr Val  
 165 170 175  
 25  
 Ser Leu Val Gly Val Ser Asp Thr Val Asn Gln Met Phe Thr Gln Lys  
 180 185 190  
 Ser Ala Thr Ile Gln Leu Arg Leu Tyr Phe Asp Ser Ser Gly Asn Leu  
 195 200 205  
 30  
 Leu Thr Asp Glu Ser Asn Leu Lys Ile Pro Leu Lys Asn Lys Ser Ser  
 210 215 220  
 35  
 Thr Ala Thr Ser Glu Ala Ala Thr Ser Ser Lys Ala Phe Met Pro Ser  
 225 230 235 240  
 Thr Thr Ala Tyr Pro Phe Asn Thr Thr Thr Arg Asp Ser Glu Asn Tyr  
 245 250 255  
 40  
 Ile His Gly Ile Cys Tyr Tyr Met Thr Ser Tyr Asp Arg Ser Leu Val  
 260 265 270  
 Pro Leu Asn Ile Ser Ile Met Leu Asn Ser Arg Thr Ile Ser Ser Asn  
 275 280 285  
 45  
 Val Ala Tyr Ala Ile Gln Phe Glu Trp Asn Leu Asn Ala Lys Glu Ser  
 290 295 300  
 50  
 Pro Glu Ser Asn Ile Ala Thr Leu Thr Thr Ser Pro Phe Phe Phe Ser  
 305 310 315 320  
 Tyr Ile Ile Glu Asp  
 55

Claims

1. A gene delivery vehicle comprising at least one of the adenovirus serotype 35 elements or a functional equivalent thereof, responsible for avoiding or deminishing neutralising activity against adenoviral elements by the host to which the gene is to be delivered and a gene of interest.
2. Adenovirus serotype 35 or a functional homologue thereof or a chimaeric virus derived therefrom, or a gene delivery vehicle based on said virus its homologue or its chimaera for use as a pharmaceutical.
3. A gene delivery vehicle according to claim 1, whereby said elements comprise adenovirus 35 E3 expression products or the genes encoding them.
4. A gene delivery vehicle according to claim 1 or 3, whereby said elements comprise adenovirus 35 fiber, penton and/or hexon proteins or a gene encoding either.
5. A gene delivery according to any one of claims 1,3, or 4 which is a chimaera of adenovirus 35 with at least one other adenovirus.
6. A gene delivery vehicle according to any one of claims 1,3,4 or 5 which has a different tropism than adenovirus 35.
7. A nucleic acid encoding at least a functional part of a gene delivery vehicle according to any one of claims 1 or 3-6, or a virus, homologue or chimaera thereof according to claim 2.
8. A nucleic acid encoding at least one of the adenovirus serotype 35 elements or a functional equivalent thereof, responsible for avoiding or deminishing neutralising activity against adenoviral elements by the host to which the gene is to be delivered and having a site for introducing a gene of interest therein.
9. A nucleic acid according to claim 7 or 8, further comprising at least one ITR.
10. A nucleic acid according to claim 7, 8 or 9 further comprising a region of nucleotides designed or useable for homologous recombination.
11. At least one set of two nucleic acids comprising a nucleic acid according to any one of claims 7-10, whereby said set of nucleic acids is capable of a single homologous recombination event with each other, which leads to a nucleic acid encoding a functional gene delivery vehicle.
12. A cell comprising a nucleic acid according to any one of claims 7-10 or a set of nucleic acids according to claim 11.
13. A cell according to claim 12 which complements the necessary elements for adenoviral replication which are absent from the nucleic acid according to any one of claims 7-10 or a set of nucleic acids according to claim 11.
14. A cell according to claim 12 or 13, which originates from a PER.C6 cell (ECACC deposit number 96022940).
15. A method for producing a gene delivery vehicle according to claim 1, or 3-6, comprising expressing a nucleic acid according to any one of claims 7-10 in a cell according to claim 12 or 13 and harvesting the resulting gene delivery vehicle.
16. A method for producing a gene delivery vehicle according to claim 1, or 3-6, comprising culturing a cell according to claim 12 or 13 in a suitable culture medium and harvesting the resulting gene delivery vehicle.
17. A gene delivery vehicle obtainable by a method according to claims 15 or 16.
18. A gene delivery vehicle according to any one of claims 1,3-6 or 17, which is derived from a chimaera of an adenovirus and an integrating virus.
19. A gene delivery vehicle according to claim 18, wherein said integrating virus is adeno associated virus.
20. A gene delivery vehicle according to any one of claims 1, 3-6 or 17-19, which has the tropism determining parts of

adenovirus 16 or functional equivalents thereof.

21. A gene delivery vehicle according to anyone of claims 1, 3-6 or 17-20 for use as a pharmaceutical.

5 22. A pharmaceutical formulation comprising a gene delivery vehicle according to any one of claims 1, 3-6 or 17-20 and a suitable excipient.

23. A pharmaceutical formulation comprising an adenovirus, a chimaera thereof, or a functional homologue thereof according to claim 2 and a suitable excipient.

10

15

20

25

30

35

40

45

50

55

**Figure 1:**  
**% of human sera with neutralising capacity for h man adenovirus (n=100)**




Figure 2






Figure 3: Ad35 plasmid-based system for virus generation



**Figure 4**  
Neutralisation in human sera





**Figure 5**

Neutralisation in human sera from different geographic locations




Figure 6: Total sequence of Ad35.

```

1 CATCATCAAT AATATACCTT ATAGATGGAA TGGTGCCAAT ATGTAAATGA GGTGATTTTA AAAAGTGTGG
71 GCCGTGTGGT GATTGGCTGT GGGGTTAACG GTTAAAGGG GCGGCGCGGC CGTGGGAAAA TGACGTTTTA
141 TGGGGGTGGA GTTTTTTTCG AAGTTGTCGC GGGAAATGTT ACGCATAAAA AGGCTTCTTT TCTCACGGAA
211 CTACTTAGTT TTCCACGGT ATTTAACAGC AAATGACGTA GTTTTGACCG CATGCAAGTG AAAATTGCTG
281 ATTTTCGCGC GAAAACTGAA TGAGGAAGTG TTTTCTGAA TAATGTGGTA TTTATGGCAG GGTGGAGTAT
351 TTGTTACGGG CCAGGTAGAC TTTGACCCAT TACGTGGAGG TTTGATTAC CGTGTTTTTT ACCTGAATTT
421 CCGCGTACCG TGTCAAAGTC TTCTGTTTTT ACGTAGGTGT CAGCTGATCG CTAGGGTATT TATACCTCAG
491 GGTTTGTGTC AAGAGGCCAC TCTGAGTGC CAGCGAGAAG AGTTTTCTCC TCTGCGCCGG CAGTTTAATA
561 ATAAAAAAT GAGAGATTTG CGATTTCTGC CTCAGGAAAT AATCTCTGCT GAGACTGGAA ATGAAATATT
631 GGAGCTTGTG GTGCACGCCC TGATGGGAGA CGATCCGGAG CCACCTGTGC AGCTTTTTGA GCCTCCTACG
701 CTTACGGAAC TGTATGATTT AGAGGTAGAG GGTACGGAGG ATTCTAATGA GGAAGCTGTG AATGGCTTTT
771 TTACCGATTG TATGCTTTTA GCTGCTAATG AAGGATTAGA ATTAGATCCG CCTTTGGACA CTTTCAATAC
841 TCCAGGGGTG ATTTGGAAA GCGGTACAGG TGTAAGAAAA TTACCTGATT TGAGTTCCGT GGACTGTGAT
911 TTGCACTGCT ATGAAGACGG GTTTCCTCCG AGTATGAGG AGGACCATGA AAAGGAGCAG TCCATGCAGA
981 CTGACCGGGG TGAGGGAGTG AAGGCTGCCA ATGTTGGTTT TCAGTTGGAT TGCCCGGAGC TTCCTGGACA
1051 TGGCTGTGAT TCTTGTGAAT TTCACAGGAA AAATACTGGA GTAAAGGAAC TGTTATGTTT GCTTTGTTAT
1121 ATGAGAACGC ACTGCCACTT TATTACAGT AAGTGTGTTT AAGTTAAAT TTAAGGAAT ATGCTGTTTT
1191 TCACATGTAT ATTAGGTGTG AGTTTTGTGC TTCTTATTAT AGGTCTGTG TCTGATGCTG ATGAATCACC
1261 ATCTCCTGAT TCTACTACCT CACCTCCTGA TATTCAAGCA CCTGTTCTGT TGGACGTGCG CAAGCCCAT
1331 CCTGTGAAGC TTAAGCCTGG GAAACGTCCA GCAGTGGAGA AACTTGAGGA CTTGTTACAG GGTGGGGACG
1401 GACCTTTGGA CTTGAGTACA CGGAAACGTC CAAGACAATA AGTGTTCAT ATCCGTGTTT ACTTAAGGTG
1471 ALGICAAAT TGTGTGAGA GTGAAATGA ATAAAAAT GTTAACTGT CACTGTTTTT TATTGTTTT
1541 TGGGCGGGGA CTCAGGTATA TAAGTAGAAG CAGACCTGTG TGGTTAGCTC ATAGGAGCTG GCTTTCATCC
1611 ATGGAGGTTT GGGCCATTTT GGAAGACCTT AGGAAGACTA GGCAACTGTT AGAGAGCGCT TCGGACGGAG
1681 TCTCCGGTTT TTGGAGATTC TGTTTCGCTA GTGAATTAGC TAGGGTAGTT TTAGGATAA AACAGGACTA
1751 TAAACAGAA TTTGAAAAGT TGTTGGTAGA TTGCCCAGGA CTTTTGAAG CTCTTAATTT GGGCCATCAG
1821 GTTCACTTTA AAGAAAAAGT TTTATCAGTT TTAGACTTTT CAACCCAGG TAGAAGCTGT GCTGCTGTGG
1891 CTTTTCTTAC TTTTATATTA GATAAATGGA TCCCGCAGAC TCATTTCAGC AGGGGATACG TTTTGGATTT
1961 CATAGCCACA CATTGTGGA GAACATGGAA GGTTCGCAAG ATGAGGACAA TCTTAGTTA CTGGCAGTG
2031 CAGCCTTTGG GTGTAGCGGG AATCCTGAGG CATCCACCGG TCATGCCAGC GGTCTGTGAG GAGGAACAGC
2101 AAGAGGACAA CCGGAGAGCC GGCTGGACC CTCAGTGGG GGAGGCGGAG TAGCTGACTT GTCTCTGAA
2171 CTGCAACGGG TCCTTACTGG ATCTACGTCC ACTGGACGGG ATAGGGGCGT TAAGAGGGAG AGGGCATCCA
2241 GTGGTACTGA TGCTAGATCT GAGTTGGCTT TAAGTTTAAAT GAGTCGCAGA CGTCTGAAA CCATTTGGTG
2311 GCATGAGGTT CAGAAAGAGG GAAGGGATGA AGTTTCTGTA TTGCAGGAGA AATATTCAT GGAACAGGTG
2381 AAAACATGTT GGTGGAGGCC AGAGGATGAT TGGCGGGTGG CCATTAATAA TTATGCCAAG ATAGCTTTGA
2451 GGCCTGATAA ACAGTATAAG ATCAGTAGAC GGATTAATAT CCGGAATGCT TGTTACATAT CTGGAATGG
2521 GGCTGAGGTG GTAATAGATA CTCAGACAA GACAGTTATT AGATGCTGCA TGATGGATAT GTGGCTTGA
2591 GTAGTCGGTA TGGAAAGCAGT CACTTTTGTG AATGTTAAGT TTAGGGGAGA TGGTTATAAT GGAATAGTGT
2661 TTATGGCCAA TACCAAACTT ATATTGCATG GTTGTAGCTT TTTTGGTTT AACAACTCT GTGTAGATGC
2731 CTGGGGACAG GTTAGTGTAC GGGGGTGTAG TTCTATGCG TGTGGATTG CCACAGCTGG CAGAACCAAG
2801 AGTCAATTGT CTTGAAGAA ATGCATATTC CAAAGATGTA ACCTGGGCAT TCTGAATGAA GGCGAAGCAA
2871 GGGTCCGTCA CTGCGCTTCT ACAGATACTG GATGTTTTAT TTTAATTAG GGAATGCCA GCGTAAAGCA
2941 TAACATGATT TGTGGTGCTT CCGATGAGAG GCCTTATCAA ATGCTCACTT GTGCTGGTGG GCATGTGAAT
3011 ATGCTGGCTA CTGTGCATAT TGTITCCCAT CAACGCAAAA AATGGCCTGT TTTTGATCAC AATGTGTTGA
3081 CCAAGTGAC CATGCATGCA GGTGGGCGTA GAGGAATGTT TATGCCTTAC CAGTGTAAAC TGAATCATGT
3151 GAAAGTGTG TTGGAACAG ATGCCTTTTC CAGAAATGAGC CTAACAGGAA TCTTTGACAT GAACACGCAA
3221 ATCTGGAAGA TCCTGAGGTA TGATGATACG AGATCGAGGG TGCGCGCATG CGAATGCGGA GGCAAGCATG
3291 CCAGGTTCCA GCCGGTGTGT GTAGATGTGA CCGAAGATCT CAGACCGGAT CATTTGGTTA TTGCCCGCAC
3361 TGGAGCAGAG TTCGGATCCA GTGGAGAAGA AACTGACTAA GGTGAGTATT GGGAAAACTT TGGGGTGGGA
3431 TTTTCAGATG GACAGATTGA GTAAAAATTT GTTTTTCTG TCTTGACGCT GACATGAGTG GAAATGCTTC
3501 TTTTAAGGGG GGAGTCTTCA GCCCTTATCT GACAGGGCGT CTCCCATCCT GGGCAGGAGT TCGTCAGAA
3571 GTTATGGGAT CTACTGTGGA TGGAAAGCCC GTTCAACCCG CCAATTCCTT AACGCTGACC TATGCTACTT
3641 TAAGTTCTTC ACCTTTGGAC GCAGCTGCAG CCGCTGCCG CGCTCTGTC GCGCTAACA CTGTGCTTGG
3711 AATGGGTTAC TATGGAAGCA TCGTGGCTAA TTCCACTTCC TCTAATAACC CTTCTACACT GACTCAGGAC
3781 AAGTTACTTG TCCTTTTGGC CCAGCTGGAG GCTTTGACCC AACGTCGCG TGAACTTTCT CAGCAGGTGG
3851 CCGAGTTGCG AGTACAACT GAGTCTGCTG TCGGCACGGC AAAGTCTAAA TAAAAAAT TCCAGAAATCA
3921 ATGAATAAAT AAACGAGCTT GTTGTGATT TAAAAATCA TGTTTTTATT TCAATTTTCG CGCACGGTAT
3991 GCCCTGGACC ACCGATCTCG ATCATTGAGA ACTCGGTGGA TTTTTCCAG AATCCTATAG AGGTGGGATT
4061 GAATGTTTAT ATACATGGGC ATTAGGCCGT CTTTGGGGTG GAGATAGCTC CATTTGAAGG ATTCTATGCTC
4131 CGGGGTAGTG TTGTAATCA CCCAGTCTCA ACAAGTCCG AGTGATGGT GTTGACAAT ATCTTTTAGA
4201 AGTAGGCTGA TTGCCACAGA TAAGCCCTTG GTGTAGGTGT TTACAAACCG GTTGAGCTGG GAGGGGTGCA
4271 TTCAGGTTGA AATTATGTGC ATTTTGGATT GGATTTTAA GTTGGCAATA TTGCCGCCAA GATCCCGTCT

```

Figure 6, contd.

4341 TGGGTTTCATG TTATGAAGGA CTACCAAGAC GGTGATCCG GTACATTAG GAAATTTATC GTGCAGCTTG  
 4411 GATGGAAAAG CGTGGAAAAA TTTGGAGACA CCTTGTGTG CTCCGAGATT TTCCATGCAC TCATCCATGA  
 4481 TAATAGCAAT GGGGCGGTGG GCAGCGGCGC GGGCAAAACAC GTTCCGTGGG TCTGACACAT CATAGTTATG  
 4551 TTCCTGAGTT AAATCATCAT AAGCCATTTT AATGAATTTG GGGCGGAGCG TACCAGATTG GGGTATGAAT  
 4621 GTTCTTTCGG GCGCCGAGC ATAGTTCGCC TCACAGATTG GCATTTCCCA AGCTTTTCACT TCTGAGGGTG  
 4691 GAATCATGTC CACCTGGGGG GCTATGAAGA ACACCGTTTC GGGGGCGGGG GTGATTAGTT GGGATGATAG  
 4761 CAAGTTTCTG AGCAATTGAG ATTTGCCACA TCCGGTGGGG CCATAAATAA TTCCGATTAC AGGTTGCAGG  
 4831 TGGTAGTTTA GGGAAACGGCA ACTGCCGTCT TCTCGAAGCA AGGGGGCCAC CTCGTTTATC ATTTCCCTTA  
 4901 CATGCATATT TTCCCGCACC AAATCCATTA GGAGGCGCTC TCCTCCTAGT GATAGAAGTT CTGTAGTGA  
 4971 GGAAAAGTTT TTCAGCGGTT TTAGACCGTC AGCCATGGGC ATTTTGGAAA GAGTTTGTCT CAAAAGTTCT  
 5041 AGTCTGTTC ACAGTTCAGT GATGTGTCT ATGGCATCTC GATCCAGCAG ACCTCCTCGT TTCGCGGGT  
 5111 TGGACGGCTC CTGGAGTAGG GTATGAGACG ATGGGCGTCC AGCGCTGCCA GGGTTCCGTC CTTCAGGGT  
 5181 CTGAGTGTTC GAGTCAGGGT TGTTTCCGT ACAGTGAAGG GGTGTGCGCC TGCTTGGGCG CTTCAGGGT  
 5251 TGCCTTCAG ACTCATCTG CTGTTGGAGA ACTTCTGTCT CTGCGGCCG TGATGTCTCG CCAAGTAGCA  
 5321 GTTACCATG AGTTCTGAGT TGAGCGCTC GGTCTGCTGG CCTTTGGCGC GGAGCTTACC TTTGGAAGTT  
 5391 TTCTTGCTA CCGGGCAGTA TAGGCATTTT AGCGCATACA GGTGGGCGC AAGGAAAATG GATTCTGGGG  
 5461 AGTATGCAT CGCGCCGCG GAGGCGCAAA CAGTTTCACA TTCCACCAGC CAGGTTAAAT CCGGTTTCTT  
 5531 GGGGTCAAAA ACAAGTTTTC CGCATATTTT TTTGATGCGT TTCTTACCTT TGGTCTCCAT AAGTTCTGTG  
 5601 CCTCGTTGAG TGACAAACAG GCTGTCCGTA CTCCGTGAGA CTGATTTTAC AGGCTCTTTC TCCAGTGGAG  
 5671 TGCCTCGTC TTCTTCTGAC AGGAACCTCT ACCACTCTGA TACAAAGGCG CGCGTCCAGG CCAGCACAAA  
 5741 GGAGGCTATG TGGGAGGGGT AGCGATCGTT GTCAACCAGG GGGTCCACCT TTTCCAAAGT ATGCAACAC  
 5811 ATGTACCCCT CTTCACATC CAGGAATGTC ATTGGCTTGT AGGTGTATT CACGTGACCT GGGGTCCTCG  
 5881 CTGGGGGGGT ATAAAAGGGG GCGGTTCTTT GCTCTTCTC ACTGTCTTCC GGATCGCTGT CCAGGAACGT  
 5951 CAGCTGTGG GGTAGGATT CCTCTGCA GGGGGGATG ACTCTGAC TCGGTTGTC AGTTCTTAA  
 6021 AACGAGGAGG ATTTGATATT GACAGTCCG GGTGAGATGC CTTCATGAG GTTTTCGTCC ATTTGGTCAG  
 6091 AAAACACAAT TTTTATGTT TCAAGTTTGG TGGCAATGA TCCATACAGG CGGTTGGATA AAAGTTTGGC  
 6161 AATGGATCGC ATGTTTGGT TCTTTCTCT GTCCGCGCGC TCTTTGGCGG CGATGTTGAG TTGGACATAC  
 6231 TCGCGTGCCA GGCATTCTCA TTCGGGGAAG ATAGTTGTTA ATTCATCTGG CACGATTCTC ACTTGCCACC  
 6301 CTCGATTATG CAAGGTAATT AAATCCACAC TGGTGGCCAC CTCGCTCTCA AGGGGTTTCA TGGTCCAACA  
 6371 GAGCCTACCT CCTTTCCTAG AACAGAAAGG GGAAGTGGG TCTAGCATAA GTTCATCGGG AGGGTCTGCA  
 6441 TCCATGGTAA AGATTCGCGG AAGTAAATCC TTATCAAAAT AGCTGATGGG AGTGGGGTCA TCTAAGGCCA  
 6511 TTTGCCATTG TCGAGCTGCC AGTGGCGCT CATATGGGTT AAGGGGACTG CCCCAGGGCA TGGGATGGGT  
 6581 GAGAGCAGAG GCATACATGC CACAGATGTC ATAGACGTAG ATGGGATCCT CAAAGATGCC TATGTAGGTT  
 6651 GGATAGCATC GCGCCCTCTG GATACCTTGT CGCACATAGT CATATAGTTC ATGTGATGGC GCTAGCAGCC  
 6721 CCGGACCCAA GTTGGTGCGA TTGGGTTTTT CTGTCTGTA GACGATCTGG CGAAAGATGG CGTGAGAATT  
 6791 GGAAGAGATG GTGGGTCTTT GAAAAATGTT GAAATGGGCA TGAGGTAGAC CTACAGAGTC TCTGACAAAG  
 6861 TGGGCAATAG ATTCTTGAAG CTGTGTAC AGTTCCGGCG TGACAAGTAC GCTTAGGGCG CAGTAGTCAA  
 6931 GTGTTTCTTG AATGATGTC TAACCTGGTT GGTTTTCTT TTCCACAGT TCGCGGTTGA GAAGGTATTC  
 7001 TTCGCGATCC TTCCAGTACT CTCTAGCGG AAACCCGTCT TTGTCTGAC GGTAAAGATCC TAGCATGTAG  
 7071 AACTGATTAA CTGCTTGTG AGGGCAGCAG CCTTCTCTA CCGGTAGAGA GTATGCTTGA GCAGCTTTTC  
 7141 GTAGCGAAGC GTGAGTAAGG GCAAAGGTGT CTCTGACCAT GACTTTGAGA AATTGGTATT TGAAGTCCAT  
 7211 GTGCTACAG GCTCCCTGTT CCCAGAGTTG GAAGTCTACC CGTTTCTGT AGGCGGGGTT GGGCAAGCG  
 7281 AAAGTAACAT CATTGAAGAG AATCTTACC GCTCTGGGCA TAAATTTGCG AGTGATGCGG AAAGGCTGTG  
 7351 GTACTTCCGC TCGATTGTTG ATCAGCTGGG CAGCTAGGAC GATTTCTGTC AAACGTTGA TGTGTGTCC  
 7421 TACGATGTAT AATTCTATGA AACGCGGCGT GCCTCTGACG TGAGGTAGCT TACTGAGCTC ATCAAAGGTT  
 7491 AGGTCTGTGG GGTGAGATAA GCGTAGTGT TCGAGAGCCC ATTCGTGACG GTGAGGATT GCATGTAGGA  
 7561 ATGATGACCA AAGATCTACC GCCAGTGTG TTTGTAAGT GTCCCGATAC TGACGAAAAT GCCGGCCAAT  
 7631 TGCCATTTT TCTGGAGTGA CACAGTAGAA GGTCTTGGG TCTTGTGTC ATCGATCCCA CTGAGTTTA  
 7701 ATGGCTAGAT CGTGGGCCAT GTTGACGAGA CGCTCTTCTC CTGAGAGTTT CATGACCAGC ATGAAAGGAA  
 7771 CTAGTTGTTT GCCAAAGGAT CCCATCCAGG TGTAAGTTTC CACATCGTAG GTCAGGAAGA GTCTTCTGT  
 7841 GCGAGGATGA GAGCCGATCG GGAAGAACTG GATTTCTGTC CACCAAGTTG AGGATTGGCT GTTGATGTGA  
 7911 TGGAAGTAGA AGTTTCTGCG GCGCGCCGAG CATTCGTGTT TGTGCTTGA CAGACGGGCG CAGTAGTCG  
 7981 AGCGTTGCAC GGGTTGTATC TCGTGAATGA GCTGTACCTG GCTTCCCTTG ACGAGAAAT TCAGTGGGAA  
 8051 GCCGAGGCTT GCGGATTGTA TCTCGTGCTC TTCTATATTC GCTGTATCGG CCTGTTTATC TTCTGTTTCG  
 8121 ATGGTGGTCA TGCTGACGAG CCCCCGCGG AGGCAAGTCC AGACCTCGG GCGGGAGGGG CGGAGCTGAA  
 8191 GGACGAGAGC GCGCAGGCTG GAGCTGTCCA GAGTCTGAG ACCTGCGGA CTCAGGTTAG TAGGTAGGGA  
 8261 CAGAAGATTA ACTTGATGA TCTTTTCCAG GCGGTGCGGG AGGTTGAGT GGTACTTGAT TTCCACAGGT  
 8331 TCGTTTGTAG AGACGTCAAT GGTCTGACG GTTCCGTGTC CTTTGGGCG CACTACCGTA CCTTTGTTTT  
 8401 TTCTTTTGT CCGTGGTGGC TCTCTGTCT GTTGCATGCT CAGAAGCGGT GACGGGGACG CGCGCCGGG  
 8471 GGCAGCGGTT GTTCCGACG CCGGGGCGAT GCTGTAGTG GCACGTCGGC GCGCGCACG GGCAGGTTCT  
 8541 GGTATTGCGC TGTGAGAAGA CTTGCGTGCG CCACACGCG CTGATTGACG TCTGTATCT GACGTCTCTG  
 8611 GGTGAAAGCT ACCGGCCCCG TGAGCTTGA AATCAATTC AGTTCAACAG AATCAATTC GGTATCGTTA  
 8681 ACGGACGCTT GTCTCAGTAT TTCTGTACG TCACCAGAGT TGTCTGGTA GCGATCTCC GCCATCACT  
 8751 GCTCGATTTC TTCTCTCTGA AGATCTCCG GACCCGCTCT TTCGACGGT GCGCGAGGT CATTGGAGAT

Figure 6, contd.

8821 ACGGCCCATG AGTTGGGAGA ATGCATTCAT GCCCGCCTCG TTCCAGACGC GGCTGTAAAC CACGGCCCCC  
 8891 TCGGAGTCTC TTGCGCGCAT CACCACCTGA GCGAGGTTAA GCTCCACGTG TCTGGTGAAG ACCGCATAGT  
 8961 TGCATAGGCG CTGAAAAAGG TAGTTGAGTG TGGTGGCAAT GTGTTCCGGC ACGAAGAAAT ACATGATCCA  
 9031 TCGTCTCAGC GGCATTTTCG TAACATCGCC CAGAGCTTCC AAGCGCTCCA TGGCCCTGTA GAAGTCCACG  
 9101 GCAAAATTAA AAAACTGGGA GTTTCGCGCG GACACGGTCA ATTCTCTCTC GAGAAGACGG ATGAGTTCCG  
 9171 CTATGGTGGC CCGTACTTCG CGTTCGAAGG CTCCCGGGAT CTCTTCTTCC TCTTCTATCT CTTCTTCCAC  
 9241 TAACATCTCT TCTTCGTCTT CAGGCGGGGG CGGAGGGGGC ACBCGGCGAC GTCGACGGCG CACGGGCAAA  
 9311 CCGTCGATGA ATCGTTCAAT GACCTCTCCG CGCGGGCGGC GCATGGTTTC AGTGACGGCG CGGCGTTCT  
 9381 CGCGCGGTG CAGAGTAAAA ACACCGCCCG GCATCTCTT AAAGTGGTGA CTGGGAGGTT CTCGGTTTGG  
 9451 GAGGGAGAGG GCGCTGATTA TACATTTTAT TAATTGGCCC GTAGGGACTG CCGCGCAGAGA TCTGATCGTG  
 9521 TCAAGATCCA CGGGATCTGA AAACCTTTCC ACGAAAGCGT CTAACCACTC ACAGTCACAA GGTAGGCTGA  
 9591 GTACGGCTTC TTGTGGGCGG GGGTGGTTAT GTGTTCCGTC TGGGTCTTCT GTTTCTTCTT CATCTCGGGA  
 9661 AGGTGAGACG ATGCTGCTGG TGATGAAATT AAAGTAGGCA GTTCTAAGAC GCGCGATGGT GCGGAGGAGC  
 9731 ACCAGGCTTT TGGGTCGGC TTGCTGGATA CGCAGGCGAT TGCCCATTC CCAAGCATT TCTGACATC  
 9801 TAGCAAGATC TTTGTAGTAG TCTTGATGA GCCGTTCTAC GGGCACTTCT TCCTCACCCG TTCTGCCATG  
 9871 CATACGTGTG AGTCCAAATC CGCGCATTTG TTGTACCAGT GCCAAGTCAG CTACGACTCT TTCGGCGAGG  
 9941 ATGGCTTGCT TCGCTTGGT AAGGGTGGT TGAAGTCAT CAAATCCAC AAAGCGGTG TAAGCCCTG  
 10011 TATTAATGGT GTAAGCACAG TTGGCCATGA CTGACCAGTT AACTGTCTGG TGACCAGGGC GCACGAGCTC  
 10081 GGTGTATTTA AGGCGCGAAT AGGCGCGGGT GTCAAAGATG TAATCGTTGC AGGTGCGCAC CAGATCTGG  
 10151 TACCTATATA GAAATCGCG CGGTGGTTGG CGGTAGAGAG GCCATCGTTC TGTAGTGGG GCGCCAGGGG  
 10221 CGAGGTCTTC CAACATAAGG CGGTGATAGC CGTAGATGTA CCTGGACATC CAGGTGATTC CTGCGGCGGT  
 10291 AGTAGAAGCC CGAGGAAACT CGCGTACGCG GTTCCAAATG TTGCGTAGCG GCATGAAGTA GTTCAATTGA  
 10361 GGCACGGTTT GACCACTGAG CGCGCGCGAG TCATTGATGC TCTATAGACA CGGAGAAAAA GAAAGCGTTT  
 10431 AGGACTGCGA CTGCTGAGC TGGGAGAGC TGAAGGCTT GGTGCGGT GTACCCCGT TCGAGCTTG  
 10501 TACTCGAGCC GCGCGGAGCC GCGGCTAAGC TGGTATTGGC ACTCCCGTCT CGACCCAGCC TACAAAAATC  
 10571 CAGGATACGG AATCGAGTCG TTTTGTGGT TTCCGAATG CAGGGAAGTG AGTCCTATT TTTTTTTTT  
 10641 TTTGCCGCTC AGATGCATCC CGTGTGCGA CAGATGCGCC CCCAACACAA GCCCCCCCTC CAGCAGCAGC  
 10711 AGCAGCAACC AAAAAAGGCT GTCCCTGCAA CTACTGCAAC TGCCGCGGTG AGCGGTGCGG GACAGCCCCG  
 10781 CTATGATCTG GACTTGAAG AGGCGCAAGG ATCGGCACT CTAGGTGCGC CTTCCGCCGA CCGGCATCCG  
 10851 CGAGTTCAAC TGAAAAAGA TTCTCGCGAG CGGTATGTGC CCCAACAGAA CCTATTTAGA GACAGAAGCG  
 10921 CGAGGAGGCC GGAGGAGATG CGAGCTTCCC CGTTTAAACG GGGTCTGTAG CTGCGTCAAG GTTTGGACCG  
 10991 AAGACGAGTG TTGCGAGACG AGGATTTCGA AGTTGATGAA GTGACAGGGA TCAGTCTCTG CAGGGCACAC  
 11061 GTGGCTGCAG CCAACCTTGT ATCGGCTTAC GAGCAGACAG TAAAGGAAGA GCGTAACTTC CAAAAGTCTT  
 11131 TTAATAATCA TGTGCGAACC CTGATTGCCC GCGAAGAAGT TACCCTTGGT TTGATGCATT TGTGGGATTT  
 11201 GATGGAAGCT ATCATTAGA ACCCTACTAG ACCGCCCAGC TGTTTCTGGT GTGTCAACAC  
 11271 AGCAGAGACA ATGAGGCTTT CAGAGAGGCG CTGCTGAACA TCACCGAACC CGAGGGGAGA TGGTTGTATG  
 11341 ATCTTATCAA CATTCTACAG AGTATCATAG TGCAGGAGCG GAGCCTGGGC CTGCGCCAGA AGGTAGCTGC  
 11411 CATCAATTAC TCGGTTTTGA GCTTGGGAAA ATATTACGCT CGCAAAATCT ACAAGACTCC ATACGTTCCC  
 11481 ATAGACAAGG AGGTGAAGAT AGATGGGTTT TACATGCGCA TGACGCTCAA GGTCTTGACC CTGAGCGATG  
 11551 ATCTTGGGGT GTATCGCAAT GACAGAATGC ATCGCGCGGT TAGCGCCAGC AGGAGGCGCG AGTTAAGCGA  
 11621 CAGGGAAGTG TGCACAGTT TGCAAAGAGC TCTGACTGGA GCTGGAACCG AGGGTGAGAA TTACTTCGAC  
 11691 ATGGGAGCTG ACTTGCAGTG GCAGCTAGT CGCAGGGCTC TGAGCGCCGC GACGGCAGGA TGTGAGCTTC  
 11761 CTTACATAGA AGAGGCGGAT GAAGGCGAGG AGGAAGAGGG CGAGTACTTG GAAGACTGAT GGCACAACCC  
 11831 GTGTTTTTTG CTAGATGGAA CAGCAAGCAC CGGATCCCGC AATGCGGGCG GCGCTGCAGA GCCAGCGCTC  
 11901 CGGCATTAACT TCCTCGGACG ATTGGACCCA GGCCATGCAA CGTATCATGG CGTTGACGAC TCGCAACCCC  
 11971 GAAGCCTTTA GACAGCAACC CCAGGCCAAC CGTCTATCGG CCATCATGGA AGCTGTAGTG CCTTCCCGAT  
 12041 CTAATCCCACT TCATGAGAAG GTCCTGGCCA TCGTGAACGC GTTGGTGGAG AACAAAGCTA TTCGTCAGAT  
 12111 TGAGGCCGGA CTGGTATACA ACGCTCTCTT AGAACGCGTG GCTCGCTACA ACAGTAGCAA TGTGCAAAAC  
 12181 AATTGGGACC GTATGATAAC AGATGTACGC GAAGCCGCTG CTGAGCGCGA AAGGTTCCAG CGTGATGCCA  
 12251 ACCTGGGTTT GCTGGTGGCG TTAATGCTT TCTTGTAGTAC TACGCTGCT AATGTGCCG GTGTCAACA  
 12321 GGATTATACT AACTTTTTAA GTGCTTTGAG ACTGATGTA TCAGAAGTAC CTCAGAGCGA AGTGTATCAG  
 12391 TCCGGTCTCG ATTACTTCTT TCAGACTAGC AGACAGGGCT TGCAGACGGT AAATCTGAGC CAAGCTTTTA  
 12461 AAAACCTTAA CAGTTTGTGG GGAGTGCATG CCCCCTAGG AGAAGAGCA ACCGTGTCTA GCTTGTAAAC  
 12531 TCCGAACCTC CGCTGTAT TACTGTGGT AGCTCCTTTC ACCGACAGCG GTAGCATCGA CCGTAATTCC  
 12601 TATTTGGGTT ACCTACTAAA CCTGTATCGC GAAGCCATAG GGCAGAGTCA GGTGGACGAG CAGACCTATC  
 12671 AAGAAATTAC CCAAGTCAGT CGCGCTTTGG GACAGGAAGA CACTGGCACT TTGGAAGCCA CTCTGAACCT  
 12741 CTTGCTTACC AATCGGCTC AAAAGATCCC TCCTCAATAT GCTCTTACTG CCGAGGAGGA GAGGATCCTT  
 12811 AGATATGTGC AGCAGAGCGT GGGATTGTTT CTGATGCAAG AGGGGGCAAC TCCGACTGCA GCACTGGACA  
 12881 TGACAGCGCG AAATATGGAG CCCAGCATGT ATGCCAGTAA CCGACCTTTC ATTAACAAAC TGCTGGACTA  
 12951 CTTGCACAGA GCTGCCGCTA TGAACCTGTA TTATTTCACC AATGCCATCT TAAACCCGCA CTGGCTGCC  
 13021 CCACCTGGTT TCTACACGGG CGAATATGAC ATGCCCGACC CTAATGACGG ATTTCTGTGG GACGACGTGG  
 13091 ACAGCGATGT TTTTTCACCT CTTTCTGATC ATCCGACGTG GAAAAAGGAA GCGCGTGATA GAATGCACTT  
 13161 TTCTGCATCG CTGTCGGGG TCAATGGGTG TACGCGGCT GAGCCGAGT CTGCAAGTCC TTTTCTAGT  
 13231 CTACCCTTTT CTCTACACAG TGTACGTAGC AGCGAAGTGG GTAGAATAAG TCGCCCGAGT TTAATGGGCG

Figure 6, contd.

```

13301 AAGAGGAGTA CCTAAACGAT TCCTTGCTCA GACCGGCAAG AGAAAAAAT TTCCCAAACA ATGGAATAGA
13371 AAGTTTGGTG GATAAAATGA GTAGATGGAA GACTTATGCT CAGGATCACA GAGACGAGCC TGGGATCATG
13441 GGGACTACAA GTAGAGCGAG CCGTAGACGC CAGCGCCATG ACAGACAGAG GGGTCTTGTG TGGGACGATG
13511 AGGATTCGGC CGATGATAGC AGCGTGTTGG ACTTGGGTGG GAGAGGAAGG GGCAACCCGT TTGCTCATTT
13581 GCGCCCTCGC TTGGGTGGTA TGTGTGAAAA AAAAATAAAA AAGAAAACT CACCAAGGCC ATGGCGACGA
13651 GCGTACGTTT GTTCTTCTTT ATTATCTGTG TCTAGTATAA TGAGGCGAGT CGTGCTAGGC GGAGCGGTGG
13721 TGTATCCGGA GGGTCCCTCT CTTTCTGACG AGAGCGTGAT GCAGCAGCAG CAGCGCAGCG CGGTGATGCA
13791 ATCCCCACTG GAGGCTCCCT TTGTGCCTCC GCGATACCTG GCACCTACGG AGGGCAGAAA CAGCATTCTG
13861 TACTCGGAAC TGGCACCTCA GTACGATACC ACCAGGTTGT ATCTGGTGGA CAACAAGTCG GCGGACATTG
13931 CTTCTCTGAA CTATCAGAA GACCACAGCA ACTTCTTGAC CACGGTGGTG CAGAACAATG ACTTTACCCC
14001 TACGGAAGCC AGCACCAGA CCATTAACCT TGATGAACGA TCGCGGTGGG GCGGTACGCT AAAGACCATC
14071 ATGCATACTA ACATGCCAAA CGTGAACGAG TATATGTTTA GTAACAAGTT CAAAGCGCGT GTGATGGTGT
14141 CCAGAAAACC TCCCGACGGT GCTGCAGTTG GGGATACTTA TGATCACAAG CAGGATATTT TGAATATGA
14211 GTGGTTCGAG TTTACTTTGC CAGAAGGCAA CTTTTCAGTT ACTATGACTA TTGATTTGAT GAACAATGCC
14281 ATCATAGATA ATTACTTGAA AGTGGGTAGA CAGAATGGAG TGCTTGAAAG TGACATTGGT GTTAAGTTGG
14351 ACACCAGGAA CTCAAGCTG GGATGGGATC CCGAAACCAA GTTGATCATG CCTGGAGTGT ATACGTATGA
14421 AGCCTTCCAT CCGTACATGG TCTTACTGCC TGGCTGCGGA GTGGATTTTA CCGAGAGTCG TTTGAGCAAC
14491 CTTCTTGGTA TCAGAAAAAA ACAGCCATTT CAAGAGGGTT TTAAGATTTT GTATGAAGAT GTAGAAGTGT
14561 GTAATATTCG GGCCTCTTGG GATGTAGATG CCTATGAGAA CAGTAAGAAA GAACAAAAAG CCAAAATAGA
14631 AGCTGCTACA GCTGCTGCGA AAGCTAAGGC AAACATAGTT GCCAGCGACT CTACAAGGGT TGTAAACGCT
14701 GAGAGAGGTA GAGGAGACAA TTTTGCCECA ACACCTGTTT CCACTGACGA ATCATTATTG CCGCATGTGT
14771 CTGAAGGAAC GGACGTGAAA CTCACATATC AACCTGTAGA AAAAGATAGT AAGAATAGAA GCTATAATGT
14841 GTTGAAGAAC AAAATCAACA CAGCCTATCG CAGTTGGTAT CTTTCTGACA ATTATGGCGA TCCCGAAAAA
14911 GAGTGGGTCT CTTGGGCAAT GTTACGACCC TGGATGTTCA CTTGGGAGG GAGGAGGTTT TACTGGTCCG
14981 TTCCAGACAT GATGAAGGAT CCTGTCACTT TCCGCTCCAC TAGACAAGTC AGTAACTACC CTGTGGTGGG
15051 TGCAGAGCTT ATGCCCGTCT TCTCAAAGAG CTCTTACAAC GAACAAGCTG TGTAATCCCA GCAGCTCCGC
15121 CAGTCCAGCT CGCTTACGCA CGTCTTCAAC CGCTTCTCTG AGAACCCAGT TTTAATCCGT CCGCGGGCGC
15191 CCACCATTAC CACCGTCAGT GAAAACGTTT CTGCTCTCAC AGATCACGGG ACCCTGCCGT TGCBCAGCAG
15261 TATCCGGGGA GTCCAACGTG TGACCGTTAC TGACGCCAGA CGCCGCACCT GTCCCTACGT GTACAAGCCA
15331 CTGGGCATAG TGGCACCGCG CGTCTTTTCA ACCTGCACTT TCTAAAAAAA AAAAATGTCC ATTCTTATCT
15401 CGCCCACTAA TAACACCGGT TGGGGTCTGC GCGCTCCAAG CAAGATGTAC GGAGGCGCAC GCAAACTGTC
15471 TACCCAACAT CCGGTGCGGT TTCGCGGACA TTTTTCGCGT CCATGGGGTG CCCTCAAGGG CCGCACTGCG
15541 GTTCGAACCA CCGTCGATGA TGTAACTGAT CAGGTGGTTG CCGACGCGCG TAATTATACT CCTACTCGCG
15611 CTACATCTAC TGTGGATGCA GTTATTGACA GTGTAGTGGC TGACGCTCGC AACTATGCTC GACGTAAGAG
15681 CCGGCGAAGG CGCATTTGCA GACGCCACCG AGCTACCAC TGCATGCGAG CCGCAAGAGC TCTGCTACGA
15751 AGAGCTAGAC TGGGTGGGCG AAGAGCCATG CTTAGGGCGG CCAGACGTGC AGCTTCGGGC GCCAGCGCGC
15821 GCAGGTCCCG CAGGCAAGCA GCGCGTGTGC CAGCGCGCAC TATTGCCGAC ATGGCCCAAT CGCGAAGAGG
15891 CAATGTATAC TGGGTGCGTG ACGCTGCCAC CGGTCAACGT GTACCCGTGC GCACCCGTCC CCTCTGCACT
15961 TAGAAGATAC TGAGCAGTCT CCGATGTTGT GTCCAGCGG CGAGGATGTC CAAGCGCAAA TACAAGGAAG
16031 AAATGCTGCA GGTATTCGCA CCTGAAGTCT ACGGCCAACC GTTGAAGGAT GATGATGGGC TGGCGGAGTT TGTGCGCGAG
16101 CAAGCGGGTT AAAAAGGACA AAAAAGAAGA GGAAGATGGC GATGATGGGC TGGCGGAGTT TGTGCGCGAG
16171 TTTGCCCCAC GGCGACGCGT GCAATGGCGT GGGCGCAAG TTCGACATGT GTTGAGACCT GGAACCTCGG
16241 TGGTCTTTAC ACCCGGCGAG CGTTCAAGCG CTACTTTTAA GCGTTCCTAT GATGAGGTGT ACGGGGATGA
16311 TGATATTCCT GAGCAGGCGG CTGACCGATT AGGCGAGTTT GCTTATGGCA AGCGTAGTAG AATAACTTCC
16381 AAGGATGAGA CAGTGTCAAT ACCCTTGGAT CATGGAAATC CCACCCCTAG TCTTAAACCG GTCACCTTTC
16451 AGCAAGTGTT ACCCGTAAC CCGCGAACAG GTGTTAAACG CGAAGGTGAA GATTGTATC CCACTATGCA
16521 ACTGATGGTA CCAAAACGCC AGAAGTTGGA GGACGTTTTG GAGAAAGTAA AAGTGGATCC AGATATTCAA
16591 CCTGAGGTTA AAGTGAGACC CATTAAAGCAG GTAGCGCCTG GTCTGGGGGT ACAAACCTGT GACATTAAGA
16661 TTCCCACTGA AAGTATGGAA GTGCAAACTG AACCCGCAAA GCCTACTGCC ACCTCCAAGT AAGTGCAAAAC
16731 GGTCCATGAG ATGCCCATGC CTATTACAAC TGACGCCGCC GGTCCCACTC GAAGATCCCG ACGAAAGTAC
16801 GGTCCAGCAA GTCTGTTGAT GCCCAATTAT GTTGTACACC CATCTATTAT TCTACTCCT GGTTACCGAG
16871 GCACTCGCTA CTATCGCAGC CGAAACAGTA CTTCCCGCGG TCGCGGCAAG ACACCTGCAA ATCGCAGTCG
16941 TCGCCGTAGA CGCAACAAGCA AACCGACTCC CGCGCCCTG GTGCGGCAAG TGTACCGCAA TGGTAGTGCG
17011 GAACCTTTGA CACTGCCGCG TGCGCGTTAC CATCGAGTA TCACTACTTA ATCAATGTTG CCGCTGCCCT
17081 CTTGCAGATA TGGCCCTCAC TTGTGCGCTT CGCGTTCCCA TCACTGGTTA CCGAGGAAGA AACTCGCGCC
17151 GTAGAAGAGG SATGTTGGGA CGCGGAATGC GACGCTACAG GCGACGCGGT GCTATCCGCA AGCAATTGCG
17221 GGGTGGTTTT TTACCAGCCT TAATTTCAAT TATCGCTGCT GCAATTGGCG CGATACCAGG CATAGCTTCC
17291 GTGGCGGTTT AGGCCCTGCA ACGCAATTGA CATTGGAAAA AAAACGTATA AATAAAAAAA AATACAATGG
17361 ACTCTGACAC TCCTGGTCTT GTGACTATGT TTTCTTAGAG ATGGAAGACA TCAATTTTTC ATCTTGGCT
17431 CCGCGACACG GCACGAAGCC GTACATGGGC ACCTGGAGCG ACATCGGCAC GAGCCAACCT AACGGGGGCG
17501 CTTTCAATTG GAGCAGTATC TGGAGCGGGT TTAATAATTT TGGCTCAACC ATAAAAACAT ACGGGAACAA
17571 AGCTTGAAC AGCAGTACAG GACAGGCGCT TAGAAATAAA CTTAAAGACC AGAACTTCCA ACAAAGATAA
17641 GTCGATGGGA TAGCTTCCGG CATCAATGGA GTGGTAGATT TGGCTAACCA GGCTGTGCGA AAAAAGATAA
17711 ACAGTCGTTT GGACCCGCCG CCAGCAACCC CAGGTGAAAT GCAAGTGGAG GAAGAAATTC CTCCGCCAGA

```

Figure 6, contd.

```

17781 AAAACGAGGC GACAAGCGTC CGCGTCCCGA TTTGGAAGAG ACGCTGGTGA CGCGCGTAGA TGAACCGCCT
17851 TCTTATGAGG AAGCAACGAA GCTTGAATG CCCACCACTA GACCGATAGC CCCAATGGCC ACCGGGGTGA
17921 TGAAACCTTC TCAGTTGCAT CGACCCGTCA CCTTGGATTG GCCCCCTCCC CCTGCTGCTA CTGCTGTACC
17991 CGCTTCTAAG CCTGTCGCTG CCCCAGAACCC AGTCGCGCTA GCCAGGTGAC GTCCCCGGGG CGCTCCTCGT
18061 CCAATGCGC ACTGGCAAAA TACTCTGAAC AGCATCGTGG GTCTAGGCGT GCAAAGTGTG AAACGCGGTC
18131 GCTGCTTTTA ATTAAATATG GAGTAGCGCT TAACCTTGCT ATCTGTGTAT ATGTGTCAIT ACACGCCGTC
18201 ACAGCAGCAG AGGAAAAAAG GAAGAGGTCG TGCCTCGACG CTGAGTTACT TTCAAGATGG CCACCCCATC
18271 GATGCTGCCC CAATGGGCGT ACATGCACAT CGCGCGACAG GATGCTTCGG AGTACCTGAG TCCGGGTCTG
18341 GTGCAGTTCG CCCGCGCCAC AGACACCTAC TTCAATCTGG GAAATAAGTT TAGAAATCCC ACCGTAGCGC
18411 CGACCCACGA TGTGACCACC GACCGTAGCC AGCGGCTCAT GTTGCCTTC GTGCCGTTG ACCGGGAGGA
18481 CAATACATAC TCTTACAAAG TGGCGTACAC CCTGGCCGTG GCGGACAACA GAGTGCTGGA TATGGCCAGC
18551 ACGTTCCTTG ACATTAGGGG CGTGTGGGAC AGAGGTCCCA GTTTCAAACC CTATTCTGGT ACGGCTTACA
18621 ACTCTCTGGC TCTTAAAGGC GCTCCAAATG CATCTCAATG GATTGCAAAA GCGGTACCAA CTGCAGCAGC
18691 CGCAGGCAAT GGTGAAGAAG AACATGAAAC AGAGGAGAAA ACTGCTACTT ACACCTTTGC CAATGCTCCT
18761 GTAAAAGCCG AGGCTCAAAT TACAAAAGAG GGCTTACCAA TAGGTTTGGG GATTTCAGCT GAAAAAGCAAT
18831 CTAACCCCAT CTATGCAGAT AAACCTTATC AGCCAGAACCC TCAAGTGGGA GATGAAACTT GGACTGACCT
18901 AGACGGAAAA ACCGAAGAGT ATGGAGGCGG GGCTCTAAAG CCTACTACTA ACATGAAACC CTGTTACGGG
18971 TCCTATGCGA AGCCTACTAA TTTAAAAGGT TTTGAGACAA CAGTCTATGC CCAACAGACC CAACTACATT GCGTTCAGAG
19041 AAATTGAATA TGATATTGAC ATGGAATTTT TTGATAACTC ATCGCAAGA ACAAACCTTC GTCTTAAAT
19111 TGTCTGTAT GCAGAAAATG TAGGTTTGGG AACGCCAGAC ACTCATGTAG TGTACAAACC TGGAACAGAA
19181 GACACAAGTT CCGAAGCTAA TTTGGGACAA CAGTCTATGC CCAACAGACC CAACTACATT GCGTTCAGAG
19251 ATAACCTTAT TGGACTCATG TACTATAACA GTACTGGTAA CATGGGGGTG CTGGCTGGTC AAGCGTCTCA
19321 GTTAAATGCA GTGGTTGACT TGCAGGACAG AAACACAGAA CTTTCTTACC AACTCTTGCT TGACTCTCTG
19391 GCGGACAGAA CCGGATATCT TACGCTGCTG AATCAGGCTG TGGACGTTA TGTCTGCTAT CTACTGCTTA
19461 TTGAAATCA TGGTGTGGAA GATGAACCTC CCAACTATTG TTTTCCACTG GACGGCATAG GTGTTCCAAAC
19531 AACCAGTTAC AAATCAATAG TTCCAAATGG AGAAGATAAT AATAATTGGA AAGAACCTGA AGTAAATGGA
19601 AACAAGTGGG TCGGACAGGG TAATTTGTTT GGTCAAGGAA TTAACCTTCA AGCCAATCTA TGGCGAAGTT
19671 TCCTTTATTC CAATGTGGCT CTGTATCTCC CAGACTCGTA CAAATACACC CCGTCCAAATG TCACCTCTCC
19741 AGAAAAACAA AACACCTACG ACTACATGAA CGGGCGGGTG GTGCCGCCAT CTCTAGTAGA CACCTATGTG
19811 AACATTGGTG CCAAGTGGTG TCTGGATGCC ATGGACAATG TCAACCCATT CAACCCACAC CGTAACGCTG
19881 GCTTGGCTTA CCGATCTATG CTCTGGGTA ACGGACGTTA TGTGCTTTC CACATACAAG TGCCTCAAAA
19951 ATCTTTCGCT GTTAAAAACC TGCTGCTTCT CCCAGGCTCC TACACTTATG AGTGGAACTT TAGGAAGGAT
20021 GTGAACATGG TTCTACAGAG TTCCCTCGGT AACGACCTGC GGGTAGATGG CGCCAGCATC AGTTTCACGA
20091 GCATCAACCT CTATGCTACT TTTTCCCCA TGGCTCAAAA CACCGCTTCC ACCCTTGAAG CCATGCTGCG
20161 GAATGACACC AATGATCAGT CATTCAACGA CTACCTATCT GCAGCTAACA TGCTCTACCC CATCTCGCC
20231 AATGCAACCA ATATTCCCAT TTCTTCCCT TCTCGCAACT GGGCGGCTTT CAGAGGCTGG TCATTTACCA
20301 GACTGAAACCA CAAAGAAACT CCCTCTTTGG GGTCTGGATT TGACCCCTAC TTTGTCTATT CTGGTTCTAT
20371 TCCCTACCTG GATGGTACCT TCTACCTGAA CCACACTTTT AAGAAGGTTT CCATCATGTT TGACTCTTCA
20441 GTGAGCTGGC CTGGAAATGA CAGGTTACTA TCTCTAACG AATTTGAAAT AAAGCGCACT GTGGATGGCG
20511 AAGGCTACAA CGTAGCCCAA TGCAACATGA CCAAGAGACTG GTTCTTGGTA CAGATGCTCG CCAACTACAA
20581 CATCGGCTAT CAGGCTTCT ACATTCCAGA AGGATACAAA GATCGCATGT ATTCATTTTT CAGAACTTC
20651 CAGCCCATGA GCAGGCAGGT GGTGATGAG GTCAATTACA AAGACTTCAA GGGCGTCCGC ATACCTTACC
20721 AACACAACAA CTCTGGCTTT GTGGGTTACA TGGCTCCGAC CATGCGCCAA GGTCAACCTT ATCCCGCTAA
20791 CTATCCCTAT CCACTCATTG GAACAACCTG CGTAAATAGT GTTACGCAGA AAAAGTTCTT GTGTGACAGA
20861 ACCATGTGGC GCATACCGTT CTCGAGCAAC TTCTATGCTA TGGGGGCCCT TACAGACTTG GGACAGAATA
20931 TGCTCTATGC CAACTCAGCT CATGCTTGG ACATGACCTT TGAGGTGGAT CCCATGGATG AGCCCAACCT
21001 GCTTTATCTT CTCTTCGAAG TTTTCGACGT GGTGAGAGTG CATCAGCCAC ACCGCGGCAT CATCGAGGCA
21071 GTCTACCTGC GTACACCGTT CTCGGCCGCT AACGCTACCA CGTAAGAAGC TTCTTGCTTC TTGCAATAG
21141 CAGCTGCAAC CATGGCCTGC GGATCCCAAA ACGGCTCCAG CGAGCAAGAG CTCAGAGCCA TTGTCCAAGA
21211 CCTGGGTTGC GGACCTTATT TTTTGGGAAC CTACGATAAG CGCTTCCCGG GGTTCATGGC CCCCAGTAAG
21281 CTCGCCCTGC CCATTGTAAA TACGGCCGGA CAGTAGACGG GGGGAGAGCA CTGGTTGGCT TTCGGTTGGA
21351 ACCCACGTTT TAACACCTGC TACCTTTTTG ATCCTTTTGG ATTCTCGGAT GATCGTCTCA AACAGATTTA
21421 CCAGTTTGAA TATGAGGGTC TCCTGCGCGT CAGCGCTCTT GCTACCAAGG ACCGCTGTAT TACGCTGGAA
21491 AAATCTACCC AGACCGTGCA GGGCCCCGCT CTGCGCCCTT CCGGACTTTT CTGCTGCATG TTCCTTACCG
21561 CCTTTGTGCA CTGGCCTGAC CGTCCCATGG ACGGAAACCC CACCATGAAA TTGCTAACTG GAGTGCCAAA
21631 CAACATGCTT CATCTCTCTA AAGTCCAGCC CACCTGTGTG GACAATCAAA AAGCACTCTA CCATTTCTT
21701 AATGTTGCGT CGCCTTATTT TCGCTTCTAT CGTACACACA TCGAAAGGGC CACTGCGTTC GACCGTATGG
21771 ATGTTCAATA ATGACTCATG TAAACAACGT GTTCAATAAA CATCACTTTA TTTTTTTACA TGTATCAAGG
21841 CTCTGGATTA CTTATTTATT TACAAGTCGA ATGGGTTCTG ACGAGAATCA GAATGACCCG CAGGCACTGA
21911 TACGTTGCGG AACTGATACT TGGGTTGCCA CTGGAATTCG GGAATCACCA ACTTGGGAAC CGGTATATCG
21981 GGCAGGATGT CACTCCACAG CTTTCTGGTC AGCTGCAAGG CTCCAAGCAG GTCAGGAGCC GAAATCTTGA
22051 AATCACAATT AGGACCACTG CTCTGAGCGC GAGAGTTGCG GTACACCGGA TTGACGCTAG GAAACACCAT
22121 CAGCGACGGA TGTCTCACGC TTGCCAGCAC GGTGGGATCT GCAATCATGC CCACATCCAG ATCTTACGCA
22191 TTGGCAATGC TGAACGGGGT CATCTTGACG GTCTGCCCTAC CCATGGCGGG CACCCAATTA GCCTTGTTGT

```

Figure 6, contd.

22261	TGCAATCGCA	GTGCAGGGGG	ATCAGTATCA	TCTTGGCCTG	ATCCTGTCTG	ATTCTTGGAT	ACACGGCTCT
22331	CATGAAAGCA	TCATATTGCT	TGAAAGCCTG	CTGGGCTTTA	CTACCCCTCG	TATAAAACAT	CCCGCAGGAC
22401	CTGCTCGAAA	ACTGGTTAGC	TGCACAGCCG	GCATCATTCA	CACAGCAGCG	GGCGTCATTG	TTGGCTATTT
22471	GCACCACACT	TCTGCCCCAG	CGGTTTTGGG	TGATTTTGGT	TCGCTCGGGA	TTCTCCTTTA	AGGCTCGTTG
22541	TCCGTTCCTG	CTGGCCACAT	CCATCTCGAT	AATCTGCTCC	TTCTGAATCA	TAATATTGCC	ATGCAGGCAC
22611	TTCAAGCTTG	CCTCATAATC	ATTGCAAGCA	TGAGGCCACA	ACGCACAGCC	TGTACATTCC	CAATTATGGT
22681	GGGCGATCTG	AGAAAAAGAA	TGTATCATTC	CCTGCAGAAA	TCTTCCCATC	ATCGTGCTCA	GTGTCTTGTG
22751	ACTAGTGAAG	GTTAACTGGA	TGCCTCGGTG	CTCTTCGTTT	ACGTACTGGT	SACAGATGCG	CTTGATTGTG
22821	TCGTGTGCT	CAGGCATTAG	TTTAAACAG	GTTCTAAGTT	CGTTATCCAG	CCTGTACTTC	TCCATCAGCA
22891	GACACATCAC	TTCCATGCCT	TTCTCCCAAG	CAGACACCAG	GGGCAAGCTA	ATCGGATTCT	TAACAGTGCA
22961	GGCAGCAGCT	CCTTTAGCCA	GAGGGTCATC	TTTAGCGATC	TTCTCAATGC	TTCTTTTGCC	ATCCTTCTCA
23031	ACGATGCGCA	CGGGCGGGTA	GCTGAAACCC	ACTGCTACAA	GTTGCGCCTC	TTCTCTTCT	TCTTCGCTGT
23101	CTTGACTGAT	GTCTTGCAAT	GGGATATGTT	TGGTCTTCCT	TGGCTTCTTT	TTGGGGGGTA	TCGGAGGAGG
23171	AGGACTGTG	CTCGTTCCG	GAGACAGGGA	GGATTGTGAC	GTTTCGCTCA	CCATTACCAA	CTGACTGTG
23241	GTAGAAGAAC	CTGACCCAC	ACGGCGACAG	GTGTTTTTCT	TCGGGGGAG	AGGTGGAGGC	GATTGCGAAG
23311	GGCTGCGGTC	AGACCTGGAA	GGCGGATGAC	TGGCAGAACC	CCTTCCGCGT	TCGGGGGTGT	GCTCCTGTG
23381	CGGGTCGCTT	AACGTGATT	CTTCGCGGCT	GGCCATTGTG	TTCTCCTAGG	CAGAGAAACA	ACAGACATGG
23451	AAACTCAGCC	ATTGCTGTCA	ACATCGCCAC	GAGTGCCATC	ACATCTCGTC	CTCAGCGACG	AGGAAAGGGA
23521	GCAGAGCTTA	AGCATTCAC	CGCCAGTCC	TGCCACCACC	TCTACCCTAG	AAGATAAGGA	GGTCAGCGCA
23591	TCTCATGACA	TGCAGAATA	AAAAGCGAAA	GAGTCTGAGA	CAGACATCGA	GCAAGACCCG	GGCTATGTGA
23661	CAACGGGTGGA	ACACGAGGAA	GAGTTGAAAC	GCTTCTTAGA	GAGAGAGGAT	GAAAACTGCC	CAAAACAGCG
23731	AGCAGATAAC	TATCACCAG	ATGCTGGAAA	TAGGGATCAG	AACACCGACT	ACCTCATAGG	GCTTGACGGG
23801	GAAGACGCGC	TCCTTAAACA	TCTAGCAAGA	CAGTCGCTCA	TAGTCAAGGA	TGCATTATTG	GACAGAACTG
23871	AAATGCGCT	CAATGCGAA	AGCTCAGCT	CGGCTACGA	GTAAACCTT	TTTCACTTC	GTACTCCGCG
23941	CAAAACGTCAG	CCAAACGGCA	CCTGCGAGCC	AAATCCTCGC	TTAAACTTTT	ATCCAGCTTT	TGCTGTGCCA
24011	GAAGTACTGG	CTACCTATCA	CATCTTTTTT	AAAAATCAAA	AAATTCCAGT	CTCCTGCCGC	GCTAATCGCA
24081	CCCGCGCGGA	TGCCCTACTC	AATCTGGGAC	CTGGTTCACG	CTTACCTGAT	ATAGCTTCCT	TGGAAAGAGT
24151	TCCAAGATC	TTCGAGGGTC	TGGGCAATAA	TGAGACTCGG	GCCGCAAAATG	CTCTGCAAAA	GGGAGAAAAT
24221	GGCATGGBATG	AGCATCACAG	CGTTCGTGTG	GAATTGGAAG	GCGATAATGC	CAGACTCGCA	GTACTCAAGC
24291	GAAGCGTCGA	GGTCACACAC	TTGCGATATC	CCGCTGTCAA	CCTGCCCCCT	AAAGTCAATGA	CGGCGGTCAAT
24361	GGACCACTTA	CTCATTAAGC	GCGCAAGTCC	CCTTTCAGAA	GACATGCATG	ACCCAGATGC	CTGTGATGAG
24431	GGTAAACCG	TGGTCAGTGA	TGAGCAGCTA	ACCCCATGCC	TGGGCACCGA	CTCTCCCGGG	GATTTGGAAG
24501	AGCGTCGCAA	GCTTATGATG	GCCGTGGTGC	TGGTTACCGT	AGAACTAGAG	TGTCTCCGAC	GTTTCTTTAC
24571	CGATTACAGAA	ACCTTGCGCA	AACTCGAAGA	GAATCTGCAC	TACACTTTTA	GACACGGCTT	TGTGCGCGAG
24641	GCATGCAAGA	TATCTAACGT	GGAACCTACC	AACCTGGTTT	CCTACATGGG	TATTCTGCAT	GAGAATCGCC
24711	TAGGACAAAG	CGTGCTGCAC	AGCACCCCTTA	AGGGGGAAGC	CCGCCGTGAT	TACATCCGCG	ATTGTGTCTA
24781	TCTCTACCTG	TGCCACACGT	GGCAACCCGG	CATGGGTGTA	TGGCAGCAAT	GTTTAGAAGA	ACAGAATCTG
24851	AAAGAGCTTG	ACAAGCTCTT	ACAGAAATCT	CTTAAGGTTT	TGTGGACAGG	GTTGACGAG	CGCACCGTGC
24921	CTTCCGACCT	GGCAGACCTC	ATCTTCCCAG	AGCGTCTCAG	GGTACTTTTG	CGAAACBGAT	TGCCGTGACTT
24991	TATGAGCCAG	AGCATGCTTA	ACAATTTTCG	CTCTTTCATC	CTGGAACGCT	CCGGTATCCT	CGCCGCCACC
25061	TGCTGCGCAC	TGCCCTCCGA	CTTTGTGCTT	CTCACCTACC	GCGAGTGCCC	CCCGCCGCTA	TGGAGTCACT
25131	GCTACCTGTT	CGTCTGGCC	AACTATCTCT	CCTACCACTC	GGATGTGATC	GAGGATGTGA	GGGGAGACGG
25201	CTTGCTGGAG	TGCCACTGCC	GCTGCAATCT	GCTGACGCC	CACCGGTCCC	TAGCTTGCAA	CCCCAGTTTG
25271	ATGAGCGAAA	CCAGATAAAT	AGGCACCTTT	GAATTGCAAG	GCCCCAGCAG	CCAAGGCGAT	GGGTCTTCTC
25341	CTGGGCAAAAG	TTTAAAACTG	ACCCCCGGAC	TGTGGACCTC	CGCCTACTTG	CGCAAGTTTG	CTCCGGAAGA
25411	TTACCAACCC	TATGAAATCA	AGTTCTATGA	GGACCAATCA	CAGCCTCCAA	AGGCCGAATC	TTGCGCTTGC
25481	GTCATCACCC	AGGGGGCAAT	TCTGGCCCAA	TTGCAAGCCA	TCCAAAAATC	CCGCCAAGAA	TTTCTACTGA
25551	AAAAGGGTAA	GGGGGTCTAC	CTTGACCCCC	AGACCGGCGA	GGAACCTAAC	ACAAGGTTCC	CTCAGGATGT
25621	CCCAACGACG	AGAAAACAAG	AAGTTGAAGG	TGCAGCCGCC	GCCCCAGAA	GATATGGAGG	AAGATTGGGA
25691	CAGTCAGGCA	GAGGAGGCGG	AGGAGGACAG	TCTGGAGGAC	AGTCTGGAGG	AAGACAGTTT	GGAGGAGGAA
25761	AACGAGGAGG	CAGAGGAGGT	GGAAAGAGTA	ACCGCGACA	AACAGTTATC	CTCGGCTGCG	GAGACAAGCA
25831	ACAGCGCTAC	CATCTCCGCT	CCGAGTCCAG	GAACCCGGCG	GCGTCCCAGC	AGTAGATGGG	ACGAGACCGG
25901	ACGCTTCCCG	AACCCAACCA	GCGCTTCCAA	GACCGGTAAG	AAGGATCGGC	AGGATACAA	GTCTTGCGCG
25971	GGGCATAAGA	ATGCCATCAT	CTCCTGCTTG	CATGAGTGGC	GGGGCAACAT	ATCCTTCACG	CGGCGCTACT
26041	TGCTATTCCA	CCATGGGGTG	AACTTTCCCG	GCAATGTTTT	GCATTACTAC	CGTCACCTCC	ACAGCCCCTA
26111	CTATAGCCAG	CAAAATCCCGA	CAGTCTCGAC	AGATAAAGAC	AGCGGCGGCG	ACCTCCAACA	GAAGACCAGC
26181	AGCGGCAGTT	AGAAAATACA	CAACAAGTGC	AGCAACAGGA	GGATTAAAGA	TTACAGCCAA	CGAGCCAGCG
26251	CAAAACCCGAG	AGTTAAGAAA	TCGGATCTTT	CCAACCTGT	ATGCCATCTT	CCAGCAGAGT	CGGGGTCAAG
26321	AGCAGGAAGT	GAATAAATAA	AACCGATCTC	TGCGTTGCTT	CACCAGAAGT	TGTTTGTATC	ACAAGAGCGA
26391	AGATCAACTT	CAGCGCACTC	TCGAGGACGC	CGAGGCTCTC	TTCAACAAGT	ACTGCGCGCT	GACTCTTAAA
26461	GAGTAGGCGC	CGACCGCGCT	TATTCAAAAA	AGGCGGGAAT	TACATCATCC	TCGACATGAG	TAAAGAAATT
26531	CCCACGCTT	ACATGTGGAG	TTATCAACCC	CAAATGGGAT	TGGCAGCAGG	CGCCTCCAG	GACTACTCCA
26601	CCCGCATGAA	TTGGCTCAGC	GCCGGGCTTT	CTATGATTTT	TCGAGTTAAT	GATATACGCG	CCTACCGAAA
26671	CCAAATACTT	TTGGAACAGT	CAGCTCTTAC	CACCACGCCC	CGCCAACACC	TTAATCCAG	AAATTGGCCC

Figure 6, contd.

```

26741 GCCGCCCTAG TGTACCAGGA AAGTCCCGCT CCCACCCTG TATTACTTCC TCGAGACGCC CAGGCCGAAG
26811 TCCAAATGAC TAATGCAGGT GCGCAGTTAG CTGGCGGCTC CACCCTATGT CGTCACAGGC CTCGGCATAA
26881 TATAAACGCG CTGATGATCA GAGGCCGAGG TATCCAGCTC AACGACGAGT CCGGTGAGCTC TCCGCTTGGT
26951 CTACGACCAG ACGGAATCTT TCAGATTGCC GGCCTCGGGA GATCTTCTCT CACCCCTCGT CAGGCTGTTC
27021 TGACTTTTGA AAGTTTCGCT TCGCAACCCC GCTCGGGCGG AATCGGGACC GTTCAATTTG TAGAGGAGTT
27091 TACTCCCTCT GTCTACTTCA ACCCTTCTCT CGGATCTCCT GGGCACTACC CCGACGAGTT CATAACGAAC
27161 TTCGACGCGA TTAGCGAGTC AGTGGACGGC TACGATTGAT GTCTGGTGAC GCGGCTGAGC TATCTCGGCT
27231 GCGACATCTA GACCACTGCC GCCGCTTTCG CTGCTTTGCC CGGGAACCTA TTGAGTTTCA CTACTTCGAA
27301 CTCCTCAAGG ATCACCCTCA AGGTCGCGCC CACGAGTGC GGATTACTAT CGAAGGCAAA ATAGACTCTC
27371 GCCTGCAACG AATTTTCTCC CAGCGGCCCG TGCTGATCGA GCGAGACCAG GGAAACACCA CGGTTTCCAT
27441 CTACTGCATT TGTAATCACC CCGGATTGCA TGAAAGCCTT TGCTGTCTTA TGTGACTGA GTTTAATAAA
27511 AACTGAATTA AGACTCTCCT ACGGACTGCC GCTTCTTCAA CCCGGATTTT ACAACCAAGG GAACAAAACCT
27581 TTTCTGTGCG TCCAGGACTC TGTTAACTTC ACCTTTCTTA CTCACAAACT AGAAGCTCAA CGACTACACC
27651 GCTTTTCCAG AAGCATTTTC CTTACTAATA CTACTTTCAA AACCGGAGGT GAGCTCCAGC GTCTCCCTAC
27721 AGAAAACCTT TGGGTGGAAG CCGGCTTGT AGTACTAGGA ATTCTTCCGG GTGGGCTTGT GATTATTTCT
27791 TGCTACCTAT ACACACCTTG CTTACATTTT CTAGTGGTGT TGTTGATTGT GTTTAAAAAA TGGGGCCCAT
27861 ACTAGTCTTG CTGTGTTTTC TTTGCTTTT GGAACCGGGT TCTGCCAATT ACGATCCATG TCTAGACTTT
27931 GACCCAGAAA ACTGCACACT TACTTTTGCA CCCGACACAA GCGCATCTG TGGAGTTCTT ATTAAGTGGC
28001 GATGGGAATG CAGGTCCGTT GAAATTACAC ACAATAACAA AACCTGGAAC AATACCTTAT CCACCACATG
28071 GGAGCCAGGA GTTCCCGAGT GGTACACTGT CTCTGTCCGA GGTCTGACG GTTCCATCCG CATTAGTAAC
28141 AACACTTTCA TTTTCTGTA AATGTGCGAT CTGGCCATGT TCATGAGCAA ACAGTATTCT CTATGGCCTC
28211 CTAGCAAGGA CAACATCGTA ACGTTCTCCA TTGCTTATTG CTGTGCGCT TGCTTCTTA CTGCTTACT
28281 GTGCGTATGC ATACACCTGC TTGTAACCA CCGCATCAAA AACGCCAATA ACAAAGAAAA AATGCCTTAA
28351 GGCCTCTCTAT CCCACTAGGA CATTAATTACA CTCTCATAGG ACCCCCAATC ACTTCAGAGG
28421 GGACAAACAG TCGTCTCTAT CCCACTAGGA CATTAATTACA CTCTCATAGG ACCCCCAATC ACTTCAGAGG
28491 TCATCTGGAC CAAACTGGGA AGCGTTGATT ACCTTGATAT AATCTGTAAC AAAACAAAAA CAATAATAGT
28561 AACTTGCAAC ATACAAATC TTACATTGAT TAATGTTAGC AAAGTTTACA GCGGTTACTA TTATGTTTAT
28631 GACAGATACA GTAGTCAATA TAGAAATTAC TTGGTTCGTC TTACCCAGTT GAAACACACG AAAATGCCAA
28701 ATATGGCAAA GATTCGATCC GATGACAATT CTCTAGAAAC TTTTACATCT CCCACCACAC CCGACGAAAA
28771 AAACATCCCA GATTCAATGA TTGCAATTGT TGCAGCGGTG GCAGTGGTGA TGGCACTAAT AATAATATGC
28841 ATGCTTTTAT ATGCTTGTG CTACAAAAAG TTTTCACTTA AAAACAAGAA TCTCTACTA AGGCTTAACA
28911 TTTAATTTCT TTTTATACAG CCATGGTTTT CACTACCACA TTTCTTATGC TTACTAGTCT CGCACTCTG
28981 ACTTCTGCTC GCTCACACCT CACTGTAAC ATAGGCTCAA ACTGCACACT AAAAGGACCT CAAGGTGGTC
29051 ATGCTTTTTG GTGGAGAATA TATGACAATG GATGGTTTAC AAAACCATGT GACCAACCTG TAGATTTTTT
29121 CTGCAACGGC AGAGACCTAA CCATTATCAA CGTACAGCA AATGACAAAG GCTTCTATTA TGGAACCCAG
29191 TATAAAAGTA GTTTAGATTA TAACATTATT GTACTGCCAT CTACCCTCC AGCACCCCGC ACAACTACTT
29261 TCTCTAGCAG CAGTGTGCTG AACAATACAA TTTCCAATCC AACCTTTGCC GCGCTTTTAA AACGCCTGT
29331 GAATTAATCT ACACCTTCA ATACAACAAT TCTCACTTCA ACAATCAGCA TCATCGCTGC AGTGACAATT
29401 GGAATATCTA TTCTTGTITT TACCATAACC TACTACGCTT GCTGCTATAG AAAAGACAAA CATAAAGGTG
29471 ATCCATTACT TAGATTGAT ATTTAATTTG TTCTTTTTTT TTATTTACAG TATGGTGAAC ACCAATCATG
29541 GTACCTAGAA ATTTCTTCTT CACCATACTC ATCTGTGCTT TTAATGTTTT CGCTACTTTC ACAGCAGTAG
29611 CCACAGCAAC CCCAGACTGT ATAGGAGCAT TTGCTTCTTA TGCACTTTTT GCTTTTGTTA CTGTGATCTG
29681 CGTATGTAGC ATAGTCTGCC TGGTTATTAA TTTTTTCAA CTCTAGACT GGATCCTTGT GCGAATTGCC
29751 TACCTGCGCC ACCATCCCGA ATACCGCAAC CAAAATATCG CCGCACTTCT TAGACTCATC TAAAACCATG
29821 CAGGCTATAC TACCAATATT TTTGCTTCTA TTGCTTCCCT ACGCTGTCTC AACCCAGCT GCCTATAGTA
29891 CTCCACCAGA ACACCTTAGA AAATGCAAA TCCAACAACC GTGGTCATT CTGTCTTGT ATCGAGAAAA
29961 ATCAGAAATC CCCCCAAAT TAATAATGAT TGCTGGAATA ATTAATATA TCTGTTGCAC CATAATTCA
30031 TTTTGTATAT ACCCCCTATT TGATTTTGGC TGGAAATGCT CCAATGCACA TGATCATCCA CAAGACCCAG
30101 AGGAACACAT TCCCCACAA AACATGCAAC ATCCAATAGC GCTAATAGAT TACGAAAGTG AACCAACCC
30171 CCCACTACTC CCTGCTATTA GTTACTTCAA CCTAACCGGC GGAGATGACT GAAACACTCA CCACCTCCAA
30241 TTCGCGGAG GATCTGCTCG ATATGGACGG CCGGCTCTCA GAACAACGAC TTGCCCCAAT ACGCATCCGC
30311 CAGCAGCAGG AACCGGTGGC CAAAGAGCTC AGAGATGTCA TCCAATTTCA CCAATGCAAA AAAGGCATAT
30381 TCTGTTTGGT AAAACAAGCC AAGATATCCT ACGAGATCAC CGCTACTGAC CATCGCCTCT CTTACGAAT
30451 TGGCCCCCAA CGACAAAAAT TTACCTGCAT GGTGGGAATC AACCCCATAG TTATCACCCTA CCAAAGTGGG
30521 GATACTAAGG GTTGCAATCA CTGCTCCTGC GATTCCATCG AGTGACCTTA CACCCTGCTG AAGACCTTAT
30591 GCGGCTTAAG AGACCTGCTA CCAATGAAT AAAAAAAAT GATTAATAAA AAATCACTTA CTTGAAATCA
30661 GCAATAAGGT CTCTGTTGAA ATTTTCTCCC AGCAGCACCT CACTTCCCTC TTCCCACTC TGGTATTCTA
30731 AACCCCGTTC AGCGGCATAC TTTCTCCATA CTTTAAAGGG GATGTCAAAT TTTAGCTCCT CTCCTGTACC
30801 CACAATCTTC ATGTCTTTCT TCCAGATGA CCAAGAGAGT CCGGCTCAGT GACTCTTCA ACCCTGTCTA
30871 CCCCATGAA GATGAAAGCA CCTCCCAACA CCCCCTTATA AACCCAGGGT TTATTTCCCC AAATGGCTTC
30941 ACACAAAGCC CAGACGGAGT TCTTACTTTA AAATGTTTAA CCCCCTAAC AACCAAGGC GGATCTCTAC
31011 AGCTAAAGT GGGAGGGGGA CTTACAGTGG ATGACACTGA TGGTACCTTA CAAGAAAAA TACGTGCTAC
31081 AGCACCCATT ATCACTCTGT AGAAGTATCC ATTGGAATG GATTAGAAAC TCAAAACCAAT
31151 AAACATATGT CCAAAATGGG AAATGGGTTA AAATTTAACA ACGGTGACAT TTGTATAAAG GATAGTATTA

```



Figure 6, contd.

```

31221 ACACCTTATG GACTGGAATA AACCTCCAC CTAAGTGTCA AATTGTGGAA AACACTAATA CAAATGATGG
31291 CAAACTTACT TTAGTATTAG TAAAAATGG AGGGCTGTG AATGGCTACG TGTCTCTAGT TGGTGTATCA
31361 GACACTGTGA ACCAAATGTT CACACAAAAG ACAGCAAACA TCCAATTAAG ATTATATTTT GACTCTTCTG
31431 GAAATCTATT AACTGAGGAA TCAGACTTAA AAATTCACCT TAAAAATAAA TCTTCTACAG CGACCACTGA
31501 AACTGTAGCC AGCAGCAAAG CCTTATGCC AAGTACTACA GCTTATCCCT TCAACACCAC TACTAGGGAT
31571 AGTGAAGAACT ACATTATGTT AATATGTTAC TACATGACTA GTTATGATAG AAGTCTATTT CCTTGAACA
31641 TTTCTATAAT GCTAAACAGC CGTATGATTT CTTCGAATGT TGCCTATGCC ATACAATTTG AATGGAATCT
31711 AAATGCAAGT GAATCTCCAG AAAGCAACAT AGCTACGCTG ACCACATCCC CCTTTTTCTT TTCTTACATT
31781 ACAGAAGACG ACAACTAAAA TAAAGTTTAA GTGTTTTTAT TTAAATCAC AAAATTCGAG TAGTTATTTT
31851 GCCTCCACCT TCCCATTTGA CAGAATACAC CAATCTCTCC CCACGCACAG CTTTAAACAT TTGGATACCA
31921 TTAGAGATAG ACATTGTTTT AGATTCCACA TTCCAACAG TTTAGAGCGG AGCCAATCTG GGGTCAGTGA
31991 TAGATAAAAA TCCATCGCGA TAGTCTTTTA AAGCGCTTTC ACAGTCCAAC TGTGCGGAT GCGACTCCGG
32061 AGTTTGGATC ACGGTCATCT GGAAGAAGAA CGATGGGAAT CATAATCCGA AAACGGTATC AAACGATTGT
32131 GTCTCATCAA ACCACAAGC AGCCGCTGTC TGCCTCGCTC CGTGCAGCTG CTGTTTATGG GATCAGGGTC
32201 CACAGTTTCC TGAAGCATGA TTTAATAGC CCTTAACATC AACTTTCTGG TGGATGCGC GCAGCAACGC
32271 ATTCTGATTT CACTCAAAAT TTTGCACTAG GTACAACACA TTATTACAAT ATTGTTTAAAT AAACATAAT
32341 TAAAAGCGCT CCAGCCAAAA CTCATATCTG ATATAATCGC CCCTGCATGA CCATCATACC AAAGTTTAAAT
32411 ATAAATTAAA TGACGTTCCC TCAAAAACAC ACTACCCACA TACATGATCT CTTTGGCAT GTGCATATTA
32481 ACAATCTGTC TGTACCATGG ACAACGTTGG TTAATCATGC AACCCAATAT AACCTTCCGG AACCACTG
32551 CCAACACCGC TCCCCAGCC ATGCATTGAA GTGAACCTG CTGATTACAA TGACAATGAA GAACCAAT
32621 CTCTCGACCG TGAATCACTT GAGAATGAAA AATATCTATA GTGGCACAAC ATAGACATAA ATGCATGCAT
32691 CTTCTCATAA TTTTAACTC CTCAGGATTT AGAAACATAT CCCAGGGAAT AGGAAGCTCT TGCAGAACAG
32761 TAAAGCTGGC AGAACAAGGA AGACCACGAA CACAACCTAC ACTATGCATA GTCATAGTAT CACAATCTGG
32831 CAAACGCGC TGGCTTCTG TCTAGAGC TCGGCTTCA TTTCTCTAC AACCTGTAH CTGGCTCTG
32901 GTGTAAGGGT GATGTCTGGC GCATGATGTC GAGCGTGCGC GCAACCTTGT CATAATGGAG TTGCTTCTG
32971 ACATTCTCGT ATTTGTGATA GCAAAACGCG GCCCTGGCAG AACACACTCT TCTTCGCTT CTATCCTGCC
33041 GCTTAGCGTG TTCCGTGTGA TAGTTCAAGT ACAGCCACAC TCTTAAGTTG GTCAAAAGAA TGCTGGCTTC
33111 AGTTGTAATC AAAACTCCAT CGCATCTAAT TGTCTGAGG AAATCATCCA CGGTAGCATA TGCAAAATCCC
33181 AACCAAGCAA TGCAACTGGA TTGCGTTTCA AGCAGGAGAG GAGAGGGAAG AGACGGAAGA ACCATGTTAA
33251 TTTTATTCC AAACGATCTC GCAGTACTTC AAATGTAGA TCGCGCAGAT GGCATCTCTC GCCCCACTG
33321 TGTGGTGAA AAAGCACAGC TAAATCAAAA GAAATGCGAT TTTCAAGGTG CTCAACGGTG GCTTCCAACA
33391 AAGCCTCCAC GCGCACATCC AAGAACAAAA GAATACCAAA AGAAGGAGCA TTTTCTAACT CCTCAATCAT
33461 CATATTACAT TCCTGCACCA TTCCCAGATA ATTTTCAGCT TTCCAGCCTT GAATATTTCG TGTCAATTCT
33531 TGTGGTAAAT CCAATCCACA CATTACAAAC AGGTCCCGGA GGGCGCCCTC CACCACCATT CTTAAACACA
33601 CCCTCATAAT GACAAAATAT CTTGCTCTG TGTACCTGT AGCGAATTGA GAATGGCAAC ATCAATTGAC
33671 ATGCCCTTGG CTCTAAGTTC TTTCTTAAGT TCTAGTTGTA AAAACTCTCT CATATTATCA CCAAACTGCT
33741 TAGCCAGAAG CCCCCCGGA ACAAGAGCAG GGGACGCTAC AGTGCAGTAC AAGCGCAGAC CTCCCCAATT
33811 GGCTCCAGCA AAAACAAGAT TGAATAAGC ATATTGGGAA CCACCAGTAA TATCATCGAA GTTGCTGGAA
33881 ATATAATCAG GCAGAGTTTC TTGTAGAAAT TGAATAAAG AAAAATTTGC CAAAAAACA TTCAAAACCT
33951 CTGGGATGCA AATGCAATAG GTTACCGCGC TCGCTCCAA CATTGTTAGT TTTGAATTAG TCTGCAAAAA
34021 TAAAAAATAA ACAAGCGTCA TATCATAGTA GCCTGACGAA CAGGTGGATA AATCAGTCTT TCCATCACAA
34091 GACAAGCCAC AGGGTCTCCA GCTCGACCTT CGTAAACCT GTCATCGTGA TTAACAACA GCACCGAAG
34161 TTCCTCGCGG TGACCAAGCAT GAATAAGTCT TGATGAAGCA TACAATCCAG ACATGTTAGC ATCAGTTAAG
34231 GAGAAAAAAC AGCCAACATA GCCTTTGGGT ATAATTATGC TTAATCGTAA GTATAGCAAA GCCACCCCTC
34301 GCGGATACAA AGTAAAAGGC ACAGGAGAAAT AAAAATATA ATTTTCTCT TGTGCTGTT TAGGCAACGT
34371 CGCCCCGGT CCCTCTAAAT ACACATACAA AGCCTCATCA GCCATGGCTT ACCAGAGAAA GTACAGCGGG
34441 CACACAAACC ACAAGCTCTA AAGTCACTCT CCAACCTSTC CACAATATAT ATACACAAGC CCTAACTGA
34511 CGTAATGGGA CTAAAGTGTA AAAAATCCCG CCAAAACCAA CACACACCCC GAAACTGCGT CACCAAGGAA
34581 AAGTACAGTT TCACCTCCGC AATCCCAACA AGCGTCACTT CCTCTTCTC ACGGTACGTC ACATCCCAT
34651 AACTTACAAC GTCATTTTCC CACGGCCGCG CCGCCCTTTT TAACCGTTAA CCCCACAGCC AATCACCACA
34721 CGGCCACAC TTTTAAAT CACCTCATTT ACATATTGGC ACCATTCCAT CTATAAGGTA TATTATTGAT
34791 GATG

```

Figure 7




Figure 8




Figure 9




Figure 10




Figure 11





Figure 12



## Construction of cosmid vector pWE.Ad 35.pIX-rITR




Figure 13



Figure 14




Figure 15




Figure 16




Figure 17




Figure 18




Figure 19




Figure 20




Figure 21






Figure 22a




Figure 22b




FIGURE 23

1 MLLQMKRRARPS EDTFNPVYPYDTE TGPPTVPFLT PPFVSP Fib 5 protein  
 1 MLLQMKRRARPS EDTFNPVYPYDEESSQH-PPINP(GFI)S Fib 16 protein  
 1 MLLQMKRRARPS EDTFNPVYPYDEESSQH-PPINP(GFI)S Fib 35 protein  
 1 MLLQMKRRARPS EDTFNPVYPYDEESSQH-PPINP(GFI)S Fib 51 protein

41 NGFOESPPGVLS LRLSEPLVTSNGMLALKMGNGLSLDEAG Fib 5 protein  
 40 NGFAQSPPGVLT LKCVNPLTTASGRLLQLKVGSSLTVDITD Fib 16 protein  
 40 NGFTQSPDGVLT LKCLTPLTTTGGSLQLKVGGLTVDDTD Fib 35 protein  
 40 NGFTQSPDGVLT LKCLTPLTTTGGSLQLKVGGLTVDDTD Fib 51 protein

81 NLTSONVTTVSPPLKKT KSNINLRISAPLTVTSEALTVA Fib 5 protein  
 80 GSLEENIT-AAAAPLTKTNHSLIGLLIGSGLTQT- Fib 16 protein  
 80 GTLOENIR-ATAFITKNNHSVELSIGNGLET- Fib 35 protein  
 80 GTLOENIR-VTAFITKNNHSVELSIGNGLET- Fib 51 protein

121 AAPLMVAGNTLT MOSOAPLTVHDSKLSIATOGPLTVSEK Fib 5 protein  
 110 - - - - - KDKLCLSLLEDGLVTKDDK Fib 16 protein  
 110 - - - - - QNNKLC- - - - - Fib 35 protein  
 110 - - - - - QNNKLC- - - - - Fib 51 protein

161 LALQTSGLPLTTTDSSTLTITASPLTTATGSLGIDLKEPI Fib 5 protein  
 129 LGL- - - - - Fib 16 protein  
 116 - - - - - Fib 35 protein  
 116 - - - - - Fib 51 protein

201 YTONGKLGKLYGAPLHVTD DLTNTLT VATGPGVTINNTSLO Fib 5 protein  
 132 - - - - - Fib 16 protein  
 116 - - - - - Fib 35 protein  
 116 - - - - - Fib 51 protein

241 TKVTGALGPD SQGNMQLNVAGGLRIDSONRRLLIDVSYPP Fib 5 protein  
 132 - - - - - Fib 16 protein  
 116 - - - - - Fib 35 protein  
 116 - - - - - Fib 51 protein

281 DAQNQLNRL LGGGLPINSAHNLDINYNKGLYLFTASNNS Fib 5 protein  
 132 - - - - - SLGTLG- - - - - Fib 16 protein  
 116 - - - - - Fib 35 protein  
 116 - - - - - Fib 51 protein

321 KKLEVNLTAKGLMFDATAIAINAGDGLFPGSPNAPNTNP Fib 5 protein  
 137 - - - - - Fib 16 protein  
 116 - - - - - Fib 35 protein  
 116 - - - - - Fib 51 protein

361 LKTKIGHGLEFDSNKAMVPKLG TGLSPDSTGAITVGNKNN Fib 5 protein  
 137 LITN- - - - - NDVLC AKLGHGLVPSI-SNX-ITIDNN Fib 16 protein  
 116 - - - - - AKLGNGLKFPNN-GDICI KDSIN Fib 35 protein  
 116 - - - - - AKLGNGLKFPNN-GDICI KDSIN Fib 51 protein

401 DKLTLTWTTAPSPNCRL- - - NAEKDAKLTTLVLTKCGSOIL Fib 5 protein  
 166 - - - TLWTGAKPSANCVIKEGEDSDCKLTTLVLVKNGGLIN Fib 16 protein  
 137 - - - TLWTGINFPNCQIVENTNTNDGKLTTLVLVKNGGLVN Fib 35 protein  
 137 - - - TLWTGIRFPNCQIVENTDTNDGKLTTLVLVKNGGLVN Fib 51 protein

438 ATVSVLAVKGS LAPISGTVQSAHLIIRFDENGVLNNNSP Fib 5 protein  
 203 GYITLMGASEYTNTLPKNNQVTIDYNLAFDNTGQIITYLS Fib 16 protein  
 174 GYVSLVGVS DTVNQMFOTKTANIQLRLYFDSSGNLLTEES Fib 35 protein  
 174 GYVSLVGVS DTVNQMFOTKSATIOQLRLYFDSSGNLLTDES Fib 51 protein


477 LDPEYWNFRNGDLTEGTAYTNAVGFMPNLSAYPKSHGKTA Fib 5 protein  
 243 SLKSNINFKDNQNMATGTIT SARGFMPSTTAYPFI- - - TY Fib 16 protein  
 214 DLKIPLKNKSSTA-TSETVASSKAFMPSTTAYPFN- - - TT Fib 35 protein  
 214 NLKIPLKNKSSTA-TSEATTSKAFMPSTTAYPFN- - - TT Fib 51 protein

517 KSNIVSQVYLNGLD- - - KTK- - - - - PVTLLITLNGTOETG Fib 5 protein  
 280 ATETLNECYIYIGECYVNST-NGTLFP LKVTITLNRRLAS Fib 16 protein  
 250 TRDS- - - ENYIHGICYVMTSYDRSLVPLNISIMLNSRMIS Fib 35 protein  
 250 TRDS- - - ENYIHGICYVMTSYDRSLVPLNISIMLNSRTISS Fib 51 protein

548 DTPPSAYSMSFSWDWSGHNYINE- - - IPATSSYTFPSYIAQ Fib 5 protein  
 319 GM- - - AYAMNFSWLSNAEEAPETTEVTLITSPFFPSYIRE Fib 16 protein  
 288 NV- - - AYAIQFENLNAESPE SNIMTLTSPFFPSYITE Fib 35 protein  
 288 NV- - - AYAIQFENLNAKESPE SNIA TLTSPFFPSYILE Fib 51 protein

585 E Fib 5 protein  
 356 D Fib 16 protein  
 325 D Fib 35 protein  
 325 D Fib 51 protein

Figure 24






Figure 26




Figure 27




Figure 28








Figure 29



**Figure 30 Temperature dependent growth of  
PER.C6**



**Figure 31** DBP levels in PER.C6 cells transfected with pcDNA3, pcDNA3wtE2A or pcDNA3 $\Delta$ 125E2A







Figure 32 Suspension growth of PE3.C6ts125E2A C5-9



**Figure 33** Growth curve PER.C6 and PER.C6tsE2A



# Figure 34 Stability of PER.C6ts125E2A







Figure 35 B tTa activity in Per/E2A/t A clones







European Patent  
Office

# EUROPEAN SEARCH REPORT

Application Number  
EP 00 20 1738

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X,D	BASLER C. F. ET AL.: "Sequence of the immunoregulatory early region 3 and flanking sequences of adenovirus type 35" GENE, vol. 170, no. 2, 8 May 1996 (1996-05-08), page 249-254 XP004042835 ISSN: 0378-1119	8,9	C12N15/86 C12N15/34 C12N5/10 A61K48/00
Y	* the whole document *	1-3,5-7, 10-19, 21,22	
X	WO 96 12030 A (RHONE-POULENC RORER SA ;LEE MARTIN (FR); PERRICAUDET MICHEL (FR)) 25 April 1996 (1996-04-25)	23	
Y	* the whole document *	1-3,5-7, 10-19, 21,22	
Y	FALLAUX F. J. ET AL.: "New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses" HUMAN GENE THERAPY, vol. 9, no. 13, 1 September 1998 (1998-09-01), pages 1909-1917, XP002111678 ISSN: 1043-0342	14	
	* the whole document *		
Y	WO 96 13598 A (UNIV PENNSYLVANIA ;WILSON JAMES M (US); KELLEY WILLIAM M (US); FIS) 9 May 1996 (1996-05-09)	18,19	
	* the whole document *		
	-/--		
The present search report has been drawn up for all claims			
Place of search <b>THE HAGUE</b>		Date of completion of the search <b>7 September 2000</b>	Examiner <b>Mandl, B</b>
<b>CATEGORY OF CITED DOCUMENTS</b> X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

EPO FORM 1503 03 82 (P4/C01)



European Patent  
Office

# EUROPEAN SEARCH REPORT

Application Number  
EP 00 20 1738

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X,D	<p>FLOMENBERG P. R. ET AL.: "Sequence and genetic organization of Adenovirus Type 35 early region 3." JOURNAL OF VIROLOGY, vol. 62, no. 11, 1988, pages 4431-4437, XP002119500 * the whole document *</p>	8,9	
X	<p>BASLER C.F. ET AL.: "Subgroup B adenovirus type 35 early region 3 mRNAs differ from those of the subgroup C adenoviruses." VIROLOGY, vol. 215, 1996, pages 165-177, XP002119501 * the whole document *</p>	8,9	
A	<p>LEE M. G. ET AL.: "THE CONSTITUTIVE EXPRESSION OF THE IMMUNOMODULATORY GP 19K PROTEIN IN E1-, E3- ADENOVIRAL VECTORS STRONGLY REDUCES THE HOST CYTOTOXIC T CELL RESPONSE AGAINST THE VECTOR" GENE THERAPY, vol. 2, no. 4, 1 June 1995 (1995-06-01), pages 256-262, XP000561548 ISSN: 0969-7128 * the whole document *</p>	1-23	
A	<p>WO 97 12986 A (CORNELL RES FOUNDATION INC) 10 April 1997 (1997-04-10) * page 11, line 3 - line 35 * * page 13, line 1 - line 30 *</p>	1-23	
A	<p>WO 98 22609 A (ARMENTANO DONNA E ; GREGORY RICHARD J (US); GENZYME CORP (US); SMIT) 28 May 1998 (1998-05-28) * the whole document *</p>	1-23	
The present search report has been drawn up for all claims			
Place of search <b>THE HAGUE</b>		Date of completion of the search <b>7 September 2000</b>	Examiner <b>Mandl, B</b>
<p><b>CATEGORY OF CITED DOCUMENTS</b></p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons &amp; : member of the same patent family, corresponding document</p>			

EPO FORM 1503 03 02 (P04C01)



European Patent  
Office

# EUROPEAN SEARCH REPORT

Application Number  
EP 00 20 1738

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
A	GALL J. ET AL.: "ADENOVIRUS TYPE 5 AND 7 CAPSID CHIMERA: FIBER REPLACEMENT ALTERS RECEPTOR TROPISM WITHOUT AFFECTING PRIMARY IMMUNE NEUTRALIZATION EPITOPES" JOURNAL OF VIROLOGY, vol. 70, no. 4, 1 April 1996 (1996-04-01), pages 2116-2123, XP002050655 ISSN: 0022-538X * the whole document *	1-23	
P,X	SHAYAKHMETOV D. M. ET AL.: "Efficient gene transfer into human CD34+ cells by a retargeted adenovirus vector." JOURNAL OF VIROLOGY, vol. 74, no. 6, March 2000 (2000-03), pages 2567-2583, XP000938716 ISSN: 0022-538X * the whole document *	1,2,4-9, 12,13, 15-17, 20-23	
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
The present search report has been drawn up for all claims			
Place of search <b>THE HAGUE</b>		Date of completion of the search <b>7 September 2000</b>	Examiner <b>Mandl, B</b>
<p><b>CATEGORY OF CITED DOCUMENTS</b></p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons &amp; : member of the same patent family, corresponding document</p>			

EPO FORM 1503 03/82 (P4/C01)

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 00 20 1738

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.  
The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

07-09-2000

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9612030 A	25-04-1996	FR 2725726 A	19-04-1996
		AU 712243 B	04-11-1999
		AU 3658495 A	06-05-1996
		CA 2201399 A	25-04-1996
		EP 0787198 A	06-08-1997
		FI 971613 A	16-04-1997
		JP 10507079 T	14-07-1998
		NO 971590 A	07-04-1997
		ZA 9508686 A	22-05-1996
WO 9613598 A	09-05-1996	US 5856152 A	05-01-1999
		AU 695811 B	20-08-1998
		AU 4405596 A	23-05-1996
		CA 2203808 A	09-05-1996
		EP 0797678 A	01-10-1997
		JP 10507928 T	04-08-1998
		US 5871982 A	16-02-1999
WO 9712986 A	10-04-1997	US 5837511 A	17-11-1998
		EP 0866873 A	30-09-1998
		JP 11514866 T	21-12-1999
WO 9822609 A	28-05-1998	US 5877011 A	02-03-1999
		AU 5455298 A	10-06-1998
		EP 0946742 A	06-10-1999

EPO FORM P439

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82